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Abstract
Denosumab, raloxifene, romosozumab and teriparatide to
prevent osteoporotic fragility fractures: a systematic review
and economic evaluation
Sarah Davis ,1* Emma Simpson ,1 Jean Hamilton ,1
Marrissa Martyn-St James ,1 Andrew Rawdin ,1 Ruth Wong ,1
Edward Goka ,1 Neil Gittoes 2 and Peter Selby 3
1Health Economics and Decision Science, School of Health and Related Research (ScHARR),
University of Sheffield, Sheffield, UK
2University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
3School of Medical Sciences, University of Manchester, Manchester, UK
*Corresponding author s.davis@sheffield.ac.uk
Background: Fragility fractures are fractures that result from mechanical forces that would not
ordinarily result in fracture.
Objectives: The objectives were to evaluate the clinical effectiveness, safety and cost-effectiveness of non-
bisphosphonates {denosumab [Prolia®; Amgen Inc., Thousand Oaks, CA, USA], raloxifene [Evista®; Daiichi
Sankyo Company, Ltd, Tokyo, Japan], romosozumab [Evenity®; Union Chimique Belge (UCB) S.A. (Brussels,
Belgium) and Amgen Inc.] and teriparatide [Forsteo®; Eli Lilly and Company, Indianapolis, IN, USA]},
compared with each other, bisphosphonates or no treatment, for the prevention of fragility fracture.
Data sources: For the clinical effectiveness review, nine electronic databases (including MEDLINE,
EMBASE and the World Health Organization International Clinical Trials Registry Platform) were
searched up to July 2018.
Review methods: A systematic review and network meta-analysis of fracture and femoral neck bone
mineral density were conducted. A review of published economic analyses was undertaken and a
model previously used to evaluate bisphosphonates was adapted. Discrete event simulation was
used to estimate lifetime costs and quality-adjusted life-years for a simulated cohort of patients with
heterogeneous characteristics. This was done for each non-bisphosphonate treatment, a strategy of
no treatment, and the five bisphosphonate treatments previously evaluated. The model was populated
with effectiveness evidence from the systematic review and network meta-analysis. All other parameters
were estimated from published sources. An NHS and Personal Social Services perspective was taken,
and costs and benefits were discounted at 3.5% per annum. Fracture risk was estimated from patient
characteristics using the QFracture® (QFracture-2012 open source revision 38, Clinrisk Ltd, Leeds, UK)
and FRAX® (web version 3.9, University of Sheffield, Sheffield, UK) tools. The relationship between
fracture risk and incremental net monetary benefit was estimated using non-parametric regression.
A probabilistic sensitivity analysis and scenario analyses were used to assess uncertainty.
Results: Fifty-two randomised controlled trials of non-bisphosphonates were included in the clinical
effectiveness systematic review and an additional 51 randomised controlled trials of bisphosphonates
were included in the network meta-analysis. All treatments had beneficial effects compared with
placebo for vertebral, non-vertebral and hip fractures, with hazard ratios varying from 0.23 to 0.94,
depending on treatment and fracture type. The effects on vertebral fractures and the percentage change
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v
in bone mineral density were statistically significant for all treatments. The rate of serious adverse events
varied across trials (0–33%), with most between-group differences not being statistically significant for
comparisons with placebo/no active treatment, non-bisphosphonates or bisphosphonates. The incremental
cost-effectiveness ratios were > £20,000 per quality-adjusted life-year for all non-bisphosphonate
interventions compared with no treatment across the range of QFracture and FRAX scores expected
in the population eligible for fracture risk assessment. The incremental cost-effectiveness ratio for
denosumab may fall below £30,000 per quality-adjusted life-year at very high levels of risk or for
high-risk patients with specific characteristics. Raloxifene was dominated by no treatment (resulted
in fewer quality-adjusted life-years) in most risk categories.
Limitations: The incremental cost-effectiveness ratios are uncertain for very high-risk patients.
Conclusions: Non-bisphosphonates are effective in preventing fragility fractures, but the incremental
cost-effectiveness ratios are generally greater than the commonly applied threshold of £20,000–30,000
per quality-adjusted life-year.
Study registration: This study is registered as PROSPERO CRD42018107651.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 29. See the NIHR Journals Library website for further project information.
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NOGG National Osteoporosis
Guideline Group
ONJ osteonecrosis of the jaw
PAS Patient Access Scheme
PB probability of being the
best-ranking treatment
PE pulmonary embolism
PrI prediction interval
PRISMA Preferred Reporting Items for
Systematic Reviews and
Meta-Analyses
PSA probabilistic sensitivity analysis
PSS Personal Social Services
PSSRU Personal Social Services
Research Unit
QALY quality-adjusted life-year
QS quality standard
QUALEFFO-41 Quality of Life Questionnaire
of the European Foundation
for Osteoporosis-41 items
RCT randomised controlled trial
RevMan Review Manager
RIS risedronate
RLX raloxifene
ROMO romosozumab
RR risk ratio
SA sensitivity analysis
SAE serious adverse event
s.c. subcutaneous
ScHARR School of Health and Related
Research
SD standard deviation
SmPC Summary of Product
Characteristics
TA technology appraisal
TPTD teriparatide
VBA Visual Basic for Applications
VERO VERtebral fracture treatment
comparisons in Osteoporotic
women
VTE venous thromboembolism
WHO World Health Organization
ZOL zoledronic acid
Note
This monograph is based on the Technology Assessment Report produced for NICE. The full
report contained a considerable number of data that were deemed confidential. The full report
was used by the Appraisal Committee at NICE in their deliberations. The full report with each
piece of confidential data removed and replaced by the statement ‘confidential information
(or data) removed’ is available on the NICE website: www.nice.org.uk.
The present monograph presents as full a version of the report as is possible while
retaining readability, but some sections, sentences, tables and figures have been removed.
Readers should bear in mind that the discussion, conclusions and implications for practice
and research are based on all the data considered in the original full NICE report.
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Plain English summary
Background
Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in
fracture, known as low-level (or ‘low-energy’) trauma. Some people are at particularly high risk of
fragility fractures. The first treatment used is often a bisphosphonate, but non-bisphosphonate
treatments are alternatives.
Aims
We aimed to determine how effective non-bisphosphonates {denosumab [Prolia®; Amgen Inc.,
Thousand Oaks, CA, USA], raloxifene [Evista®; Daiichi Sankyo Company, Ltd, Tokyo, Japan],
romosozumab [Evenity®; Union Chimique Belge (UCB) S.A. (Brussels, Belgium) and Amgen Inc.]
and teriparatide [Forsteo®; Eli Lilly and Company, Indianapolis, IN, USA]} are at preventing fractures,
whether or not treatment has any risks for patients and whether or not the clinical benefits are
achieved at a reasonable cost.
Methods
We have systematically identified and examined trials that assessed the clinical effects of non-
bisphosphonates. For each clinical outcome, we have combined data from multiple trials to estimate
the clinical effectiveness of each non-bisphosphonate treatment.
We combined data from published sources in an economic model to estimate lifetime costs and clinical
benefits for each non-bisphosphonate and compared these with the estimated costs and clinical
outcomes for untreated patients and patients treated with bisphosphonates.
Results
All non-bisphosphonates reduced the risk of vertebral fractures compared with no treatment. For
fractures at the hip or at any non-vertebral site, all of the non-bisphosphonates reduced the average
number of fractures, but, for some non-bisphosphonates, we could not exclude the possibility that this
was a chance finding.
The chance of patients experiencing serious side effects was generally similar regardless of whether
patients took non-bisphosphonates, bisphosphonates or placebo (a dummy pill). Blood clots were more
common in patients taking raloxifene than in those taking placebo, but these were still a rare outcome
(fewer than 1 in 100).
The benefits of denosumab, teriparatide and romosozumab are few compared with their costs.
For raloxifene, the risks generally outweigh the benefits. Treatment with bisphosphonates is likely
to represent better value for money than treatment with non-bisphosphonates.
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Scientific summary
Background
Osteoporosis is a disease characterised by low bone mass and structural deterioration of bone tissue,
with a consequent increase in susceptibility to fragility fracture (defined by the World Health Organization
as a broken bone resulting from a fall from standing height or lower). In the UK, the number of women
and men aged > 50 years with osteoporosis has been estimated as 2,527,331 women and 679,424 men,
with approximately 536,000 new fragility fractures, comprising 79,000 hip fractures, 66,000 vertebral
fractures, 69,000 forearm fractures and 322,000 other fractures. Osteoporotic fractures cause significant
pain, disability and loss of independence, and can be fatal.
Objectives
The objectives were to determine the clinical effectiveness and cost-effectiveness of denosumab
(Prolia®; Amgen Inc., Thousand Oaks, CA, USA), raloxifene (Evista®; Daiichi Sankyo Company, Ltd,
Tokyo, Japan), romosozumab [Evenity®; Union Chimique Belge (UCB) S.A. (Brussels, Belgium) and
Amgen Inc.] and teriparatide (Forsteo®; Eli Lilly and Company, Indianapolis, IN, USA) within their
licensed indications, for the prevention of osteoporotic fragility fractures, compared with each other,
bisphosphonates or a non-active treatment.
Methods
A systematic review and network meta-analysis of clinical effectiveness and safety evidence for
interventions of interest were conducted. Nine electronic databases (including MEDLINE, EMBASE
and the World Health Organization International Clinical Trials Registry Platform) were searched up to
July 2018. Studies were eligible for inclusion if they were randomised controlled trials comparing the
non-bisphosphonates denosumab, raloxifene, romosozumab or teriparatide with each other, placebo or
bisphosphonates within their licensed indication for an osteoporosis population, and reported either
fracture or bone mineral density data. The quality of included studies was assessed using the Cochrane
risk-of-bias tool.
A review of the existing cost-effectiveness literature was undertaken, including economic evaluations
described in the company submissions. The identified cost-effectiveness analyses were compared
with the model that was developed to inform the National Institute for Health and Care Excellence
Multiple Technology Appraisal of bisphosphonates [National Institute for Health and Care Excellence.
Bisphosphonates for Treating Osteoporosis. Technology Appraisal Guidance [TA464]. 2017. URL: www.nice.
org.uk/guidance/ta464/resources/bisphosphonates-for-treating-osteoporosis-pdf-82604905556677
(accessed 20 November 2018)] to identify areas of difference. The model used in Technology Appraisal
Guidance 464 was then adapted to evaluate the cost-effectiveness of non-bisphosphonates when
compared with either no treatment or treatment with bisphosphonates across the whole population
eligible for fracture risk assessment {as defined by the National Institute for Health and Care
Excellence Clinical Guideline 146 [National Institute for Health and Care Excellence. Osteoporosis:
Assessing the Risk of Fragility Fracture. Clinical Guideline [CG146]. 2012. URL: www.nice.org.uk/guidance/
cg146/resources/osteoporosis-assessing-the-risk-of-fragility-fracture-pdf-35109574194373 (accessed
20 November 2018)]}. Incremental analyses were conducted for 10 risk categories based on deciles of
risk when using either the QFracture® (QFracture-2012 open source revision 38, Clinrisk Ltd, Leeds, UK)
or FRAX® (web version 3.9, University of Sheffield, Sheffield, UK) risk-scoring algorithms to determine risk.
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In the economic analyses, treatment with romosozumab was modelled as a treatment sequence of
romosozumab followed by the bisphosphonate alendronate (romosozumab/alendronate). All of the
other treatment strategies modelled consisted of a single intervention followed by no treatment.
Results
The systematic review of clinical effectiveness identified 7898 citations. Fifty-two randomised controlled
trials of non-bisphosphonates were included in the review, and an additional 51 randomised controlled
trials of bisphosphonates were included for the network meta-analyses. Studies varied in quality,
particularly on the domains of blinding and attrition, and were not all well reported.
Across studies reporting overall mortality, there were no significant differences between non-
bisphosphonate treatment arms and their comparators of placebo, other non-bisphosphonates or
bisphosphonates. The ranges of serious adverse event rates were as follows: denosumab, 1.6–25.8%;
raloxifene, 2.0–18.6%; romosozumab, 3.2–12.9%; and teriparatide, 0.0–33.0%.
Network meta-analyses were conducted for vertebral fractures (46 randomised controlled trials,
11 interventions), non-vertebral fractures (42 randomised controlled trials, 11 interventions), hip fractures
(23 randomised controlled trials, nine interventions), wrist fractures (15 randomised controlled trials,
eight interventions), proximal humerus fractures (13 proximal humerus fractures, eight interventions) and
percentage change in femoral neck bone mineral density (73 proximal humerus fractures, 12 interventions).
For vertebral, non-vertebral and hip fractures and for femoral neck bone mineral density, all treatments
were associated with beneficial effects relative to placebo. For both vertebral fractures and percentage
change in femoral neck bone mineral density, the treatment effects were statistically significant at a
conventional 5% level for all treatments. For vertebral, non-vertebral and hip fractures, teriparatide
provided the largest treatment effect, although, in general, the ranking of treatments varied for the
different outcomes. For wrist and proximal humerus fractures, there was less randomised controlled
trial evidence, and so there is considerable uncertainty in treatment effects for certain interventions
in these networks. Sensitivity analyses conducted to assess the impact of assessment method for
vertebral fractures (radiographic or clinical), duration of study, issues with data quality and effect of
prior bisphosphonate treatment demonstrated that the results of the network meta-analysis were
robust to these potential issues.
In the economic evaluation conducted by the assessment group, the incremental cost-effectiveness
ratios were found to be > £30,000 per quality-adjusted life-year for all of the non-bisphosphonate
treatments (raloxifene, denosumab, teriparatide and romosozumab/alendronate) compared with no
treatment across all 10 risk categories when using either QFracture or FRAX to estimate the 10-year
absolute risk of fracture. This finding was unchanged when sensitivity analyses were conducted
exploring alternative assumptions regarding the duration of persistence with treatment and the
duration of time it takes for the treatment effect to fall to zero after treatment stops (the offset
period). The results of the regression of incremental net monetary benefit against fracture risk
predicted a positive incremental net monetary benefit for denosumab compared with no treatment
when valuing a quality-adjusted life-year at £30,000 at very high levels of risk (FRAX score of
> 45%), but the estimates of cost-effectiveness are very uncertain at this level of risk. Otherwise,
the results of the regression analysis were consistent with the findings based on the 10 risk categories.
An exploratory scenario analysis examining an example high-risk patient also suggested that the
cost-effectiveness of denosumab may be more favourable among high-risk patients with specific
characteristics.
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Discussion
Fracture and bone mineral density data were available for all four non-bisphosphonate interventions.
All of these interventions were associated with beneficial effects compared with placebo.
One of the strengths of this analysis is that we have been able to estimate the cost-effectiveness of
each intervention across the broad range of absolute fracture risk observed in the population eligible
for risk assessment under Clinical Guideline 146. However, the downside of the approach we have
taken is that the estimates of cost-effectiveness are uncertain for patients at high risk of fracture
(e.g. > 30%), as they are informed by fewer simulated patients.
The results of the assessment group’s economic evaluation differ from the cost-effectiveness results
presented in the submissions by the companies for denosumab and romosozumab. However, the
review of cost-effectiveness analyses highlighted a number of important differences between these
economic evaluations.
Conclusions
The non-bisphosphonate interventions (raloxifene, denosumab, teriparatide and romosozumab) are all
clinically effective at reducing vertebral fracture risk when compared with placebo. However, the
effectiveness estimates for other fracture sites are more uncertain and the treatment effects were
not statistically significant at a conventional 5% level for all non-bisphosphonate treatments for
non-vertebral fractures.
The incremental cost-effectiveness ratios compared with no treatment are above the National Institute for
Health and Care Excellence threshold of £20,000 per quality-adjusted life-year for all non-bisphosphonate
interventions across the range of QFracture and FRAX scores expected in the population eligible for
fracture risk assessment. The incremental cost-effectiveness ratio for denosumab was < £30,000 per
quality-adjusted life-year for very high-risk patients (FRAX score of > 45%), based on the regression,
but the estimates of cost-effectiveness for high-risk patients are very uncertain.
Study registration:
This study is registered as PROSPERO CRD42018107651.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 29.
See the NIHR Journals Library website for further project information.
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Chapter 1 Background
Description of the health problem
Osteoporosis is a disease characterised by low bone mass and structural deterioration of bone tissue,
with a consequent increase in susceptibility to fragility fracture (a broken bone as a result of a fall from
standing height or lower). The definition provided by the World Health Organization (WHO)1 defines
the condition as bone mineral density (BMD) that is 2.5 standard deviations (SDs) below the average
peak bone mass of healthy females aged 20–29 years, as measured by dual-energy X-ray absorptiometry
(DXA). The WHO operational definition is updated to refer specifically to DXA at the femoral neck.2 The
term ‘established osteoporosis’ includes the presence of a fragility fracture.1 Primary osteoporosis can
occur in both men and women, but is most common in women after menopause, when it is termed
postmenopausal osteoporosis. In contrast, secondary osteoporosis may occur in anyone as a result of
medications, specifically glucocorticoids, or in the presence of particular hormonal disorders and other
chronic diseases.3
Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in
fracture, known as low-level (or ‘low-energy’) trauma, quantified as forces equivalent to a fall from a
standing height or lower.1 Although osteoporosis is an important predictor of the risk of fragility
fracture, 70% of fragility fractures in postmenopausal women occur in those who do not meet the
criteria for osteoporosis.4
The prevalence of osteoporosis in the EU has been estimated at 22 million women and 5.5 million
men.5 In the UK, the number of women and men aged > 50 years with osteoporosis has been
estimated as 2,527,331 women and 679,424 men, with approximately 536,000 new fragility fractures,
comprising 79,000 hip fractures, 66,000 vertebral fractures, 69,000 forearm fractures and 322,000
other fractures (i.e. fractures of the pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum and
other femoral fractures).6
In 2010, the number of postmenopausal women living with osteoporosis in the UK, based on the
definition of a BMD at least 2.5 SDs lower than a young healthy woman (T-score of ≤ –2.5 SDs), was
predicted to increase to 2.1 million in 2020 (+ 16.5%).7 The prevalence of osteoporosis in the general
population of women aged ≥ 50 years in the UK was assumed to remain stable over time, at
approximately 15.5%.
Current service provision
Clinical guidelines
Currently, related National Institute for Health and Care Excellence (NICE) guidance includes a clinical
guideline (CG) for identifying women and men at risk of fracture (CG1468) and four technology appraisals
(TAs) of treatments for osteoporosis (TA464,9 TA204,10 TA16111 and TA16012).
Current National Institute for Health and Care Excellence technology appraisal guidance
The NICE guidance TA4649 recommends oral bisphosphonates [alendronate (ALN), ibandronate (IBN)
and risedronate (RIS)] and intravenous (i.v.) bisphosphonates [IBN and zoledronic acid (ZOL)] as options
for treating osteoporosis in people who are eligible for risk assessment, as defined in NICE’s CG146 on
osteoporosis,8 depending on the person’s risk of fragility fracture.9 However, the risk level at which oral
bisphosphonates are cost-effective is not a clinical intervention threshold. NICE guidance TA4649
should be applied clinically in conjunction with the NICE quality standard (QS) 149 on osteoporosis,13
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which defines the clinical intervention thresholds. These thresholds are based on the NICE-accredited
National Osteoporosis Guideline Group (NOGG) guideline.14
The NICE guidance TA20410 recommends denosumab (DEN) (Prolia®; Amgen Inc., Thousand Oaks, CA,
USA) for the primary prevention of fragility fractures in postmenopausal women at specified fracture
risks, defined by age, T-score and number of independent clinical risk factors for fracture, who have
osteoporosis and who are unable to comply with the special instructions for administering ALN and
either RIS or etidronate (which is no longer marketed in the UK), or have an intolerance of, or a
contraindication to, those treatments. TA20410 also recommends DEN for the secondary prevention
of osteoporotic fragility fractures in postmenopausal women who are at an increased risk of fractures
and who are unable to comply with the special instructions for administering ALN and either RIS or
etidronate, or have an intolerance of, or a contraindication to, ALN and either RIS or etidronate.
The NICE guidance TA16111 recommends raloxifene (RLX) (Evista®; Daiichi Sankyo Company, Ltd,
Tokyo, Japan) and strontium ranelate (discontinued at the time this research was conducted), and
teriparatide (TPTD) (Forsteo®; Eli Lilly and Company, Indianapolis, IN, USA) at specified fracture risks,
defined by age, T-score and number of independent clinical risk factors for fracture, for women who
have already sustained a fracture and who cannot take ALN.11 NICE guidance TA16012 does not
recommend RLX as a treatment option for the primary prevention of osteoporotic fragility fractures in
postmenopausal women.12
Current service cost
Hernlund et al.5 reviewed the literature on fracture incidence and costs of fractures in the 27 EU
countries and incorporated data into a model estimating the clinical and economic burden of osteoporotic
fractures in 2010. The cost of osteoporosis, including pharmacological intervention in the EU in 2010
was estimated at €37B. Costs of treating incident fractures represented 66% of this cost, pharmacological
prevention represented 5% and long-term fracture care represented 29%. Excluding the costs of
pharmacological prevention, hip fractures represented 54% of the costs, vertebral and forearm
fractures represented 5% and 1%, respectively, of the costs and ‘other fractures’ represented 39%.
The estimated number of life-years lost in the EU as a result of incident fractures was approximately
26,300 in 2010. The total health burden, measured in terms of lost quality-adjusted life-years (QALYs),
was estimated at 1,180,000 QALYs for the EU.
In the UK, the cost of osteoporosis (excluding the value of QALYs lost) in 2010 was estimated by
Hernlund et al.5 at €103M (£91.8M in 2017 prices) for pharmacological fracture prevention, €3977M
(£3546M in 2017 prices) for cost of fractures, and €1328M (£1185M in 2017 prices) for cost of long-
term disability. The 2010 cost of UK osteoporosis fracture in relation to population and health-care
spending was €5408M (£4822M in 2017 prices). The 2010 prices reported by Hernlund et al.5 in euros
were converted back to Great British pounds (2006 prices). The conversion ratio from 2006 prices to
2010 prices used by Hernlund et al.5 was estimated by the School of Health and Related Research
(ScHARR) as 1.4065 by comparing the unit cost for nursing home stay against the cited UK-specific
source data from 2006.15 Costs were then uplifted to 2017 prices using the Hospital and Community
Health Service inflation indices from the Personal Social Services Research Unit (PSSRU)16 (302.3 for
2016/17 vs. 240.9 for 2005/6).
Current treatment pathway
The NICE 2018 osteoporosis overview pathway17 and fragility fracture risk assessment pathway18
cover NICE guidance on osteoporosis in adults (aged ≥ 18 years), including assessing the risk of
fragility fracture and drug treatment for the primary and secondary prevention of osteoporotic fragility
fractures. (The recommendations on assessment of fracture risk in CG1468 are summarised in
Measurement of disease.)
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Description of the technology under assessment
Interventions considered in the scope of this report
Four interventions are considered in this assessment: DEN, RLX, romosozumab (ROMO) [Evenity®;
Union Chimique Belge (UCB) S.A. (Brussels, Belgium) and Amgen Inc.] and TPTD.
Mode of action
Treatments for osteoporosis generally fall into two classes: bone-forming agents (ROMO and TPTD)
and anti-resorptive agents (bisphosphonates, DEN and RLX). Bone-forming agents are used for shorter
durations of treatment, often in patients at very high risk of fracture, whereas anti-resorptive agents
are used as long-term treatments and sometimes after bone-forming agents.19 It should be noted that
the company submission by UCB S.A. states that ROMO leads to ‘an increase in bone formation and
reduction in bone resorption’, suggesting that it has both bone-forming and anti-resportive properties.20
Marketing licence and administration method
Denosumab is a monoclonal antibody that reduces osteoclast activity, and so reduces bone breakdown.
It is administered as a single 60-mg subcutaneous (s.c.) injection once every 6 months. DEN has a
marketing authorisation in the UK for the treatment of osteoporosis in postmenopausal women and in
men at increased risk of fractures.19 DEN also has a marketing authorisation for the treatment of bone
loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk
of fracture.21
Raloxifene is a selective oestrogen receptor modulator. It is administered orally at a dose of 60 mg
daily. RLX has a marketing authorisation in the UK for the treatment and prevention of osteoporosis in
postmenopausal women. Non-proprietary RLX [Sandoz International GmBH (Holzkirchen, Germany),
Consilient Health Ltd (Dublin, Ireland), Actavis UK (now Accord-UK Ltd, Barnstaple, UK), Mylan
Pharma UK Ltd (Sandwich, UK)] is also available for the same indication.19
Romosozumab is a monoclonal antibody that inhibits the protein sclerostin, increasing bone formation and
decreasing bone breakdown. It has been studied in clinical trials as 12 months of ROMO followed by at
least 12 months of ALN, compared with at least 24 months of ALN alone, in postmenopausal women. It
has also been studied in a randomised, placebo-controlled clinical trial for treating osteoporosis in men.19
This report was prepared while ROMO was still being assessed by the European Medicines Agency;
therefore, it was based on the anticipated licensed indication for ROMO. A marketing authorisation was
issued in December 2019; the recommended dose is 210 mg (administered as two s.c. injections of 105 mg
each) once monthly for 12 months. This is consistent with the anticipated licensed indication used in
preparation of this report.
Teriparatide is a recombinant fragment of human parathyroid hormone and, as an anabolic agent, it
stimulates formation of new bone and increases resistance to fracture. It is administered subcutaneously
at a dose of 20 µg daily for up to 24 months. TPTD has a marketing authorisation in the UK for
treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. It also
has a marketing authorisation in the UK for treatment of osteoporosis associated with sustained
systemic glucocorticoid therapy in women and men at increased risk of fracture. Biosimilar versions
of TPTD [Movymia, Internis Pharmaceuticals Ltd (Huddersfield, UK);22 Terrosa, Gedeon Richter plc
(Budapest, Hungary)23] have been licensed for the same indications.19
Contraindications, special warnings and precautions
The Summary of Product Characteristics (SmPC) for each intervention describes the contraindications
and special warnings for bisphosphonates.20,24,25
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A s.c. injection of 60 mg of DEN once every 6 months is contraindicated in patients with hypocalcaemia
or hypersensitivity to the active substance or to any of its excipients. Adequate intake of calcium and
vitamin D is important in all patients.24 Special warnings and precautions include hypocalcaemia, renal
impairment, skin infections, osteonecrosis of the jaw (ONJ) and atypical femoral fracture.24
A 60-mg daily oral dose of RLX is contraindicated in women with child-bearing potential and in patients
with an active or past history of venous thromboembolism (VTE), including deep-vein thrombosis (DVT),
pulmonary embolism (PE) and retinal vein thrombosis; hepatic impairment including cholestasis;
severe renal impairment; unexplained uterine bleeding; signs or symptoms of endometrial cancer;
or hypersensitivity to the active substance or to any of the excipients.25
The draft SmPC for ROMO notes special precautions in patients (confidential information has been
removed). Special warnings and precautions include (confidential information has been removed).20
Teriparatide administered subcutaneously at a dose of 20 µg daily is contraindicated in women who are
pregnant or breastfeeding and in patients with pre-existing hypercalcaemia, severe renal impairment,
metabolic bone diseases (including hyperparathyroidism and Paget’s disease of bone) (other than primary
osteoporosis or glucocorticoid-induced osteoporosis), unexplained elevations of alkaline phosphatase,
prior external beam or implant radiation therapy to the skeleton, skeletal malignancies or bone
metastases, or hypersensitivity to the active substance or to any of the excipients.25 Precautions
include elevations of serum calcium concentrations, active or recent urolithiasis, orthostatic
hypotension and renal impairment.25
Place in treatment pathway
Denosumab is recommended as a treatment option for the primary prevention of osteoporotic fragility
fractures only in postmenopausal women at increased risk of fracture who are unable to comply with
the special instructions for administering ALN and either RIS or etidronate, or have an intolerance of, or
a contraindication to, those treatments and who have a sufficiently high risk of fracture as determined by
a combination of T-score, age and number of independent clinical risk factors for fracture.10 DEN is also
recommended ‘as a treatment option for the secondary prevention of osteoporotic fragility fractures
in postmenopausal women at increased risk of fractures who are unable to comply with the special
instructions for administering alendronate and either risedronate or etidronate, or have an intolerance
of, or a contraindication to, those treatments’ (TA204)10 (© NICE 2010 Denosumab for the Prevention of
Osteoporotic Fractures in Postmenopausal Women. Technology Appraisal Guidance [TA204]. Available from
www.nice.org.uk/guidance/ta204. All rights reserved. Subject to Notice of rights. NICE guidance is
prepared for the National Health Service in England. All NICE guidance is subject to regular review
and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this
product/publication.). DEN has a marketing authorisation in the UK for the treatment of osteoporosis
in postmenopausal women and in men at increased risk of fractures, and for the treatment of bone loss
associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.21
Raloxifene is recommended as an alternative treatment option for the secondary prevention of
osteoporotic fragility fractures in postmenopausal women who are unable to comply with the special
instructions for the administration of ALN and RIS, or have a contraindication to, or are intolerant of,
ALN and RIS and who also are at a sufficiently high risk of fracture as determined by a combination of
T-score, age and number of independent clinical risk factors for fracture.
Romosozumab is not currently part of any NICE osteoporosis treatment pathway.
Teriparatide is recommended as an alternative treatment option for the secondary prevention of
osteoporotic fragility fractures in postmenopausal women who are unable to take ALN and RIS, or
who have a contraindication to or are intolerant of ALN and RIS, or who have had an unsatisfactory
response to treatment with ALN or RIS, and who are aged ≥ 65 years and have a T-score of ≤ –4.0 SD,
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or a T-score of ≤ –3.5 SD plus more than two fractures, or who are aged 55–64 years and have a
T-score of ≤ –4 SD plus more than two fractures.12
Identification of important subgroups
The final NICE scope specified subgroups based on patient characteristics that increase the risk of
fracture (those specified in NICE CG1468) or that affect the impact of fracture on lifetime costs
and outcomes.19
Current usage in the NHS
Data from the 2017 Prescription Cost Analysis26 were analysed to determine the level of
non-bisphosphonate usage in primary care across England in 2017. It can be seen from the data
summarised in Table 1 that generic RLX was the most commonly prescribed preparation in primary
care. The prescribing costs in hospitals and the community in England in 2016/17 for treatment of
osteoporosis was £11,930,475 for DEN, £355,530 for RLX and £4,409,696 for TPTD.27
Anticipated costs associated with interventions
Table 2 summarises the 2018 net costs associated with the interventions, based on their list prices.28
TABLE 1 Primary care prescribing of non-bisphosphonates per annum in 2017
Drug
Generic or
branded
Dosing
schedule
Prescriptions
in thousandsa Description of preparations
DEN Branded Once every
6 months
43.063 Prolia injection, 60 mg/1 ml pre-filled syringe
RLX Branded Daily 1.738 Evista tablet, 60 mg
Generic Daily 57.301 RLX hydrochloride tablet, 60 mg
TPTD Branded Daily 0.964 Forsteo injection, 250 µg/ml, 2.4 ml pre-filled pen
a Prescription items dispensed in the community in 2017.26
TABLE 2 Acquisition costs associated with DEN, RLX and TPTD
Drug
Generic or
branded Unit type and dose Price per unit28
DEN Branded Prolia injection, 60 mg/1 ml, one
pre-filled disposable injection
l NHS indicative price = £183.00
l Drug Tariff (Part VIIIA Category C) price= £183.00
RLX Branded Evista tablet, 60 mg, 28 tablets l NHS indicative price = £17.06
l Drug Tariff (Part VIIIA Category M) price = £3.27
Generic RLX HCl tablet, 60 mg, 28 tablets Activis UK:
l NHS indicative price = £4.60
l Drug Tariff (Part VIIIA Category M) price = £3.27
TPTD Branded Forsteo injection, 250 µg/ml 2.4 ml
pre-filled pen, one pre-filled
disposable injection (i.e. 30 daily
doses)
l NHS indicative price = £271.88
l Drug Tariff (Part VIIIA Category C) price= £271.88
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Impact of health problem
Significance for patients
Fractures cause significant pain, disability and loss of independence and can be fatal.1 In the UK, the
number of fracture-related deaths in 2010 was estimated at 6059.6 Hip, vertebral and other fractures
accounted for 2764, 1795 and 1500 deaths, respectively.6
Significance for the NHS
The cost of osteoporosis in the UK in 2010 was estimated at £4.4B. First-year costs, subsequent-year
costs and pharmacological fracture prevention costs amounted to £3.2B, £1.1B and £84M, respectively.6
Measurement of disease
Quantitative diagnosis in the UK relies on the assessment of BMD, usually by central DXA. BMD at the
femoral neck provides the reference site. It is defined as a value for BMD of ≥ 2.5 SDs below the young
female adult mean (i.e. a T-score of ≤ –2.5 SDs). Severe osteoporosis (established osteoporosis) describes
osteoporosis in the presence of one or more fragility fractures.29
The NICE CG1468 recommends the estimation of absolute risk of fragility fracture when assessing risk
of fracture and recommends the use either FRAX® (web version 3.9, University of Sheffield, Sheffield,
UK)30 (without a BMD value if DXA has not previously been undertaken) or QFracture® (QFracture-
2012 open source revision 38, Clinrisk Ltd, Leeds, UK),31 within their allowed age ranges, to estimate
the 10-year predicted absolute fracture risk when assessing risk of fracture.8 Above the upper age
limits defined by the tools, people are considered to be at high risk.8
The guideline8 recommends that assessment is indicated in all women aged ≥ 65 years and all men aged
≥ 75 years and in women aged < 65 years and men aged < 75 years in the presence of risk factors
(i.e. previous fragility fracture, current use or frequent recent use of oral or systemic glucocorticoids,
history of falls, family history of hip fracture, other causes of secondary osteoporosis, low body mass
index, smoking and alcohol intake of > 14 units per week for women and of > 21 units per week for
men). The guideline8 recommends not routinely assessing fracture risk in people aged < 50 years unless
they have major risk factors (i.e. current or frequent recent use of systemic corticosteroids, untreated
premature menopause or previous fragility fracture). The guideline8 also recommends interpretation with
caution of the estimated absolute risk of fracture in people aged > 80 years, because predicted 10-year
fracture risk may underestimate their short-term fracture risk.
BACKGROUND
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Chapter 2 Definition of the decision problem
Decision problem
This assessment addresses the following question: what is the clinical effectiveness and cost-effectiveness
of DEN, RLX, ROMO and TPTD, within their licensed indications, for the prevention of osteoporotic
fragility fractures, as compared with each other, bisphosphonates or a non-active treatment?
Overall aims and objectives of the assessment
l To evaluate the clinical effectiveness of each intervention in terms of osteoporotic fragility
fractures, and femoral neck BMD.
¢ Population: adults assessed for risk of osteoporotic fragility fracture, according to the
recommendations in NICE CG146.8
¢ Interventions: DEN, RLX, ROMO and TPTD.
¢ Comparators: placebo or no active treatment control; interventions compared with each other;
the bisphosphonates ALN, RIS, IBN (oral or i.v.) and ZOL.
¢ Outcomes: osteoporotic fragility fracture, BMD at the femoral neck, adverse events (AEs) and
health-related quality of life (HRQoL).
l To evaluate the incremental cost-effectiveness of each intervention compared with (1) each other,
(2) the bisphosphonates ALN, IBN (oral or i.v.), RIS and ZOL and (3) no active treatment.
From here on, the term bisphosphonates will be used to refer only to those bisphosphonates included
as comparators in this assessment, namely ALN, RIS, IBN (oral or i.v.) and ZOL.
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Chapter 3 Assessment of clinical effectiveness
This report contains reference to confidential information provided as part of the NICE appraisalprocess. This information has been removed from the report and the results, discussions and
conclusions of the report do not include the confidential information. These sections are clearly marked
in the report.
A systematic review of the literature and network meta-analyses (NMAs) were conducted to evaluate
the clinical effectiveness of DEN, RLX, ROMO and TPTD in the treatment of adults with osteoporosis
in terms of preventing osteoporotic fragility fractures.
The systematic review of the evidence was undertaken in accordance with the general principles
recommended in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement.32,33
Methods for reviewing effectiveness
Search strategy
A comprehensive search was undertaken to systematically identify clinical effectiveness literature
relating to the bisphosphonates ALN, IBN, RIS and ZOL, and the non-bisphosphonates DEN, RLX,
ROMO and TPTD, within their licensed indications, for the prevention of fragility fractures.
The search strategy comprised the following main elements:
l searching of electronic databases
l contact with experts in the field
l scrutiny of bibliographies of retrieved papers.
The following database and trials registries were searched on 11 July 2018:
l MEDLINE and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and MEDLINE
(via Ovid), searched from 1946 to 2018
l EMBASE (via Ovid), searched from 1974 to 2018
l Cochrane Database of Systematic Reviews (via Wiley Online Library), searched from 1996 to 2018
l Database of Abstracts of Reviews of Effects (via Wiley Online Library), searched from 1995 to 2015
l Cochrane Central Register of Controlled Trials (via Wiley Online Library), searched from 1898 to 2018
l Health Technology Assessment Database (via Wiley Online Library), searched from 1995 to 2016
l Science Citation Index Expanded (via Web of Science), searched from 1900 to 2018
l Conference Proceedings Citation Index – Science (via Web of Science), searched from 1990 to 2018
l WHO International Clinical Trials Registry Platform.
Existing evidence reviews commissioned by NICE, which included literature published up to September
2014, were assumed to have identified all papers published prior to 2014 that were relevant to this review.
Searches were not restricted by language or publication type. Subject headings and keywords for
‘osteoporosis’ were combined with each of the named drug interventions. The MEDLINE search strategy is
presented in Appendix 1. The search was adapted across the other databases. Highly sensitive study design
filters were used to retrieve clinical trials and systematic reviews on MEDLINE and other databases, when
appropriate. Industry submissions and relevant systematic reviews were also hand-searched to identify any
further relevant clinical trials. The WHO International Clinical Trials Registry Platform was searched for
ongoing and recently completed research projects. Citation searches of key included studies were also
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undertaken using the Web of Science database. All potentially relevant citations were downloaded to the
bibliographic software EndNote version X9.1 [Clarivate Analytics (formerly Thomson Reuters), Philadelphia,
PA, USA] and deduplication of citation records undertaken.
Other resources
In addition to database searches, the reference lists of relevant studies were checked. Identified
systematic reviews were checked to identify any additional trials meeting the inclusion criteria.
Bisphosphonate studies were identified from the assessment report34 used to inform the development
of NICE TA464.9 As the searches for this TA were last updated in September 2014, more recent
studies were sought from the database searches.
When data from included trials were missing, the company submissions were checked. Any academic
or commercial-in-confidence data taken from a company submission were underlined and highlighted
in the assessment report.
Study selection
All titles and abstracts identified by the searches were screened by one reviewer, and 10% were
screened by a second reviewer. Full-text articles were assessed by one reviewer, with queries
addressed by a second reviewer; discrepancies were resolved by discussion.
Inclusion and exclusion criteria for the selection of clinical effectiveness evidence were defined
according to the decision problem outlined in the NICE scope.19
Inclusion criteria
Population
Adults at risk of osteoporotic fragility fracture, according to the recommendations in NICE CG1468
(see Chapter 1, Measurement of disease).
Interventions
Four interventions are considered in this assessment: DEN, RLX, ROMO and TPTD. These four
interventions were assessed in accordance with their licensed indications, at licensed doses. At the
time that searches were conducted, ROMO did not have a marketing authorisation in the UK for
treating osteoporosis, but had been submitted to the European Medicines Agency, given as monthly
210-mg s.c. injections (draft SmPC, as provided in the company submission).20
Comparators
Interventions may be compared with placebo, no active treatment control, each other or the bisphosphonates
ALN, RIS, IBN (oral or i.v.) and ZOL, within their licensed indications (including s.c. and i.v. where licensed).
Studies that allowed concomitant treatment with calcium and/or vitamin D for patients in both the
intervention and comparator arms were included.
Studies that planned treatment sequences or open-label extensions with participants in allocated
randomised groups were included.
Outcomes
The main outcome sought was osteoporotic fragility fracture. Vertebral fractures, when data allowed,
were considered separately for clinical/symptomatic fractures and morphometric/radiographic fractures.
Radiographic fractures, defined according to Genant et al.,35 were those resulting in a ≥ 20% reduction
in vertebral height; however, if a study did not specify that the Genant et al.35 definition was used,
morphometric/radiographic fracture data were still included. Non-vertebral fracture data were sought,
and, when reported, hip, wrist and proximal humerus fractures were considered separately. Although
planned, data on concordance were not extracted owing to time constraints.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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In addition, BMD at the femoral neck (assessed by DXA) data were sought. Only femoral neck BMD
data were included in the NMA; however, when trials did not report these data, BMD measured at the
lumbar spine was tabulated.
The following outcome measures were also included: mortality (overall or following fracture), AEs of
treatment, and HRQoL.
Study design
Randomised controlled trials (RCTs) were included. Studies published as abstracts or conference
presentations were included only if sufficient details were presented to allow both an appraisal of the
methodology and an assessment of the results to be undertaken. Systematic reviews and CGs were
used only as potential sources of additional RCTs of efficacy evidence.
Exclusion criteria
l Studies with patients with normal or unspecified BMD.
l Studies with patients with other indications for the same drugs. Cancer populations at risk of
osteoporosis that are covered by NICE guideline (NG) 10136 and NICE CG175.37
l Studies in which interventions were administered not in accordance with licensed indications.
l Studies in which interventions were co-administered with any other therapy with the potential to
augment bone, unless concomitant treatments are specified in the SmPC.
l Studies that were considered methodologically unsound in terms of study design or the method
used to assess outcomes.
l Reports published as abstracts or conference presentations only, for which insufficient details are
reported to allow an assessment of study quality or results.
l Studies that were published in languages other than English.
l Studies based on animal models, and pre-clinical and biological studies.
l Narrative reviews, editorials, opinions.
Data extraction and critical appraisal
Data relevant to the decision problem were extracted by one reviewer and checked by a second
reviewer. Discrepancies were resolved by discussion. Data were extracted without blinding to authors
or journal. Data from study arms for which intervention treatments were administered in line with
licensed indications were extracted; data from unlicensed treatment arms were not extracted.
For studies included in NICE TA464, the data used were those previously extracted.34
Methodological quality of RCTs identified for inclusion were assessed using the Cochrane
Collaboration risk-of-bias assessment criteria.38 Two independent reviewers undertook quality
assessment. Risk-of-bias plots were produced using Cochrane Review Manager (RevMan) version 5.3
(The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark).
The revised tool (RoB 2.0)39 to assess the risk of bias in randomised trials,39 published in September
2018, was not applied as this review commenced prior to the publication of the revised risk-of-bias tool.
Randomised controlled trials were classified as being at high risk of attrition bias when the dropout
rate in any treatment arm was ≥ 10%.40
Data synthesis
The extracted data and quality assessment variables were presented for each study, both in structured
tables and as a narrative description. Information on between-group differences extracted from included
studies were presented. When these were not reported by included studies, these were estimated using
Cochrane RevMan version 5.3, as either risk ratio (RR) or mean difference (MD).
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Data were pooled across studies in NMAs, the methods of which are described in Methods for the
network meta-analysis.
Results
Quantity of research available
Study selection is shown in Figure 1. As a result of the searches described in Search strategy, a total
of 7898 citations were identified for the clinical review. At abstract sift, 7792 were excluded. At
full-text sift, 34 records were excluded. These are listed in Appendix 2, along with reasons for exclusion.
Fifty-two RCTs of the interventions of interest were included (published in 69 articles; see Table 3).
In addition, three bisphosphonate RCTs were identified and added to the 48 RCTs of bisphosphonates
identified from TA46434 (see Appendix 3).
Randomised controlled trials included in the systematic review of clinical effectiveness of fracture and
femoral neck BMD are presented in Table 3; data from licensed dose arms only for DEN, RLX, ROMO
and TPTD were extracted and presented in this assessment report.
Records identified through database
searching after duplicates removed
(n = 7897) 
Additional records identified
through other sources
(n = 1)
Total records screened
(n = 7898)
Records excluded at title
and abstract sift
(n = 7792)
Full-text articles assessed
for eligibility
(n = 106) Studies excluded, with reasons
(n = 34)
Reasons for exclusion
• Population outside scope, n = 15
• Intervention or comparator
    outside scope, n = 12
• Outcomes outside scope, n = 4
• Conference abstract; insufficient
    details, n = 3
Trials included
(n = 72 comprising 69 references
of 52 non-bisphosphonate trials and
3 references of 3 bisphosphonate trials)
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FIGURE 1 The PRISMA flow diagram of study selection.
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TABLE 3 Trials included in the review
Trial
Intervention and
comparators Population
Reported
vertebral
fracture data
Reported
femoral neck
BMD data
DEN vs. placebo
FREEDOM41 l DEN
l Placebo
Postmenopausal women
with osteoporosis
Yes Yes
ADAMO (Orwoll 2012)42 l DEN
l Placebo
Men with osteoporosis Yes Yes
DIRECT43 l DEN followed by DEN
l Placebo followed by DEN
Postmenopausal women
with osteoporosis and
men with osteoporosis
Yes Yes
Nakamura 201244 l DEN
l Placebo
Postmenopausal women
with osteoporosis
Yes No
Koh 201645 l DEN
l Placebo
Postmenopausal women
with osteoporosis
No Yes
RLX vs. placebo
Adami 200846 l RLX
l Placebo
Postmenopausal women
with osteoporosis
No Yes
Morii 200347 l RLX
l Placebo
Postmenopausal women
with osteoporosis
Yes No
Liu 200448 l RLX
l Placebo
Postmenopausal women
with osteoporosis
Yes Yes
Gorai 201249 l RLX
l RLX plus alfacalcidol
l Alfacalcidol
Postmenopausal women
with osteoporosis
No No, lumbar
spine BMD
Silverman 200850 l RLX
l Placebo
Postmenopausal women
with osteoporosis
Yes Yes
MORE51 l RLX
l Placebo
Postmenopausal women
with osteoporosis
Yes Yes
Lufkin 199852 l RLX
l Control
Postmenopausal women
with osteoporosis
Yes No
Mok 201153 l RLX
l Placebo
Postmenopausal women
with osteoporosis
Yes Yes
ROMO vs. placebo
FRAME54 l ROMO followed by DEN
l Placebo followed by DEN
Postmenopausal women
with osteoporosis
Yes Yes
Ishibashi 201755 l ROMO
l Placebo
Postmenopausal women
with osteoporosis
No Yes
BRIDGE56 l ROMO
l Placebo
Men with osteoporosis No Yes
TPTD vs. placebo
Orwoll 200357 l TPTD
l Placebo
Men with osteoporosis No Yes
Miyauchi 201058 l TPTD
l Placebo
Women and men with
osteoporosis
Yes Yes
Miyauchi 200859 l TPTD
l Placebo
Women with
osteoporosis
No Yes
continued
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TABLE 3 Trials included in the review (continued )
Trial
Intervention and
comparators Population
Reported
vertebral
fracture data
Reported
femoral neck
BMD data
ACTIVE60 l TPTD
l Placebo
Postmenopausal women
with osteoporosis
Yes Yes
Leder 201561 l TPTD
l Placebo
Postmenopausal women
with osteoporosis
No Yes
FPT62 l TPTD
l Placebo
Postmenopausal women
with prior fractures
Yes Yes
Sethi 200863 l TPTD
l Control
Postmenopausal women
with osteoporosis
No Yes
Head-to-head non-bisphosphonates
l DATA64
l DATA-Switch65
l DEN (then switch to TPTD)
l TPTD (then switch to DEN)
l Combined DEN and TPTD
(then switch to DEN)
Postmenopausal women
with osteoporosis
No Yes
EUROFORS66 l TPTD followed by RLX
l TPTD
Postmenopausal women
with osteoporosis
Yes Yes
STRUCTURE67 l ROMO
l TPTD
Postmenopausal women
with osteoporosis
Yes Yes
McClung 201468
(also bisphosphonate
comparator)
l ROMO
l TPTD
l ALN
l Placebo
Postmenopausal women
with osteoporosis
No Yes
DEN vs. bisphosphonates
DECIDE69 l DEN plus placebo
l ALN plus placebo
Postmenopausal women
with osteoporosis
No Yes
STAND70 l DEN
l ALN
l (Both arms received ALN
prior to being randomised
to either DEN or ALN)
Postmenopausal women
with osteoporosis
No Yes
DAPS71 l DEN followed by ALN
l ALN followed by DEN
Postmenopausal women
with osteoporosis
No Yes
AMG 162 Bone Loss
study72
l DEN
l ALN
l Placebo
Postmenopausal women
with osteoporosis
No Yes
Recknor 201373 l DEN
l IBN (oral)
Postmenopausal women
with osteoporosis
No Yes
Saag 201874 l DEN
l RIS
Glucocorticoid-induced
osteoporosis (men and
women)
No Yes
Miller 201675 l DEN plus placebo
l ZOL plus placebo
Postmenopausal women
with osteoporosis
No Yes
RLX vs. bisphosphonates
EFFECT (international)76 l RLX plus placebo
l ALN plus placebo
Postmenopausal women
with osteoporosis
Yes Yes
EFFECT (USA)77 l RLX plus placebo
l ALN plus placebo
Postmenopausal women
with osteoporosis
No Yes
Johnell 200278 l RLX
l ALN
Postmenopausal women
with osteoporosis
No Yes
ASSESSMENT OF CLINICAL EFFECTIVENESS
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TABLE 3 Trials included in the review (continued )
Trial
Intervention and
comparators Population
Reported
vertebral
fracture data
Reported
femoral neck
BMD data
Muscoso 200479 l RLX
l ALN
l RIS
Postmenopausal women
with osteoporosis
Yes No
EVA80 l RLX
l ALN
Postmenopausal women
with osteoporosis
Yes Yes
Sanad 201181 l RLX
l ALN
Postmenopausal women
with osteoporosis
No Yes
Michalská 200682 l RLX
l ALN
l Placebo
Postmenopausal women
with osteoporosis
No Yes
ROMO vs. bisphosphonates
ARCH83 l ROMO followed by ALN
l ALN
Postmenopausal women
with osteoporosis
Yes Yes
TPTD vs. bisphosphonates
FACT84 l TPTD plus placebo
l ALN plus placebo
Postmenopausal women
with osteoporosis
No Yes
Saag 200985 l TPTD
l ALN
Glucocorticoid-induced
osteoporosis (men and
women)
Yes Yes
Panico 201186 l TPTD
l ALN
Postmenopausal women
with osteoporosis
Yes Yes
EuroGIOPs87 l TPTD
l RIS
Glucocorticoid-induced
osteoporosis (men)
No Yes
Anastasilakis 200888 l TPTD
l RIS
Postmenopausal women
with osteoporosis
No No, lumbar
spine BMD
Walker 201389 l TPTD
l RIS
Glucocorticoid-induced
osteoporosis (men)
Yes Yes
VERO90 l TPTD plus placebo
l RIS plus placebo
Postmenopausal women
with osteoporosis
Yes No
Hadji 201291 l TPTD plus placebo
l RIS plus placebo
Postmenopausal women
with osteoporosis
Yes Yes
MOVE92 l TPTD plus placebo
l RIS plus placebo
Post surgery for
osteoporotic hip
fracture
Yes Yes
Cosman 201193 l TPTD
l ZOL
Postmenopausal women
with osteoporosis
Yes Yes
ACTIVE, Abaloparatide Comparator Trial In Vertebral Endpoints; ADAMO, A multicenter, randomized, double-blind,
placebo-controlled study to compare the efficacy and safety DenosumAb versus placebo in Males with Osteoporosis;
ARCH, Active-controlled fracture study in postmenopausal women with osteoporosis at high risk; BRIDGE, phase III
randomized placeBo-contRolled double-blind study evaluatIng the efficacy and safety of Romosozumab in treatinG
mEn with osteoporosis; DAPS, Denosumab Adherence Preference Satisfaction; DATA, Denosumab and Teriparatide
Administration; DECIDE, Determining Efficacy: Comparison of Initiating Denosumab versus alendronate; DIRECT,
Denosumab fracture Intervention RandomizEd placebo Controlled Trial; EFFECT, EFficacy of Fosamax versus Evista
Comparison Trial; EUROFORS, European Study of Forsteo; EVA, EVista Alendronate comparison; FACT, Forteo
Alendronate Comparator Trial; FPT, Fracture Prevention Trial; FRAME, Fracture Study in Postmenopausal Women
with Osteoporosis; FREEDOM, Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months;
MORE, Multiple Outcomes for Raloxifene Evaluation; STAND, Study of Transitioning from Alendronate to Denosumab;
STRUCTURE, STudy evaluating effect of RomosozUmab Compared with Teriparatide in postmenopaUsal women with
osteoporosis at high risk for fracture pReviously treated with bisphosphonatE therapy; VERO, VERtebral fracture
treatment comparisons in Osteoporotic women.
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Of the 52 RCTs included, 23 compared non-bisphosphonates with placebo, four were head-to-head
comparisons of non-bisphosphonates (of which one RCT also included a bisphosphonate arm) and
25 RCTs compared a non-bisphosphonate with a bisphosphonate.
Listed treatment arms were all at licensed doses.
Trial characteristics are shown in Appendix 4. All 52 included trials were RCTs, with the majority being
multicentre studies. All trials providing data for the NMAs involved concomitant treatment with
calcium and vitamin D. The most common primary outcome measure was percentage change in BMD
from baseline.
The majority of RCTs had populations of postmenopausal women. Population baseline characteristics of
RCTs are shown in Appendix 4. There was some variation between trials in baseline BMD T-scores and
the percentage of participants with fractures at baseline. In the RCTs, population baseline characteristics
were balanced between treatment arms.
Quality of research available
Results of the risk-of-bias assessment
Non-bisphosphonates versus placebo
A summary of the Cochrane risk-of-bias assessment across the placebo-controlled non-bisphosphonate
studies is presented in Figure 2.
Denosumab versus placebo
None of the five studies comparing DEN with placebo41–45 reported how the random sequence was
generated, and only two reported that allocation to treatment groups was concealed.41,42
Four of the five studies reported that participants and personnel were blinded to treatment allocation.41–43,45
Four studies reported that fracture assessment was blinded to treatment allocation.42–45 However, only one
reported that BMD assessment was blinded to treatment allocation.42
One study was considered to have a high risk of attrition bias for both fracture and BMD outcomes as
≥ 10% of participants in both treatment groups did not complete the study.41
Only one study did not report the location of a study protocol, against which the reported outcomes
could be checked for selective reporting.44 The remaining four studies of DEN vs. placebo were all
considered to have a low risk of bias for this domain.41–43,45
Raloxifene versus placebo
Of the eight studies comparing RLX with placebo,46–48,50–53,94 only one reported how the random
sequence was generated (it was computer generated), and was considered to have a low risk of bias
for this domain.50 Only three of the eight studies reported that allocation to treatment groups was
concealed.47,50,51
Six of the studies reported that participants and personnel were blinded to treatment allocation.47,48,50–53
One study was considered to have a high risk of bias for this domain as it was described as open label.94
Four of the studies comparing RLX with placebo reported that fracture assessment was blinded to
treatment allocation,47,50,51,53 and three reported that BMD assessment was blinded to treatment
allocation.46,47,53 One study reported that BMD assessment was not blinded to treatment allocation;94
this study was therefore considered to have a high risk of bias for this domain.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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FIGURE 2 Cochrane risk-of-bias summary across placebo-controlled non-bisphosphonate studies. ?, Unclear-risk of bias;
+, low-risk of bias; –, high-risk of bias; blank cells, not a study outcome. ACTIVE, Abaloparatide Comparator Trial In
Vertebral Endpoints; ADAMO, A multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy
and safety DenosumAb versus placebo in Males with Osteoporosis; BRIDGE, phase III randomized placeBo-contRolled
double-blind study evaluatIng the efficacy and safety of Romosozumab in treatinG mEn with osteoporosis; DIRECT
Denosumab fracture Intervention RandomizEd placebo Controlled Trial; FRAME, Fracture Study in Postmenopausal
Women with Osteoporosis; FREEDOM, Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months;
MORE, Multiple Outcomes for Raloxifene Evaluation.
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Four studies were considered to have a high risk of attrition bias for fracture and/or BMD outcomes,
as ≥ 10% of participants did not complete the study.47,51,53,94
Only three studies reported the location of a protocol, against which outcomes could be checked;50,52,53
these studies were considered to have a low risk of bias, as all outcomes in the protocol had been
reported.50,52,53
In one study, which did not report a protocol location, BMD was reported for only a subset of
participants and AEs were not reported by the different RLX doses.51 This study was considered to
have a high risk of bias for selective reporting.
Romosozumab versus placebo
All three of the studies comparing ROMO with placebo reported that allocation to treatment groups was
concealed,54–56 and two reported how the random sequence was generated (all adequate methods).55,56
All three reported that participants and personnel were blinded to treatment allocation.54–56
All three studies assessed BMD,54–56 but none reported whether or not the assessment was blinded.
Only one54 of the two studies54,55 assessing fracture reported that this outcome was blinded to
treatment allocation.
One study was considered to have a high risk of attrition bias (≥ 10% participants did not complete the
study) for both BMD and fracture outcomes,54 and one study was considered to have a low risk of bias
for BMD and fracture outcomes,55 as was one study that assessed only BMD.56
All three studies reported the location of the protocol and all items in the protocol were reported in all
three study publications.54–56
Teriparatide versus placebo
Across the seven studies comparing TPTD with placebo,57–59,61–63,95 four reported a method for the
random sequence generation (all adequate)57–59,61 and three reported that allocation to treatment
groups was concealed.58,59,61
Three of the studies were described as open label and were considered to have a high risk of bias for
blinding of participants and study personnel.63,65,95 The other four trials were considered to have a low
risk of bias for this domain.57–59,62
When fractures and/or BMD were outcomes, only two of the studies reported that fracture
assessment was blinded62,95 and only one reported that BMD assessment was blinded to treatment
allocation.62 One study that reported that BMD assessment was unblinded (fractures were not an
outcome) was considered to have a high risk of bias for this domain.63
Attrition bias of ≥ 10% was evident for reporting of fracture outcomes in three studies,57,62,95 and
evident for five studies reporting BMD outcomes, all of which were judged to be at high risk of
attrition bias.57,59,62,63,65
Three studies reporting the location of a protocol were judged to be at low risk of selective reporting
bias.58,63,95 One study was judged to be at high risk of selective reporting bias62 as safety outcomes
were not clearly reported in the publication and, although the online protocol described safety as a
planned outcome, no results for any outcome had been posted.96
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When considering studies of non-bisphosphonates compared with placebo, those reporting fracture
data had a similar risk of bias to those reporting BMD data, although a higher percentage of studies
reporting fracture data reported blinding of outcome assessors than did those reporting BMD data. 97
Head-to-head non-bisphosphonates
The summary of the Cochrane risk-of-bias assessment across the head-to-head non-bisphosphonate
studies is presented in Figure 3.
Of the four head-to-head studies,64,66–68 three reported the method for the random sequence
generation,64,66,67 and three reported that allocation was concealed.66–68
All four studies were reported as open label and were considered to have a high risk of bias for
blinding of participants and personnel.64,66–68
All four studies reported fractures as an outcome;64,66–68 of these, two studies reported that fracture
assessment was not blinded to treatment allocation.66,67 All four studies assessed BMD and three were
considered to have a low risk of bias for the blinding of BMD assessments.64,66,67
Two66,67 of the three studies assessing fracture were considered to have a low risk of attrition bias
(< 10% of participants withdrew/were not included in the analysis).64,66,67 All four studies reported BMD
outcomes;64,66–68 one of these was considered to have a high risk of attrition bias (≥ 10% of participants
in both treatment groups did not complete the study) for this domain.68 All other studies were
considered to have a low risk of bias.
Three studies reporting the location of a protocol were judged to be at low risk of selective reporting
bias.64,67,68
Non-bisphosphonates versus bisphosphonates
The summary of the Cochrane risk-of-bias assessment across the non-bisphosphonate versus
bisphosphonate studies is presented in Figure 4.
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FIGURE 3 Cochrane risk-of-bias summary across head-to-head non-bisphosphonate studies. ?, Unclear-risk of bias;
+, low-risk of bias; –, high-risk of bias; blank cells, not a study outcome. DATA, Denosumab and Teriparatide
Administration; DIRECT, Denosumab fracture Intervention RandomizEd placebo Controlled Trial; EUROFORS, European
Study of Forsteo; EVA, EVista Alendronate comparison; STRUCTURE, STudy evaluating effect of RomosozUmab Compared
with Teriparatide in postmenopaUsal women with osteoporosis at high risk for fracture pReviously treated with
bisphosphonatE therapy.
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FIGURE 4 Cochrane risk-of-bias summary across non-bisphosphonate vs. bisphosphonate studies. ?, Unclear-risk of bias;
+, low-risk of bias; –, high-risk of bias; blank cells, not a study outcome. ARCH, Active-controlled fracture study in
postmenopausal women with osteoporosis at high risk; DAPS, Denosumab Adherence Preference Satisfaction;
DECIDE, Determining Efficacy: Comparison of Initiating Denosumab versus alEndronate; EFFECT, EFficacy of Fosamax
versus Evista Comparison Trial; EVA, EVista Alendronate comparison; FACT, Forteo Alendronate Comparator Trial;
STAND, Study of Transitioning from Alendronate to Denosumab; VERO, VERtebral fracture treatment comparisons in
Osteoporotic women.
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Denosumab versus bisphosphonates
Of the seven studies comparing DEN with a bisphosphonate,69–75 only one reported the method for
the random sequence generation,71 and only three reported the method of treatment allocation
concealment.69,73,74
Three studies comparing DEN with a bisphosphonate were reported as open label and were
considered to have a high risk of bias for blinding of participants and personnel.71–73
All seven studies assessed BMD as an outcome, but only one reported that the assessment was
blinded to treatment allocation.75 The remaining six studies were considered to have an unclear risk of
bias for this domain.69–74 Four of these studies were also considered to have a high risk of attrition bias
(≥ 10% of participants in both treatment groups did not complete the study) for BMD outcomes.71–74
The six studies that assessed fracture as an outcome were all considered at unclear-risk of bias for
blinded assessment.70–75 All six studies were also considered at unclear risk of attrition bias (≥ 10% of
participants in both treatment groups did not complete the study) for BMD outcomes.
Only one of the studies comparing DEN with a bisphosphonate reported the location of a protocol
against which to check outcomes; this study was considered to have a low risk of bias for selective
reporting.73
For one study,69 HRQoL was reported as an outcome in the manufacturer’s company submission.100
However, this outcome was not reported in the published study, which was considered to have a high
risk of bias for selective reporting.69
Raloxifene versus bisphosphonates
Of the seven studies comparing RLX with a bisphosphonate,76–82 four reported the method for the
random sequence generation (all adequate).76–78,80 However, only one reported a method of treatment
allocation concealment.80
Two of the studies comparing RLX with a bisphosphonate reported that participants and personnel
were blinded to treatment allocation (low risk of bias)76,80 and one study reported an open-label design
(high risk of bias).82 All other studies comparing RLX with a bisphosphonate were considered to have
an unclear risk of bias for blinding of participants and study personnel.77–79,81
Across studies comparing RLX with a bisphosphonate that assessed fracture and/or BMD,76–82 only one
study reported that the fracture assessment was blinded to treatment allocation,80 and only two
reported that fracture assessment was blinded to treatment allocation.76,77
One study comparing RLX with a bisphosphonate that reported fracture outcomes was considered
to have a high risk of attrition bias (≥ 10% of participants in both treatment groups did not complete
the study),80 and four studies assessing BMD were considered to have a high risk of attrition bias
(≥ 10% of participants in both treatment groups did not complete the study).76–78,80
No study comparing RLX with a bisphosphonate reported the location of a study protocol. In one of
the studies, AEs were not fully reported in the study publication,78 and one study reported that
fracture was an assessed outcome, but did not report any results in the study publication.81 These two
studies were considered to have a high risk of selective reporting.
Romosozumab versus bisphosphonates
In the one study that compared ROMO with a bisphosphonate,83 the method for the sequence
generation was not reported, although the method for allocation concealment was. This study was
described as open label and was considered to have a high risk of bias for blinding of participants and
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study personnel. Blinding of fracture outcome assessment was reported; however, blinding of BMD
assessment was not. Both fracture and BMD outcomes were considered to have a high risk of attrition
bias (≥ 10% of participants in both treatment groups did not complete the study). All outcomes in the
study protocol were reported.
Teriparatide versus bisphosphonates
Across the 11 studies that compared TPTD with a bisphosphonate,84–89,91–93,99,101 four92,93,99,101 reported
an adequate method of random sequence generation and only one study reported an adequate method
of treatment allocation concealment.99 One study reported that unblinded pharmacists distributed the
study drug, and was considered to have a high risk of bias for allocation concealment.93
Three of the studies comparing TPTD with a bisphosphonate reported that participants and personnel
were blinded to treatment allocation (low risk of bias),85,99,101 and five studies reported an open-label
design (high risk of bias).86–88,92,93 The other three studies comparing TPTD with a bisphosphonate were
considered to have an unclear risk of bias for blinding of participants and study personnel.84,89,91
Four of the studies comparing TPTD with a bisphosphonate reported that fracture assessment was
blinded to treatment allocation,85,89,91,99 and three reported that BMD assessment was blinded to
treatment allocation.87,89,92
Five of the studies (comparing TPTD with a bisphosphonate) that reported fracture outcomes were
considered to have a high risk of attrition bias (≥ 10% of participants in both treatment groups did not
complete the study),85,91,92,99,101 and five studies assessing BMD were considered to have a high risk of
attrition bias (≥ 10% of participants in both treatment groups did not complete the study).84,85,87,91,92
Six studies (comparing TPTD with a bisphosphonate) that reported the location of a protocol against
which to check outcomes were considered to have a low risk of selective reporting bias.84,85,87,92,99,101
One study reporting an intention-to-treat and a per-protocol analysis stated in the study publication
that the data from the per-protocol analysis were not reported.89 This study was considered to have a
high risk of selective reporting.89
Assessment of effectiveness: fractures
Here we summarise the fracture results for the individual non-bisphosphonate RCTs included in the
review. The results of the NMAs, which include both the bisphosphonate and non-bisphosphonate
studies, are summarised in Results of the network meta-analysis.
Vertebral fractures
Results for vertebral fractures reported in the included studies are presented in Appendix 5, Table 17,
for the non-bisphosphonate treatments compared with placebo, non-bisphosphonate treatments
compared head to head, and non-bisphosphonate treatments compared with bisphosphonates. Fracture
data used in the NMAs are shown in Appendix 9.
Clinical vertebral fractures: efficacy
Non-bisphosphonates versus placebo: clinical vertebral fractures One study comparing DEN with
placebo reported a statistically significant between-group difference in clinical vertebral fractures at
36 months in favour of DEN in postmenopausal women with osteoporosis (p < 0.001).41
Three of the studies comparing RLX with placebo in postmenopausal women with osteoporosis reported
on clinical vertebral fractures.48,50,102 One of these reported a statistically significant between-group
difference in favour of RLX at 12 months in postmenopausal women with osteoporosis (p < 0.001).102 In
the other two studies comparing RLX with placebo,48,50 the between-group difference was not statistically
significant (RLX, 0% vs. placebo, 4.90%; p > 0.05;48 and RLX, 2.36% vs. placebo, 4.10%; p = 0.8950).
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None of the studies comparing ROMO with placebo reported on clinical vertebral fractures.
Only one study comparing TPTD (prescribed open label) with placebo reported on clinical vertebral
fractures at 18 months in postmenopausal women with osteoporosis.95 The estimated between-group
difference was not statistically significant (TPTD, 0.40% vs. placebo, 1.10%; p = 0.10).
Non-bisphosphonates compared head to head: clinical vertebral fractures One study comparing
TPTD with RLX in an open-label design, in postmenopausal women with severe osteoporosis who
were all pre-treated with TPTD for 12 months prior to randomisation, reported that there was no
statistically significant between-group difference in clinical vertebral fractures at 12 months following
randomisation (TPTD, 1.32% vs. RLX, 0%; p-value not reported).66
Non-bisphosphonates versus bisphosphonates: clinical vertebral fractures The estimated between-
group difference in clinical vertebral fractures for one study comparing DEN with RIS in women and
men receiving glucocorticoids was not statistically significant at 12 months (DEN, 3.00% vs. RIS, 4.00%;
p = 0.34).74
The estimated between-group difference in clinical vertebral fractures for one study comparing
RLX with ALN in postmenopausal women with osteoporosis was not statistically significant after
approximately 45 weeks of treatment (study stopped early owing to difficulty in finding treatment-
naive women) (ALN, 3.14% vs. RLX, 1.93%; p = 0.20).80
The reported between-group difference in clinical vertebral fractures for one study comparing ROMO
with ALN in postmenopausal women with osteoporosis was not statistically significant at 12 months
(ALN, 0.9% vs. ROMO, 0.50%; p = 0.14).83
The reported between-group difference in clinical vertebral fractures for one study comparing TPTD
with ALN in women and men receiving glucocorticoids was not statistically significant at 18 months
(p = 0.07).103 However, the between-group difference at 36 months was statistically significant, in
favour of TPTD (p = 0.037).103
Morphometric vertebral fractures: efficacy Morphometric assessment was not always defined, but for
studies that assessed vertebral fracture as an efficacy measure, this was most often reported as using
the method described by Genant et al.35
Non-bisphosphonates versus placebo: new morphometric vertebral fractures One study comparing
DEN with placebo in postmenopausal women with osteoporosis reported a statistically significant
between-group difference at 36 months in new morphometric vertebral fractures in favour of DEN
(p < 0.001).41 The estimated between-group differences for this study over 0-12, 12-24 and 24-36
months were also statistically significant in favour of DEN (p < 0.05).104 However, the estimated
between-group difference at the end of the 7-year open-label extension to this study following
treatment-switching (all participants received DEN) was not statistically significant (placebo switched
to DEN, 7.30% vs. continued DEN, 7.04%; p = 0.76).105
In a single study comparing DEN with placebo in women and men with osteoporosis, the reported between-
group difference in new morphometric vertebral fractures at 24 months was statistically significant in favour
of DEN (p< 0.0001).43 The estimated between-group difference was also statistically significant in favour of
DEN at 36 months, including a 12-month open-label extension following treatment-switching (all participants
received DEN) (p < 0.0001).106 The estimated between-group difference for the 12-month open-label
extension alone was p = 0.05 (placebo switched to DEN, 2.00% vs. continued DEN, 0.25%).106
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Across two studies comparing RLX with placebo in postmenopausal women with osteoporosis, at
36 months the reported or estimated between-group differences were statistically significant in favour
of RLX in reducing new morphometric vertebral fractures (p < 0.05).50,51 However, the between-group
difference was not statistically significant in two studies of postmenopausal women with osteoporosis
that reported this outcome at 12 months (placebo, 2.30% vs. RLX, 0%; estimated p = 0.3347 and
placebo, 40.00% vs. RLX, 48.84%; estimated p = 0.4152) and in one study of postmenopausal women
on long-term glucocorticoids that reported this outcome at 12 months (placebo, 5.36% vs. RLX, 0%;
reported p = 0.24).53
In the one study that compared ROMO with placebo in postmenopausal women with osteoporosis,
statistically significant between-group differences in new morphometric vertebral fractures in favour
of ROMO were reported at 12 months (p < 0.001) and 24 months (p < 0.001).54 Following treatment-
switching to DEN (all participants), (confidential information has been removed) between-group
differences in new vertebral fracture (confidential information has been removed) group were reported
at 36 months (confidential information has been removed).20
In one study comparing TPTD with placebo in postmenopausal women with osteoporosis, the reported
between-group difference at 18 months was statistically significant in favour of TPTD in reducing new
morphometric vertebral fractures (p < 0.001).95 However, the estimated between-group difference was
not statistically significant in one study in postmenopausal women with osteoporosis that reported this
outcome at 12 months (placebo, 5.97% vs. TPTD, 3.68%; p = 0.46).58
Non-bisphosphonates compared head to head: new morphometric vertebral fractures New
morphometric vertebral fracture was not an outcome in the study comparing TPTD with RLX in
postmenopausal women with osteoporosis.66
Non-bisphosphonates versus bisphosphonates: new morphometric vertebral fractures The estimated
between-group difference in new morphometric vertebral fractures after approximately 45 weeks of
treatment in one study comparing RLX with ALN in postmenopausal women with osteoporosis (study
stopped early owing to difficulty in finding treatment-naive women) was not statistically significant
(ALN, 3.14% vs. RLX, 1.93%; p = 0.39).80
The reported between-group difference between new morphometric vertebral fractures for one study
comparing ROMO with ALN in postmenopausal women with osteoporosis was statistically significant
at 12 months [modified intent to treat (mITT), p = 0.003; last observation carried forward (LOCF),
p = 0.008] and 24 months following treatment-switching to ALN, in favour of the group that switched
from ROMO to ALN (mITT and LOCF, p < 0.001).83
The reported between-group difference in new morphometric vertebral fractures for one study
comparing TPTD with ALN in women and men receiving glucocorticoids was statistically significant
at 18 months (p = 0.004) and 36 months (p = 0.007) in favour of TPTD.103 However, the estimated
between-group difference at 18 months for men and women separately was not statistically significant
(men: ALN, 4.48% vs. TPTD, 0.72%; p = 0.09; women: ALN, 12.90% vs. TPTD, 0%; p = 0.13).107 One
open-label study of postmenopausal women with severe osteoporosis receiving treatment for osteoporosis
reported that there was no statistically significant difference between TPTD and ALN at 18 months
(p-value not reported) (ALN, 15.7% vs. TPTD, 2.4%; estimated p = 0.08).86
Across studies comparing TPTD with RIS, no statistically significant between-group differences in new
morphometric vertebral fractures were evident at 18 months in men with osteoporosis (RIS, 10.00%
vs. TPTD, 0%; estimated p = 0.52)89 or at 6 months in postmenopausal women with osteoporosis (RIS,
5.10% vs. TPTD, 4.20%; reported p = 0.6).91 However, statistically significant between-group differences
in new morphometric vertebral fractures in postmenopausal women with osteoporosis in favour of
TPTD were reported at 18 months (p = 0.01)91 and at 24 months (p < 0.0001).99
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Vertebral fractures assessed as safety or when the efficacy assessment method was not
reported One study comparing DEN with placebo in men with osteoporosis reported that there was
no statistically significant between-group difference in clinical fractures assessed as a safety outcome
at 12 months (placebo, 0.83% vs. DEN, 0%; p = 0.50).42
One study comparing RLX with ALN in postmenopausal women with osteoporosis reported vertebral
fractures as a safety outcome, but did not report the assessment method.76 Zero events were reported
in both treatment groups in this study.76 One study comparing RLX, ALN and RIS in postmenopausal
women with osteoporosis reported vertebral fractures as an efficacy outcome, but did not report the
assessment method.79 When estimable, the between-group difference was not statistically significant in
this study (ALN, 0.2% vs. RLX, 0%; p = 0.66; RIS, 0% vs. RLX, 0%; p-value not estimable).79
In one study comparing TPTD with RIS in women and men with low BMD following hip fracture
surgery, for which clinical vertebral fractures were a safety outcome,108 zero events were reported in
both groups at 6 months. The between-group difference at 18 months was not statistically significant
(RIS, 1.00% vs. TPTD, 0%; p = 1.00).92
One study of postmenopausal women with osteoporosis comparing TPTD (plus a placebo for ZOL)
with ZOL (without a placebo for TPTD) also reported vertebral fractures as a safety outcome (the
assessment method was not reported).93 The estimated between-group difference at 12 months was
not statistically significant (TPTD + placebo, 0.70% vs. ZOL, 3.70%; p = 0.14).93
Summary: clinical vertebral fractures There is evidence from a single study41 that DEN is statistically
more effective than placebo at reducing clinical vertebral fractures at 36 months in postmenopausal
women with osteoporosis. There is also evidence from a single study48 that RLX is statistically more
effective than placebo at reducing clinical vertebral fractures at 12 months in postmenopausal women
with osteoporosis. Evidence from a single open-label study95 has found no statistical difference
between TPTD and placebo on clinical vertebral fractures at 18 months in postmenopausal women
with osteoporosis. There are, at present, no placebo-controlled studies of ROMO that evaluate clinical
vertebral fractures.
There is evidence from a single study that there is no statistically significant difference between DEN
and RIS,74 between RLX and ALN,76 and between ROMO and ALN83 in the reduction of clinical
vertebral fractures at up to 12 months in postmenopausal women with osteoporosis.
There is also evidence from a single study103 that there is a statistically significant between-group
difference between TPTD and ALN in favour of TPTD in the reduction of clinical vertebral fractures at
36 months in women and men receiving glucocorticoids.
Summary: new morphometric vertebral fractures There is evidence from a single study41 that DEN is
statistically more effective than placebo at reducing new morphometric vertebral fractures at 24 months
and 36 months in postmenopausal women with osteoporosis, and at 24 months in men and women with
osteoporosis. There is evidence from two studies50,51 that RLX is statistically more effective than placebo at
reducing new morphometric vertebral fractures at 36 months in postmenopausal women with osteoporosis.
There is evidence from a single study54 that ROMO is statistically more effective than placebo at reducing
new morphometric vertebral fractures at 12 and 24 months in postmenopausal women with osteoporosis.
There is also evidence from a single study95 that TPTD is statistically more effective than placebo at
reducing new morphometric vertebral fractures at 18 months in postmenopausal women with osteoporosis.
There is evidence from a single study that there is no statistically significant difference in new
morphometric vertebral fractures between RLX and ALN at approximately 45 weeks (study stopped
early owing to difficulty in finding treatment-naive women) in postmenopausal women with
osteoporosis,80 between TPTD and ALN at 18 months in women with severe osteoporosis receiving
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treatment for osteoporosis,103 and between TPTD and RIS at 18 months in men with osteoporosis.89
However, there is evidence from a single study that ROMO is significantly more effective than ALN
at reducing new morphometric vertebral fractures at 12 months in postmenopausal women with
osteoporosis,83 and that TPTD is significantly more effective than ALN at reducing new morphometric
vertebral fractures at 18 and 36 months in women and men receiving glucocorticoids.103 There is also
evidence from two studies89,99 that TPTD is significantly more effective than RIS at reducing new
morphometric vertebral fractures at 18 and 24 months in postmenopausal women with osteoporosis.
Non-vertebral fractures
Non-vertebral fracture outcomes were reported in 28 RCTs and are shown in Appendix 5, Table 18.
Hip, wrist and proximal humerus fracture outcomes were reported separately in 22 RCTS; these are
shown in Appendix 5, Table 19. These fractures are also counted among the non-vertebral fracture
total. Results of the NMAs for these outcomes are shown in Results of the network meta-analysis.
Fracture data used in the NMAs are shown in Appendix 9.
Non-bisphosphonates versus placebo
The Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months (FREEDOM) trial41
reported a significant (p = 0.01) advantage in non-vertebral fractures for DEN (6.1%) over placebo
(7.5%) at 36 months for postmenopausal women. The FREEDOM trial41 also had a lower rate of non-
vertebral fractures for DEN (7.3%) than for placebo/DEN (9.9%) (significance not reported; estimated
in RevMan as p = 0.01) 84 months into the open-label extension. At 36 months, the FREEDOM trial41
reported a significantly (p = 0.04) lower rate of hip fracture for DEN (0.7%) than for placebo (1.2%)
(see Appendix 5, Table 19). The Denosumab fracture Intervention RandomizEd placebo Controlled Trial
(DIRECT),43 a RCT of postmenopausal women and of men, did not find a difference in the number of
non-vertebral fractures at 24 months between the DEN and placebo groups (both 4.1%), although
there was a trend (p = 0.0577) towards fewer major non-vertebral fractures in the DEN group (1.6%)
than in the placebo group (3.7%). The rate of non-vertebral fractures in the DEN group at 24 months
of the international population of FREEDOM41 was similar to that of the Japanese population of
DIRECT.43 Following a further year during which all participants received DEN, DIRECT106 reported
non-vertebral fracture rates of 6.7% for placebo/DEN and 5.2% for DEN, with rates of major non-
vertebral fractures of 5.4% and 2.0%, respectively. At 24 months, DIRECT43 reported 0% hip fractures
for DEN and 0.4% for placebo.
Of the RLX versus placebo RCTs, the Morii et al.47 and Lufkin et al.52 studies were not powered to
detect a difference between groups; however, both studies had a 0% rate of non-vertebral fractures
in the RLX group at 12 months. In the Silverman et al.50 RCT, there was no significant difference
(estimated in RevMan as p = 0.6409) in non-vertebral fractures at 36 months between the RLX (6.3%)
and placebo (5.7%) groups (see Appendix 5, Table 18), with rates of hip fracture of 0.3% in both groups
(see Appendix 5, Table 19).
The Fracture Study in Postmenopausal Women with Osteoporosis (FRAME)54 reported a non-significant
(p = 0.096) difference between ROMO (1.6%) and placebo (2.1%) at 12 months for non-vertebral
fractures. At 24 months, FRAME54 reported a significant advantage for ROMO/DEN over placebo/DEN
in non-vertebral fractures (2.7% vs. 3.6%; p = 0.029), with a trend (p = 0.059) favouring ROMO/DEN
for hip fractures (0.3%) over placebo/DEN (0.6%).
The Miyauchi et al.58 trial, which included women and men, reported a lower (significance not reported;
estimated in RevMan as p = 0.1838) rate of non-vertebral fractures for TPTD (2.2%) than for placebo
(6.0%) at 12 months. In postmenopausal women, the Abaloparatide Comparator Trial In Vertebral
Endpoints (ACTIVE)95 did not find a significant difference (p = 0.22) between TPTD (3.3%) and placebo
(4.7%) in the prevention of non-vertebral fractures at 18 months. In ACTIVE,95 no hip fractures were
reported in the TPTD group, whereas 0.2% of participants in the placebo group reported hip fractures.
The Fracture Prevention Trial (FPT)62 found a significant (p = 0.04) advantage of TPTD (6.3%) over
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placebo (9.7%) in the prevention of non-vertebral fractures. The FPT62 reported hip fracture rates
of 0.4% in the TPTD group and of 0.7% in the placebo group. The population in the FPT62 all had
vertebral fractures at baseline, in contrast to ACTIVE,95 in which two-thirds had prior fractures at
baseline. The FPT62 was blinded, whereas the TPTD arm in ACTIVE95 was open label, as the trial was
designed compare abaloparatide with placebo.
Studies reporting non-vertebral fracture rates as safety data reported, for postmenopausal women, the
6-month non-vertebral fracture rates for DEN (1.5%) and placebo (1.5%)45 and the 12-month rates for
ROMO (3.2%) and placebo 1.6%,55 and, for men, the 12-month rates of DEN (0.8%) and placebo (1.7%).42
Head-to-head non-bisphosphonates
The European Study of Forsteo (EUROFORS)66 reported fractures as an efficacy outcome, and found
no significant difference between TPTD (2.96%) and RLX (2.06%) in non-vertebral fractures at
12 months’ follow-up in postmenopausal women with prior TPTD treatment. Rates of hip fracture
were 0.3% for TPTD and 0% for RLX.
The STudy evaluating effect of RomosozUmab Compared with Teriparatide in postmenopaUsal
women with osteoporosis at high risk for fracture pReviously treated with bisphosphonatE therapy
(STRUCTURE)67 reported fractures as a safety outcome in postmenopausal women. The rates of
non-vertebral fractures at 12 months were 3.21% for ROMO and 3.67% for TPTD. Rates of hip
fracture were 0.5% for ROMO and 0% for TPTD.67
Non-bisphosphonates versus bisphosphonates
Saag et al.74 reported rates (no significance reported; estimated in RevMan as p = 0.1781) of
non-vertebral fractures of 4.0% for DEN and 3.0% for RIS at 12 months’ follow-up, and hip fracture
rates of 0.3% for both groups.
Muscoso et al.79 reported rates of non-vertebral fractures of 0% in both the RLX and RIS groups and
of 0.2% in the ALN group in both the first and second years of the RCT. The EVista Alendronate
comparison (EVA)80 RCT found no significant difference (estimated in RevMan as p = 0.8092) between
rates of non-vertebral fracture in the RLX (2.2%) and ALN (2.0%) groups. The EVA80 RCT reported hip
fracture rates of 0.3% for RLX and 0.1% for ALN.
The Active-controlled fracture study in postmenopausal women with osteoporosis at high risk (ARCH)83
reported a trend (p = 0.057) favouring ROMO (3.4%) over ALN (4.6%) for the prevention of non-vertebral
fractures at 12 months; for the prevention of major non-vertebral fractures (pelvis, distal femur, proximal
tibia, ribs, proximal humerus, forearm and hip), there was a significant (p = 0.019) difference between the
groups (2.9% for ROMO and 4.3% for ALN). There was no significant (p = 0.19) difference in hip fracture
rates at 12 months.83 The results of the primary analysis show that there was a significant (p = 0.037)
advantage of ROMO/ALN (8.7%) over ALN (10.6%) in the prevention of non-vertebral fractures, as well
as the prevention of major non-vertebral fractures (p = 0.004) and hip fractures (p = 0.015).
Saag et al.103 found no significant (p = 0.6) difference between rates of non-vertebral fractures for
TPTD (5.6%) and ALN (3.7%) at 18 months, and also no significant treatment difference for subgroups
of men (p = 0.6) or women (p = 0.3). Two RCTs of postmenopausal women comparing TPTD with RIS
found no significant treatment difference for the prevention of non-vertebral fractures: VERtebral
fracture treatment comparisons in Osteoporotic women (VERO) (Kendler et al.)99 at 24 months (TPTD,
4.0% and RIS, 6.0%; p = 0.10) and Hadji et al.91 at 6 months (TPTD, 7.8% and RIS, 8.3%; p = 0.89).
The population in the Hadji et al.91 study were selected because they had back pain due to vertebral
fracture, which may explain why the rates were higher in both these groups than they were in VERO.99
The rates of hip fracture were 0.3% for TPTD and 0.7% for RIS in VERO,99 and 1.4% for TPTD and
0.6% for RIS in Hadji et al.91
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For studies reporting fractures as safety data, non-vertebral fracture rates for postmenopausal women
at 12 months were 0.8% for DEN and 0.9% for ALN,109 3.9% for RLX and 2.5% for ALN,77 5.1% for
TPTD,93 5.8% for ZOL93 and, for women pre treated (with ALN), 3.2% for DEN and 1.6% for ALN.70 At
24 months, non-vertebral fracture rates were 3.0% for RLX, 3.0% for ALN and 6.0% for placebo for
women pre treated (with ALN).82 Hip fracture rates at 12 months were reported as 0.4% for RLX and
0.0% for ALN.76 For men with glucocorticoid-induced osteoporosis, non-vertebral fracture rates of 0.0%
for TPTD and 10.6% for RIS (trend p = 0.056) were reported at 18 months.87 In a population that had
had hip surgery, at 18 months’ follow-up reported non-vertebral fracture rates were 4.7% for TPTD
and 9.1% for RIS; hip fracture rates were 1.9% for TPTD and 6.4% for RIS.92
Across placebo-controlled trials and trials with comparators of non-bisphosphonates or bisphosphonates,
when reported, non-bisphosphonates had wrist fracture rates of no more than 2.5% and proximal
humerus fracture rates of no more than 1.1%.
Assessment of effectiveness: bone mineral density
Here we summarise the BMD results of the individual non-bisphosphonate RCTs included in the
review. The results of the NMAs, which include both the bisphosphonate and non-bisphosphonate
studies, are summarised in Results of the network meta-analysis. Given the multiple time points often
reported for BMD, we decided to focus on annual or final follow-up.
Femoral neck bone mineral density
Results for femoral neck BMD reported by the included studies are presented in Appendix 5, Table 20,
for the non-bisphosphonate treatments compared with placebo, non-bisphosphonate treatments
compared head to head, and non-bisphosphonate treatments compared with bisphosphonates.
Non-bisphosphonates versus placebo: femoral neck bone mineral density
Three studies comparing DEN with placebo reported a statistically significant between-group
difference in femoral neck BMD in favour of DEN: at 6 months in postmenopausal women with
osteoporosis (p = 0.0042),45 at 12 months in men with osteoporosis (p < 0.0001)42 and at 24 months in
women and men with osteoporosis (p < 0.0001).43 The estimated between-group differences were also
statistically significant in favour of DEN in the open-label extensions to these studies. However, the
open-label extension estimates were all reliant on data extracted from graphs.
Statistically significant between-group differences in femoral neck BMD in favour of RLX over placebo
were evident at 36 months for two studies of postmenopausal women with osteoporosis (p < 0.0000150
and p < 0.00151) and at 12 months for one study of postmenopausal women with osteoporosis who
were pre treated with TPTD (p < 0.001).46 However, the between-group difference in the open-label
extensions to the study of postmenopausal women with osteoporosis pre treated with TPTD was not
statistically significant (see Appendix 5, Table 20).46 The estimated between-group difference at 12
months in one study of postmenopausal women with osteoporosis was not statistically significant,48
nor was the between-group difference at 12 months in one study of postmenopausal women receiving
long-term glucocorticoids (data estimated from graph).53
Statistically significant between-group differences in femoral neck BMD in favour of ROMO over
placebo were reported at 12 months for two studies of postmenopausal women with osteoporosis
(p < 0.00154 and p < 0.0000155), and at 12 months in one study of men with osteoporosis (p < 0.001).56
The reported between-group difference was also statistically significant at 24 months in one study
following an open-label treatment-switching extension, favouring switching from ROMO to DEN over
switching from placebo to DEN (p < 0.001)54 (see Appendix 5, Table 20). A study of postmenopausal
women with osteoporosis reported statistically significant between-group differences in femoral neck
BMD in favour of ROMO over ALN at 12 months (p < 0.001), and in favour of ROMO/ALN over
ALN/ALN at 24 and 36 months (p < 0.001).
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Four studies comparing TPTD with placebo reported a statistically significant between-group
difference in femoral neck BMD in favour of TPTD at 6 months in postmenopausal women with
osteoporosis (p < 0.01).61 Statistically significant between-group differences in favour of TPTD at
12 months were also reported by one study (p = 0.015),58 at 18 months by one study (p < 0.0001)95 and
at 24 months by one study (p < 0.001).62 The estimated between-group difference was also statistically
significant in favour of continued TPTD in the open-label extension in one of these studies, compared
with switching from placebo to TPTD at 18 months (p = 0.03), but not at 24 months (see Appendix 5,
Table 20).58 The estimated between-group difference at 6 months for one study comparing TPTD with
placebo in postmenopausal women with osteoporosis was not statistically significant,59 nor was the
estimated between-group difference at 6 months of one study comparing TPTD plus calcium and
vitamin D with calcium and vitamin D alone.63
Non-bisphosphonates compared head to head: femoral neck bone mineral density
One study comparing TPTD with DEN in postmenopausal women with osteoporosis reported no
statistically significant between-group difference in femoral neck BMD at either 1264 or 24 months.110
However, statistically significant differences were reported in the open-label extension following
treatment-switching, in favour of the group switching from TPTD to DEN, at 24 and 48 months
following switching.65
A statistically significant between-group difference in femoral neck BMD at 12 months in
postmenopausal women with osteoporosis, who were pre treated with ALN prior to randomisation,
was reported by one study comparing TPTD with ROMO, in favour of ROMO (p < 0.0001).67
One study comparing TPTD, RLX and a non-active control in postmenopausal women with osteoporosis
who were pre treated with ALN reported on the between-group difference in femoral neck BMD for
TPTD compared with control only; the result was statistically significantly in favour of the non-active
treatment (p < 0.05).66 No variance estimates were reported by this study. Therefore, the other
between-group comparisons could not be estimated.
The estimated between-group difference in femoral neck BMD at 12 months for one study comparing
TPTD with ROMO in postmenopausal women was not statistically significant.68 In this study, the estimated
between-group differences for both non-bisphosphonates compared with placebo were statistically
significant in favour of the active treatment (TPTD, p = 0.0007; ROMO, p = 0.0002). However, when
comparing ROMO with ALN and TPTD with ALN, the results were not statistically significant.
Non-bisphosphonates versus bisphosphonates: femoral neck bone mineral density
Across two open-label studies comparing DEN with ALN, statistically significant between-group
differences in femoral neck BMD in favour of DEN were reported at 12 months in one study of
postmenopausal women with osteoporosis (p = 0.0001),69 and at 12 months in one study of
postmenopausal women with osteoporosis already receiving ALN (p < 0.0121).70 The estimated
between-group difference for one study comparing DEN with ALN in postmenopausal women
with osteoporosis, which was not powered for femoral neck BMD, was not statistically significant
(see Appendix 5, Table 20).71
In one open-label study comparing DEN with IBN (oral) in postmenopausal women with osteoporosis,
at 12 months the between-group difference in femoral neck BMD was statistically significant in favour
of DEN (p < 0.001).73
Statistically significant between-group differences in femoral neck BMD in favour of DEN at 12 months
were also reported by one study comparing DEN with RIS in women and men with osteoporosis who
were continuing or initiating glucocorticoids (continuing: p = 0.004; initiating: p = 0.020),74 and at
12 months by one study comparing DEN with ZOL in postmenopausal women with osteoporosis
previously treated with bisphosphonates (p < 0.0001).75
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Two studies comparing RLX with ALN in postmenopausal women with osteoporosis reported statistically
significant between-group differences in femoral neck BMD in favour of RLX at 12 months (p = 0.0001)76
and 24 months (p = 0.002).80 However, one study comparing RLX with ALN in postmenopausal women
with osteoporosis,77 and one study comparing RLX with ALN in postmenopausal women with osteoporosis
who were previously treated with bisphosphonates,82 reported that the between-group difference at
12 months was not statistically significant. In one of these studies,82 the estimated between-group
difference following a 12-month open-label extension to 24 months (data estimated from graph) was
statistically significant in favour of ALN (p = 0.03). One other study comparing RLX with ALN in
postmenopausal women with osteoporosis also reported a statistically significant between-group
difference in favour of ALN at 12 months (p < 0.05).78
One study comparing TPTD with ALN in women and men with osteoporosis receiving glucocorticoids
reported a statistically significant between-group difference in femoral neck BMD at 36 months
(p < 0.001).103 The between-group difference reported by one study comparing TPTD with ALN at
18 months in postmenopausal women with osteoporosis was p = 0.05.84
Across three studies comparing TPTD with RIS, statistically significant between-group differences in
femoral neck BMD in favour of TPTD were reported at 18 months: in men with osteoporosis receiving
glucocorticoids (p = 0.026),87 in postmenopausal women with osteoporosis (p = 0.02)91 and in women
and men with low BMD following hip fracture surgery (p = 0.003).92 However, one of these studies91
reported an imbalance in femoral neck BMD across study groups at baseline. One study comparing
TPTD with RIS in men with osteoporosis reported that the between-group difference at 18 months
was not statistically significant.89
One study comparing TPTD (plus a placebo for ZOL) with ZOL (without a placebo for TPTD) reported
a statistically significant between-group difference in femoral neck BMD in favour of ZOL at
12 months in postmenopausal women with osteoporosis (p < 0.05).93
Summary: femoral neck bone mineral density
There is evidence that DEN is statistically more effective than placebo at increasing femoral neck BMD
at 6 months in postmenopausal women with osteoporosis,45 at 12 months in men with osteoporosis42
and at 24 months in women and men with osteoporosis.43
The evidence is mixed for RLX increasing femoral neck BMD, compared with placebo. There is evidence
from a single study that RLX is statistically more effective than placebo at 36 months in postmenopausal
women with osteoporosis50,51 and at 12 months in postmenopausal women with osteoporosis who were
pre treated with TPTD.46 However, there is evidence from a single study that the between-group difference
between RLX and placebo is not statistically significantly different at 12 months in postmenopausal women
with osteoporosis46 or at 12 months in postmenopausal women receiving long-term glucocorticoids
(data estimated from graph).53
There is evidence from two studies that ROMO is statistically more effective than placebo at increasing
femoral neck BMD at 12 months in postmenopausal women with osteoporosis.54,55 and at 12 months in
men with osteoporosis.56
The evidence is mixed for TPTD increasing femoral neck BMD, compared with placebo. There is
evidence from a single study that TPTD is statistically more effective than placebo at 6,61 1258 and
18 months95 in postmenopausal women with osteoporosis. However, there is evidence from a single
study that the between-group difference in TPTD compared with placebo,59 or TPTD plus calcium
and vitamin D compared with calcium or vitamin D alone,63 is not statistically significantly different at
6 months in postmenopausal women with osteoporosis.
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There is evidence from a single study that, although TPTD is not statistically more effective than
placebo at increasing femoral neck BMD at 12 or 24 months in postmenopausal women with
osteoporosis, treatment-switching from TPTD to DEN is significantly more effective than continued
DEN at a further 24 and 48 months (open label).65
There is evidence from a single study that ROMO is statistically more effective than TPTD at
increasing femoral neck BMD at 12 months in postmenopausal women with osteoporosis who were
pre treated with ALN.67
There is evidence from a single study that DEN is statistically more effective than ALN at increasing
femoral neck BMD at 12 months in postmenopausal women with osteoporosis69 and at 12 months in
postmenopausal women with osteoporosis already receiving ALN.70 There is also evidence from a
single study that DEN is statistically more effective than oral IBN at 12 months in postmenopausal
women with osteoporosis,73 that DEN is statistically more effective than RIS at 12 months in women
and men with osteoporosis continuing or initiating glucocorticoids,74 and that DEN is statistically more
effective than ZOL at 12 months in postmenopausal women with osteoporosis who were previously
treated with bisphosphonates.75
The evidence for RLX compared with ALN is mixed. There is evidence from a single study that RLX is
statistically more effective than ALN at increasing femoral neck BMD at 12 months in postmenopausal
women with osteoporosis.76 However, there is evidence that the between-group difference between
RLX and placebo is not statistically significantly different at 12 months in postmenopausal women with
osteoporosis (two studies).77,82 There is also evidence that ALN is statistically more effective than RLX at
increasing femoral neck BMD at 12 months in postmenopausal women with osteoporosis (two studies).78,82
There is evidence from a single study that ROMO is statistically more effective than ALN at increasing
femoral neck BMD at 12 months in postmenopausal women with osteoporosis and that switching from
ROMO to ALN is statistically more effective than continued ALN at 24 and 36 months (open label).83
The evidence is mixed for TPTD increasing femoral neck BMD, compared with placebo. There is evidence
that TPTD is statistically more effective than RIS at increasing femoral neck BMD at 12 months in
postmenopausal women with osteoporosis (two studies). There is also evidence from a single study that
TPTD is statistically more effective than RIS at increasing femoral neck BMD at 18 months in women and
men with osteoporosis receiving glucocorticoids, in men with osteoporosis receiving glucocorticoids and in
women and men with low BMD following hip fracture surgery. However, there is evidence from a single
study that the between-group difference for TPTD and RIS is not statistically significantly different at
18 months in men with osteoporosis.
There is evidence from a single study that ZOL without placebo is statistically more effective than
TPTD with placebo at increasing femoral neck BMD at 12 months in postmenopausal women with
osteoporosis.93
Lumbar spine bone mineral density
Six RCTs did not report femoral neck BMD, but did report lumbar spine BMD (see Appendix 5, Table 23).
One RCT reported a significant increase in lumbar spine BMD for DEN, compared with placebo.44 A
placebo-controlled trial reported a significant increase in lumbar spine BMD for RLX,47 and a small RCT
reported an advantage for RLX plus alfacalcidol (n = 31), compared with alfacalcidol alone (n = 34),49
whereas another small trial found no significant difference for RLX (n = 48) compared with a non-active
treatment control (n = 48).52 One RCT of RLX versus bisphosphonates reported that ALN and RIS had a
higher percentage increase in lumbar spine BMD at 24 months than RLX (estimated in RevMan as
p < 0.001).79 One small RCT did not find a significant difference between TPTD (n = 22) and RIS (n = 22)
in the improvement of lumbar spine BMD.88
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Assessment of effectiveness: adverse events
Mortality
Mortality across the included studies is presented in Appendix 5, Table 21, for the non-bisphosphonate
treatments compared with placebo, non-bisphosphonate treatments compared head to head and non-
bisphosphonate treatments compared with bisphosphonates. None of the included studies reported on
mortality following hip fracture, mortality following vertebral fracture or mortality following any other
type of fracture.
Non-bisphosphonates versus placebo: mortality
Of the studies comparing DEN with placebo, six reported on mortality;41–43,45,106,111 of the studies
comparing RLX with placebo, two reported on mortality;48,50 and of studies comparing ROMO with
placebo, three reported on mortality.54–56 Six studies comparing TPTD with placebo reported on
numbers of mortality;57–59,61,63,95 one reported that there was no statistically significant between-group
difference (data were not reported).62
When mortality was reported in studies comparing non-bisphosphonates with placebo, event rates were
low with active treatment (0.0–1.8%). Only one study reported a between-group difference,41 which was
not statistically significant (p = 0.08). For the studies for which between-group differences were not
reported, the estimated between-group differences were not statistically significant (p > 0.05).
Non-bisphosphonates compared head to head: mortality
The Denosumab and Teriparatide Administration (DATA)64 and DATA-Switch studies,65 that compared
DEN with TPTD, did not report on mortality; neither did the EUROFORS,66 which compared TPTD with
RLX. In the two studies that compared ROMO with TPTD and reported on mortality,67,68 event rates
for mortality were low with either treatment (0–2%). The estimated between-group differences were
not statistically significant (p > 0.05).
Non-bisphosphonates versus bisphosphonates: mortality
Of the studies comparing DEN with bisphosphonates and reporting on mortality, three studies
compared DEN with ALN;69,70,72 one compared DEN with oral IBN,73 one compared DEN with RIS74
and one compared DEN with ZOL.75 Across these studies event rates for mortality were low across
treatments (< 1%) and the estimated between-group differences were not statistically significant
(p > 0.05).
Of the studies comparing RLX with bisphosphonates, two studies comparing RLX with ALN reported on
mortality.76,80 Of these two studies,76,80 event rates for mortality were low across treatments (< 1%) and
the estimated between-group differences were not statistically significant (p > 0.05).
One study comparing ROMO with ALN reported mortality rates of < 2% with either treatment at
12 months prior to treatment-switching and of < 5% at 24 months following treatment-switching.83
The estimated between-group differences were not statistically significant (p > 0.05).
Of the studies of TPTD compared with bisphosphonates, one study comparing TPTD with ALN;74
four comparing TPTD with RIS,87,91,99,101 and one comparing TPTD with ZOL93 reported on mortality.
Across these studies, event rates ranged from 0% to 4.4% with TPTD and from < 1% to 6.4% with
bisphosphonates. The estimated between-group differences were not statistically significant (p > 0.05).
Adverse events and serious adverse events
Adverse events and serious adverse events (SAEs) reported across the included studies are
presented in Appendix 5, Table 22, for the non-bisphosphonate treatments compared with placebo,
non-bisphosphonate treatments compared head to head and non-bisphosphonate treatments
compared with bisphosphonates.
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Non-bisphosphonates versus placebo: adverse events
Five studies comparing DEN with placebo,41–45,106,111 three studies comparing RLX with placebo,47,50,94 three
studies comparing ROMO with placebo54–56 and five studies comparing TPTD with placebo,57–59,61,63,95 reported
on AEs. Event rates ranged from 37% to 94.3% with DEN, from 27.1% to 96% with RLX, from 12.9% to
78.4% with ROMO and from 21.9% to 91.9% with TPTD. The between-group differences that were reported
were not statistically significant, nor were those that were estimated by ScHARR (p> 0.05).
Non-bisphosphonates versus placebo: serious adverse events
Five studies comparing DEN with placebo,41–45,106,111 three studies comparing RLX with placebo,47,48,50,94 three
studies comparing ROMO with placebo54–56 and six studies comparing TPTD with placebo57–59,61–63,95 reported
on SAEs. Event rates ranged from 2.0% to 25.8% with DEN, from 2.0% to 18.6% with RLX, from 3.2% to
12.9% with ROMO and from 0% to 10.0% with TPTD. The between-group differences that were reported
were not statistically significant, nor were those that were estimated (p> 0.05).
Non-bisphosphonates compared head to head: adverse events
One study that compared TPTD with DEN,64 one study that compared TPTD with RLX66 and two
studies that compared TPTD with ROMO67,68 reported on AEs. Across these studies, event rates for
TPTD ranged from 16.1%64 to 90%,68 and from 75.0%67 to 82.0%68 for ROMO; event rates were
12.1%64 for DEN and 54.6%66 for RLX. The reported and estimated between-group differences were
not statistically significant (p > 0.05).
Non-bisphosphonates compared head to head: serious adverse events
The DATA64 and DATA-Switch65 studies, which compared TPTD with DEN before and after treatment-
switching,64 and two studies that compared TPTD with ROMO,67,68 reported on SAEs. Across these
studies, event rates for TPTD ranged from 6.5%64 to 11.0%95 (22.0% following treatment-switching to
DEN64) and from 8.0%67 to 10.0%68 for ROMO; the event rate for DEN was 3%.64 The estimated
between-group differences were not statistically significant (p > 0.05).
Non-bisphosphonates versus bisphosphonates: adverse events
Of the studies of DEN compared with bisphosphonates, three studies comparing DEN with
ALN,69,71,72,109 one comparing DEN with oral IBN,73 one comparing DEN with RIS74 and one comparing
DEN with ZOL75 reported on AEs. Across these studies, event rates for DEN ranged from 59.6%73 to
80.9%;69 event rates for bisphosphonates ranged from 64.1%71 to 91.3%72 for ALN, and were 56.1%73
for IBN, 69.0%74 for RIS and 62.2%75 for ZOL. Across these studies, both the reported and estimated
between-group differences were not statistically significant (p > 0.05).
Of the studies of RLX compared with bisphosphonates, four studies comparing RLX with ALN reported
on AEs.76,77,80,82 Across these studies,76,77,80,82 event rates ranged from 24% to 75.2% for RLX and from
12.0% to 74.2% for ALN. Across these studies, both the reported and estimated between-group
differences were not statistically significant (p > 0.05).
One study comparing ROMO with ALN reported AEs at 12 months prior to treatment-switching
(75.7% vs. 78.6%) and at 24 months following treatment-switching to ALN (86.6% vs. 88.6%).83 The
estimated between-group difference was p = 0.02 at 12 months in favour of ROMO and was p = 0.05
at 24 months in favour of switching from ROMO to ALN.
Of the studies comparing TPTD with bisphosphonates, one study comparing TPTD with ALN,74 six
comparing TPTD with RIS87,88,91,92,99,101 and one comparing TPTD with ZOL93 reported on AEs. Across
these studies, event rates ranged from 31.9% to 79.1% for TPTD and from 33.3% to 81.4% for RIS;
the event rate was 86% for ALN and 70.1% for ZOL.93 The estimated between-group difference for
the study comparing TPTD with ZOL93 was statistically significantly in favour of TPTD (p = 0.006). All
other reported or estimated between-group differences were not statistically significant (p > 0.05).
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Non-bisphosphonates versus bisphosphonates: serious adverse events
Of the studies comparing DEN with bisphosphonates, three studies comparing DEN with ALN,69,71,72,109
one comparing DEN with oral IBN,73 one comparing DEN with RIS74 and one comparing DEN with
ZOL75 reported on SAEs. Across these studies, event rates for DEN ranged from 2.4% to 16.0%. Event
rates for bisphosphonates ranged from 2.2% to 6.4% for ALN, and were 5.4% for IBN, 17% for RIS and
9.1% for ZOL. The study comparing DEN with IBN73 reported a between-group difference in favour of
IBN of p = 0.046. Across all other studies, both the reported and estimated between-group differences
were not statistically significant (p > 0.05).
Of the studies comparing RLX with bisphosphonates, four studies comparing RLX with ALN reported
on SAEs.76,77,82 Across these studies, event rates ranged from 24% to 75.2% for RLX and from 12% to
74.2% for ALN. Across these studies, both the reported and estimated between-group differences
were not statistically significant (p > 0.05).
One study comparing ROMO with ALN reported on SAEs at 12 months prior to treatment-switching
(ROMO, 12.8% vs. ALN, 13.8%) and 24 months following treatment-switching to ALN (ROMO switched
to ALN, 28.7% vs. continued ALN, 30.0%).83 The estimated between-group differences were not
statistically significant (p > 0.05).
Of the studies comparing TPTD with bisphosphonates, one study comparing TPTD with ALN74 four
comparing TPTD with RIS87,91,92,99,101 and one comparing TPTD with ZOL93 reported on SAEs. Across
these studies, event rates ranged from 11% to 28.9% for TPTD and from 16.6% to 46.8% for RIS,
and were 30% for ALN and 14.6% for ZOL. The estimated between-group difference for the study
comparing TPTD with ZOL93 was statistically in favour of TPTD (p = 0.006). All other reported or
estimated between-group differences were not statistically significant (p > 0.05).
Specific adverse events
Details of VTE, stroke, ONJ and atypical femoral fractures reported by the included studies are
presented in Appendix 7.
Other evidence on adverse events
Denosumab: National Institute for Health and Care Excellence Technology Appraisal – summary of
adverse events evidence The NICE TA20410 found that, although the SmPC indicates that conditions
associated with DEN include urinary tract infection, upper respiratory tract infection, sciatica, cataracts,
constipation, rash, pain in extremity and skin infections, there is no evidence of increased incidence of
cataracts or diverticulitis in postmenopausal women with osteoporosis and that cataracts and diverticulitis
occur only in patients with prostate cancer.21 The SmPC also states that ONJ has been reported in
patients receiving DEN or bisphosphonates, with most cases occurring in people with cancer, but that
some occurred in people with osteoporosis.21
The NICE TA20410 for DEN also found that studies of DEN for other indications have shown that
treatment may be associated with ONJ, but that there is no evidence of this from the clinical studies
of DEN in women with osteoporosis and that that the available clinical evidence indicates that DEN is a
well-tolerated treatment for the prevention of osteoporotic fragility fractures in postmenopausal women.
Denosumab: European Medicines Agency assessment report – summary of adverse events evidence
The European Medicines Agency assessment report for DEN112 found that no cases of ONJ were seen
in the clinical studies it summarised and that there was no increased frequency of cardiovascular events
or abnormal electrocardiographs in DEN-treated patients. The report112 found that, in one study in
postmenopausal women, more subjects receiving DEN than those receiving placebo developed an
infection that necessitated hospitalisation. The report112 found that infections reported among DEN-
treated subjects were characterised by common infections (e.g. pneumonia, urinary tract infection,
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cellulitis, appendicitis and diverticulitis) and were not distinguishable as opportunistic infections, and
that serious infection events tended to occur 6–12 months after the initial administration of DEN.
The report112 found that, in the combined safety analysis across the four pivotal trials, the small
differences noted in individual studies in the number of certain SAEs were not evident across the
postmenopausal women and hormone ablation therapy populations. For other SAEs, the report found
that fatalities in DEN and placebo groups occurred with the same frequencies. In one study of
postmenopausal women, the report observed that significantly more patients in the DEN group than in
the placebo group reported SAEs, particularly osteoarthritis and pneumonia. However, in another study
of postmenopausal women, the report observed that there were no significant differences in SAEs
between treatment groups.
The report112 also found that no single type of malignancy was reported at an increased frequency in
any trial of DEN. However, a significantly greater incidence of cataracts was evident in males receiving
hormone ablation therapy treated with DEN than in males receiving the control.
Raloxifene: National Institute for Health and Care Excellence Technology Appraisal – summary of
adverse events evidence The NICE TA161,11 which included RLX for the secondary prevention of
osteoporotic fragility fractures in postmenopausal women, found that VTE is the most SAE reported
with RLX, with an approximate threefold increased risk of VTE. The incidence of hot flushes, arthralgia,
dizziness, leg cramps, influenza-like symptoms, endometrial cavity fluid, peripheral oedema and
worsening diabetes is also statistically significantly greater with RLX than with placebo. The report also
found that, although the impact that RLX had on cardiovascular disease is unclear, there is evidence
that it lowers serum concentrations of fibrinogen, as well as total and low-density lipoprotein
cholesterol levels, without increasing high-density lipoprotein cholesterol.
Raloxifene: European Medicines Agency assessment report – summary of adverse events
evidence The European Medicines Agency SmPC for RLX24 states that RLX is associated with an
increased risk of venous thromboembolic events in postmenopausal women, which occurred in < 1.1%
of treated patients.
Raloxifene: European Medicines Agency Summary of Product Characteristics – summary of adverse
events evidence The European Medicines Agency public assessment report for RLX113 states that the
most common side effects (seen in more than one patient in 10) are vasodilation and influenza-like
symptoms.
Romosozumab: draft Summary of Product Characteristics The draft SmPC for ROMO12 notes under
special precautions that (confidential information has been removed).
Teriparatide: National Institute for Health and Care Excellence Technology Appraisal – summary of
adverse events evidence The NICE TA161,11 which included TPTD for the secondary prevention of
osteoporotic fragility fractures in postmenopausal women, reported only on AEs associated with TPTD
administered at 40 µg per day compared with placebo, which were nausea and headache.
Teriparatide: European Medicines Agency scientific discussion – summary of adverse events
evidence The European Medicines Agency’s initial marketing scientific discussion for TPTD114 reported
that, in the clinical pharmacology studies, orthostatic hypotension was observed in healthy subjects
following administration of TPTD at doses of more than 20 µg per day; at the proposed therapeutic
dose of 20 µg per day, the most frequently reported AEs were leg cramps, nausea and headache.
The more recent European Medicines Agency variation on the scientific discussion115 concluded that
no further safety issues had been identified from further studies. The European Medicines Agency
SmPC115 states that the most commonly reported adverse reactions in patients treated with TPTD
are nausea, pain in limb, headache and dizziness.
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Health-related quality of life
Five studies86,90,101,116,117 published results of reported HRQoL, measured by a validated assessment tool
(see Appendix 6).
Non-bisphosphonates versus placebo: health-related quality of life
Health-related quality of life was reported as part of the FREEDOM trial.116,118 At 3 years’ follow-up,
there were no significant differences between DEN and placebo groups on the physical function,
emotional status or back-pain dimension of the Osteoporosis Assessment Questionnaire-Short Version
(OPAQ-SV) (see Appendix 6).116
The HRQoL of the RLX and placebo groups did not change significantly from baseline, as measured by
the Women’s Health Questionnaire, the Quality of Life Questionnaire of the European Foundation
for Osteoporosis-41 items (QUALEFFO-41), the EuroQol - Visual Analogue Scale (EQ-VAS) or the
EuroQol-5 Dimensions (EQ-5D) Health State Profile Utility Score (see Appendix 6) at 36 months’
follow-up in the Silverman et al.50 RCT.
Non-bisphosphonates versus bisphosphonates: health-related quality of life
In the Panico et al.86 RCT, both the ALN and TPTD groups improved significantly at 18 months on the
QUALEFFO-41 domains of pain, everyday activities, domestic job, locomotor function, social activities
and health perception, with more improvement (p-value not reported) for TPTD. In the mood domain,
only the TPTD group improved significantly (see Appendix 6).
In the VERO RCT,90 there was no significant difference between the TPTD and RIS groups: both
showed significant improvement in the EQ-VAS. The MOVE RCT101 also reported no significant
difference between the TPTD and RIS groups, which both showed significant improvement in the
physical component of the Short Form questionnaire-36 items.
Network meta-analysis
Methods for the network meta-analysis
A network meta-analysis was conducted for each of the five main fracture types (vertebral,
non-vertebral, hip, wrist and proximal humerus) and for femoral neck BMD.
For consistency with NICE TA464,34 the model for the NMA assumed exchangeable treatment effects
(i.e. a class effect) for bisphosphonate treatments, whereby individual treatment effects are estimated
for each bisphosphonate treatment, but these are assumed to arise from a common distribution
(or class). Unrelated treatment effects were assumed for all non-bisphosphonate interventions. For
comparison, sensitivity analyses were also conducted using a standard random effects model with
unrelated treatment effects for all interventions. Further details of the statistical models are provided
in Appendix 8.
For fracture outcomes, treatment effects are presented as hazard ratios (HRs) relative to placebo, with
a HR of < 1 reflecting a reduced risk of fracture relative to the comparator treatment. To account for
different durations of follow-up across the trials, the model assumed an underlying Poisson process for
each trial arm, with constant event rate.119 For femoral neck BMD, the model for the NMA included a
covariate for the duration of follow-up in each study, and treatment effects are presented as the
difference in mean percentage change from baseline in BMD relative to placebo after 1.6 years of
follow-up (which was the average duration of follow-up in these studies).
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
For fracture outcomes (i.e. binomial data), heterogeneity in treatments effects was characterised as
being mild (SD < 0.1), moderate (0.1 ≤ SD < 0.5), high (0.5 ≤ SD < 1) or extremely high (SD ≥ 1); for
femoral neck BMD, characterisation was based on a conversion as described in Ren et al.120 When
appropriate, heterogeneity in treatment effects was explored by considering potential treatment effect
modifiers using meta-regression.121 Baseline risk/response can be used as a proxy for differences in
participant characteristics across trials that may be modifiers of treatment effect. Adjustment for
baseline risk/response was assessed using the method of Achana et al.122
Potential inconsistency between direct and indirect evidence was assessed using node-splitting.123
All analyses were conducted in the freely available software package WinBUGS (MRC Biostatistics
Unit, Cambridge, UK)124 and R (The R Foundation for Statistical Computing, Vienna, Austria), using the
R2Winbugs125 interface package. Convergence to the target posterior distributions was assessed using
the Gelman–Rubin statistic, as modified by Brooks and Gelman,126 for two chains with different initial
values. For all outcomes, a burn-in of 75,000 iterations of the Markov chain was used, with a further
20,000 iterations retained to estimate parameters. Samples from the posterior distributions exhibited
moderate correlation between successive iterations of the Markov chain, so were thinned by retaining
every 15th sample.
The absolute goodness of fit was checked by comparing the total residual deviance with the total
number of data points included in an analysis. The deviance information criterion (DIC) provides a
relative measure of goodness of fit that penalises complexity and was used to compare different
models for the same likelihood and data.127 Lower values of DIC are favourable, suggesting a more
parsimonious model.
Results are presented using the posterior median treatment effects, 95% credible intervals (CrIs) and
95% prediction intervals (PrIs). The probability of each intervention ranking was computed by counting
the proportion of iterations of the Markov chain in which each intervention had each rank. The
treatment effects of each intervention compared with placebo, together with the median rank and the
probability of being the highest-ranking treatment, are displayed in forest plots (see Figures 6, 8, 13
and 14).
Selection of evidence contributing to the network meta-analysis
Studies included in the systematic literature review were eligible to be included in the NMA.
Characteristics of the studies are summarised in Appendix 4, Table 15, and vertebral fractures are
summarised in Appendix 5, Table 17.
Vertebral fractures may be assessed using either clinical methods or radiographic techniques. For studies
that reported outcomes using multiple methods/definitions, radiographical assessment was selected for
the main analysis, as this was the most widely reported outcome. If radiographical assessment was not
available for a given study, then clinically assessed outcomes were included. Studies that did not state
the assessment method were also included. A sensitivity analysis was performed (SA2) to assess the
impact of including only those RCTs with clinical assessment of fractures.
Outcomes may be reported at different time points across studies. For the primary analysis data set,
the longest reported time point was selected for each study and the difference in trial durations is
accounted for in the statistical model, under the assumption that the fracture event rate in each study
arm is constant over time. To assess this assumption, a sensitivity analysis (SA1) was conducted that
restricted the analysis to studies that reported outcomes at 12 months.
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To contribute to the NMA, studies were required to provide the number of events and the analysed
sample size in each arm. When not reported, these quantities were estimated from other information
(e.g. reported percentages, figures); however, the exact numbers are subject to uncertainty. Sensitivity
was therefore assessed (SA3) by excluding these studies, along with other studies that raised concerns
regarding risk of bias due to blinding issues and early study termination.
A sensitivity analysis was also conducted that excluded studies for which prior treatment with
bisphosphonates was permitted (SA4).
In summary, the following four sensitivity analyses were conducted for vertebral fracture outcomes:
1. SA1 – 12-month data
2. SA2 – clinical assessment
3. SA3 – exclusion for quality issues
4. SA4 – exclusion for prior bisphosphonate treatment.
For each of the sensitivity analyses, results were compared with the main analysis to assess the impact
of the NMA inclusion criteria.
Data for femoral neck BMD outcomes were presented in two different formats: as the percentage
change in femoral neck BMD for each treatment group or as the MD in the percentage change
between treatment groups. In addition, data were presented either numerically or in graphical format.
When available, numerical estimates for each treatment group were selected as the most
accurate summaries of means and variances. For RCTs that presented results for each treatment
group in graphical format, although presenting MDs numerically in the text, MDs were selected.
Six RCTs51,81,82,86,92,104 that did not provide variance estimates (in any format) were excluded.
Results of the network meta-analysis
Network diagrams for fracture outcomes and femoral neck BMD are presented in Figures 5 and 6,
respectively.
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FIGURE 5 Network diagrams for fracture outcomes. (a) Vertebral; (b) non-vertebral; (c) hip; (d) wrist; and (e) proximal
humerus fracture outcomes. (continued )
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FIGURE 5 Network diagrams for fracture outcomes. (a) Vertebral; (b) non-vertebral; (c) hip; (d) wrist; and (e) proximal
humerus fracture outcomes. (continued )
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The effects of each treatment relative to placebo are presented in Figure 7 for all fracture outcomes
based on the primary model, with class effect for bisphosphonate treatments, and unrelated treatment
effects for all other interventions. Model fit is summarised in Table 4. For all outcomes, the model
fitted the data well, with total residual deviance close to the number of data points in the network.
For comparison, results using a standard random effects model with unrelated treatment effects for all
interventions are provided in Appendix 10. Results from the two models were found to be consistent,
with a better fit (as indicated by a lower DIC) provided by the primary model.
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FIGURE 5 Network diagrams for fracture outcomes. (a) Vertebral; (b) non-vertebral; (c) hip; (d) wrist; and (e) proximal
humerus fracture outcomes.
RIS
ALN
ZOL
IBNdaily
IBNmonthly
DEN
ROMO
ROMO/ALN
IBNiv
RLX
TPTD
Placebo
Comparisons
1
2
3
4
5
8
15
FIGURE 6 Network diagram for percentage change in femoral neck BMD.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
Vertebral fractures
Vertebral fracture data were available from 46 RCTs; 45 of these compared two treatments and one
was a three-arm study.79 Nineteen of these studies were included in TA46434 (including one study79 for
which an additional non-bisphosphonate treatment arm was added for the current review). Two further
bisphosphonate studies129,130 not already in TA464,34 and 24 non-bisphosphonate studies were included
from the current review. A total of 11 interventions were assessed, including five non-bisphosphonate
treatments.
The effects of each treatment relative to placebo are presented in Figure 7, and pairwise comparisons
between treatments are provided in Appendix 12, Table 34. All treatments were associated with
statistically significant beneficial treatment effects relative to placebo. TPTD was associated with the
greatest effect (HR 0.23, 95% CrI 0.16 to 0.32), with the highest probability of being the best-ranking
Treatment
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FIGURE 7 Forest plot for all fracture outcomes, main analysis. PB, probability of being the best-ranking treatment.
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treatment (PB) (0.38), and was statistically significantly more effective than all active treatments apart
from DEN, ROMO and ROMO/ALN (see Appendix 12, Table 34). The HR for a randomly chosen study
for a new bisphosphonate is 0.47 (95% PrI 0.19 to 1.16), with the reported prediction interval allowing
for both between-study and between-treatment heterogeneity.
In the network, both direct and indirect comparisons were available for 12 treatment pairs. None of
the comparisons showed significant evidence of inconsistency (see Appendix 13, Table 40).
Four sensitivity analyses were conducted for the main vertebral fracture network. Treatment effects
are provided in Appendix 11, Figure 14, and a summary of model fit and heterogeneity is shown in
Appendix 11, Table 33.
Sensitivity analysis 1 included data reported at 12 months only. Data were available from 29 RCTs,
which assessed a total of 10 interventions, including four non-bisphosphonate treatments. The main
difference in the results is that RIS has a more beneficial treatment effect in the 12-month sensitivity
(HR 0.44, 95% CrI 0.32 to 0.60) than in the primary analysis (HR 0.52, 95% CrI 0.42 to 0.65). In both
analyses, RIS has zero probability of being the best-ranking treatment. It was concluded that the
results are generally consistent with those of the primary analysis, which included the longest duration
of follow-up for each study, and therefore supports the use of a constant HR.
Sensitivity analysis 2 included outcomes assessed by clinical methods only. Data were available from
20 RCTs, which assessed a total of 11 interventions, including five non-bisphosphonate treatments.
It was concluded that the results are generally consistent with those of the primary analysis, which
includes both clinical and morphometric/radiographic outcomes. This supports the assumption that the
treatment effect is not highly influenced by assessment method.
Sensitivity analysis 3 excluded studies for which there was a risk of bias in the reported outcomes.
Four studies86,92,93,95 were excluded owing to blinding issues, two studies62,80 were terminated early and,
for 10 studies,42,43,50,129,131–136 the number of events or analysis sample size was estimated from other
information. Data were available from 30 RCTs, which assessed a total of 10 interventions, including
five non-bisphosphonate treatments. It was concluded that the results are consistent with those of
the primary analysis, which includes all studies, and therefore supports the use of the full network of
46 studies to improve the strength of the network.
TABLE 4 Summary of model fit and heterogeneity between studies and between bisphosphonate treatments, all outcomes
Outcome
Absolute model fit
DIC
Heterogeneity
Dres Data points (n) SD
a (95% CrI) SDtb (95% CrI)
Vertebral 91.21 93 153.31 0.17 (0.02 to 0.37) 0.21 (0.01 to 0.90)
Non-vertebral 74.05 86 128.40 0.08 (0 to 0.24) 0.15 (0.01 to 0.73)
Hipc 38.63 47 70.23 0.12 (0.01 to 0.4) 0.13 (0.01 to 0.53)
Wristc 30.38 31 54.64 0.32 (0.04 to 0.67) 0.17 (0.01 to 0.62)
Proximal humerusc 21.99 26 41.83 0.17 (0.01 to 0.57) 0.21 (0.01 to 0.7)
Femoral neck BMD 144.70 137 258.86 0.85 (0.64 to 1.12) 0.74 (0.25 to 2.26)
Dres,total residual deviance; SDt, standard deviation – treatment.
a Between-study SD.
b Between-bisphosphonate treatment SD.
c For hip, wrist and humerus fractures, weakly informative priors were used for the between-study and between-
treatment SDs, such that SD, SDt ∼half-normal(0, 0.322).
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Sensitivity analysis 4 excluded studies for which prior treatment with bisphosphonates was permitted.
The proportion of individuals receiving prior treatment ranged from 8–73% across the studies.
Data were available from 36 RCTs, which assessed a total of 11 interventions, including five non-
bisphosphonate treatments. It was concluded that the results were consistent with those of the
primary analysis.
Non-vertebral fractures
Non-vertebral fracture data were available from 42 RCTs; 40 of these compared two treatments,
and two were three-arm studies.79,82 Fifteen of these studies were included in TA46434 (including one
study79 for which an additional non-bisphosphonate treatment arm was added for the current review),
and 27 non-bisphosphonate studies from the current review were included. A total of 11 interventions
were assessed, including four non-bisphosphonate treatments.
Pairwise comparisons between treatments are provided in Appendix 12, Table 35. All treatments
were associated with beneficial treatment effects relative to placebo, although the results were not
statistically significant for all treatments. TPTD was associated with the greatest effect (HR 0.58,
95% CrI 0.45 to 0.76), with the highest PB (0.52), although there was insufficient evidence to
differentiate between TPTD and the other active treatments apart from IBN daily, DEN and RLX
(see Appendix 12, Table 35). The HR for a randomly chosen study for a new bisphosphonate is 0.78
(95% CrI 0.60 to 1.08), with the reported prediction interval allowing for both between-study and
between-treatment heterogeneity.
In the network, both direct and indirect comparisons were available for 14 treatment pairs. None of
the comparisons showed significant evidence of inconsistency (see Appendix 12, Table 35).
Hip fractures
Hip fracture data were available from 23 RCTs; 22 of these studies compared two treatments and one
was a three-arm study.79 Eight of these studies were included in TA46434 (including one study79 for
which an additional non-bisphosphonate treatment arm was added for the current review), and 15
non-bisphosphonate studies from the current review were included. A total of nine interventions were
assessed, including five non-bisphosphonate treatments.
Pairwise comparisons between treatments are provided in Appendix 12, Table 36. All treatments
were associated with beneficial treatment effects relative to placebo, although the comparison with
placebo was not statistically significant for RLX. TPTD was associated with the greatest effect (HR
0.35, 95% CrI 0.15 to 0.73), with the highest PB (0.50), although there was insufficient evidence to
differentiate between TPTD and the other active treatments (see Appendix 12, Table 36). The HR for a
randomly chosen study for a new bisphosphonate is 0.64 (95% PrI 0.32 to 1.29), with the reported PrI
allowing for both between-study and between-treatment heterogeneity.
In the network, both direct and indirect comparisons were available for 14 treatment pairs. None of
the comparisons showed significant evidence of inconsistency (see Appendix 13, Table 42).
Wrist fractures
Wrist fracture data were available from 15 RCTs; 14 of these compared two treatments and one
was a three-arm study.79 Six of these studies were included in TA46434 (including one study79 for
which an additional non-bisphosphonate treatment arm was added for the current review), and eight
non-bisphosphonate studies from the current review were included. A total of eight interventions
were assessed, including four non-bisphosphonate treatments.
Pairwise comparisons between treatments are provided in Appendix 12, Table 37. All treatments were
associated with beneficial treatment effects relative to placebo, apart from DEN and RLX. Treatment
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effects for DEN are based only on one small study with two events in the ALN arm and three events in
the DEN arm.70 Treatment effects for these interventions are therefore highly uncertain.
Romosozumab was associated with the greatest effect (HR 0.12, 95% CrI 0.00 to 1.19), with the
highest PB (0.88), although there was insufficient evidence to differentiate between ROMO and the
other active treatments (see Appendix 12, Table 37). The HR for a randomly chosen study for a new
bisphosphonate is 0.84 (95% PrI 0.29 to 2.50), with the reported PrI allowing for both between-study
and between-treatment heterogeneity.
In the network, both direct and indirect comparisons were available for eight treatment pairs. None of
the comparisons showed significant evidence of inconsistency (see Appendix 13, Table 43).
Proximal humerus fractures
Proximal humerus fracture data were available from 13 RCTs, each comparing two treatments. Two of
these studies were included in TA46434 and 11 non-bisphosphonate studies from the current review
were included. A total of eight interventions were assessed, including two bisphosphonate treatments.
Pairwise comparisons between treatments are provided in Appendix 12, Table 38. All treatments were
associated with beneficial treatment effects relative to placebo, apart from RLX. Treatment effects for
RLX are based on one small study77 only, with zero events in the ALN arm and one event in the RLX
arm, and so treatment effects are highly uncertain. Event numbers were generally low in this network
and five of the 13 included RCTs had zero counts in one of the treatments arms.
Romosozumab was associated with the greatest effect (HR 0.10, 95% CrI 0.0 to 3.66), with the highest
PB (0.77), although the treatment effect was highly uncertain and there was insufficient evidence to
differentiate between ROMO and the other active treatments (see Appendix 12, Table 38). Only RIS
was associated with a HR that was statistically significant compared with placebo (HR 0.49, 95% CrI
0.23 to 0.96). The HR for a randomly chosen study for a new bisphosphonate is 0.47 (95% CrI 0.18 to
1.15), with the reported PrI allowing for both between-study and between-treatment heterogeneity.
In the network, both direct and indirect comparisons were available for five treatment pairs. None of
the comparisons showed significant evidence of inconsistency (see Appendix 12, Table 38).
Heterogeneity in treatment effects between studies, and between bisphosphonates, is summarised in
Table 4. The estimates of between-study SD suggest mild (non-vertebral) and moderate (vertebral, hip,
wrist, proximal humerus, femoral neck BMD) heterogeneity in treatment effects between RCTs. The
estimates of between-treatment SD indicate moderate heterogeneity in effects between treatments
for all outcomes (i.e. the effects of the bisphosphonates are relatively similar).
Meta-regressions were conducted to test for different treatment effects separately, according to
the mean age of participants in each study and the proportion of female participants. A common
meta-regression coefficient was assumed for all treatments.121 Based on comparison of models with
and without a covariate for mean age or mean percentage of females, there was no evidence that
treatment effect varied with age or sex. Meta-regression coefficients were not statistically significantly
different from zero, and DIC estimates were higher, implying a less favourable model. A summary of
the results is provided in Appendix 14, Table 45.
Baseline fracture risk can be used as a proxy for differences in participant characteristics across trials
that may be modifiers of treatment effect, and so introduce a potential source of heterogeneity in
the NMA. The effect of baseline fracture risk as a potential treatment-effect modifier was explored
using the method of Achana et al.,122 assuming a common meta-regression coefficient for all treatments
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(as for age and sex), and assuming that the baselines of each study follow a normal distribution with
common mean and between-study variance. Based on a comparison of models with and without an
adjustment for baseline risk, and inspection of the regression coefficients, there was no evidence that
treatment effect varied with baseline risk for any of the fracture outcomes (see Appendix 14, Table 45).
Femoral neck bone mineral density
Femoral neck BMD data were available from 73 RCTs; 69 of these each compared two treatments,
one was a four-arm study68 and three were three-arm studies.72,78,137 Thirty-two of these studies
were included in TA464.34 Three further bisphosphonate studies129,137,138 not already in TA464,34 and
38 non-bisphosphonate studies, were included from the current review. A total of 12 interventions
were assessed, including five non-bisphosphonate treatments. The network is shown in Figure 6.
The effects of each treatment relative to placebo are presented in Figure 8. Pairwise comparisons between
treatments are provided in Appendix 12, Table 39. All treatments were associated with statistically
significant beneficial treatment effects relative to placebo. ROMO/ALN was associated with the greatest
treatment effect (MD 6.08, 95% CrI 4.25 to 7.91), with the highest PB (0.96), and was statistically
significantly more effective than all active treatments apart from ROMO (see Appendix 12, Table 39). The
treatment effect for a randomly chosen study for a new bisphosphonate is 2.34 (95% PrI 1.26 to 3.28),
with the reported PrI allowing for both between-study and between-treatment heterogeneity.
To account for differing trial durations, study duration was included as a trial-level covariate. The
estimated impact on treatment effect of study duration, assuming a common relationship for each
treatment, was 1.09 (95% CrI 0.73 to 1.45), indicating an increase in treatment effect with increasing
duration of study, as expected.
As for fracture outcomes, there was no evidence that treatment effect varied with age, sex or baseline
response (see Appendix 14, Table 45).
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FIGURE 8 Forest plot for percentage change in femoral neck BMD.
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Discussion
Quantity and quality of randomised controlled trial evidence
A systematic literature search identified 7898 records. Fifty-two RCTs of non-bisphosphonates were
included (published in 69 references). Of the 52 RCTs included, 23 were RCTs comparing non-
bisphosphonates with placebo, four were head-to-head comparisons of non-bisphosphonates (of which
one RCT also included a bisphosphonate arm) and 25 were RCTs comparing a non-bisphosphonate with
a bisphosphonate.
Studies varied in quality according to blinding and attrition. However, a sensitivity analysis removing
lower-quality studies from the NMA gave results consistent with those of the main analysis. Most of
the included RCTs were conducted with postmenopausal women, although there were some trials of
men and steroid-induced osteoporosis for interventions for which these were licensed indications.
The majority of included trials typically excluded people with underlying conditions that influence bone
metabolism or people taking medications that influence bone metabolism.
Quality assessment of other domains, particularly methods for randomisation and allocation
concealment, indicated a lack of reporting of the methods used by the included studies to minimise
selection bias, detection bias, attrition bias and reporting bias, resulting in a judgement of ‘unclear risk
of bias’ for many of the domains across the included studies. As a result, we were unable to identify
those studies that were deemed to be at either high or low risk for all quality assessment domains.
Therefore, the degree that methodological biases contributed to study results, and thus the findings of
this assessment report, is unknown for some studies, meaning that the findings of this assessment
report should be interpreted with caution.
Adverse events and health-related quality of life
Across studies reporting on overall mortality, event rates ranged from 0% to 6.4% across non-
bisphosphonates and comparators, and between-group differences were not statistically significant.
None of the included studies reported on mortality following hip fracture, mortality following vertebral
fracture or mortality following any other type of fracture.
Adverse event rates ranged from 12.1% to 94.3% for DEN, from 24.0% to 96% for RLX and from
74.6% to 82% for ROMO across non-treatment-switch studies; AE rates were 86.6% in one study in
which ROMO was switched to ALN, and ranged from 16.1% to 91.9% for TPTD. The majority of
reported and estimated between-group differences were not statistically significant for comparisons
with placebo/no active treatment, head-to-head non-bisphosphonate comparisons or comparisons with
bisphosphonates. This was with the exception of one study reporting a comparison of ROMO with
ALN, for which the estimated between-group difference was p = 0.02 at 12 months in favour of ROMO
and p = 0.05 at 24 months in favour of ROMO switched to ALN, and one study comparing TPTD with
ZOL for which the between-group difference was statistically in favour of TPTD (p = 0.006).
Serious adverse event rates ranged from 2% to 25.8% for DEN, from 2% to 18.6% for RLX, from 3.2%
to 12.9% for ROMO and from 0% to 33% for TPTD. The majority of reported and estimated between-
group differences were not statistically significant for comparisons with placebo/no active treatment,
head-to-head non-bisphosphonate comparisons or comparisons with bisphosphonates. This was with
the exception of one study that compared DEN with oral IBN, for which the between-group difference
was statistically in favour of IBN (p = 0.046).
Disease-specific measures of HRQoL were reported as showing no treatment difference between DEN
and placebo, or between RLX and placebo, but more improvement with TPTD than with ALN, suggested
by one RCT for each comparison. On generic measures of HRQoL, there was similarity for RLX and
placebo (one RCT), and TPTD and RIS (two RCTs).
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Discussion of network meta-analysis results
Network meta-analyses were conducted for vertebral fractures (46 RCTs, 11 interventions), non-
vertebral fractures (42 RCTs, 11 interventions), hip fractures (23 RCTs, nine interventions), wrist
fractures (15 RCTs, eight interventions), proximal humerus fractures (13 RCTs, eight interventions) and
femoral neck BMD (73 RCTs, 12 interventions).
For vertebral, non-vertebral and hip fractures and for femoral neck BMD, all treatments were
associated with beneficial effects, relative to placebo. For both vertebral fractures and percentage
change in femoral neck BMD, the treatment effects were statistically significant at a conventional 5%
level for all treatments. TPTD was associated with the greatest effect for vertebral (HR 0.23, 95% CrI
0.16 to 0.32, PB 0.38), non-vertebral (HR 0.58, 95% CrI 0.45 to 0.76, PB 0.52) and hip fractures
(HR 0.35, 95% CrI 0.15 to 0.73, PB 0.50), whereas ROMO was the most effective for wrist (HR 0.12,
95% CrI 0.00 to 1.19) and proximal humerus fractures (HR 0.10, 95% CrI 0.00 to 3.66), and ROMO/ALN
(HR 0.10, 95% CrI 0 to 3.66, PB 0.77) was the most effective for percentage change in femoral neck
BMD. For wrist and proximal humerus fractures networks, there was less RCT evidence, with treatment
effects for non-bisphosphonate treatments often contributed by single studies with low event numbers,
and so there is considerable uncertainty in treatment effects for certain interventions in these networks.
The reported primary analyses used outcomes reported at the longest available time point for each
study and assume that the fracture event rate is constant over time. Inclusion of studies reporting
vertebral fractures at 12 months only did not provide any evidence to suggest different treatment
effects when the analysis is limited to specific outcome measurement times. Assessment within the
studies of vertebral fractures was based on both clinical and morphometric fractures. Consideration
of the studies reporting clinical fractures did not provide any evidence to suggest different treatment
effects according to assessment method. Similarly, sensitivity analyses conducted to assess the impact
of study quality and prior bisphosphonate treatment did not suggest different treatment effects when
the affected studies were excluded.
The primary analysis model for the NMA assumed exchangeable treatment effects (i.e. a class effect) for
bisphosphonate treatments and unrelated treatment effects are assumed for all non-bisphosphonate
interventions. The treatment effects estimated using the primary model were broadly similar qualitatively
(i.e. direction of effect) and quantitatively (i.e. magnitude of effect) to those estimated using the standard
random-effects model with unrelated treatment effects for all interventions. The estimates of treatment
effects for bisphosphonate interventions from the primary model are slightly closer together than those
from the unrelated treatment effect model (as would be expected); however, the difference is small.
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Chapter 4 Assessment of cost-effectiveness
Systematic review of existing cost-effectiveness evidence
Methods
A comprehensive search was undertaken, with a cut-off date of 16 July 2018, to identify papers
published in 2006 or later that evaluated the cost-effectiveness of DEN, RLX, ROMO or TPTD in any
of the patient groups eligible for risk assessment within CG146.8 Subject headings and keywords for
‘osteoporosis’ were combined with an economic filter without named interventions from 2014 to 2018
to update the searches conducted for TA464.34 In addition, for records between 2006 and 2013, each
of the named non-bisphosphonate interventions (RLX, DEN, ROMO and TPTD) was combined with an
economics search filter to cover the years between 2006 and 2013, as studies for interventions would not
have been retrieved in the review for TA464. The search strategy is provided in Appendix 1. The searches
were limited to those published since the start of 2006 because studies reporting cost-effectiveness
estimates for RLX, DEN and TPTD are assumed to have been captured in the searches and reviews
that informed TA160,12 TA16111 and TA20410 and studies reporting the cost-effectiveness of ROMO
are not expected prior to 2006. However, any relevant studies published prior to 2006 that were
identified in these previous appraisals or in published systematic reviews were included.
The following databases were searched:
l MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) (via Ovid), 1946–2018
l EMBASE (via Ovid), 1974–2018
l Database of Abstract of Reviews of Effects [via Centre for Reviews and Dissemination (CRD)
database], 1995–2015
l Health Technology Assessment Database (via CRD database), 1995–2016
l NHS Economic Evaluation Database (via CRD database), 1995–2015.
Published economic evaluations cited in the consultee submissions were cross-checked with those
identified from the search. Searches of key included studies were undertaken using the Web of Science.
Inclusion/exclusion criteria
Studies were included in the review if they reported full economic evaluations comparing DEN, RLX,
ROMO or TPTD with each other, with bisphosphonates or with no treatment. Studies were included if
any of the population considered would be eligible for risk assessment as per CG146.8 For example,
studies of postmenopausal women were included whether or not they specified that the women had
risk factors, as those aged > 65 years would be eligible for risk assessment under CG1468 even
without risk factors being present.8 Studies that did not assess outcomes using QALYs or that did not
report the incremental cost per QALY of alternative treatment strategies were excluded. Studies that
did not assess the cost-effectiveness in a UK setting were excluded, to ensure consistency with the
NICE reference case.139 Studies that assessed the cost-effectiveness of treatment at non-licensed doses
were also excluded, as were studies that used treatments for other indications such as the treatment
of Paget’s disease or metastatic bone disease. Studies published prior to 2006 were included when
identified in existing NICE appraisals or published systematic reviews, as described previously. Studies
were included only if they were reported as full papers; conference abstracts were excluded from the
review as they present insufficient detail to allow for a rigorous assessment of study quality. Studies
not reported in the English language were also excluded. De novo economic analyses reported in the
consultee submissions were included if they met the inclusion criteria of the review.
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Review methods
The results of the economic searches described above were combined with the results of the searches
conducted for the HRQoL review (see Appendix 11) and a combined sift was conducted to pick up any
cross-relevant papers. The combined database was sifted by title and abstract by one reviewer. The full
papers of studies that potentially met the inclusion criteria were retrieved for further inspection by the
same reviewer. Studies included in the systematic review were examined to determine whether or not
they met the NICE reference case.139 We stated in our protocol that we would critically appraise the
included cost-effectiveness analyses using the checklist published by Philips et al.,140 but this was not
done owing to time constraints.
Results
The study selection process is summarised in the form of a PRISMA flow diagram32 in Figure 9, with the
most common reason for exclusion being that they were non-UK studies.
Quantity of evidence identified
The database search identified 3853 citations across the combined cost-effectiveness and HRQoL
searches. Three additional articles141–143 were identified from the reference list of published reviews.
None of the consultee submissions identified any published analyses not already picked up by the
systematic search, but two reported de novo economic analyses, which were included, giving a total of
3858 citations. Of these, 3837 were excluded at the title and abstract stage and a further 11 were
excluded at the full-paper stage; the most common reasons for exclusion were that they were non-UK
Potentially relevant health economic
studies identified through the
systematic searches
(n = 3853)
Studies excluded at title and
abstract sift
(n = 3837)
Potentially relevant studies retrieved for
detailed inspection
(n = 21)
Relevant economic studies included
in the economic review (n = 10 articles
relating to 8 unique analyses) 
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• Abstract only, n =3
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FIGURE 9 The PRISMA flow diagram of the study selection process: cost-effectiveness review.
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studies or conference abstracts with limited data presented. Appendix 15 provides the reasons for
exclusion for those papers that were included during the title and abstract sift, but were later excluded
after considering the full paper.
A total of 10 articles20,34,100,141–147 were included; however, one paper, Kanis et al.,142 reported a previous
version of the model reported by Stevenson et al.,143 and was therefore not separately extracted, and
two articles provided the Evidence Review Group’s summary of the company submission for TA204.145,147
Therefore, the review included eight unique cost-effectiveness analyses. Additional documents related
to TA20410 were downloaded from the NICE website to allow a full examination of this model [note
that this model is referred to as ‘Waugh et al.147’ to avoid confusion with the Amgen submission for
the current multiple technology appraisal (MTA)]. The model described in the Amgen submission
for the current MTA100 was an adaptation of the model described in the company submission for
TA204,145,147 but these were separately extracted owing to differences between the decision problems.
Although the assessment report for TA464 by Davis et al.34 did not strictly meet the inclusion criteria
for this review, as it did not include any non-bisphosphonate interventions, it has been included as
it was stated in the protocol for this MTA that, to ensure consistency across related appraisals, the
economic analysis conducted to inform TA464 was intended to be used as the starting point for any
cost-effectiveness analysis conducted by the assessment group (AG). Therefore, it was necessary to
compare this model with the relevant published analyses to identify any significant areas of difference.
Study characteristics
The characteristics of the included studies are summarised in Table 5. Here we describe the key
differences between the models in terms of their population, structure and assumptions.
Population and subgroups
Six of the included studies20,141,143,144,146,147 were of postmenopausal women. The company submission by
UCB S.A. restricted the population modelled to postmenopausal women at imminent risk of fracture,
which it characterised as those with a recent major osteoporotic fracture.20 Although no results were
presented for men, UCB S.A.20 argued that the results would also be applicable to men, as it is assumed
that men will not respond differently to postmenopausal women. The AG model for TA464 (Davis et al.34)
included all patients eligible for risk assessment under CG146,8 thereby including both men and women,
those with steroid-induced osteoporosis and those with and those without a prior fracture. However,
Davis et al.34 examined subgroups according to absolute fracture risk rather than according to any of
these specific patient characteristics. The submission by Amgen Inc.100 did not restrict the population to
postmenopausal women; instead, it included people eligible for risk assessment under CG1468 at varying
levels of absolute fracture risk. This was similar to the approach taken in TA464,34 except that the only
risk cut-off points examined in the Amgen Inc.100 submission were 10-year risks of 10% and 20%, whereas
Davis et al.34 reported outcomes for 10 risk deciles and also used regression to estimate thresholds for
cost-effective intervention when treating risk as a continuous variable.
Several of the analyses presented results separately for those with and those without a prior fracture141,
143,144,147 or presented separate estimates for subgroups defined by combinations of age and T-Score,147
age and number of risk factors146 or T-Score and risk factors.147 Two studies34,146 estimated the threshold
for cost-effective intervention and expressed this using 10-year risk of fracture. Two studies20,100
provided results for patients with a specific level of absolute fracture risk, but explored alternative
specified levels of absolute fracture risk in scenario analyses.
None of the included economic evaluations provided an incremental analysis across all of the
interventions and comparators identified in the scope of this appraisal. Two141,144 provided comparisons
of RLX versus no treatment. Strom et al.146 compared DEN with bisphosphonates (ALN and RIS) and
no treatment. Stevenson et al.143 conducted an incremental analysis across multiple technologies, but
did not include DEN or ROMO. The submission by UCB S.A.20 did not provide a comparison with oral
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TABLE 5 Characteristics of included studies: cost-effectiveness review
First author
Population and
interventions
Type of
evaluation Perspective
Time
horizon
Cost year
and cost
discount
rate Cost source
Benefits
population
and benefits
discount rate
Benefits source
and benefits
instrument Effectiveness data
Kanis 2005141
(MORE)
l Postmenopausal
women – subgroups
for those with and
those without
prior fracture
l RLX, no treatment
Cohort Markov
model
UK NHS Not stated l 2002
l 6%
Published estimates
and reference costs
l Patient only
l 1.5%
EQ-5D in
Swedish patients
using UK
valuation set
Single study estimate
(MORE). In addition
to fracture outcomes,
includes beneficial
effect on breast
cancer and heart
disease and adverse
effect on VTE
Stevenson
2005143
l Postmenopausal
women
l Bisphosphonates,
RLX; TPTD;
no treatmenta
Patient-level
Markov model
UK NHS and
PSS
Lifetime l 2001/2
l 6%
Fracture costs were
based on published
estimates that were
uplifted
l Patient only
l 1.5%
l Observational
data
l EQ-5D
Systematic review
and meta-analysis
conducted by authors
Kanis 2008144
(BONE)
l Postmenopausal
women
l Bisphosphonates,
RLX,a no treatment
Cohort Markov
model
UK NHS
(includes nursing
home admission)
Lifetime l 2004/5
l 3.5%
Published literature
(UK estimates of
length of stay and
cost per bed-day and
Swedish estimates of
ratio of outpatient to
inpatient costs)
3.5% EQ-5D in
Swedish patients
using UK tariff
Published systematic
review and meta-
analysis including
breast cancer
reduction for RLX
Scotland145/Waugh
2011147/Amgen
submission for
TA204147
l Postmenopausal
women unable
to take, comply
with or tolerate
bisphosphonates –
70 years, T-score of
–2.5; subgroups of
those with and
those without
prior fracture
l DEN, RLX, i.v.
bisphosphonates,
TPTD, oral
bisphosphonates,
no treatmenta
Cohort Markov
model
UK NHS and
PSS
Lifetime l 2009
l 3.5%
HRG costs and BNF
drug prices
l Patients
l 3.5%
EQ-5D using UK
tariff
Company’s
systematic review
and meta-analysis
with indirect
comparison (Bucher
method148)
A
SSE
SSM
E
N
T
O
F
C
O
ST
-E
F
F
E
C
T
IV
E
N
E
SS
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
a
lslib
ra
ry
.n
ih
r.a
c.u
k
5
2
First author
Population and
interventions
Type of
evaluation Perspective
Time
horizon
Cost year
and cost
discount
rate Cost source
Benefits
population
and benefits
discount rate
Benefits source
and benefits
instrument Effectiveness data
Strom 2013146 l Postmenopausal
women – subgroups
by fracture risk
l DEN, ALN, RIS,
no treatmenta
Cohort Markov
model
UK NHS Lifetime l 2010
l 3.5%
Published literature
(UK estimates of
length of stay and
cost per bed-day and
Swedish estimates of
ratio of outpatient to
inpatient costs)
l Patient only
l 3.5%
EQ-5D in
Swedish patients
using UK tariff
Systematic review
and meta-analysis
Davis 201634 l People eligible for
risk assessment as
per CG1468
l Bisphosphonates,
no treatment
Discrete event
simulation
(patient-level
model to
capture
individual’s
history)
UK NHS and
PSS
Lifetime l 2014
l 3.5%
NHS reference costs,
PSSRU unit costs,
national drug tariff
and database of
generic drug costs
l Patient only
l 3.5%
EQ-5D using UK
tariff from
published studies
identified by
systematic
review
Author’s systematic
review and NMA
UCB S.A. 201820 l Women at
imminent risk of
fracture (recent
major fracture,
10-year risk
of 30%)
l ROMO, ALN, RIS,
i.v. ZOL, TPTD, DEN
Patient-level
Markov model
UK NHS and
PSS
Lifetime l 2017/18
l 3.5%
NHS reference costs,
PSSRU unit costs,
national drug tariff
(same source cited
for fracture costs but
different figures
provided)
l Patient only
l 3.5%
l Observational
study
l EQ-5D using
UK tariff
Company’s
systematic review
and NMA
Amgen Inc.
2018100
l People eligible for
risk assessment
as per CG1468
who cannot
take oral
bisphosphonates
l DEN, RLX, no
treatment
(i.v. ZOL and oral
bisphosphonates in
secondary analysis)
Cohort Markov
model
UK NHS and
PSS
Lifetime l 2016/17
l 3.5%
NHS reference costs,
PSSRU unit costs,
national drug tariff
and database of
generic drug costs
(costs as for TA46434
except changes in
monitoring and
administration costs)
l Patient only
l 3.5%
l Systematic
review
in TA46434
l EQ-5D using
UK tariff
Company’s review
and NMA
BNF, British National Formulary; HRG, Healthcare Resource Group; PSS, Personal Social Services.
a Other non-relevant interventions were also modelled, for example oestrogen, strontium ranelate.
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3
or i.v. IBN, but included all other comparators. The Amgen Inc. submission100 stated that DEN was
primarily used in primary care by patients unable to take an oral bisphosphonate; therefore, the main
comparator was RLX or no treatment. However, secondary analyses were provided comparing DEN
with i.v. ZOL and oral bisphosphonates. The company submission for TA204, described by Waugh
et al.,147 also restricted the decision problem to patients unable to take bisphosphonates. Their primary
analysis compared DEN with RLX and no treatment, but they also included comparisons with i.v.
IBN, i.v. ZOL, TPTD and oral bisphosphonates in secondary analyses. Davis et al. included only
bisphosphonates and no treatment in their incremental analysis, which was consistent with the
scope of TA464.34
Model structure and outcomes modelled
Seven studies20,100,141,143,144,146,147 used a Markov model framework: five used a cohort-level modelling
approach and two20,143 used a patient-level Markov simulation. Four20,100,146,147 of the Markov models
employed a 6-monthly cycle length, whereas the other three141,143,144 used an annual cycle length.
The AG for TA464 used a discrete event framework, which is a patient-level simulation that does
not require the use of fixed time cycles. All of the studies included separate health states for hip
fracture and vertebral fracture, and all of the studies incorporated long-term consequences for
these two fracture sites either by incorporating post-hip and post-vertebral fracture health states
in a cohort-level model or by tracking patient’s prior fracture status in a patient-level simulation.
All studies included wrist fracture. All but one study141 included fractures at sites other than the
hip, wrist and vertebrae, but some34,100,141,143,147 modelled wrist fractures separately to other fracture
sites. One study20 bundled wrist fracture together in a health state with fractures at other sites.
Davis et al.34 incorporated separate health states for wrist and proximal humerus fracture; fractures
at additional sites (femoral shaft, humeral shaft, pelvis, scapula, clavicle, sternum, ribs, tibia and fibula)
were incorporated by increasing the incidence of fractures at the four main sites (hip, wrist, vertebral
and proximal humerus), with the allocation of these additional fractures to the main fracture type
expected to have similar costs and utilities. The majority of the other studies included fractures at
additional sites in a single health state, with the costs, mortality and utility estimates being based on
either a weighted mean across the included sites or an assumption that the consequences would be
consistent with those for a known fracture site such as the wrist.
The use of a cohort-level approach meant that, in four models,141,144,146,147 future fractures were restricted
for a patient experiencing a hip or vertebral fracture to ensure that patients did not transition to a health
state with lower costs or better quality of life when experiencing a subsequent fracture that was less
severe than the initial fracture experienced. In general, the approach taken was that patients experiencing
a hip fracture were only at risk of subsequent hip fractures and patients experiencing a vertebral fracture
were only at risk of hip or subsequent vertebral fractures. One model,100 which used a similar hierarchical
Markov structure, adjusted for the missing fracture outcomes in patients having hip and vertebral
fractures by estimating the ‘downstream’ costs of subsequent fractures that were prevented by the
hierarchical Markov structure. It was not necessary to restrict the sequence of fractures experienced in
either of the patient-level simulations, as costs and utilities can be made dependent on an individual’s
entire history. However, Davis et al.34 restricted the number of fractures possible for each fracture
type to one per bone, with an additional limit of four vertebral fractures, four rib fractures and two
pelvic fractures.
Three studies included non-skeletal health outcomes, with three141,143,144 including breast cancer,
two141,144 including coronary heart disease (CHD) and two141,144 including either stroke or VTE. All
except one study141 reported including an increased risk of nursing home admission after hip
fracture.20,34,100,143,144,146,147 None of the studies included an increased risk of nursing home admission
following fractures at other sites, but Davis et al.34 presented a sensitivity analysis in which an
equivalent rate of nursing home admission occurred for both vertebral fracture and hip fracture.
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Treatment duration
Four of the studies modelled a maximum treatment duration of 5 years for all treatments.141,144,146,147
Davis et al.34 assumed a 5-year intended treatment duration for all bisphosphonates except i.v. ZOL,
for which a 3-year intended treatment duration was assumed. Stevenson et al.143 assumed a 5-year
treatment duration for all treatments except TPTD, for which the treatment duration was assumed to
be 18 months. One study (Amgen Inc.100) assumed a treatment duration of 10 years for DEN, 3 years
for ZOL and 5 years for RLX. Another study assumed a 4-year treatment duration for all interventions
except DEN, which was assumed to be given lifelong (UCB S.A.20) (although it was noted that, in the
actual model, persistence data were set to zero from 5 years, so it is unclear what treatment duration
was actually implemented).
Treatment initiation, monitoring, and administration
All but one of the studies (Davis et al.34) incorporated resource use for the monitoring of treatment.
None of the studies included any costs for the administration of oral therapies. However, there was
inconsistency across the studies for the administration costs for s.c. and i.v. therapies. The exact costs
for administration and monitoring are discussed further in Treatment initiation, administration and
monitoring, where we also describe the approach taken in the AG analysis.
Persistence
Persistence was included in either the base-case or sensitivity analysis in six of the models.20,34,100,144,146,147
In Davis et al.,34 the persistence data applied in the model were identified from a review of systematic
reviews. In the other models, one146 used published estimates but did not describe how they were
identified, one20 used a mixture of published and unpublished data, two100,147 used data on file from an
unpublished study and one applied the assumption made in the model that informed TA160 and TA161.149
Many of the estimates came from analyses of real-world data sources, such as administrative databases,
with three models incorporating estimates from a large UK primary care database [Clinical Practice
Research Datalink (CPRD)/General Practice Research Database (GPRD)].20,100,147 A full discussion of
the data sources used in these models and the choice of data source for the AG model is provided in
Treatment persistence.
Treatment effectiveness beyond the treatment period
All of the studies assumed that treatment effectiveness falls linearly over time after patients
discontinue treatment. The period between treatment discontinuation and when the treatment effect
has fallen to zero is known as the offset period. Three studies assumed an offset period equal to the
treatment duration for all interventions.141,144,146 Davis et al.34 and Stevenson et al.143 made the same
assumption for all but one intervention. Owing to the shorter treatment period for TPTD (18 months),
Stevenson et al.143 applied the full treatment effect for 3.5 years after the end of treatment, and this
was noted as a very favourable assumption. Davis et al.34 assumed a longer offset (7 years) for ZOL,
such that the treatment effect fell to zero by 10 years, despite the shorter treatment duration of
3 years. In the base-case analysis, in which the treatment persistence was < 3 years, the same ratio
of offset period to treatment duration was applied by Davis et al.34 (i.e. offset = 7/3 × treatment
persistence). Two studies assumed a 1-year offset for all treatments,100,147 and one study20 assumed
an offset equal to treatment duration for all interventions except DEN, for which it was set to 1 year.
The evidence regarding offset periods and the choice of offset period assumed in the AG model is
discussed further in Offset period.
Adverse events
All of the studies included some AEs in either their base-case or their sensitivity analyses, but there was
considerable inconsistency between the studies in terms of the AEs included. Three papers included
gastrointestinal (GI) AEs in their base-case analysis20,34,147 and two included them in a sensitivity
analysis.144,146 The model reported in the company submission by Amgen Inc. for TA204 (Waugh et al.147),
included GI AEs for oral bisphosphonates, but these were not included in the updated version of this
model reported in the company submission by Amgen Inc. for the current appraisal.100 Stevenson et al.143
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did not include any GI AEs for bisphosphonates in their analysis, but their model was later adapted to
include GI AEs for bisphosphonates in an analysis by Stevenson and Davis149 conducted to inform TA160
and TA161. There was some consistency in the assumptions regarding GI AEs across the various models,
with three models144,146,147 using the assumptions from TA160 and TA161 and one20 using assumptions
consistent with those applied in TA464 (Davis et al.34), which themselves were very similar to those
applied by Stevenson and Davis.149 Davis et al.34 included a one-off QALY loss to account for influenza-
like symptoms following administration of i.v. bisphosphonates. None of the other studies included any
AEs for i.v. bisphosphonates. Two studies included VTE as a side effect of RLX.141,144 Amgen Inc. included
cellulitis (a common bacterial skin infection) as an AE of DEN in the model reported in the company
submission for TA204,147 but did not include any AEs for DEN in the model reported in the company
submission for the current appraisal.100 Strom et al.146 did note that skin infections are more frequently
reported for DEN, but did not include cellulitis in their model. No studies reported including AEs for
ROMO or TPTD. None of the studies included atypical femoral fracture or ONJ as AEs.
Mortality following fracture
Davis et al.34 incorporated post-hip fracture mortality by assuming that a fixed proportion (which was
sex and age specific) of patients experiencing hip fracture would die 3 months after fracture. This was
based on evidence from a study by Tosteson et al.,150 which found that the excess risk of mortality
was limited to the first 6 months after fracture when adjusting for a number of prognostic factors
including pre-fracture health status, and evidence from a study by Abrahamsen et al.,151 which found
that approximately half of all excess mortality had occurred at 3 months. Davis et al.34 incorporated
an increased risk of death following hip and vertebral fracture and assumed no increased risk for
fractures at other sites. The same temporal pattern of risk was assumed for vertebral fractures.
Four of the other models identified in the review20,100,146,147 applied HRs to the general population
mortality rate, with the HRs for hip and vertebral fracture applied for 8 years following fracture and
the HRs for non-hip non-vertebral fractures applied for 1 year following fracture. The data inputs
appear to be consistent across these four models, with the primary source cited being Johnell et al.152
for clinical vertebral fractures, Jönsson et al.153 for hip fractures and Barrett et al.154 for ‘other fractures’.
These four models all assumed that only 30% of the increased risk was attributable to the fracture itself
and downweighted the additional mortality risks accordingly. Kanis et al.141 cited the same data source152
for mortality after vertebral fracture, but details are not provided on the duration over which the HR is
applied or the proportion of excess risk that is considered attributable to fracture. Kanis et al.144 cited
alternative sources155–157 and stated that 30% was assumed to be causally related, but does not describe
the duration over which the HRs are applied. Stevenson et al.143 used unpublished estimates from the
Anglian audit of hip fracture,158 which reported mortality risk for several different age bands, and
adjusted these to remove those deaths not causally related to hip fracture using the data from Parker
and Anand.157 Stevenson et al.143 based their risk of death following vertebral fracture on a study by
Center et al.159 Stevenson et al.143 included a twofold increase in mortality following proximal humerus
fracture, citing Johnell et al.,152 but assumed no increased risk of mortality following wrist fractures. None
of the published models identified sources of data that were more recent than those identified by the
AG during TA464.34
Consistency with the National Institute for Health and Care Excellence reference case
All of the included studies measured direct health effects for patients, and none included any benefits for
carers. All of the studies reported using published estimates of utility following fracture from studies that
had measured utility using the EQ-5D using the UK general population valuation set. There was some
inconsistency in the approach taken to estimating utility following nursing home admission, with one
study147 reporting no additional disutility, one study143 reporting using a value based on an expert panel,
one study34 reporting a value based on the EQ-5D and several studies not reporting the approach taken to
estimating utility values for nursing home admission.20,100,141,144,146
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One study141 based its effectiveness estimate on a single RCT and reported a comparison only between
the interventions included in the RCT (RLX vs. no treatment). The other studies all sourced their
effectiveness estimates from a systematic review and meta-analysis, although only the three most
recent models20,34,100 used NMA to estimate the relative treatment between active comparators.
One study147 used the method published by Bucher et al.148 to conduct an indirect comparison. Two
studies143,146 present incremental analyses that appear to be based on naive indirect comparisons based
on equivalent outcomes for patients receiving placebo. The remaining study144 provided comparisons
only against no treatment.
Five studies explicitly reported using an NHS and Personal Social Services (PSS) perspective.20,34,100,143,147
Three studies reported taking a health-care perspective,141,144,146 but two of these144,146 also included
nursing home costs, which are likely to fall under PSS rather than NHS in a UK context, although some
may also fall under societal costs if families pay privately for nursing home care. Discounting consistent
with the current NICE reference case (3.5% for both costs and QALYs)139 was applied in all but two
studies,141,143 in which discounting was applied at rates consistent with previous NICE methods guidance
(6% for costs and 1.5% for QALYs). The time horizon is not explicitly stated for the 2005 publication by
Kanis et al.,141 but, otherwise, all of the included economic evaluations incorporated a lifetime horizon,
although, in the analysis by Stevenson et al.,143 the Markov model was used for the first 10 years and
then additional calculations were used to estimate QALYs gained over the remaining lifetime.
Quality and applicability of studies
The only analyses considered to be broadly consistent with the NICE reference case were the models
described in the submissions by UCB S.A.20 and Amgen Inc.100 and the analysis by Davis et al.,34 which
informed TA464.9 None of the other models provided an incremental analysis informed by a systematic
review and NMA, which is a significant deviation from the NICE reference case, and may be a potential
source of bias. However, it is noted that the analysis by Davis et al.34 was not relevant to the decision
problem; it was included purely to allow comparisons to be made between the published models and
the model we intended to adapt for this appraisal.
Study conclusions
Owing to the concerns regarding applicability to the decision problem and consistency with the NICE
reference case, for several of the studies34,141,144–147 included in the review, results are summarised here
only for the UCB S.A.20 and Amgen Inc.100 submissions.
In the Amgen Inc. company submission,100 which investigated the cost-effectiveness of DEN in a population
of patients with a 10-year fracture risk of 20%, DEN was found to be associated with an incremental
cost-effectiveness ratio (ICER) of £27,792 per QALY, compared with RLX, and an ICER of £27,363 per
QALY compared with no treatment. At the same risk of facture, DEN was also found to dominate ZOL.
In the UCB S.A. submission,20 which investigated the cost-effectiveness of a treatment sequence of
1 year of ROMO followed by 4 years of ALN (ROMO/ALN), in a population of postmenopausal
women with a 10-year fracture risk of 30%, ROMO/ALN was found to be associated with an ICER of
(confidential information has been removed) per QALY compared with ALN alone, and (confidential
information has been removed) per QALY compared with no treatment. The UCB S.A. submission20 also
presented scenario analyses comparing ROMO/ALN with RIS, ZOL, RLX, DEN and TPTD (administered
for 18 months and 24 months). The ICERs for ROMO/ALN when compared with these alternative
comparators were (confidential information has been removed) and dominating (ROMO/ALN had more
QALYs and a lower cost than TPTD for both the 18- and 24-month treatment durations), respectively,
when using the Patient Access Scheme (PAS) price for ROMO.
Review conclusions
The review has identified that there are no published cost-effectiveness studies that compare all of the
interventions and comparators specified in the scope of this appraisal across the broad population specified
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in the scope, which is patients eligible for risk assessment under CG146.8 Although the Amgen Inc.100
and UCB S.A.20 submissions provide an incremental analysis for the majority of the interventions and
comparators specified in the scope (neither compared with i.v. IBN), their analyses are restricted to high-risk
subgroups of the population. However, this review was useful in identifying areas where the model used
in TA46434 differed from the models included in the review. These are discussed further in Independent
economic assessment, where we describe the changes made to the model reported by Davis et al.34
Independent economic assessment
Methods
Having considered the review of published models and the models included in the company
submissions, the AG decided to adapt the model used to inform TA464 (Davis et al.34) rather than
developing a de novo model for this assessment. However, based on the review of models, the AG
recognised that there were several areas where it would be useful to consider whether or not the
model should be updated or adapted. The areas identified for consideration were as follows:
l treatment persistence – the duration of time the patient persists with treatment
l offset period – the period between when treatment ends and the treatment effect reaches zero
l incorporation of AEs specific to non-bisphosphonates
l resource use associated with monitoring and administration of treatments
l utility values following fracture
l drug prices
l disease costs (i.e. fracture, nursing home admission).
It was not feasible to conduct a full systematic review of the literature to inform each of these updates
to the model. Instead, the AG considered any additional sources of evidence provided in the company
submission or cited in the published cost-effectiveness studies. This was supplemented by ad hoc searches
using Google Scholar (Google Inc., Mountain View, CA, USA) to identify any recent systematic reviews. A
more rigorous approach was taken to identifying updated estimates of utility following fracture. For this,
we conducted a full systematic search for studies reporting utility pre and post fracture, as measured by
the EQ-5D. The aim of this review was to update the review conducted for TA464 by Davis et al.34
In addition to these updates, the AG also identified that changes to the Visual Basic for Applications
(VBA) code would be needed to (1) increase the number of treatment strategies that can be modelled,
(2) allow for drug-specific offset periods and (3) allow for sequences of treatments to be modelled.
Unless otherwise stated, all other aspects of the model remain unchanged from the model used to
inform TA464,9 as described in the Assessment Report for TA464 (Davis et al.34), with the additional
change regarding nursing and residential care home costs described in the addendum provided before
the second committee meeting.160 The other changes documented in the addendum are superseded by
the updated NMA reported in Chapter 3, Network meta-analysis, and the need to update drug costs to
reflect current prices.
Model structure
The ScHARR osteoporosis model (used in TA46434) is a discrete event simulation (DES), which simulates
the clinical events occurring over the lifetimes of individual patients with heterogeneous characteristics.
A patient-level simulation approach was chosen to allow the future events experienced by patients to
be affected by prior events such as incident fractures. We chose to model a heterogeneous population
because we anticipated that certain patient characteristics, such as age, would be non-linearly related to
cost-effectiveness. For example, older patients are more likely to have experienced a prior fracture, and
may therefore have a lower quality of life at baseline, and they are also more likely than younger patients
to be admitted to a long-term nursing or residential care home following a hip fracture. Both of these
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factors will influence the costs and QALYs that can be gained from avoiding a fracture. In this situation,
the cost-effectiveness for a patient with average characteristics is not the same as the average cost-
effectiveness when taking into account the distribution of that characteristic across the population.
In general, in a DES model, a patient’s progression through the model is determined by the events that
occur, rather than by the health states they occupy. Figure 10 shows the clinical events that can occur
during a patient’s lifetime, with the arrows showing which events can occur following other events
(note that this is not a state-transition diagram, as patients do not reside in the state defined by the
most recent event until the next event is experienced). In the ScHARR osteoporosis model, the main
clinical events were fracture, death and new admission to residential care. Fractures at different sites
were processed using separate fracture events for hip; wrist; vertebral and proximal humerus. These
are the sites most strongly associated with osteoporosis and these are the fracture sites included by
both the QFracture and FRAX risk calculators. Fractures at additional sites (e.g. femoral shaft, humeral
shaft, pelvis, scapula, clavicle, sternum, ribs, tibia and fibula) have been incorporated by increasing the
incidence of these four event types, rather than by adding additional competing events.
In a DES, no changes are made to a patient’s attributes between events, but the event list that
determines the future events experienced can be resampled each time an event occurs to incorporate
any changes in patient characteristics. Dummy events were included in the model to ensure that
patient attributes were updated at 1 year after the start of the model, at the end of treatment, at the
end of the offset period, at 5 years, at 10 years and 1 year after each incident fracture. Linear
approximation is used to adjust for age-related changes in utilty between events.
Utility in the model is based on a combination of sex, age, fracture history and residential status
(community dwelling or institutionalised). Separate utility multipliers and costs are applied to the first
and subsequent years after fracture to reflect the differences between the acute and chronic impact of
Fracture-related death
Residential care admission
Vertebral fracture
Proximal humerus fracture
Wrist fracture
All-cause mortality
Hip fracture
FIGURE 10 Clinical events that can occur during a patient’s lifetime in the DES.
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fracture. The chronic cost is set to the maximum chronic cost for all fracture events experienced so far.
Therefore, the maximum chronic cost for any individual is the cost for institutionalised patients.
Drug costs are applied from the start of the simulation until the end of the treatment period and are
assumed to accrue at a constant rate across time. Death does not incur any additional costs in the
model, but the acute cost of fracture is incurred for both fatal and non-fatal fractures.
The model also incorporates the following structural assumptions:
l There are no restrictions on the sequence of fractures that can be experienced.
l The maximum number of fractures that can be experienced is limited to one per bone (i.e. two
hip fractures), with an additional limit of four vertebral fractures, four rib fractures and two
pelvic fractures.
l Death attributable to fracture occurs 3 months after fracture, with other fracture events possible
during this period, but no mortality from non-fracture-related causes.
l Incident fractures increase the risk of future fractures.
l A fracture event occurring < 1 year after a previous event supersedes the dummy event used to update
patient attributes 1 year after fracture, thus reducing the acute period for the earlier fracture.
l Nursing home admission can occur only following fracture; therefore, patients who are community
dwelling at the start of the simulation do not transfer to nursing home care as they age unless this
is simulated to occur following a fracture.
A brief overview of the key features of the ScHARR osteoporosis model used in TA46434 is provided in
Table 6, alongside a description of the key changes to the model since TA464. The only deviation from
the NICE reference case to note is that the utility estimates for ONJ have been valued using the US
rather than the UK valuation set for the EQ-5D.
Population
The population is patients eligible for risk assessment under CG146,8 as per the final NICE scope
(see Chapter 1, Measurement of disease). It should be noted that this includes both men and women,
those with and those without a prior fracture, those with steroid-induced osteoporosis, those with
secondary osteoporosis and those with other risk factors for fragility fracture. CG146 recommends
that either FRAX30 or QFracture31,163,164 be used to assess the absolute risk of fracture. To explore
whether or not the most cost-effective treatment varies for patients at different levels of absolute
fracture risk, we report the variation in incremental net monetary benefit (INMB) across risk using
TABLE 6 Overview of the modelling methodology and key data sources
Model feature Description of model in TA46434 Description of revised model
Decision problem To assess the cost-effectiveness of
bisphosphonates compared with no
treatment at varying levels of absolute
fracture risk as defined by the FRAX and
QFracture risk assessment tools
To assess the cost-effectiveness of
non-bisphosphonates compared with
bisphosphonates and no treatment at
varying levels of absolute fracture risk as
defined by the FRAX and QFracture risk
assessment tools
Type of economic evaluation Cost-effectiveness analysis with benefits
expressed as QALYs
No change
Population/subgroups l The model simulates the heterogeneous
patient population eligible for risk
assessment under CG1468
l The population is stratified into 10 risk
categories and results are presented for
each risk category. This is done once
using FRAX and once using QFracture
No change (see Population)
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TABLE 6 Overview of the modelling methodology and key data sources (continued )
Model feature Description of model in TA46434 Description of revised model
Interventions l ALN
l RIS
l Oral IBN
l i.v. IBN
l i.v. ZOL
l DEN
l RLX
l ROMO
l TPTD
l (see Interventions and comparators)
Comparators No treatment No treatment and the bisphosphonates
listed as comparators for TA464
(see Interventions and comparators)
Perspective NHS and PSS No change
Model type DES with heterogeneous patient population No change
Model events Clinical events are fracture, death (all-cause
mortality and fracture-related mortality) and
nursing home admission. There are four
possible fracture events (hip, wrist, vertebral
and proximal humerus), with fracture at
other sites included by increasing the
incidence of these events
Dummy events are used to update
attributes 1 year after fracture and to
update the fracture risks once treatment
finishes
No change (see description of model
events in Model structure)
Time horizon Lifetime (up to the age of 100 years) No change
Duration of treatment Mean duration of persistence with
treatment from observational studies
Data sources for persistence with oral
bisphosphonates have been updated.
Additional persistence data have been
identified for non-bisphosphonates
(see Treatment persistence)
Natural history Time to fracture is based on the estimate
of absolute fracture risk for major
osteoporotic fractures (hip, wrist,
proximal humerus and vertebral) provided
by either QFracture or FRAX, which is
uplifted to include fractures at additional
sites. The distribution of fractures across
different sites is based on incidence data
from Sweden. The increased risks of
fracture following incident fracture are
based on a published systematic review
No change
Effectiveness The HRs from the systematic review and
NMA are applied for the duration of
treatment. Some effectiveness is assumed
to persist beyond treatment during the
‘offset period’. A linear decline in treatment
effect is assumed during this time
l The NMA has been updated to include
studies for non-bisphosphonates
and any new bisphosphonates
studies published since TA464
(see Effectiveness data)
l Data have been identified on the
duration of treatment effect after
treatment cessation for the non-
bisphosphonates (see Offset period)
l No changes were made to offset
assumptions for bisphosphonates
(see Offset period)
AEs Upper GI side effects for oral
bisphosphonates and influenza-like
symptoms for i.v. bisphosphonates are
included by applying one-off cost and
QALY deductions in the first month of
treatment
Additional AEs have been incorporated
for the following (see Adverse events):
l ONJ
l VTE
l Cellulitis
continued
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two approaches. First, we report outcomes for 10 risk categories, based on deciles of absolute fracture
risk. Second, we use regression to determine the relationship between INMB and absolute risk as a
continuous variable. These steps are undertaken for absolute risk assessed by FRAX and for absolute
risk assessed by QFracture.
TABLE 6 Overview of the modelling methodology and key data sources (continued )
Model feature Description of model in TA46434 Description of revised model
Mortality l All-cause mortality is based on
UK lifetables161
l Fracture-related mortality is based
on estimates of excess mortality
attributable to hip and vertebral
fractures from a case–control study162
using routine data from UK
general practice
No change
Utility data Utility decrements based on EQ-5D
scores pre and post fracture were
obtained from a systematic review. Utility
decrement for nursing home admission
was based on a single study, identified
from the literature, that used EQ-5D.
Variation in baseline utility by age and
sex was based on UK EQ-5D population
estimates
l The utility decrements for fracture
have been updated to reflect new
evidence identified in an updated
systematic review (see Health-related
quality of life)
l Utility estimates have been identified
and incorpated for the AEs of ONJ,
VTE and cellulitis (see Adverse events)
l The incorporated utility estimates are
all based on EQ-5D with valuation
using the UK time trade-off data set,
with the exception of ONJ for which
the estimates are based on the US
valuation set for the EQ-5D
Resource use and unit costs l The analysis includes drug costs,
administration costs and costs of
fracture, including costs on primary
care, secondary care and PSS
l Post-fracture costs were based on a
case–control study that used routine
data from UK general practice. Nursing
home admission following hip fracture
was based on a UK observational
study of discharge destinations
l Unit costs are taken from NHS
reference costs, PSSRU unit costs, the
primary care National Drug Tariff and
the eMIT database of generic drug
costs in secondary care
l Costs are reported in Great British
pounds (£)
l Cost year is 2014
l Drug costs have been updated using
the latest National Drug Tariff and
eMIT database (see Drug costs)
l Costs for monitoring (DXA scanning
and annual physican review) have
been incorporated. (see Drug costs)
l Administration costs for i.v.
bisphosphonates have been updated
and administration costs for non-
bisphosphonates have been
incorporated. (see Treatment initiation,
administration and monitoring)
l Other costs have been inflated using
standard inflation indicies (see
Disease costs)
l Costs are reported in Great British
pounds (£)
l Cost year is 2018
Discounting 3.5% per annum for both costs and
QALYs
No change
Sensitivity analysis Probabilistic sensitivity analysis was
undertaken for the base-case scenario to
estimate the mean costs and benefits
when taking into account parameter
uncertainty
Structural uncertainty was assessed
through scenario analysis in which
parameters were set to their mid-point
values
No change
eMIT, electronic market information tool.
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Interventions and comparators
The treatment strategies modelled (and the intended treatment durations) were as follows:
l oral ALN (5 years)
l oral RIS (5 years)
l oral IBN (5 years)
l i.v. IBN (5 years)
l i.v. ZOL (3 years)
l RLX (5 years)
l DEN (10 years)
l TPTD (2 years)
l ROMO (1 year) followed by ALN (4 years).
These were all compared with a strategy of no treatment to estimate the incremental costs,
incremental QALYs and INMB relative to no treatment. We note that, in the base-case analysis, the
actual treatment duration modelled is determined by the duration of treatment persistence rather than
the intended treatment duration, but it is necessary to specify the intended treatment duration for the
scenario analysis assuming full persistence.
The intended treatment durations for bisphosphonates (3 years for ZOL and 5 years for all others) are
based on the assumption made in TA464.34 For the sequence of ROMO followed by ALN, the 1-year
treatment duration for ROMO is based on the anticipated marketing authorisation. However, the
anticipated marketing authorisation also states that ROMO should be followed by an anti-resorptive
agent, but does not specify the duration for anti-resportive treatment. In the ARCH trial,83 patients in
both arms received open-label ALN after the 1-year double-blind phase. In the clinical study report20
for the ARCH trial, the mean duration of ALN exposure after the 1-year double-blind phase is
(confidential information has been removed) in both arms, but the maximum treatment exposure is
between (confidential information has been removed) years across the two trial arms. To have the
same overall intended treatment duration as the ALN strategy, we decided to model the ROMO/ALN
strategy as including 4 years of ALN. For DEN, we have assumed an intended treatment duration
of 10 years, as this is what was assumed in the Amgen Inc. submission,100 in which it was argued
that there are data from the FREEDOM study104 on the efficacy and safety of up to 10 years of
DEN treatment.
Treatment persistence
In the AG model, we have assumed that costs and benefits are linearly related to the duration of
treatment persistence; therefore, the individual-level variation in persistence does not need to be
modelled. The assumption was found to be reasonable in sensitivity anslyses reported by Davis et al.34
Therefore, the variable that needs estimating to inform the model is the mean treatment persistence
and standard error of the mean, which describes the uncertainty around the mean for the probabilistic
sensitivity analysis (PSA).
In the model that informed TA464, Davis et al.34 used published estimates of treatment persistence
from observational cohort studies, with separate estimates applied for oral bisphosphonates, based on
a systematic review by Imaz et al.,165 and for i.v. bisphosphonates, based on a US study of Medicare
patients (Curtis et al.166). Davis et al.34 applied the mean persistence reported in these studies to all
patients receiving treatment, rather than modelling individual-level heterogeneity in treatment
persistence. The model in the Amgen Inc. submission100 used persistence data from a retrospective
analysis of a large UK primary care database (the CPRD) (Amgen Inc.,100 data on file). The proportion
persisting with treatment over 5 years was estimated from these data and extrapolated beyond
5 years in the model based on the last year of data. The model in the UCB S.A. submission20 used
published estimates for treatment persistence for bisphosphonates and RLX from a UK GPRD study
and data from a non-UK registry study for DEN. Unpublished data were cited by UCB S.A.20 as the
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source for TPTD and ZOL persistence. For the sequence of ROMO followed by ALN, the model
submitted by UCB S.A.20 assumed that 90% of patients would persist with ROMO up to 1 year, based
on experience from clinical trials, and that, once patients switched to ALN, the treatment persistence
would be 85% of that observed for DEN – the treatment with the highest persistence rate, based on
the published estimates. Strom et al.146 used persistence data for oral bisphosphonates from a UK
CPRD study (Li et al.;167 similarities suggest that this is the same study cited by UCB S.A.) to model
persistence over time for the first 3 years and then assumed that all patients reaching 3 years would
continue on oral bisphosphonates. Strom et al.146 used a non-UK randomised crossover comparison
study109 to model treatment persistence with DEN. Kanis et al.144 assumed that 50% of patients receiving
oral bisphosphonates persist up to 3 months and the rest persist up to the intended treatment duration,
based on the assumption used in the analysis that informed TA160 and TA161. It is not clear what
assumption was made by Kanis et al.144 regarding treatment persistence for RLX. In the model based on
the MORE study,141 patient compliance was not taken into account, but it was noted in the discussion
that 92% of patients took > 80% of their study medication. In the model submitted by Amgen Inc. for
TA204,147 treatment persistence was assumed to be 100% for all treatments in the base-case analysis,
but a lower rate of treatment persistence for oral bisphosphonates was applied in a sensitivity analysis
based on data from the GPRD (GPRD is the previous name of the CPRD, but the data used here appear
to be from a different study to that used in the current Amgen Inc. submission100).
Both of the company submissions used data from the same large UK primary care database (GPRD/CPRD).
The published analysis by Li et al.168 gave median durations of persistence for oral bisphosphonates ranging
from 5 to 7 months across the more commonly used weekly and monthly preparations, whereas the more
recent, but unpublished, analysis cited in the Amgen Inc. submission100 had a lower median persistence of
(confidential information has been removed) months for all oral bisphoshonates. However, the AG notes
that the data from Li et al.168 suggest that the time-to-discontinuation curve has a long tail, so mean
persistence will be longer than median persistence.
The AG estimated mean time on treatment from the Kaplan–Meier estimates published by Li et al.168
by crudely estimating the area under tha Kaplan–Meier curve, assuming linear changes between the
estimates reported. The data from the more recent analysis presented in the Amgen Inc. submission100
were considered less mature than the data presented by Li et al.168 Mean durations of persistence in
the first 5 years after starting treatment were estimated to be 1.7 years, 1.5 years and 1.4 years for
ALN, RIS and RLX, respectively. Estimates for oral IBN were not possible owing to missing data at
5 years. Although separate estimates of persistence are provided for ALN and RIS, in the absence
of any data demonstrating that treatment persistence differs significantly between different oral
bisphosphonates, we decided to apply the average persistence data from ALN and RIS to all oral
bisphosphonates. We note that mean treatment persistence is approximately three times longer
under this assumption than assumed previously in the model that informed TA464.34
The AG was not convinced that data from a primary care database, as used in the Amgen Inc. model,100
would be generalisable to i.v. bisphosphonates (and likewise TPTD) as these are usually prescribed in
secondary care. Given this concern, and in the absence of any other alternative data sources, the AG
decided to use the same estimates of treatment persistence for i.v. bisphosphonates as assumed in the
model that informed TA464.34
The evidence on the long-term persistence with DEN appears to be very limited, with most studies
reporting a maximum of 24 months’ follow-up.109,169–171 It is difficult to estimate the mean or median
duration of treatment from studies that are limited to 2 years when persistence is high at 2 years and
it is possible for DEN to be given long term. The analysis of CPRD data presented in the Amgen Inc.
submission100 presents data beyond 2 years, but these were described as exploratory analyses only. The
AG were concerned about whether or not the analysis of CPRD data presented by Amgen Inc. would
accurately capture DEN persistence as, although DEN may sometimes be administered in primary care,
treatment is usually initiated in secondary care. Therefore, any estimate of persistence derived solely
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from primary care records may fail to accurately capture treatment discontinuation in the transition
between secondary and primary care. The persistence data used for DEN in the UCB S.A. submission20
match the cited source (Karlsson et al.170) up to 24 months, but beyond that they have simply assumed
a fixed proportional decrease in the numbers that are persistent, based on a comparison between
the 18-month and 24-month persistence rates. The AG decided to estimate the mean treatment
persistence from the CRPD data presented by Amgen Inc. in their model. The estimates of persistence
appear to be very uncertain beyond 4 years, but there appears to be a constant risk of discontinuation
from years 2 to 4. The AG decided to use the rate of discontinuation between years 2 and 4 to
estimate the proportionate decrease in persistence experienced thereafter. From this, the mean
treatment persistence over 10 years was estimated to be (confidential information has been removed).
The AG notes that these estimates are uncertain owing to the exclusive use of primary care records
and the need for an assumption to be made to extrapolate persistence up to 10 years because of
the low proportion of patients captured in the analysis beyond 2 years (confidential information has
been removed).
Several sources of persistence data were identified for TPTD. As stated above, the estimates based
on UK primary care databases were discounted based on the fact that TPTD is usually prescribed in
secondary care. However, two published articles172,173 were identified from ad hoc literature searches
that described persistence in UK patients in real clinical practice based on data from the main home
care provider of TPTD in the UK. Both these studies were conducted before the maximum duration
of treatment in the marketing authorisation was extended from 18 to 24 months, but they show high
levels of persistence at 18 months of 79%172 and 74%173 for women and men, respectively. However,
these estimates were based on Kaplan–Meier data taking into account the censoring of patients
who were still on treatment at the longest follow-up. Data from the European Extended Forsteo
Observational Study (ExFOS),174 which was a large European real-life clinical practice study of TPTD
use after the licence was extended to 24 months, showed a mean treatment duration of 20.7 months,
despite 29% of patients residing in countries where the licence remained restricted to 18 months.
All three papers show a fairly linear fall-off in persistence, although a more rapid fall in persistence
was seen in the ExFOS study at 18 months in the countries with 24-month reimbursement, which
could be explained by a lack of uptake of the longer dosing schedule. We decided to use the data from
UK women to estimate the average duration of treatment. To do this, we assumed a constant rate of
discontinuation from 0 to 24 months, based on the rate observed over 18 months by Arden et al.,172
giving an estimated mean persistence time of 1.72 years (20.6 months), which is reasonably consistent
with the estimate from ExFOS, which had a mean treatment duration of 20.7 months. We decided
to take the standard error of the mean (0.14 months) from the ExFOS study as the measure of
uncertainty for the estimate applied in the model. When sampling this parameter in the PSA, the
maximum number of doses was capped at 24, as per the SmPC for TPTD.25
For ROMO, the manufacturer claimed that 90% of patients persisted to 12 months, based on data
from the clinical trials. The AG used data on doses received in the ARCH study83 to estimate mean
persistence with treatment, and found that this agreed with patients being treated for a mean of
(confidential information has been removed), although it noted that only (confidential information has
been removed) of patients received all 12 doses of ROMO. When sampling this parameter in the PSA,
the maximum number of doses was capped at 12, as per the draft SmPC for ROMO provided in the
UCB S.A. submission.12 For the sequence of ROMO followed by ALN, we have assumed that treatment
persistence with ALN is the same as for the ALN-only strategy.
Effectiveness data
The HRs estimated in the NMA (see Figure 6) were applied in the model for the duration of treatment,
with a linear increase to a HR of 1 (i.e. no treatment effect) during the offset period. For the treatment
sequence of ROMO followed by ALN, the HR for ROMO followed by ALN was applied during both
the ROMO and the ALN treatment periods, as the HR estimate in the NMA was based on fractures
occurring during both treatment phases. The NMA requires a single estimate of treatment effect for
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each study; therefore, it would not have been possible to generate separate estimates of treatment
efficacy for the ROMO and ALN parts of the treatment sequence.
When data on fracture outcomes were lacking for i.v. IBN, the AG used the NMA estimate for
daily oral IBN, as the marketing authorisation for i.v. IBN was based on studies demonstrating that
i.v. IBN had superior BMD outcomes compared with daily oral IBN. It is noted that this is potentially
unfavourable to i.v. IBN if superior BMD outcomes translate into superior fracture prevention
outcomes. However, this is consistent with the approach taken in TA464.34
For vertebral fracture, we have used the outputs of the base-case NMA, which included studies
reporting morphometric fractures. This is because the outcome of morphometric fracture was
more widely reported, and the NMA sensitivity analysis that excluded studies that reported only
morphometric fractures, leaving just those studies reporting clinical vertebral fracture, was found to
produce results that were consistent with the base-case analysis.
In the model that informed TA464,34 it was possible to use the bisphosphonate class effect estimate
when data on individual bisphosphonates were lacking. In the updated networks described in Chapter 3,
Network meta-analysis, no hip fracture data were available for i.v. IBN and monthly oral IBN, but data
were available for all non-bisphosphonates. We decided to apply the bisphosphonate class effect
estimate for i.v. IBN and monthly oral IBN when data were lacking for hip fracture. We note that the
class effect for bisphosphonates was very similar to the estimates for ALN, RIS and ZOL, and so this
was not considered to unfairly bias the cost-effectiveness analysis.
In the analysis that informed TA464,34 the data were considered too sparse for the outcome of
proximal humerus fracture, so the non-vertebral NMA estimates were used instead. In the NMAs
conducted for the current MTA, the networks were sparsely populated for non-bisphosphonates for
the outcomes of both wrist fracture and proximal humerus fracture. The AG decided to use the NMA
estimates from the non-vertebral fracture NMA for both wrist and proximal humerus fractures as
this allowed a single network to be used to estimate HRs for all interventions. This was considered
preferable to using data from different networks for bisphosphonates and non-bisphosphonates, as
the wrist and proximal humerus fracture estimates would be more uncertain than the non-vertebral
fracture estimates.
In the base-case analysis, the convergence diagnosis and output analysis (CODA) samples from the
NMA were used, as these preserve the underlying joint distribution of the HRs, but, in the deterministic
analyses, the median HR was used.
Offset period
The AG used a review by Idolazzi et al.175 and papers cited in the company submission to identify
relevant studies that could be used to inform the assumptions regarding the appropriate offset periods
for the different treatments modelled.
For ALN, the key study was considered to be the Fracture Intervention Trial Long-term Extension
(FLEX),176,177 as this provided comparative data on both fracture risk and BMD for patients remaining
on, or stopping treatment with, ALN after 5 years of treatment. This study found that it took 5 years
for total hip BMD to return to pre-treatment levels when treatment with ALN was discontinued after
5 years. This was supported by no separation of the time-to-event curves for non-vertebral fractures
for patients remaining on treatment compared with those stopping treatment. There was some
evidence of a continued treatment effect for lumbar spine BMD, and a continued reduction in
vertebral fracture risk was observed (RR 0.45, 95% CI 0.24 to 0.88) for patients who continued ALN
compared with those who discontinued ALN.
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For RIS, two studies were identified.178,179 Watts et al.179 reported the outcomes of patients randomised
to either placebo or RIS in the year after discontinuing the study drug. Eastell et al.178 reported the
outcomes of patients in the year after completing the Vertebral Efficacy with Risedronate Therapy-
Multinational (VERT-MN) study, in which patients were randomised to either RIS or placebo for
3 years, followed by a 2-year open-label extension on the allocated study drug, followed by 2 years of
open-label RIS in both groups. Both studies reported that BMD gains at the hip were lost in the 1 year
following treatment discontinuation, although Watts et al.179 observed smaller losses in lumbar spine
BMD and reported a statistically significant reduction in vertebral fracture incidence between those
previously treated with RIS and those previously treated with placebo, in the year after treatment
discontinuation.
The data identified for oral IBN were limited to those from 1-year post-trial follow-up from an early
dose-finding study,180 which included the 2.5-mg daily dose that has been shown in non-inferiority
bridging studies to be equivalent to the 150-mg monthly dose that is now licensed.181 This study180
appears to show a similar pattern to that seen for RIS, in that hip BMD appears to return to pre-
treatment levels in the year after treatment, with a slightly slower return for lumbar spine BMD.
However, as the duration of treatment was only 1 year, it is not clear whether the offset time is 1 year
regardless of treatment duration, or whether it would increase in proportion to treatment duration.
For oral bisphosphonates, the AG decided to keep the assumption made previously in the model that
informed TA464,34 which was that treatment effect falls to zero over a period equal to the initial
treatment duration for all oral bisphosphonates, as this was accepted previously by the NICE Appraisal
Committee. However, in a sensitivity analysis, we have also explored the possibility of a fixed 1-year
offset time for RIS and oral IBN.
For i.v IBN, no studies were identified that explored BMD or fracture outcomes following treatment
discontinuation. Therefore, we assumed that the offset period would be the same as for oral IBN and
set it equal to treatment duration, with a fixed 1-year offset explored in a sensitivity analysis.
For i.v. ZOL, data from the Health Outcomes and Reduced Incidence with Zoledronic Acid Once
Yearly (HORIZON) – Pivotal Fracture Trial extension study are provided by Black et al.182 In the
extension study, patients who had received 3 years of ZOL were randomised to receive either ZOL or
placebo for a further 3 years. At the end of the study, femoral neck BMD had declined in those who
switched to placebo, but not to baseline levels, suggesting an offset period that is longer than the
treatment duration when measured based on BMD changes. This suggests a slightly longer tailing-off
of treatment effect than observed for ALN in the FLEX study. There was, however, no statistically
significant difference in non-vertebral fractures between placebo and ZOL in the extension phase.
Similar to the results from the FLEX study, further gains were made in lumbar spine BMD after
discontinuation, and there was a statistically significant difference in new vertebral fractures in the
extension stage of HORIZON.
For i.v. ZOL, the AG decided to keep the assumption made previously in the model that informed
TA464,34 which was that treatment effect falls to zero 10 years after the start of a 3-year treatment
period. For patients stopping treatment early, the offset duration was assumed to decrease
proportionately. A sensitivity analysis assuming an offset period equal to treatment duration was
also conducted.
For TPTD, data on treatment in women were identified from the FPT follow-up study,183,184 which
followed up patients for a median duration of 30 months after the RCT phase of the study. The RCT
phase was terminated early (owing to concerns regarding the safety of long-term use); the median
treatment duration was 20 months. During the follow-up study, patients were treated according to
local standards and a high proportion (i.e. 56.9% of those randomised to the licensed dose of TPTD in
the RCT phase) received other osteoporosis interventions. To account for this, results were presented
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for the subgroup with no further osteoporosis intervention, in addition to the analysis for all patients.
Statistically significant reductions in vertebral fractures were reported by Lindsay et al.183 in the
18 months following discontinuations, and not all of the lumbar spine BMD gained during treatment
had been lost by 18 months. For non-vertebral fractures, statistically significant differences were not
found for the licensed dose compared with placebo at the longer follow-up point of 30 months post
discontinuation when adjusting for usage of other osteoporosis medications. Furthermore, the gains
in femoral neck and total hip BMD appeared to be lost by 18 months in the group not receiving other
osteoporosis interventions. A second smaller study185 in men with a shorter follow-up time had similar
findings. Based on these two studies, we decided to assume an offset period equal to the treatment
duration.
For RLX, two relevant studies were identified. One compared continuation with RLX with
discontinuation in patients previously treated for 96 weeks.186 Although there were some baseline
differences in BMD, the percentage change in lumbar spine BMD from baseline was no longer
statistically significant at 144 weeks in the group that had discontinued at 96 weeks, whereas the
benefit in lumbar spine BMD was maintained in those continuing RLX up to 192 weeks from baseline.
A second RCT extension study,187 which examined 1-year outcomes in patients discontinuing after
5 years of RLX, oestrogen or placebo, found that BMD values were significantly lower 1 year after
discontinuing than at the end of treatment therapy for both lumbar spine and femoral neck BMD.
Although these data are from a small study, they support a rapid loss of efficacy in the year after
treatment even for patients treated for > 2 years. Based on these two studies,186,187 we decided to
apply a 1-year offset period for RLX.
For DEN, two papers188,189 reporting outcomes from a single study were identified. The paper reporting
2 years’ follow-up post discontinuation in patients allocated to either 2 years of DEN or 2 years of
placebo found that gains in both lumbar spine BMD and total hip BMD were lost in the first year
after discontinuation, suggesting that an offset period of 1 year would be reasonable for DEN. A third
paper,190 presenting an analysis of post-trial outcomes of patients from the FREEDOM study, was
also identified, which described a rapid fall in BMD in the first year after discontinuation, even after
treatment lasting 10 years. Although this analysis was limited to 12 women from a single site, and can
therefore be considered as only weak evidence, this analysis is supportive of a fixed offset period of
1 year, rather than one that varies with treatment duration. Therefore, for DEN we have assumed a
fixed offset period equal to 1 year (or, when this is < 1 year, the treatment duration).
For ROMO, no data were identified in the published literature on the treatment effect following
discontinuation. In sequences in which ROMO is followed by ALN, we have assumed an offset period
equal to the total duration of the treatment sequence, with efficacy during the offset linearly declining
from the efficacy observed across the treatment sequence. This is consistent with the assumption
applied by UCB S.A.20
Drug costs
For drugs with multiple preparations, the cost was based on the lowest cost preparation available.
For drugs administered in primary care, the costs were taken from the NHS drug tariff.191 For drugs
administered in secondary care, the electronic market information tool (eMIT) database192 was used for
generic preparations (i.v. bisphosphonates) and the NHS drug tariff191 price was used when no generic
preparation was listed as being available (i.e. for TPTD and DEN). For ROMO, the annual costs for both
the list price and the PAS price were taken from the company submission. The PAS price was used in
the AG’s base-case analysis. The price used for TPTD was based on the branded formulation (Forsteo),
as no prices were available for the biosimilar versions (Movymia and Terrosa)22,23 when this report
was prepared.
The dosing, cost per item and annual cost for each treatment strategy are summarised in Table 7.
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TABLE 7 Treatment-specific model inputs
ALN/RIS/IBN
(oral) IBN i.v. ZOL i.v. RLX DEN TPTD ROMO/ALNa
Intended treatment duration (years) 5 5 3 5 10 2 1
Mean persistence (years) 1.60 1.1 1.7 1.38 Confidential
information has
been removed
1.72 Confidential
information has
been removed
Offset 1.60 1.10 3.96 1.00 1.00 1.72 N/Ab
Drug acquisition costs
Dosing unit 70 mg/35 mg/
150mg
3mg in 3 ml 5 mg/100 ml 60mg 60mg 20 µg 210mg
Dosing frequency Weekly/weekly/
monthly
Quarterly Annual Daily Biannual Daily Monthly
Unit cost £0.76 per 4/
£0.76 per 4/
£0.99 per 1
£7.89 per 1 £13.24 per 1 £3.27 per 28 £183.00 per 1 £271.88 per 30 Not provided
Total cost per year (£) 9.91/9.91/11.88 31.56 13.24 42.63 366.00 3307.87 Confidential
information has
been removed
Administration costs
Route of administration Oral i.v. i.v. Oral s.c. injection s.c. injection s.c. injection
Resource use for administrations N/A Outpatient Day case N/A Two as
outpatient,
then general
practice nurse
Self-administered Self-administered
Cost per administration (£) N/A 150.38 253.32 N/A 10.85 (150.38
first year)
N/A 0.00
Number of administrations per year N/A 4 1 N/A 2 N/A 12
Total cost per year (£) 0.00 601.52 253.32 0.00 21.70 (300.76
first year)
N/A 0.00
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TABLE 7 Treatment-specific model inputs (continued )
ALN/RIS/IBN
(oral) IBN i.v. ZOL i.v. RLX DEN TPTD ROMO/ALNa
Monitoring costs
Type of follow-up visit GP Outpatient Outpatient GP GP, with one in
four as
outpatient
Outpatient Outpatient
Cost (£) per follow-up visit (one per annum) 38.00 150.38 150.38 38.00 66.09 (average) 150.38 150.38
Years between DXA 5 5 3 5 5 2 1
Annualised BMD measurement costs (£) 13.66 13.66 13.66 13.66 13.66 34.14 68.29
Total monitoring costs per year (£) 51.66 165.04 173.14 51.66 79.75 184.52 218.67
Total annual costs (£) 61.57/61.57/
63.54
797.11 439.71 94.29 467.45 (746.51
in first year)
3492.40 Confidential
information has
been removed
GP, general practitioner; N/A, not applicable.
a Data here relate to the ROMO part of the ROMO/ALN sequence. Data for the ALN part of the sequence are as for ALN used first-line, with the exception that treatment duration
with ALN is 4 years, not 5 years, and DXA is assumed to occur at the end of the 4 years rather than after 5 years.
b Total offset time for sequence is (confidential information has been removed) years.
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Treatment initiation, administration and monitoring
Six of the studies assumed that patients would undergo DXA every other year while on
treatment.20,100,141,144,146,147 Stevenson et al.143 assumed that patients would undergo DXA at years 2 and
5. Davis et al.34 did not include any DXA to monitor treatment with bisphosphonates. Not all of the
papers were explicit about whether or not patients were assumed to have undergone DXA before
starting treatment, but, in Davis et al.,34 all costs that related to risk assessment, which may include
DXA for some patients, were considered to have been already inccurred prior to treatment choice,
as these were included in the cost-effectiveness analysis for risk assessment in CG146.8 The AG
considered that the inclusion of routine DXA in the model was problematic as the approach taken may
differ depending on the baseline risk of the patient and the treatment being administered. For example,
CG146 does not recommend that DXA is performed routinely as part of the risk assessment of
patients.8 Therefore, it is reasonable to assume that many patients may be started on the current first-
line therapy, which is oral bisphosphonates, without DXA, and this is consistent with the approach
recommended in the NICE-accredited NOGG guideline.14 However, the NOGG also recommends that
FRAX with BMD is used to reassess patients at the end of 5 years of bisphosphonate therapy (3 years
for ZOL). On this basis, we decided to assume that patients undergo DXA when they reach the end of
the intended treatment duration. We made an exception for DEN, as the intended treatment duration
is much longer than for other therapies, so we assumed that DXA is undertaken every 5 years. This
was based on advice from one of our clinical experts that patients receiving DEN in primary care
would be likely to be reviewed in specialist care at 3 or 5 years. For the treatment sequence of ROMO
followed by ALN, we assumed that a patient would undergo DXA once at the end of the 1 year of
ROMO and once at the end of the 4 years of ALN. Because treatment duration in the model is based
on average treatment persistence rather than the distribution of persistence across the population,
the AG incorporated the cost of DXA as an annualised cost; otherwise, no DXA costs would be applied,
as the average patient never reaches the intended treatment duration. This is consistent with the
assumption that costs and benefits are linearly related to the duration of treatment persistence and,
therefore, the individual-level variation in persistence does not need to be modelled. The cost applied
for DXA is based on the NHS reference cost for direct-access DXA (£68.29 for RD50Z).193
Four of the studies assumed that patients would attend annual general practitioner (GP) appointments
to monitor treatment.20,141,146,147 Amgen Inc.100 assumed the same for treatments given in primary care
(which included oral bisphosphonates and DEN), but assumed secondary care follow-up appointments
for i.v. bisphosphonates. Kanis et al.144 assumed one GP appointment to initiate treatment. Stevenson
et al.143 assumed two GP appointments per annum, whereas Davis et al.34 did not include any GP
appointments for monitoring. There is now a NICE QS13 that states that patients having bone-sparing
treatments should have medication reviews to discuss AEs and adherence, but the frequency of the
reviews is not specified. We have assumed that patients will have annual reviews and that those
reviews will occur in primary care for oral bisphosphonates and RLX. For this, we applied the cost per
average GP patient contact (£38.00 per 9.22 minutes).16 For DEN, we were advised that patients would
be reviewed in secondary care every 3–5 years, so we have assumed that one in four annual reviews
will occur in secondary care. For i.v. bisphosphonates, ROMO and TPTD, we have assumed that the
annual review occurs in secondary care as an outpatient endocrinology appointment. The cost
(£150.38) for a consultant-led, non-admitted, face-to-face follow-up attendance at endocrinology
outpatient has been applied [Healthcare Resource Group (HRG) currency code WF01A, service
code 302].193
As noted previously, none of the studies identified in the review included any costs for the
administration of oral therapies; this was the assumption applied in our model. UCB S.A.20 also
assumed no administration costs for s.c. therapies (i.e. DEN, TPTD and ROMO). In the Amgen Inc.
submission for this MTA,100 it was assumed that DEN would be given by a general practice nurse,
whereas, in the Amgen Inc. submission for TA204,147 they assumed that one injection would be
administered during the annual GP visit, and therefore one additional GP appointment was required
per annum for the second injection. For DEN, we assumed that patients would initiate treatment in
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secondary care, with the first two doses being given as an outpatient procedure using the same
HRG codes as applied for i.v. IBN. Thereafter, it was assumed that DEN would be administered under
a shared care agreement, with a primary care nurse providing future doses during a 15.5-minute
appointment at a cost of £10.85 (based on £42.00 per hour for general practice nurse contact time).16
This was based on advice from our clinical experts that, ideally, only the first one or two doses would
be given in secondary care, although they also noted that there is significant variation in practice
surrounding shared care agreements, with some local areas having a poor uptake of primary care
administration.
Stevenson et al.143 do not describe any additional administration costs for TPTD. Waugh et al.147
included one additional GP appointment for initiation of TPTD. The AG did not consider that any
additional costs were necessary for the administration of TPTD, given that it is self-administered,
and an annual secondary care review has already been included for TPTD, as described previously.
Davis et al.34 assumed that i.v. IBN is delivered during an outpatient endocrinology appointment and
that i.v. ZOL is delivered as a day-case procedure using the HRG code for administration of a simple
parenteral chemotherapy (SB12Z). UCB S.A.20 assumed that administration of i.v. ZOL occurred in
secondary care, but the exact source of the cost applied is unclear. In the Amgen Inc. submission for
TA204, administration of i.v. bisphosphonates was assumed to occur in secondary care under the same
HRG code as used by Davis et al.34 for i.v. ZOL. However, in the Amgen Inc. submission for the current
MTA,100 it was argued that the use of an oncology HRG was inappropriate; instead, the cost was based
on day case and elective inpatient spells averaged over nine HRG codes related to non-inflammatory
bone and joint disorders and pathological fractures. The AG was already aware of a study that compared
the cost of secondary care infusion of ZOL with a home-care delivery model in a UK NHS setting.194 In
correspondence with the study author (Opinder Sahota, Nottingham University Hospitals NHS Trust,
2018, personal communication), it was stated that the reference cost, including the drug costs, for this
activity was £300 per patient (£14,980 per 50 patients), and this included acquisition of the drug at a
discounted (undisclosed) cost from the manufacturer. However, the income for the activity based on the
tariff was much lower, at £143 per patient, which also includes the cost of drug acquisition. Based on
these figures, we felt that the estimates provided by Amgen Inc. were probably too high and we decided
to use the HRG codes applied in the model that informed TA464,34 but updated to the latest reference
costs,193 giving a cost of £253 for day-case infusion of i.v. ZOL (day case, SB12Z delivery of simple
parenteral chemotherapy at first attendance).
For i.v. IBN, no alternative estimates of administration costs were identified from the studies included
in the review. Therefore, we decided to assume the same resource use as in the model used to inform
TA46434 (one outpatient endocrinology follow-up appointment), but we updated the unit cost to reflect
the latest reference costs,193 giving a cost of £150.
Adverse events
For oral and i.v. bisphosphonates, the AG decided not to change the approach to modelling AEs that
was adopted in TA464,34 as there was no new evidence on which to base alternative assumptions
identified from the review of cost-effectiveness studies.
The AG decided to include serious (i.e. leading to hospitalisation) cellulitis as an AE for DEN because it
had been included in the model that informed TA204,147 although it was noted that the 10-year results
of the FREEDOM study41,104 suggest that the incidence rate of cellulitis is low, at ≤ 0.2% in each of the
study years. The HRG cost for a non-elective inpatient spell for minor skin conditions with interventions
ranges from £2588 to £7764, depending on the level of complications and comorbidities, with a weighted
average of £4467.193 Assuming an incidence rate of 0.2% per annum and applying this weighted cost to
the incident population would increase the cost of DEN by £8.93 per annum. The AG identified a paper
that had estimated the QALY loss of cellulitis as 0.005 QALYs (reduction in EQ-5D score by 26.3% for
7 days), based on a comparison of EQ-5D scores in a prospective RCT of antibiotics versus placebo to
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prevent recurrent cellulitis.195 This is equivalent to a loss in INMB of £0.20 per annum. As the duration
of treatment persistence with DEN in the model is (confidential information has been removed) years,
this would suggest that the total impact of cellulitis is a reduction in INMB for DEN of the order of
(confidential information has been removed). Costs and QALY losses for cellulitis per year of exposure to
DEN have been included in the base-case model.
The AG notes that the Medicines and Healthcare products Regulatory Agency (MHRA)/Commission
on Human Medicines (CHM) has issued advice regarding the risk of atypical femoral fractures for
both DEN and bisphosphonates,28 but this advice states that these events are rare and that they are
primarily related to long-term use. The AG decided not to include atypical femoral fractures as a
separate AE in the model. This was, first, because the HRs for fractures estimated from the clinical
trials would already include any impact of the drug on atypical femoral fractures, and including them
as a separate event may result in these outcomes being double-counted in the model. The AG accepts
that atypical femoral fractures may not have been captured in the trials if they occur only after long-
term use of osteoporosis treatment. However, the AG notes that the base-case scenario incorporates
real-world treatment persistence, which is much shorter than the intended treatment duration for both
bisphosphonates and DEN, making these AEs that occur with long-term use less relevant to these
treatments as they are modelled.
The AG notes the MHRA/CHM advice regarding the risk of ONJ in patients receiving
bisphosphonates.28 The advice states that the risk is considered to be substantially higher in those
receiving i.v. bisphosphonates in the treatment of cancer than in those receiving i.v. bisphosphonates
for the treatment of osteoporosis, and the risk is said to be related to cumulative dose. Similarly, the
MHRA/CHM advice on DEN states that it is a common side effect for those patients receiving DEN for
the treatment of cancer and recommends dental examination and preventative dentistry treatment in
all patients starting DEN for cancer.28 It should be noted that the dose for cancer is 120 mg monthly,
rather than 60 mg every 6 months, and, in the context of using DEN to prevent osteoporotic fracture,
such precautions are recommended by the MHRA/CHM only for those with risk factors.28 The AG also
notes that a systematic review by Boquete-Castro et al.196 states ‘it should be stressed that most of
the adverse effects of DEN appear with doses of 120 mg. Adverse effects with doses of 60 mg are
directly related to the duration of treatment.’. Although there appears to be less concern regarding
ONJ in patients receiving anti-resportive agents for osteoporosis than for ONJ in patients receiving
anti-resportive agents for cancer, the AG decided to incorporate this AE in the model to establish the
likely impact on the cost-effectiveness estimates.
The AG examined a systematic review reported by Khan et al.,197 which was conducted to inform an
international consensus statement on ONJ. Khan et al.197 conclude from their review that ‘the incidence
of ONJ in the osteoporosis patient population appears to be very low, ranging from 0.15% to < 0.001%
person-years of exposure and may be only slightly higher than the frequency observed in the general
population’. For oral bisphosphonates, the review by Khan et al.197 identified a UK (Scottish) prospective
case series that reported an incidence for ONJ of one case per 4545 drug patient-years (0.022%) for
patients exposed to ALN.198 This was within the incidence range of 1.04–69 cases per 100,000 patient-
years reported by the other studies identified in the review by Khan et al.197 It should be noted that Lo
et al.199 found, in a cross-sectional survey conducted in the USA, that prevalence of ONJ was related to
duration of exposure, with estimated prevalences of 0%, 0.05% and 0.21% in patients exposed for
< 2 years, 2 to just under 4 years and ≥ 4 years. For i.v. bisphosphonates, Khan et al.197 reported
an incidence range of 0–90 per 100,000 patient-years. The incidence estimated across five RCTs is
given by Khan et al.197 as < 1 in 14,200 patient-years of exposure (< 0.007%). For DEN, Khan et al.197
reported that the estimates of incidence ranged from 0 to 30.2 per 100,000 patient-years. However,
more recent data from the 10-year follow-up of the FREEDOM trial41,104 gave an exposure-adjusted
incidence of ONJ of 5.2 per 10,000 participant-years (0.052%). The SmPC for DEN states that the
incidence is related to the duration of exposure.200 Given that there is a lack of comparative data
on the incidence of ONJ across the different forms of anti-resportives, and that the estimates for
DOI: 10.3310/hta24290 Health Technology Assessment 2020 Vol. 24 No. 29
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Davis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
73
the different anti-resportive drugs all relate to different periods of exposure, we have decided to
assume the same incidence per year of drug exposure across all anti-resportives. This was based
on the estimate from the prospective case series in Scotland.198 This was because this estimate fell
within the range provided by Kahn et al.197 for each type of anti-resportive (oral bisphosphonates, i.v.
bisphosphonates and DEN) and was based on the average duration of use in clinical practice; therefore,
it would be more applicable to the duration of treatment persistence modelled in this analysis.
A paper201 measuring health utility in patients with ONJ was identied using ad hoc searches of
Google Scholar. It reported utility measured by the EQ-5D in 34 cancer patients with bisphosphonate-
associated ONJ. However, it should be noted that it was not compliant with the reference case in
several ways. First, although the pateints had all themselves experienced ONJ, they were asked to
value clinical vignettes describing different stages of ONJ in patients who also have cancer, rather
than being asked to value their own health state. Second, the utilty weights applied were from the US,
rather than the UK, valuation set. However, given the lack of alternative estimates, we calculated the
average utility decrement based on the utility decrements (relative to patients with cancer but without
ONJ) for stages 2 and 3 (–0.33 and –0.61, respectively) and the distribution of ONJ stages (two were
stage 3 and nine were stage 2) across the UK prospective case series reported by Malden and Lopes.198
This gave an average utility decrement of –0.38. The mean time from diagnosis to healing (6.5 months)
was taken from the same study198 to give an average QALY loss of 0.206 per case of ONJ. The NHS
reference cost for a minor outpatient oral surgical procedure was applied (HRG code CD03A, £166)193
to account for the cost of surgical management, as most patients in the Malden and Lopes198 case
series had some form of surgical management, with debridement being the most common procedure.
We note that the Malden and Lopes198 case series may have missed less severe cases of ONJ, which
would be classed as stage 1. However, as cancer pateints with stage 1 ONJ were found not to have
EQ-5D values significantly different from those of cancer patients without ONJ (Miksad et al.201),
and patients with stage 1 would be more likely to be managed conservatively,197 we felt that exclusion
of this group was unlikely to significantly bias the estimates of costs and QALYs resulting from
ONJ, provided they are excluded from both the incidence estimates and the estimates of costs and
QALYs per case. Costs and QALY losses per year of exposure to DEN, oral bisphosphoantes and i.v.
bisphosphonates have been included in the base-case analysis, but we note that their impact is very
small owing to the extremely low incidence.
Kanis et al.141 applied HRG costs and a utility loss in the year after VTE, but not beyond. The utility
decrement was based on an assumption, as no estimate was identified from the literature. No other
models identified in the literature review included VTE as an adverse outcome. Rather than extend
the AG model to incorporate the competing risk of VTE in patients at risk of fracture, the AG
decided to estimate the average discounted lifetime cost and QALY loss attributable to VTE using a
published model (Pandor et al.202). As this model was constructed to estimate the costs and benefits of
thromboprophylaxis, the AG removed all costs and QALY losses attributable to the thromboprophylaxis
itself, including the increased risks of bleeding during the prophylaxis, thereby reducing the model
to a comparison of two groups whereby the only difference between them is their risk of VTE. All
conseqeunces related to asymptomatic VTE were removed from the model as these were not considered
relevant, as it is only symptomatic VTE that has been recorded as an adverse outcome. The AG then
compared costs, QALYs and the number of symptomatic VTEs for the strategies of prophyalixs for all and
prophyalixs for none. These figures were used to estimate the average discounted lifetime cost and QALY
loss per symptomatic VTE, which were estimated to be £1890 and 0.77 QALYs for a patient with a
starting age of 50 years.
The largest RCT reporting VTE as an adverse outcome for RLX was the MORE study,51,102 which
reported that 25 out of 2557 patients receiving RLX experienced VTE, whereas eight out of 2576
patients receiving placebo experienced VTE. Based on the increased incidence observed in the MORE
study, the excess rate of VTE attributable to RLX was estimated to be 0.67% over the 3-year study
period. Ettinger et al.51 did not report the proportion of these events that were PEs, but did say that a
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mixture of PE and DVT events were observed. The study by Silverman et al.50 did report the breakdown
by type of VTE: four of the 12 VTE events in the RLX-treated arm were PEs. It should be noted that, in
the model by Pandor et al.,202 30% of symptomatic VTE events are PEs, which is reasonably consistent
with the ratio of PE to DVT observed in the RLX arm of the study by Silverman et al.50
By applying the estimates of costs and QALYs per symptomatic VTE derived from Pandor et al.202 to
the excess incidence observed in the MORE study, we estimated a reduction in INMB of £116 per
patient enrolled in the MORE study when valuing a QALY at £20,000 (and assuming that VTE occurred
at 50 years of age). Given that the average duration of persistence in the model for treatment with
RLX is 1.38 years, if we assume that the absolute risk is proportional to the time spent on treatment,
the INMB loss attributable to VTE would be of the order of £53 per patient started on treatment
(cost of £5.80, QALY loss of 0.00237). It should be noted that the QALY losses would be fewer for
older patients experiencing VTE, as much of the QALY loss is attributed to long-term sequelae that
have a greater impact on patients with a higher life expectancy. However, when assuming a start age
of 75 years, the INMB loss attributable to VTE per patient started on RLX was estimated to be £47
(compared with £53 for patients aged 50 years), so the error associated with applying costs and QALYs
as estimated for a patient aged 50 years was not considered likely to have resulted in a large bias.
The average cost and QALY loss attributable to excess VTE were applied to each patient initiating
treatment with RLX, with the risk proportional to time spent on treatment, such that they have a
bigger impact in the sensitivity analysis assuming full treatment persistence.
Disease costs
The costs of fracture in the TA46434 model were based on a UK resource use study reported in two
papers by Gutiérrez et al.,203,204 which used a general practice database (The Health Improvement
Network) to estimate resource use for those who fractured compared with matched controls. Unit
costs from the 2013/14 reference costs205 and the 2014 PSSRU unit costs206 were then applied to this
resource use to estimate the total cost in the year of fracture and in the subsequent years following
fracture. None of the studies included in the review provided a more recent source of resource use.
Two studies20,100 reported using costs based on Gutiérrez et al.,203,204 and five141,143,144,146,147 used
estimates from the literature from less recent publications.
The AG identified two additional relevant UK studies in the systematic database search conducted to
identify published cost-effectiveness analyses. Lambrelli et al.207 used a methodology similar to that
employed by Gutiérrez et al., but using an alternative primary care database (the CPRD), with linkage
to a secondary care database [Hospital Episode Statistics (HES)]. Lambrelli et al.207 reported costs in
the year following hip fracture of £7359. Leal et al.208 reported higher costs, of £14,163, based on an
analysis of HES data alone. This analysis excluded activity in primary care and was focused solely on
patients admitted to hospital following fracture. For comparison, the estimate used in TA464,34 based
on the data from Gutiérrez et al.,203,204 when excluding the costs of home help, was £6274. The AG
decided to use the data from TA464,34 and to adjust it using 2017 PSSRU inflation indices,16 as the
two studies by Gutiérrez et al.203,204 provided a consistent methodology for estimating both hip and
non-hip fractures, included activity in both primary and secondary care settings and incorporated
prescription costs.
Costs for home help and residential care/nursing home admission were estimated by uplifting the
estimates used in TA46434 using PSSRU inflation indices.16
The costs applied in the first and subsequent years following fracture are summarised in Table 8.
Health-related quality of life
We conducted a rapid update of the systematic review of HRQoL studies conducted for TA464.34
This comprised a systematic serach for studies reporting EQ-5D utility data for the year post fracture.
Further details on the review methods and findings can be found in Appendix 16. In summary, the
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review identified four papers all reporting outcomes from the International Costs and Utilities Related
to Osteoporotic Fractures Study (ICUROS).209,210,212,213 This study was previously identified in the review
conducted for TA464.34 However, the four new papers identified reported additional data. ICUROS was
an international multicentre study; two of the papers210,212 reported outcomes from specific countries
that formed subgroups of the overall ICUROS population. The other two papers reported longer-term
follow-up from the overall international data set. One of these papers213 restricted its analysis to those
patients with complete follow-up on both the EQ-5D and the EQ-VAS, which resulted in a smaller
population available for analysis. The paper reporting outcomes from the international cohort without
restricting to patients who also reported EQ-VAS was chosen, as it was the larger data set.209 This
paper reported utility multipliers for the year following fracture and subsequent years for hip, wrist
and vertebral fractures. The multipliers presented in the paper were applied directly in the model.
However, no data were presented in this paper for proximal humerus fractures. The only paper
reporting outcomes following proximal humerus fracture was the one reporting outcomes for the
Australian subpopulation of ICUROS.210 Although these data were specific to a different country,
results were presented in an appendix using the UK time trade-off tariff for the EQ-5D. From these
data, we calculated utility multipliers for the year following humerus fracture and subsequent years,
using the same methodology as employed in the international paper for the other fracture types. The
utility values applied are summarised in Table 8.
Model validation
The model is designed to operate in several different modes, which facilitates debugging and validation.
A description of the general validation methods used, and the specific methods used to validate each
structural change to the model, is provided in Appendix 17.
Approach to sensitivity analysis
A PSA has been conducted to estimate the mean costs and QALYs gained when taking into account the
uncertainty in the parameter values used in the model. In general, parameters were estimated using
the following distributions: gamma distributions for costs, log-normal distributions for HRs (except the
efficacy estimates, which were based on the CODA samples from the NMA) and beta distributions for
utility values and probabilities. The treatment persistence estimates were assumed to be normally
distributed, but maximum and minimum values were applied to ensure that they did not fall below zero
or exceed the intended treatment duration. None of the parameters used to estimate fracture risk,
in the absence of treatment, was varied in the PSA. This was to ensure that a specific set of patient
characteristics was consistently mapped to the same survival curve for fracture-free survival without
any parameter uncertainty. The following additional parameters were not varied in the PSA: drug
prices; discount rates; unit costs sourced from the PSSRU; utility in the second year after proximal
TABLE 8 Costs and utility values applied in the first and subsequent years following fracture
Parameter
Fracture
New admission to
residential careHip Vertebrae Proximal humerus Wrist
Costs in year of fracturea (£) 8568 4342 1358 896 24,519
Costs in subsequent yearsa (£) 110 345 73 73 24,519
Utility multiplier in year of fracture 0.55b 0.68b 0.78c 0.83b 0.625d
Utility in subsequent years 0.86b 0.85b 1.00c 0.99b 0.625d
ICUROS, International Costs and Utilities Related to Osteoporotic Fractures Study.
a Data applied in TA464,34 but inflated using PSSRU inflation indices.16
b ICUROS data reported by Svedbom et al.209
c Calculated from the Australian ICUROS subgroup data reported by Abimanyi-Ochom et al.210 and assumed fixed in
the PSA.
d Data from Tidermark et al.211 previously applied in TA464.34
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humerus fracture; life expectancy after fracture associated with excess mortality; unit costs for
prescriptions after fracture; the proportion of self-funders for residential care; and costs and QALY
decrements for AEs.
Structural sensitivity analyses were conducted to explore whether or not the results were sensitive
to different model assumptions. To reduce model computation time, the structural sensitivity analyses
were conducted using mid-point parameter inputs, rather than using the full PSA version of the model.
Any structural sensitivity analyses conducted during TA464 that showed minimal impact were not
repeated here. The structural sensitivity analyses that were found to have the biggest impact in TA464
were those related to treatment perisistence and AEs.
We conducted the following structural sensitivity analyses:
l assuming full persistence with treatment up to the intended treatment duration
l alternative assumptions for offset periods [1-year offset periods for RIS, IBN (oral and i.v.) and
TPTD, and an offset period equal to treatment duration for ZOL, DEN and RLX]
l HRs for bisphosphonates based on class effect estimate (the predicted HR for a new drug in the
same class).
We noted that both the Amgen Inc.100 and UCB S.A.20 submissions focused on high-risk subgroups.
To generate some comparable results, we conducted an exploratory scenario analysis in which we fixed
the patient characteristics to obtain an estimate of the cost-effectiveness for an example high-risk
patient. The patient characteristics were chosen to match those used in the UCB S.A. model20 as closely
as possible, although an exact match was not possible as the AG model uses FRAX for unknown BMD
whereas the UCB S.A. model20 specifies the T-score of the patient. The patient characteristics selected
were female, aged 75 years, had a history of fracture, a body mass index of 21 kg/m2 and one
additional risk factor, which was chosen to be moderate alcohol consumption (3–6 units per day) to
give a FRAX risk that was similar to the FRAX risk of 30% reported for the patient population in the
UCB S.A. economic model. This example patient had a FRAX score of 31.6%. The model was then run for
500,000 PSA samples with these patient characteristics fixed, but allowing life expectancy to be sampled.
Base-case results
The base-case results are based on model outcomes for 2 million patients from the PSA version of the
model. For each individual patient, a unique set of PSA parameter inputs was sampled (see Approach to
the sensitivity analysis). As the cost-effectivenss is dependent on absolute risk of fracture, results are
provided for 10 risk categories, each containing approximately 200,000 patients. The results presented
for each risk category are based on the average costs and QALYs across the simulated patients falling
into that risk category. It should be noted that the patients in the risk categories differ for QFracture
and FRAX, as each risk category is based on a decile of risk scores across the population modelled
to ensure that each risk category contains approximately the same number of patients and is not
underpowered relative to the other risk categories.
The adverse clinical outcomes avoided (i.e. fractures, fatal fractures and new admissions to nursing/
residential care) compared with no treatment, when using QFracture to estimate fracture risk, are
summarised in Table 9, along with the life-years gained (the equivalent data when using FRAX to
estimate fracture risk can be found in Appendix 18). It should be noted that, as these are based on the
mean outcomes from the PSA, which incorporates estimates of efficacy based on the CODA samples
from the NMA, it is possible for a drug with a mid-point HR close to 1 and a broad CrI to have an
adverse impact on fracture, on average, across the PSA samples. This is the case for RLX, for which
the HR for hip fracture was 0.93 (95% CrI 0.30 to 2.76), resulting in a predicted small increase in hip
fractures, on average, across the PSA samples. This was not observed when running the model using
the mid-point HRs; therefore, it clear that it is being caused by the distribution of CODA samples for
the hip fracture HR for RLX.
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It can be seen from Table 9 that ROMO/ALN results in the largest number of fractures avoided,
followed by TPTD. DEN has fewer fractures avoided in total than TPTD, but a higher number of
life-years gained. This is because the life-years gained are dependent on both the number and the type
of fractures avoided, as only hip and vertebral fractures have an excess mortality risk. It can be seen
that DEN avoids a similar number of hip fractures as TPTD, but DEN avoids more vertebral fractures
than TPTD, meaning that there are fewer fatal fractures for DEN, which results in a greater number
of life-years gained.
The ICERs for non-bisphosphonates versus no treatment and the treatment with maximum INMB (when
valuing a QALY at either £20,000 or £30,000) for each risk category are summarised in Table 10. We used
a regression using a generalised additive model to estimate the relationship between INMB and absolute
risk as a continuous variable for both QFracture and FRAX. Plots of the predicted INMBs when valuing a
QALY at £20,000 for each non-bisphosphonate treatment are summarised in Figure 11 for QFracture and
in Figure 12 for FRAX (results for ROMO/ALN are confidential and have been removed). A negative INMB
in Figures 11 and 12 indicates an ICER of > £20,000 per QALY compared with no treatment. It can be
seen that the INMB relative to no treatment increases with increasing baseline risk for both QFracture
and FRAX for DEN, TPTD and ROMO/ALN, but the INMBs remain under zero across the range of fracture
risk observed in the population eligible for risk assessment. For RLX, the relationship between fracture risk
and INMB is less clear, particularly when using FRAX to estimate fracture risk. The INMB of RLX versus no
treatment predicted by the regression does go above zero from a FRAX score of 32.6–37.8%, but it should
be noted that the predictions become more uncertain as the risk scores increase, as they are informed by
estimates from fewer simulated patients. For example, only 2% of patients have a FRAX score of > 30%
and 0.2% of patients have a FRAX score of > 40%, which is why we do not present the INMB plots for
FRAX scores of > 40%. The risks of fracture predicted by QFracture are generally lower than the risks
predicted by FRAX, meaning that only 0.3% have a risk score of > 30% when using QFracture. The plot of
INMB versus risk for RLX may also be less well defined for RLX than for the other non-bisphosphonates,
as RLX resulted in the fewest number of fractures being prevented, making the estimates of average INMB
gains from prevented fractures more uncertain.
TABLE 9 Clinical outcomes across the whole population eligible for fracture risk assessment when using QFracture to
estimate fracture risk
Drug
Number of adverse clinical outcomes avoided per 100,000 patients treated,
when compared with no treatment
Total life-years
gained per patient
vs. no treatment
Total
fractures
Hip
fracture
Vertebral
fracture
Proximal
humerus
fracture
Wrist
fracture
Nursing home/
residential
care admission
Fatal
fracture
ALN 353 93 85 45 130 16 14 0.0011
RIS 366 83 85 52 147 15 13 0.0010
IBN (oral) 295 81 85 35 94 13 13 0.0010
IBN (i.v.) 147 52 55 9 31 8 9 0.0007
ZOL 617 145 161 80 231 25 26 0.0020
RLX 37 –16 27 17 9 5 –1 0.0005
DEN 507 172 182 42 110 41 30 0.0029
TPTD 660 176 147 91 247 31 27 0.0020
ROMO/
ALN
833 248 158 129 298 56 34 0.0030
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TABLE 10 The ICERs vs. no treatment and treatment with maximum INMB by risk deciles for QFracture and FRAX
Drug
ICERs by risk decile
1 2 3 4 5 6 7 8 9 10 All
Qfracture score (%) 0.5 0.7 1.0 1.4 2.0 2.7 3.9 5.5 8.4 16.0 NA
ALN £675,004 £290,229 £125,805 £126,025 £77,059 £65,281 £30,452 £14,820 £5622 Dominates £31,200
RIS £829,832 £319,027 £129,889 £100,618 £81,404 £64,979 £32,482 £17,119 £7235 Dominates £33,840
IBN (oral) £948,571 £301,165 £119,370 £137,375 £93,736 £68,805 £34,713 £21,840 £9443 Dominates £38,321
IBN (i.v.) Dominated Dominated Dominated Dominated Dominated £4,373,315 £1,250,818 £564,407 £398,475 £266,492 £1,442,071
ZOL Dominated £2,984,339 £808,583 £723,860 £442,296 £353,780 £210,441 £127,491 £93,903 £60,300 £236,247
RLX Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated
DEN £1,794,421 £1,092,301 £1,868,896 £632,830 £523,142 £502,655 £462,072 £250,729 £166,441 £126,392 £388,796
TPTD £8,610,782 £5,871,874 £3,731,997 £3,083,847 £2,356,350 £1,964,475 £1,366,400 £971,695 £671,001 £457,894 £1,419,377
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TABLE 10 The ICERs vs. no treatment and treatment with maximum INMB by risk deciles for QFracture and FRAX (continued )
Drug
ICERs by risk decile
1 2 3 4 5 6 7 8 9 10 All
FRAX score (%) 3.1 4.3 5.0 5.6 6.2 7.3 8.8 10.7 14.9 25.1 NA
ALN £28,541 £27,325 £16,808 £15,524 £11,362 £8951 £3791 Dominates Dominates Dominates £3659
RIS £32,429 £27,654 £15,575 £17,389 £11,265 £8736 £4572 Dominates Dominates Dominates £4181
IBN (oral) £34,519 £27,349 £17,728 £16,459 £12,209 £12,389 £6035 £734 Dominates Dominates £5333
IBN (i.v.) £1,214,068 £853,480 £443,563 £430,771 £342,182 £362,332 £367,423 £215,680 £163,225 £111,944 £299,662
ZOL £170,998 £145,587 £110,846 £96,012 £82,355 £82,446 £63,432 £51,057 £37,737 £20,257 £68,512
RLX Dominated Dominated Dominated Dominated Dominated Dominated Dominated £57,050 Dominated Dominated Dominated
DEN £398,751 £250,782 £195,106 £220,601 £184,386 £193,385 £140,582 £95,158 £89,300 £58,730 £145,830
TPTD £1,254,448 £1,115,769 £832,835 £745,024 £632,511 £622,664 £542,248 £439,478 £343,693 £244,558 £549,324
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The AG also ran the regression of INMB against QFracture and FRAX when assuming that a QALY
is valued at £30,000. The predicted INMBs remained under zero across the full range of risk scores
observed for RLX, TPTD and ROMO/ALN for both QFracture and FRAX. For DEN, the predicted INMB
was above zero, indicating that DEN has an ICER of < £30,000 compared with no treatment for FRAX
scores of > 45%; it remained under zero for the full range of QFracture scores. However, the AG notes
that the estimates of INMB at these very high levels of risk are uncertain as they are informed by
< 0.05% of the simulated population.
A full incremental analysis for each risk category is presented in Appendix 19 for QFracture and in
Appendix 20 for FRAX. The optimal treatment (i.e. the one with the maximum INMB) when valuing a
QALY at either £20,000 or £30,000 is summarised in Table 10 for easy reference. It can be seen that
the optimal treatment when valuing a QALY at £20,000 is no treatment for patients in the lower-risk
categories and oral bisphosphonates for patients in the higher-risk categories. When valuing a QALY at
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FIGURE 11 The INMB as a function of absolute fracture risk, as determined by QFracture.
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FIGURE 12 The INMB as a function of absolute fracture risk, as determined by FRAX.
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£30,000, oral bisphosphonates have the maximum INMB even in the lowest-risk category when using
FRAX to estimate fracture risk (average risk of 3.1%), but no treatment is still the optimal strategy in
the lowest-risk category when using QFracture to estimate fracture risk. Using the predicted INMBs
from the regression we can say that oral bisphosphonates have maximum INMB from a FRAX score of
4.5% and from a QFracture score of 5.2% when valuing a QALY at £20,000.
The i.v. bisphosphonates never have a higher INMB than the oral bisphosphonates. However, ZOL has a
positive INMB compared with no treatment for a fracture risk of 31.1% for Qfracture and of 22.5% for
FRAX. Conversely, i.v. IBN is always dominated by i.v. ZOL because of the higher costs associated with
quarterly administration and the poorer efficacy estimates.
Raloxifene is dominated by no treatment (higher costs and fewer QALYs gained) across all QFracture
risk categories and across all but one FRAX risk category (category 8, with an average risk of 10.7%).
This is explained by the few numbers of fracture prevented and the VTE risk associated with RLX.
Teriparatide is consistently dominated by ROMO/ALN across all risk categories for both QFracture
and FRAX, despite having similar efficacy estiamtes. This is because the treatment duration and offset
period for the ROMO/ALN sequence, which determine how long the efficacy estimates are appied in
the model, are based on the combined duration of the treatment sequence but the cost for the ALN
part of the sequence is much lower than the cost of TPTD.
Sensitivity analyses results
The results for the structural sensitivity analyses (conducted using mid-point parameter estimates)
are presented in Appendix 21. In broad terms, the results for non-bisphosphonates were consistent
with the base-case analysis in that none of the non-bisphosphonates had an ICER of < £30,000 per
QALY when compared with no treatment in any of the QFracture or FRAX risk categories across any
of the sensitivity analyses examined.
The exploratory scenario analysis examining a population with fixed patient characteristics, chosen to
give a FRAX score of approximately 30%, resulted in an ICER of £13,544 for DEN compared with no
treatment (see Appendix 21, Table 74). The ICER for ZOL compared with no treatment was £11,427,
but ZOL was extendedly dominated, leaving ALN, DEN and ROMO/ALN on the cost-effectiveness
frontier. ALN remained the optimal treatment when valuing a QALY at £20,000, as DEN compared
with ALN had an ICER of £26,977. However, this scenario analysis shows that the results may be more
favourable when considering specific high-risk groups, even though the ICER for DEN compared with
no treatment in the highest decile of FRAX risk scores, in which the average risk score was 25%, was
> £30,000 per QALY. However, the AG believes that this exploratory scenario analysis should be
interpreted cautiously, given that it is based on a single example set of patient characteristics and the
cost-effectiveness may differ for patients with different characteristics but the same FRAX score. It is
also noted that the results for the same patient were qualitatively different when using QFracture to
estimate fracture risk, as the risk was much lower (13.3%) than the fracture risk obtained when using
FRAX. In this scenario, none of the non-bisphosphonates had an ICER of < £30,000 when compared
with no treatment (see Appendix 21, Table 75) and using QFracture to estimate absolute fracture risk.
Discussion
A key strength of the approach we have taken is that we have been able to adapt the model used in
TA464 to allow the cost-effectiveness of non-bisphosphonates to be assessed in a manner consistent
with the approach used previously to assess the cost-effectiveness of bisphosphonates. However,
although the overall model structure and many of the data inputs have remained unchanged to maintain
consistency, there are several differences that should be noted. We have updated the estimates of
treatment persistence used for oral bisphosphonates to incorporate a new data source identified in
the UCB S.A. company submission.20 This has increased the duration of treatment persistence for oral
bisphosphonates threefold. We have incorporated monitoring costs for bisphosphonates consisting of
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annual follow-up appointments to encourage persistence and manage AEs and DXA when completing
treatment to assess the need for continued treatment. We have applied the HRs from the NMA for each
individual bisphosphonate, as per the original AG report for TA464,34 rather than the estimates based on
the bisphosphonate class effect as presented in the addendum160 that followed the original assessment
report. However, this only affects the incremental cost-effectiveness of non-bisphosphonates relative to
bisphosphonates. We have incorporated ONJ, VTE and cellulitis as AEs in the model. The utility values
applied following fracture in the revised model are based on an updated systematic review of utility
estimates. The costs following fracture have been uplifted to reflect price changes over time, and the
drug costs were updated to reflect current prices. For consistency, we have used non-vertebral fracture
HRs for wrist fractures for all interventions owing to few data on this outcome for non-bisphosphonates,
whereas previously we used wrist fracture-specific outcomes for the bisphosphonates, as the data were
less sparse when considering only the bisphosphonate interventions.
Although assessing the cost-effectiveness of non-bisphosphonates was the objective of this analysis, it
is noted that the level of fracture risk at which the oral and i.v. bisphosphonates become cost-effective
is higher than in the analysis that informed TA464.34 This is due to the inclusion of monitoring costs,
which add an additional £52 per annum to the drug costs, which are around £10 per annum. However,
these revised estimates of cost-effectiveness for oral bisphosphonates appear to be reasonably
consistent with the intervention thresholds specified in the NICE QS149,13 which provide age-related
intervention thresholds varying from a 10-year absolute risk level of 5.9% in patients aged 40 years to
20% in patients aged ≥ 70 years. In addition, it is noted that TA4649 recommends i.v. bisphosphonates
for patients with a fracture risk of ≥ 10%, but i.v. IBN and ZOL had ICERs of > £30,000 at this risk
level in the revised analysis. Again, this is likely to be as a result of the incorporation of additional
costs for monitoring in secondary care and the correction to the administration costs for i.v. IBN.
The models in the UCB S.A.20 and Amgen Inc.100 submissions both focused their analysis only on
higher-risk subgroups of the population specified in the scope, whereas the AG model provides
cost-effectiveness estimates for 10 risk categories covering the whole population eligible for risk
assessment under CG146.8 It is therefore difficult to compare the results directly. However, the AG
model provides much higher ICERs than those provided by the analyses described in the UCB S.A.20
and Amgen Inc.100 submissions, even for the highest FRAX and QFracture risk categories, although
an exploratory scenario analysis examining an example high-risk patient with a FRAX score of
approximately 30% resulted in an ICER for DEN compared with no treatment that was < £30,000 per
QALY. This finding suggests that the cost-effectiveness estimates for some non-bisphosphonates may
be more favourable for specific high-risk patients, although the AG notes that this scenario analysis
should be interpreted somewhat cautiously, as cost-effectiveness may differ for patients with a similar
FRAX score.
There are several key differences between the AG analysis and the analyses presented in the UCB
S.A.20 and Amgen Inc.100 submissions that should also be noted when interpreting these differences.
The model in the Amgen Inc. submission100 incorporated a much higher cost of administration for i.v. ZOL
than the AG model (£559 vs. £253), which resulted in a more favourable comparison of DEN with ZOL.
The model in the Amgen Inc. submission100 assumed that all DEN treatments would be administered in
primary care, whereas the AG model assumed that the first two DEN treatments would be given in
secondary care, which substantially increases the administration costs for DEN. The model in the Amgen
Inc. submission100 applied a 1-year offset to all drugs, which is unfavourable compared with what the AG
assumed for all drugs except DEN and RLX. The approach taken to model mortality following fracture
differed in the models in the Amgen Inc.100 and UCB S.A.20 submissions, which allowed for an increased
risk of mortality that persisted beyond the 6-month time frame assumed by the AG for excess mortality
attributable to fracture. However, it was not possible to assess the impact of the different assumptions
on mortality attributable to fracture in the AG model because of the different model structures employed.
The model in the UCB S.A. submission20 applied different efficacy estimates at different time points
(different estimates every 6 months, up to 4 years). The AG found that restricting the NMA to studies
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reporting vertebral fractures at 12 months did not provide any evidence to suggest different treatment
effects when the analysis is limited to specific outcome measurement times. Based on this, the NMA used
to inform the AG model incorporated outcomes reported at the longest available time point for each study,
and assumed that the fracture event rate is constant over time. UCB S.A. applied the maximum of a time-
dependent RR for recent fracture and the RR of having had a prior fracture according to FRAX. In contrast
to this, the AG model included HRs that increase the risk of fracture following an incident fracture, which
are applied for the remainder of the model. However, in the AG model, the increased risk incoporated in
the QFracture and FRAX scores is removed at the time of the incident fracture. It is unclear what effect
these different approaches have had on the estimates of future fracture risk following an incident fracture.
UCB S.A. applied different persistence assumptions for patients receiving ALN following ROMO than for
patients receiving ALN from the start of the model, whereas the AG assumed that a patient’s persistence
with ALN treatment woud be independent of whether or not they had previously received ROMO.
One of the key limitations of the AG analysis is that we have assumed that all of the treatment
strategies modelled are viable options for all patients in the population. This allowed us to run the
model once for the whole population eligible for risk assessment and to determine a single absolute
risk threshold for cost-effective intervention for each treatment. Applying a strict interpretation of the
licensed indications for each treatment would have required running the analysis multiple times for
different groups that have different treatment options, which was not feasible. Although incremental
analyses are usually conducted over a set of potentially interchangeable treatments, in reality, it is
often the case that some of the cohort of patients who are eligible for one treatment would be
contraindicated for another, and allowances are made for this when interpreting the cost-effectiveness
results. For example, it is possible to rank the treatments in order of decreasing INMB and treat with
the next most cost-effective treatment when the optimal treatment is contraindicated.
Similarly, although we have not explicitly conducted separate analyses within and between particular
drug classes, it is possible to use the INMB estimates provided to identify the optimal treatment in a
particular class. For example, deleting the RLX, TPTD and ROMO/ALN rows from the results tables
shown in Appendices 14 and 15 and examining the INMBs estimates for the remaining interventions
would allow the optimal treatment to be identified within the class of anti-resportives (ALN, RIS, IBN,
ZOL and DEN). Alternatively, deleting the bisphosphonate rows from the tables would allow the
optimal treatment to be identified for patients for whom bisphosphonates are contraindicated.
The AG economic model assumes that the relative treatment effect (i.e. HR) is consistent across all
populations included in the scope, despite there being heterogeneity in terms of sex, risk factors
(e.g. prior fracture and steroid use) and baseline risk across studies included in the NMA. However,
there was no evidence that treatment effect varied with age, sex or baseline risk, based on the
meta-regression conducted for the NMA outcomes of fracture and BMD.
We note that there are limited data on the long-term persistence for all treatments, but particularly for
the non-bisphosphonates, and the estimates of treatment persistence for TPTD and DEN, in particular,
are based on a fairly crude extrapolation of Kaplan–Meier plots for treatment discontinuation. However,
the sensitivity analyses in which patients were assumed to persist for the full intended treatment duration
did not result in ICERs falling under £30,000 per QALY for any of the non-bisphosphonate treatments.
The economic analysis of ROMO is based on the assumption that it will be used in sequence with
4 years of ALN and that the efficacy observed during the 24 months of the ARCH83 RCT will continue
during the full 4 years of ALN. This results in the treatment effect being extrapolated beyond the
trial period in the analysis, assuming full persistence with treatment. However, the overall duration of
treatment is < 4 years in the base-case model because of the application of real-world persistence data
for ALN; therefore, the need for extrapolation is minimised.
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Adverse events have been incorporated in a fairly crude manner by applying an average cost and QALY
decrement to every individual treated, based on the average incidence, rather than including the AEs
as separate competing events in the model. The benefit of doing this is that it avoids the impact of very
rare AEs, such as ONJ, being missed because they do not occur often in the simulated population. The
estimates of costs and QALY decrements attributable to AEs were also not included in the PSA, which
may mean that the decision uncertainty associted with AEs will be underestimated. However, this is
unlikely to be a significant limitation for cellulitis and ONJ, for which the AE event rates were very low
and the average costs and QALY decrements per treated patient were small and are therefore unlikely
to be significant drivers of cost-effectiveness. However, the average loss of INMB attributable to the
AE of VTE for RLX was relatively large in comparison to the cost of treatment (discounted INMB
decrement of £53 per patient started on treatment vs. an annual drug cost of £43), meaning that this
is likely to be a significant driver of cost-effectiveness for RLX. (Although an explicit scenario analysis
has not been conducted, the AG expects that, for the majority of the risk categories, the INMBs would
be unlikely to be above zero when removing the impact of VTE, based on the results presented.)
We note that the cost-effectiveness analysis is based on current prices for each intervention and,
when there is more than one preparation, we have assumed that the lowest-cost preparation is used,
which is often the generic form, when one is available. We also note that prices for the two biosimilar
versions of TPTD (Movymia and Terrosa)22,23 were not available when this report was prepared.
It is likely that these biosimilar preparations will have a lower cost; therefore, the estimates of cost-
effectiveness for TPTD may be overly pessimistic compared with what may be achieved in practice
in future years if there is widespread uptake of these biosimilars and they are made available at a
substantially lower cost than TPTD.
The scope19 of the MTA stated that treatment sequences would be considered if the evidence allowed.
The only treatment sequence modelled by the AG is ROMO/ALN, as no other treatment sequences
were included in the NMA for fracture outcomes. The AG notes that the UCB S.A. submission20 also
contained cost-effectiveness estimates for the sequence of ALN/ROMO, but it appears that this was
based on an assumption of clinical equivalence for ROMO/ALN and ALN/ROMO and assumptions
regarding the appropriate offset period. Although there was RCT evidence comparing the sequence of
ROMO/DEN with placebo followed by DEN from the FRAME54 RCT, it was not possible to include this
RCT in the NMAs (as neither study arm connected with any other studies included in the networks);
therefore, we have not been able to estimate the cost-effectiveness of the ROMO/DEN sequence.
One of the strengths of this analysis is that we have been able to estimate the cost-effectiveness of
each intervention across the broad range of absolute fracture risk observed in the population eligible
for risk assessment under CG146.8 However, the downside of the approach we have taken is that the
estimates of cost-effectiveness are uncertain in patients at high risk of fracture (e.g. > 30%) as they are
informed by fewer simulated patients. We tried to address this by conducting an exploratory sensitivity
analysis for an example high-risk patient; however, we note that the cost-effectiveness of other
patients with similar FRAX scores may differ and that the regression of INMB across the full range of
risk scores observed in the population eligible for fracture risk assessment did not identify a risk at
which the ICER fell under £20,000 for any of the non-bisphosphonates.
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Chapter 5 Assessment of factors relevant
to the NHS and other parties
The only non-bisphosphonate not currently in use in the NHS in England is ROMO. The UCB S.A.submission20 states that ‘there is likely no administration costs or initiation costs associated with
romosozumab as the training of injection techniques will be provided as part of the patient support
program provided by UCB’. The AG believes that the impact on NHS services of introducing ROMO
to the NHS in England is anticipated to be small, as the needs of patients on ROMO are likely to be
simlar to those on TPTD, which is already an established treatment.
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Chapter 6 Discussion
Statement of principal findings
Fifty-two RCTs of non-bisphosphonates were included in the review. An additional 51 RCTs of
bisphosphonates were included for the NMAs.
Across studies reporting overall mortality, there were no significant differences between non-
bisphosphonate treatment arms and their comparators of placebo, other non-bisphosphonates or
bisphosphonates. The ranges of SAE rates were as follows: DEN, 2–25.8%; RLX, 2–18.6%; ROMO,
3.2–12.9%; and TPTD, 0–33%.
In NMAs for vertebral, non-vertebral and hip fractures, and for femoral neck BMD, all treatments
were associated with beneficial effects relative to placebo. For both vertebral fractures and percentage
change in femoral neck BMD, the treatment effects were statistically significant at a conventional 5%
level for all treatments. TPTD was associated with the greatest effect for vertebral (HR 0.23, 95% CrI
0.16 to 0.32, PB 0.38), non-vertebral (HR 0.58, 95% CrI 0.45 to 0.76, PB 0.52) and hip fractures
(HR 0.35, 95% CrI 0.15 to 0.73, PB 0.50), whereas ROMO was the most effective for wrist fractures
(HR 0.12, 95% CrI 0.00 to 1.19) and proximal humerus fractures (HR 0.10, 95% CrI 0.00 to 3.66), and
ROMO/ALN was the most effective for percentage change in femoral neck BMD (HR 0.10, 95% CrI
0 to 3.66, PB 0.77). In general, the ranking of treatments varied for the different outcomes.
The cost-effectiveness review found that there are no published studies that compare all of the
interventions and comparators specified in the scope of this appraisal across the broad population
specified in the scope. The models described in the UCB S.A.20 and Amgen Inc.100 submissions focused
on high-risk poulations and a subset of comparators.
The ICERs are > £20,000 per QALY for all non-bisphosphonate interventions compared with no
treatment across the range of QFracture and FRAX scores expected in the population eligible for
fracture risk assessment. The ICER for DEN was predicted by the regression analysis to fall below
£30,000 at very high levels of risk (FRAX score of > 45%), but the estimates of cost-effectiveness are
very uncertain at this level of risk. An exploratory scenario analysis examining an example high-risk
patient also suggested that the cost-effectiveness of DEN may be more favourable for high-risk
patients with specific characteristics.
The incremental analysis found that the intervention with maximum INMB (when valuing a QALY
at either £20,000 or £30,000) was either no treatment or oral bisphosphonates across all 10 risk
categories for both QFracture and FRAX scores.
Strengths and limitations of the assessment
Strengths
A comprehensive search for RCTs was undertaken. RCTs were available for all treatments of interest,
reporting fracture data and femoral neck BMD data. NMAs were used to synthesise the evidence,
permitting a coherent comparison of the efficacy of interventions in terms of fracture and femoral
neck BMD. Although studies varied in quality, a sensitivity analysis removing lower-quality studies
from the NMA gave results consistent with the main analysis.
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A key strength of the approach we have taken in the economic evaluation is that we have been able to
adapt the model used in TA464 to allow the cost-effectiveness of non-bisphosphonates to be assessed
in a manner consistent with the approach used previously to assess the cost-effectiveness of
bisphosphonates.
Limitations
Evidence was restricted to English-language publications. Most RCTs had a primary end point of BMD,
which is a surrogate end point, rather than fractures, which are of clinical importance to patients. Studies
varied in quality, particularly on the domains of blinding and attrition, and were not all well reported.
For wrist and proximal humerus fractures, there was less RCT evidence. Although NMAs were conducted,
there is considerable uncertainty in treatment effects for certain interventions in these networks. However,
for the economic analysis, we were able to use the non-vertebral fracture NMA outcomes for wrist and
proximal humerus fracture, as the evidence in this network was less sparse.
Owing to the limitations of the evidence available, we were able to model only one treatment
sequence in the economic analysis. Although we were able to estimate the INMB as a function of
absolute risk across the full range of risk scores expected among the population eligible for risk
assessment, the estimates of INMB in patients at very high risk of fracture (e.g. > 30%) are uncertain
as they are based on a small proportion of the simulated population (< 2% for FRAX and < 0.2%
for QFracture).
Uncertainties
Although statistically significant treatment effects were found when comparing interventions with
placebo, the effects of non-bisphosphonates were generally similar (with non-statistically significant
pairwise HRs). There was evidence of moderate heterogeneity in treatment effects between studies.
Other relevant factors
Any future introduction of biosimilar treatments for TPTD or DEN would be likely to change the
cost-effectiveness of these treatments. This assessment report was prepared while ROMO was still
being assessed by the European Medicines Agency; therefore, it is based on the anticipated rather than
the final licensed indication for ROMO.
DISCUSSION
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Chapter 7 Conclusions
Randomised controlled trials, of varying quality, were available for all non-bisphosphonatetreatments of interest, reporting fracture data and femoral neck BMD data. Domains regarding
methodological quality were not consistently reported across trials. All treatments were associated
with beneficial effects, relative to placebo. For each intervention, reported SAEs varied across trials,
with the majority of between-group differences not being statistically significant for comparisons with
placebo/no active treatment, head-to-head non-bisphosphonate comparisons or comparisons with
bisphosphonates.
The ICERs are > £20,000 per QALY for all non-bisphosphonate interventions compared with no
treatment across the range of QFracture and FRAX scores expected in the population eligible for
fracture risk assessment. The ICER for DEN was predicted by the regression analysis to fall below
£30,000 at very high levels of risk (FRAX score of > 45%), but the estimates of cost-effectiveness are
very uncertain at this level of risk. An exploratory scenario analysis examining an example high-risk
patient also suggested that the cost-effectiveness of DEN may be more favourable for high-risk
patients with specific characteristics.
Implications for service provision
As the majority of the non-bisphosphonate interventions are already part of current practice, and the
additional treatment of ROMO is likely to be delivered in a similar manner to TPTD, we do not
anticipate any significant implications for service provision associated with these treatments.
Suggested research priorities
Additional head-to-head studies, of good methodological quality, comparing non-bisphosphonates
would be beneficial, as few of the RCTs identified in the systematic review were head-to-head
comparisons. In particular, it would be useful to know whether or not a treatment sequence of TPTD
followed by ALN provides similar efficacy to the ROMO/ALN sequence. RCTs with a primary end point
of fractures, rather than BMD, are preferable, as fractures are of clinical relevance to patients.
There were not many trials with a follow-up of > 36 months. The reporting of long-term outcomes
from the ARCH83 and FRAME54 studies for ROMO, in particular, would be useful, to see if the
treatment effectiveness persists during the following years of anti-resportive treatment.
Although there were few data on wrist and humerus fractures for non-bisphosphonates, further
research to gather these is unlikely to be useful, as we were able to use the outcomes from the
non-vertebral fracture network. Similarly, although there were few RCTs with men or of steroid-induced
osteoporosis, these showed similar treatment effect patterns to postmenopausal women, and so further
research in these populations is not considered a research priority.
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Appendix 1 Literature search strategies
Clinical effectiveness
Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations,
Ovid MEDLINE(R) Daily, Ovid MEDLINE and Versions(R), 1946–2018
Searched: 11 July 2018.
# Searches
1 exp osteoporosis/
2 osteoporo*.tw.
3 bone diseases, metabolic/
4 exp Bone Density/
5 (bone adj3 densit*).tw.
6 exp fractures, bone/
7 fractures, cartilage/
8 fracture*.tw.
9 (bone* adj2 fragil*).tw.
10 bone mineral densit*.tw.
11 bone loss.tw.
12 bmd.tw.
13 or/1-12
14 (alendron* or fosomax or fosavance or 121268-17-5).mp.
15 (ibandron* or boniva or bondronat or bonviva or adronil or 114084-78-5).mp.
16 (risedron* or actonel or atelvia or benet or 105462-24-6).mp.
17 (zoledron* or zometa or zomera or aclasta or reclast or 118072-93-8).mp.
18 or/14-17
19 limit 18 to yr= “2014 -Current”
20 (abaloparatide or eladynos or 247062-33-5).mp.
21 (DEN or prolia or xgeva or 615258-40-7).mp.
22 (RLX or evista or keoxifene or 84449-90-1).mp.
23 (ROMO or evenity or 909395-70-6).mp.
24 (TPTD or forsteo or 52232-67-4 or movymia or terrosa).mp.
25 or/20-24
26 13 and (19 or 25)
27 meta-analysis as topic/
28 (meta analy* or metaanaly*).tw.
29 Meta-Analysis/
30 (systematic adj (review*1 or overview*1)).tw.
31 ‘Review Literature as Topic’/
32 or/27-31
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# Searches
33 (cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or cinhal or science citation index
or bids or cancerlit).ab.
34 ((reference adj list*) or bibliograph* or hand-search* or (relevant adj journals) or (manual adj search*)).ab.
35 ((selection adj criteria) or (data adj extraction)).ab.
36 “review”/
37 35 and 36
38 comment/or editorial/or letter/
39 Animals/
40 Humans/
41 39 not (39 and 40)
42 38 or 41
43 32 or 33 or 34 or 37
44 43 not 42
45 26 and 44
46 Randomized controlled trials as Topic/
47 Randomized controlled trial/
48 Random allocation/
49 randomized controlled trial.pt.
50 Double blind method/
51 Single blind method/
52 Clinical trial/
53 exp Clinical Trials as Topic/
54 controlled clinical trial.pt.
55 clinical trial*.pt.
56 multicenter study.pt.
57 or/46-56
58 (clinic* adj25 trial*).ti,ab.
59 ((singl* or doubl* or treb* or tripl*) adj (blind* or mask*)).tw.
60 Placebos/
61 Placebo*.tw.
62 (allocated adj2 random).tw.
63 or/58-62
64 57 or 63
65 Case report.tw.
66 Letter/
67 Historical article/
68 65 or 66 or 67
69 exp Animals/
70 Humans/
71 69 not (69 and 70)
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# Searches
72 68 or 71
73 64 not 72
74 26 and 73
75 45 or 74
EMBASE, 1974–2018
Searched: 11 July 2018.
# Searches
1 exp osteoporosis/
2 osteoporo*.tw.
3 metabolic bone disease/
4 exp bone density/
5 (bone adj3 densit*).tw.
6 exp fracture/
7 cartilage fracture/
8 fracture*.ti,ab.
9 (bone* adj2 fragil*).tw.
10 bone mineral densit*.tw.
11 bone loss.tw.
12 bmd.tw.
13 or/1-12
14 (alendron* or fosomax or fosavance or 121268-17-5).mp.
15 (ibandron* or boniva or bondronat or bonviva or adronil or 114084-78-5).mp.
16 (risedron* or actonel or atelvia or benet or 105462-24-6).mp.
17 (zoledron* or zometa or zomera or aclasta or reclast or 118072-93-8).mp.
18 or/14-17
19 limit 18 to yr = “2014 -Current”
20 (abaloparatide or eladynos or 247062-33-5).mp.
21 (DEN or prolia or xgeva or 615258-40-7).mp.
22 (RLX or evista or keoxifene or 84449-90-1).mp.
23 (ROMO or evenity or 909395-70-6).mp.
24 (TPTD or forsteo or 52232-67-4 or movymia or terrosa).mp.
25 or/20-24
26 13 and (19 or 25)
27 exp Meta Analysis/
28 ((meta adj analy*) or metaanalys*).tw.
29 (systematic adj (review*1 or overview*1)).tw.
30 or/27-29
31 cancerlit.ab.
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# Searches
32 cochrane.ab.
33 embase.ab.
34 (psychlit or psyclit).ab.
35 (psychinfo or psycinfo).ab.
36 (cinahl or cinhal).ab.
37 science citation index.ab.
38 bids.ab.
39 or/31-38
40 reference lists.ab.
41 bibliograph*.ab.
42 hand-search*.ab.
43 manual search*.ab.
44 relevant journals.ab.
45 or/40-44
46 data extraction.ab.
47 selection criteria.ab.
48 46 or 47
49 review.pt.
50 48 and 49
51 letter.pt.
52 editorial.pt.
53 animal/
54 human/
55 53 not (53 and 54)
56 or/51-52,55
57 30 or 39 or 45 or 50
58 57 not 56
59 26 and 58
60 Clinical trial/
61 Randomized controlled trial/
62 Randomization/
63 Single blind procedure/
64 Double blind procedure/
65 Crossover procedure/
66 Placebo/
67 Randomi?ed controlled trial*.tw.
68 Rct.tw.
69 Random allocation.tw.
70 Randomly allocated.tw.
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# Searches
71 Allocated randomly.tw.
72 (allocated adj2 random).tw.
73 Single blind*.tw.
74 Double blind*.tw.
75 ((treble or triple) adj blind*).tw.
76 Placebo*.tw.
77 Prospective study/
78 or/60-77
79 Case study/
80 Case report.tw.
81 Abstract report/or letter/
82 or/79-81
83 animal/
84 human/
85 83 not (83 and 84)
86 or/79-81,85
87 78 not 86
88 26 and 87
89 59 or 88
Web of Science® Core Collection
Science Citation Index Expanded (1900–2018); Conference Proceedings Citation Index –
Science (1990–2018)
Searched: 11 July 2018.
# Searches
# 1 TOPIC: (osteoporo*)
# 2 TOPIC: ((bone NEAR/3 densit*))
# 3 TOPIC: (fracture*)
# 4 TOPIC: (bone mineral densit*)
# 5 TOPIC: (bone loss)
# 6 TOPIC: (bmd)
# 7 #6 OR #5 OR #4 OR #3 OR #2 OR #1
# 8 TOPIC: ((alendron* or fosomax or fosavance or 121268-17-5))
# 9 TOPIC: ((ibandron* or boniva or bondronat or bonviva or adronil or 114084-78-5))
# 10 TOPIC: ((risedron* or actonel or atelvia or benet or 105462-24-6))
# 11 TOPIC: ((zoledron* or zometa or zomera or aclasta or reclast or 118072-93-8))
# 12 #11 OR #10 OR #9 OR #8
Timespan = 2014-2018
# 13 TS = ((abaloparatide or eladynos or 247062-33-5))
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# Searches
# 14 TS = ((DEN or prolia or xgeva or 615258-40-7))
# 15 TS = ((RLX or evista or keoxifene or 84449-90-1))
# 16 TS = ((ROMO or evenity or 909395-70-6))
# 17 TS = ((TPTD or forsteo or 52232-67-4 or movymia or terrosa))
# 18 #17 OR #16 OR #15 OR #14 OR #13
# 19 #7 and (#12 or #18)
# 20 TS = ((meta-analysis or meta analy* or metaanaly*)) OR TS = ((“review literature” or “literature review”)) OR
TS = ((“systematic review*” or “systematic overview*”)) OR TS = ((cochrane or embase or psychlit or psyclit or
psychinfo or psycinfo or cinahl or cinhal or science citation index or bids or cancerlit)) OR TS = ((“reference
list*” or bibliograph* or hand-search* or “relevant journals” or “manual search*”)) OR TS = (((“selection criteria”
or “data extraction”) and review))
# 21 #20 AND #19
# 22 TS = ((“clinic* trial*” or “randomi* controlled trial*”)) OR TS = (((singl* or doubl* or treb* or tripl*) and (blind* or
mask*))) OR TS = ((placebo*)) OR TS = ((allocat* and random*))
# 23 #22 AND #19
Cochrane Database of Systematic Reviews: Wiley Online Library, 1996–2018; Cochrane
Central Register of Controlled Trials (CENTRAL): Wiley Online Library, 1898–2018; Health
Technology Assessment Database: Wiley Online Library, 1995–2016; Database of
Abstracts of Reviews of Effects (DARE): Wiley Online Library, 1995–2015
Searched: 11 July 2018.
# Searches
#1 MeSH descriptor: [Osteoporosis] explode all trees
#2 osteoporo*:ti,ab,kw
#3 MeSH descriptor: [Bone Diseases, Metabolic] this term only
#4 MeSH descriptor: [Bone Density] this term only
#5 (bone next/3 densit*):ti,ab,kw
#6 MeSH descriptor: [Fractures, Bone] explode all trees
#7 MeSH descriptor: [Fractures, Cartilage] explode all trees
#8 fracture*:ti,ab
#9 (bone* next/2 fragil*):ti,ab,kw
#10 bone mineral densit*:ti,ab,kw
#11 bone loss:ti,ab,kw
#12 bmd:ti,ab,kw
#13 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
#14 (alendron* or fosomax or fosavance or 121268-17-5):ti,ab,kw
#15 (ibandron* or boniva or bondronat or bonviva or adronil or 114084-78-5):ti,ab,kw
#16 (risedron* or actonel or atelvia or benet or 105462-24-6):ti,ab,kw
#17 (zoledron* or zometa or zomera or aclasta or reclast or 118072-93-8):ti,ab,kw
#18 (or #14-#17)
#19 #13 and #18 Publication Year from 2014 to 2018
#20 (abaloparatide or eladynos or 247062-33-5):ti,ab,kw
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# Searches
#21 (DEN or prolia or xgeva or 615258-40-7):ti,ab,kw
#22 (RLX or evista or keoxifene or 84449-90-1):ti,ab,kw
#23 (ROMO or evenity or 909395-70-6):ti,ab,kw
#24 (TPTD or forsteo or 52232-67-4 or movymia or terrosa):ti,ab,kw
#25 (or #20-#24)
#26 #19 or #25
World Health Organization International Clinical Trials Registry Platform
Searched: 11 July 2018.
# Searches
1 (alendron* or fosomax or fosavance or 121268-17-5).mp.
2 (ibandron* or boniva or bondronat or bonviva or adronil or 114084-78-5).mp.
3 (risedron* or actonel or atelvia or benet or 105462-24-6).mp.
4 (zoledron* or zometa or zomera or aclasta or reclast or 118072-93-8).mp.
5 (abaloparatide or eladynos or 247062-33-5).mp.
6 (DEN or prolia or xgeva or 615258-40-7).mp.
7 (RLX or evista or keoxifene or 84449-90-1).mp.
8 (ROMO or evenity or 909395-70-6).mp.
9 (TPTD or forsteo or 52232-67-4 or movymia or terrosa).mp.
Thirty-four systematic reviews were checked for RCTs meeting the inclusion criteria.214–247
Cost-effectiveness studies of osteoporosis
Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations,
Daily, and Versions(R), 1946–2018
Searched: 16 July 2018.
# Searches
1 exp osteoporosis/
2 osteoporo*.tw.
3 bone diseases, metabolic/
4 exp Bone Density/
5 (bone adj3 densit*).tw.
6 exp fractures, bone/
7 fractures, cartilage/
8 fracture*.tw.
9 (bone* adj2 fragil*).tw.
10 bone mineral densit*.tw.
11 bone loss.tw.
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# Searches
12 bmd.tw.
13 or/1-12
14 exp “Costs and Cost Analysis”/
15 Economics/
16 exp Economics, Hospital/
17 exp Economics, Medical/
18 Economics, Nursing/
19 exp models, economic/
20 Economics, Pharmaceutical/
21 exp “Fees and Charges”/
22 exp Budgets/
23 budget*.tw.
24 ec.fs.
25 cost*.ti.
26 (cost* adj2 (effective* or utilit* or benefit* or minimi*)).ab.
27 (economic* or pharmacoeconomic* or pharmaco-economic*).ti.
28 (price* or pricing*).tw.
29 (financial or finance or finances or financed).tw.
30 (fee or fees).tw.
31 (value adj2 (money or monetary)).tw.
32 quality-adjusted life years/
33 (qaly or qalys).af.
34 (quality adjusted life year or quality adjusted life years).af.
35 or/14-34
36 13 and 35
37 limit 36 to yr= “2014 -Current”
EMBASE, 1974–2018
Searched: 16 July 2018.
# Searches
1 exp osteoporosis/
2 osteoporo*.tw.
3 metabolic bone disease/
4 exp bone density/
5 (bone adj3 densit*).tw.
6 exp fracture/
7 cartilage fracture/
8 fracture*.ti,ab.
9 (bone* adj2 fragil*).tw.
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# Searches
10 bone mineral densit*.tw.
11 bone loss.tw.
12 bmd.tw.
13 or/1-12
14 *economics/
15 (economic adj2 model*).mp.
16 (cost minimi* or cost-utilit* or health utilit* or economic evaluation* or economic review* or cost outcome or
cost analys?s or economic analys?s or budget* impact analys?s).ti,ab,hw,kw.
17 (cost-effective* or pharmacoeconomic* or pharmaco-economic* or cost-benefit or costs).ti,hw,kw.
18 (life year or life years or qaly* or cost-benefit analys?s or cost-effectiveness analys?s).ab,hw,kw.
19 (cost or economic*).ti,hw,kw. and (costs or cost-effectiveness or markov).ab.
20 or/14-19
21 13 and 20
22 limit 21 to yr= “2014 -Current”
Health Technology Assessment Database: Centre for Reviews and Dissemination,
1995–2016; NHS Economic Evaluation Database: Centre for Reviews and Dissemination,
1995–2015; Database of Abstracts of Reviews of Effects: Centre for Reviews and
Dissemination, 1995–2015
Searched: 16 July 2018.
# Searches
1 MeSH DESCRIPTOR Osteoporosis EXPLODE ALL TREES
2 (osteoporo*)
3 MeSH DESCRIPTOR Bone Diseases, Metabolic
4 MeSH DESCRIPTOR Bone Diseases
5 (bone adj3 densit*)
6 MeSH DESCRIPTOR Fractures, Bone EXPLODE ALL TREES
7 MeSH DESCRIPTOR Fractures, Cartilage EXPLODE ALL TREES
8 (fracture*)
9 (bone* adj2 fragil*)
10 (bone mineral densit*)
11 (bone loss)
12 (bmd)
13 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12
14 (#14) FROM 2014 TO 2018
15 (#15) IN HTA FROM 2014 TO 2018
16 (#15) IN NHSEED FROM 2014 TO 2018
17 (#15) IN DARE FROM 2014 TO 2018
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The EuroQol-5 Dimensions and osteoporosis
Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations,
Daily, and Versions(R), 1946–2018
Searched: 19 July 2018.
# Searches
1 exp osteoporosis/
2 bone diseases, metabolic/
3 osteoporo*.tw.
4 or/1-3
5 (bone adj6 densit*).tw.
6 bone density/
7 bmd.ti,ab.
8 (bone or bones).mp.
9 exp densitometry/
10 tomography, x-ray computed/
11 densit*.tw.
12 10 and 11
13 9 or 12
14 8 and 13
15 5 or 6 or 7 or 14
16 exp fractures, bone/
17 fractures, cartilage/
18 fracture*.ti,ab.
19 or/16-18
20 15 or 19
21 4 and 20
22 (euroqol or euro qol or eq5d or eq 5d).mp.
23 21 and 22
24 limit 23 to yr= “2014 -Current”
EMBASE, 1974–2018
Searched: 19 July 2018.
# Searches
1 exp osteoporosis/
2 osteoporo*.tw.
3 metabolic bone disease/
4 or/1-3
5 (bone adj6 densit*).tw.
6 bone density/
7 bmd.ti,ab.
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# Searches
8 (bone or bones).mp.
9 exp densitometry/
10 tomography/
11 densit*.tw.
12 10 and 11
13 9 or 12
14 8 and 13
15 5 or 6 or 7 or 14
16 exp fracture/
17 cartilage fracture/
18 fracture*.ti,ab.
19 16 or 17 or 18
20 15 or 19
21 4 and 20
22 (euroqol or euro qol or eq5d or eq 5d).mp.
23 21 and 22
24 limit 23 to yr= “2014 -Current”
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Appendix 2 Excluded studies
Thirty-four studies of non-bisphosphonates were excluded.
TABLE 11 Excluded studies
Trial Reason for exclusion
Bone 2008188 and extension
(Bone 2011)189
l Population outside scope
l Low BMD not osteoporosis (and mean age < 65 years)
Naylor 2010186 l Population outside scope
l Low BMD not osteoporosis (and mean age < 65 years)
Dore 2010248 l Population outside scope
l Low BMD not osteoporosis (and mean age < 65 years)
Cosman 2009249 l Comparison outside scope
l Stopping study
Smith 2009250 l Population outside scope
l Cancer treatment
Ellis 2008251 l Population outside scope
l Cancer treatment
Gnant 2015252 l Population outside scope
l Cancer treatment
Klotz 2014253 l Population outside scope
l Cancer
Raje 2018254 l Population outside scope
l Cancer
Henry 2010255 l Population outside scope
l Cancer; conference abstract only
Fazeli 2014256 l Population outside scope
l Anorexia nervosa
RUTH257 l Population outside scope
l Coronary heart disease
Bonani 2012258 l Population outside scope
l Post kidney transplant
Haghverdi 2014259 l Population outside scope
l Chronic kidney disease
Szczepanek 2017260 l Population outside scope
l Low BMD not osteoporosis
l Intestinal failure
Zhu 2017261 l Conference abstract only
l Insufficient details reported
Thomas 2014262 l Conference abstract only
l Insufficient details reported
Galesanu 2015263 l Conference abstract only
l Insufficient details reported
TOWER264 l Intervention outside scope
l Unlicensed dose of TPTD
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TABLE 11 Excluded studies (continued )
Trial Reason for exclusion
Cosman 2008265 l Intervention outside scope
l Unlicensed dose of TPTD
Body 2002266 l Intervention outside scope
l Unlicensed dose of TPTD
Finkelstein 2010267 l Intervention outside scope
l Unlicensed dose of TPTD
Iseri 2017268 l Intervention outside scope
l Unlicensed dose of ALN
Iwamoto 2008269 l Intervention outside scope
l Unlicensed dose of ALN
Roux 2014270 l Intervention outside scope
l Unlicensed dose of RIS
Mok 2014271 l Intervention outside scope
l Pooled bisphosphonate data; doses not reported
Gonnelli 2006272 l Intervention outside scope
l Pooled comparator data includes treatments outside scope
CORE (extension of MORE)273 l Intervention outside scope
l Pooled unlicensed and licensed doses of RLX from MORE study51
Majima 2008274 l Comparison outside scope
l RLX vs. RLX plus alfacalcidol
Seeman 2010275 l Outcomes outside scope
l No outcomes of interest
SHOTZ276 l Outcomes outside scope
l No outcomes of interest
Bai 2013277 l Outcomes outside scope
l No usable outcomes
AVA osteoporosis278 l Outcomes outside scope
l No outcomes of interest
AVA, Anabolism Versus Antiresorption; CORE, Continuing Outcomes Relevant to Evista; RUTH, Raloxifene Use
for The Heart; SHOTZ, Skeletal Histomorphometry in subjects On Teriparatide or Zoledronic acid therapy;
TOWER, Teriparatide Once-Weekly Efficacy Research.
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Appendix 3 Bisphosphonate studies
O f 48 RCTs (reported in 59 references) included in TA464,9,34 38 RCTs (reported in 48 references)were included in the NMAs of fracture and/or femoral neck BMD data in this report.
Three additional bisphosphonate RCTs were identified by the searches in this report (see Appendix 1)
to update the review of TA464. These were included in the NMAs.
Seven RCTs from TA464 were excluded for not reporting either fracture or femoral neck BMD data.
In addition, three RCTs of bisphosphonates from TA464 were excluded for being conducted in a
cancer population.
TABLE 12 Included bisphosphonate RCTs from TA46434
Trial Population
Intervention and
comparator(s)
Vertebral
fracture
NMA
Femoral
neck BMD
NMA
Adami 1995279 Postmenopausal women
with osteoporosis
l Placebo
l ALN, 10 mg per day
Yes
FIT I (Black 1996)280 Postmenopausal women
with osteoporosis
l Placebo
l ALN, 10 mg per day
Yes Yes
FIT II (Cummings 1998)281 Postmenopausal women
with osteoporosis
l Placebo
l ALN, 10 mg per day
Yes Yes
Bone 2000282 Postmenopausal women
with osteoporosis
l Placebo
l ALN, 10 mg per day
Yes
Carfora 1998135 Postmenopausal women
with osteoporosis
l Placebo
l ALN, 10 mg per day
Yes
Dursun 2001131 Postmenopausal women
with osteoporosis
l Calcium
l ALN, 10 mg
per day+ calcium
Yes Yes
Greenspan 2002283 Postmenopausal women
with osteoporosis
l Placebo
l ALN, 10 mg per day
Yes
Greenspan 2003284 Postmenopausal women
aged ≥ 65 years
l Placebo
l ALN, 10 mg per day
Yes
Ho 2005285 Postmenopausal women
with osteoporosis
l Calcium
l ALN, 10 mg
per day+ calcium
Yes
Liberman 1995134 Postmenopausal women
with osteoporosis
l Placebo
l ALN, 10 mg per day
Yes Yes
Orwoll 2000286 Men with osteoporosis l Placebo
l ALN, 10 mg per day
Yes Yes
Miller 2004129 Men with osteoporosis l Placebo
l ALN, 70 mg per week
Yes
FOSIT (Pols 1999)287 Postmenopausal women
with osteoporosis
l Placebo
l ALN, 10 mg per day
Yes
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TABLE 12 Included bisphosphonate RCTs from TA46434 (continued )
Trial Population
Intervention and
comparator(s)
Vertebral
fracture
NMA
Femoral
neck BMD
NMA
Saag 1998;288 Adachi 2001289 Men and women with
glucocorticoid-induced
osteoporosis
l Placebo
l ALN, 10 mg per day
Yes
BONE (Chesnut 2004);136
Chesnut 2005290
Postmenopausal women
with osteoporosis
l Placebo
l IBN, 2.5 mg per day
l IBN, 20 mg every
other day
Yes Yes
McClung 2009291 Postmenopausal women
with osteoporosis
l Placebo
l IBN, 150 mg per month
Yes
DIVA (Delmas 2006);292
Eisman 2008293
Postmenopausal women
with osteoporosis
l IBN, 2.5 mg per day
l IBN, 2 mg intravenously,
twice per month
l IBN, 3 mg intravenously,
three times per month
Yes
MOBILE (Miller 2005);294
Reginster 2006181
Postmenopausal women
with osteoporosis
l IBN, 2.5 mg
l IBN, 50 mg, two doses
per month
l IBN, 100 mg per month
l IBN, 150 mg per month
Yes
Boonen 2009295 Men with osteoporosis l Placebo
l RIS, 35 mg per week
Yes Yes
Cohen 1999296 Men and women aged
18–85 years receiving
glucocorticoids
l Placebo
l RIS, 5 mg per day
Yes Yes
BMD-MN
(Fogelman 2000)297
Postmenopausal women
with osteoporosis
l Placebo
l RIS, 5 mg per day
Yes Yes
Hooper 2005132 Postmenopausal women
with osteoporosis
l Placebo
l RIS, 5 mg per day
Yes Yes
VERT-NA (Harris 1999);298
Ste-Marie (2004)299
Postmenopausal women
with osteoporosis
l Placebo
l RIS, 5 mg per day
Yes Yes
VERT-MN (Reginster 2000);300
Sorensen 2003301
Postmenopausal women
with osteoporosis
l Placebo
l RIS, 5 mg per day
Yes Yes
Leung 2005302 Postmenopausal women
with osteoporosis
l Placebo
l RIS, 5 mg per day
Yes
Reid 2000303 Men and women taking
glucocorticoids for
≥ 6 months
l Placebo
l RIS, 5 mg per day
Yes Yes
Ringe 2006;304 Ringe 2009305 Men with osteoporosis l Placebo
l RIS, 5 mg per day
Yes
HORIZON-PFT
(Black 2007);133 Reid 2010306
Postmenopausal women
with osteoporosis
l Placebo
l ZOL, 5 mg per year
Yes Yes
HORIZON-RFT
(Lyles 2007);307 Adachi 2011308
Men and women aged
≥ 50 years within 90 days
after surgical repair of a
hip fracture
l Placebo
l ZOL, 5 mg per year
Yes Yes
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
136
TABLE 12 Included bisphosphonate RCTs from TA46434 (continued )
Trial Population
Intervention and
comparator(s)
Vertebral
fracture
NMA
Femoral
neck BMD
NMA
Boonen 2012309 Men with osteoporosis l Placebo
l ZOL, 5 mg per year
Yes Yes
McClung 2009310 Postmenopausal women
with osteoporosis
l Placebo
l ZOL, 5 mg per year
Yes
MOTION (Miller 2008)311 Postmenopausal women
with osteoporosis
l ALN, 70 mg per week
l IBN, 150 mg per month
Yes Yes
Muscoso 200479 Postmenopausal women
with osteoporosis
l RIS, 5 mg per day
l ALN, 10 mg per day
Yes
Sarioglu 2006312 Postmenopausal women
with osteoporosis
l RIS, 5 mg per day
l ALN, 10 mg per day
Yes
FACT (Rosen 2005);313
Bonnick 2006314
Postmenopausal women
with osteoporosis
l ALN, 70 mg per week
l RIS, 35 mg per week
Yes
FACTS (Reid 2006;315
Reid 2008316)
Postmenopausal women
with osteoporosis
l ALN, 70 mg per week
l RIS, 35 mg per week
Yes
HORIZON (Reid 2009)317 Men and women taking
glucocorticoids for
< 3 months or ≥ 3 months
l ZOL, 5 mg per year
l RIS, 5 mg per day
Yes Yes
BMD-MN, Bone Mineral Density-Multinational; BONE, iBandronate Osteoporosis vertebral fracture trial in North
America and Europe; DIVA, Dosing IntraVenous Administration; FACT, Fosamax Actonel Comparison Trial; FACTS,
Fosamax Actonel Comparison Trial international study; FIT, Fracture Intervention Trial; FOSIT, FOSamax International
Trial; MOBILE, Monthly Oral iBandronate In LadiEs; MOTION, Monthly Oral Therapy with Ibandronate for Osteoporosis
iNtervention; PFT, Pivotal Fracture Trial; RFT, Recurrent Fracture Trial; VERT-MN, Vertebral Efficacy with Risedronate
Therapy-Multinational; VERT-NA, Vertebral Efficacy with Risedronate Therapy-North American.
TABLE 13 Included bisphosphonate RCTs from updated review (additional to the NICE TA464)
Trial Population
Intervention and
comparators
Included in fracture
rate NMA?
Included in femoral
neck BMD NMA?
TRIO137 Postmenopausal women
with osteoporosis
l ALN
l IBN
l RIS
No Yes
Tan 2016138 Postmenopausal women
with osteoporosis
l ALN
l ZOL
No Yes
ZONE130 Women and men with
osteoporosis
l Placebo
l ZOL
Yes No
TRIO, Tablets, Rings, and Injectables as Options for Women; ZONE, ZOledroNate treatment in Efficacy to osteoporosis.
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TABLE 14 Bisphosphonate RCTs excluded from TA464
Trial Population
Intervention and
comparators Reason for exclusion
Chesnut 1995318 Postmenopausal women with
osteoporosis
l Placebo
l ALN, 10 mg per day
Outcome outside scope
CORAL (Klotz 2013)319 Men with androgen deprivation
bone loss in non-metastatic
prostate cancer
l Placebo
l ALN, 70 mg per week
Population outside scope,
cancer
Shilbayeh 2004320 Postmenopausal women with
osteoporosis
l Placebo
l ALN, 10 mg per day
Outcome outside scope
Smith 2004321 Men and women with asthma
and/or chronic obstructive
airways disease
l Placebo
l ALN, 10 mg per day
Outcome outside scope
ARIBON (Lester 2008)322 Postmenopausal women with
breast cancer
l Placebo
l IBN, 150 mg
per month
Outcome outside scope
Choo 2011323 Men with androgen deprivation
bone loss in non-metastatic
prostate cancer
l Placebo
l RIS, 35 mg per week
Population outside scope;
cancer
McClung 2001324 Postmenopausal women with
osteoporosis
l Placebo
l RIS, 5 mg per day
Outcome outside scope
Taxel 2010325 Men aged > 55 years and
within 1 month of receiving an
initial injection of androgen
deprivation therapy for
prostate cancer
l Placebo
l RIS, 35 mg per week
Population outside scope;
cancer
Atmaca 2006326 Postmenopausal women with
osteoporosis
l RIS, 5 mg per day
l ALN, 10 mg per day
Outcome outside scope
ROSE (Hadji 2010;327
Hadji 2012328)
Postmenopausal women with
osteoporosis
l ZOL, 5 mg per year
l ALN, 70 mg per day
Outcome outside scope
ARIBON, reversal of anastrozole (ARImidex) induced bone loss with oral monthly IBN (BONdronat) treatment during
adjuvant therapy for breast cancer; CORAL, Cancer and Osteoporosis Research with Alendronate and Leuprolide;
ROSE, Rapid Onset and Sustained Efficacy.
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TABLE 15 Trial characteristics
Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
DEN vs. placebo
FREEDOM:
Cummings 2009;41
Bone 2017104
International, randomised,
placebo-controlled trial –
21 centres in USA and
Canada
Women between the ages of 60
and 90 years with a lumbar spine
or total hip T-score of < –2.5
l Placebo, n = 3906
l DEN, 60mg s.c., 3902
l Both every 6 months
All women received
daily supplements
containing at least
1000 mg of calcium
36 months and OLE
to 84 months
New vertebral
fracture
Excluded if they had conditions
that influence bone metabolism or
had taken oral bisphosphonates
for > 3 years
ADAMO
(NCT00980174):
Orwoll 201242
Randomised placebo-
controlled Phase III trial;
international, multicentre
(Belgium, Canada,
Denmark, France, Poland,
Sweden, the USA)
Men with low BMD, lumbar spine
or femoral neck BMD T-score
of ≤ –2.0 or ≥ –3.5, or previous
major osteoporotic fracture and
BMD-score of ≤ –1.0 or ≥ –3.5
l Placebo for 1 year, then
open-label DEN for
1 year, n= 121
l DEN: 60mg of DEN
every 6 months for
2 years (1 year blinded,
then 1 year open
label), n= 121
Daily calcium
(≥ 1000mg) and
vitamin D (≥ 800 IU)
24 months Lumbar spine
BMD percentage
change from
baseline at
12 months
Excluded if severe, or multiple,
vertebral fracture(s), conditions
that influence bone metabolism or
prior bisphosphonate treatment
(≥ 3 months in previous 2 years
or ≥ 1 month in prevous year or
within 3 months of randomisation
A
P
P
E
N
D
IX
4
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
a
lslib
ra
ry
.n
ih
r.a
c.u
k
1
4
0
Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
DIRECT
(NCT00680953):
Nakamura 201443
Randomised placebo-
controlled Phase III trial,
multicentre, Japan, OLE
Postmenopausal women and men
aged ≥ 50 with osteoporosis; 1–4
vertebral fractures and lumbar
spine BMD T-score of < –1.7
(YAM in Japan 80%), or total hip
BMD T-score of < –1.6
l Placebo for 2 years
followed by open-label
DEN for 1 year, n= 511
l DEN, 60mg every
6 months for 2 years
followed by open-label
DEN for 1 year, n= 500
Daily calcium
(≥ 600mg) and
vitamin D (≥ 400 IU)
36 months Incidence of new
or worsening
vertebral fracture
by X-ray at
24 months
Excluded if severe, or two or
more moderate, vertebral
fractures, conditions that
influence bone metabolism, or
prior bisphosphonate treatment
(≥ 3 years, or with 6 months of
randomisation), prior hormonal
treatments, calcitonin or TPTD
within 6 weeks of enrolment
Nakamura 201244 Randomised placebo-
controlled Phase II trial,
multicentre, Japan
Postmenopausal women
aged ≤ 80 years, ambulatory,
osteoporosis, lumbar spine BMD
T-score (for Japanese subjects) of
≤ –2.5 or ≥ –4.0 or femoral neck
or total hip BMD of ≤ –2.5 or
≥ –3.5
l Placebo, n = 55
l DEN, 60mg every
6 months, n= 54
l For 1 year
Daily calcium
(≥ 600mg) and
vitamin D (≥ 400 IU)
12 months Lumbar spine
BMD percentage
change from
baseline at
12 months
Excluded if any severe or two
or more moderate vertebral
fracture, hypocalcaemia, prior
bisphosphonates or parathyroid
hormone within 12 months, or
hormonal or calcium treatment
within 3 months prior to
randomisation
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TABLE 15 Trial characteristics (continued )
Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
Koh 201645
(NCT01457950)
Randomised placebo-
controlled Phase III trial,
multicentre, Korea, OLE
Postmenopausal women aged
60–90 years, Korean-born, lumbar
spine or total hip BMD of < –2.5
or ≥ –4.0
l Placebo for 6 months,
then open-label DEN for
6 months, n= 66
l DEN, 60mg for 6
months then open-label
DEN for 6 months,
n= 69
Daily calcium
(≥ 1000mg) and
vitamin D (≥ 400 IU)
12 months Lumbar spine
BMD percentage
change from
baseline at
6 months
Excluded if conditions that
influence bone metabolism,
increased risk of ONJ, hypo-
or hypercalcaemic, vitamin D
deficiency, prior treatment with
bone metabolism drugs
RLX vs. placebo
Adami 200846 International, randomised-
controlled trial – 32 clinical
centres in seven countries
(the USA, France, Germany,
Spain, Italy, Canada and
Australia)
Postmenopausal women aged
50–80 years, BMD T-score of
< –2.5 at the lumbar spine
l Placebo, n = 172
l RLX, 60 mg, n = 157
l Both daily
l All pre treated for
12 months with TPTD
(20 µg s.c. daily) prior
to randomisation
All participants
received oral
supplements of at least
500 mg per day of
elemental calcium and
400–800 IU per day of
vitamin D
12 months from
randomisation
Lumbar spine
BMD
Exclude if had condition or
receiving treatment affecting
BMD
Morii 2003;47
Japan; Clinical
Trial Research
Group
Randomised placebo-
controlled, multicentre;
Japan
Postmenopausal (≥ 2 years)
women, aged ≤ 80 years, lumbar
spine BMD of ≤ –2.5 YAM
l Placebo, n = 100
l RLX, 60 mg
daily, n= 100
Daily calcium (500 mg)
and vitamin D (200 IU)
12 months Lumbar spine
BMD percentage
change from
baseline at
12 monthsExcluded if conditions that
influence bone metabolism,
hormonal therapy, pathologic
fractures or lumbar spine BMD
unevaluable, bisphosphonates
within 6 months
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Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
Liu 200448 Randomised placebo-
controlled, multicentre;
China
Postmenopausal (≥ 2 years)
women, aged 50–80 years, lumbar
spine or femoral neck BMD
T-score of ≤ –2.5
l Placebo, n = 102
l RLX, 60 mg
daily, n= 102
Daily calcium (500 mg)
and vitamin D (200 IU)
12 months Lumbar spine
BMD percentage
change from
baseline at
12 months
Excluded if conditions or
treatments that influence bone
metabolism
Gorai 201249 Randomised controlled
trial, open-label, two
centres, Japan
Postmenopausal (≥ 2 years)
women, lumbar spine BMD of
≤ –2.0 YAM
l Alfacalcidol, 1 µg per
day, n = 46
l RLX, 60 mg per
day, n = 42
l RLX, 60 mg per day plus
alfacalcidol, 1 µg per
day, n = 45
NA 24 months Lumbar spine
BMD percentage
change from
baseline and bone
turnoverExcluded if conditions or
treatments that influence bone
metabolism, bisphosphonates
within 18 months
Silverman 200850
(NCT00205777)
Randomised controlled
trial, Phase III, multicentre,
Argentina, Australia,
Austria, Belgium, Brazil,
Bulgaria, Canada, Chile,
Croatia, Denmark, Estonia,
Finland, France, Germany,
Greece, Hong Kong,
Hungary, Italy, Lithuania,
Mexico, the Netherlands,
New Zealand, Norway,
Poland, Romania, Russian
Federation, Slovakia, South
Africa, Spain, the USA
Postmenopausal (≥ 2 years)
women, aged 55–85 years, lumbar
spine or femoral neck BMD
T-score of ≤ –2.0 or ≥ –4.0, or one
or more mild vertebral fracture and
lumbar spine or femoral neck BMD
T-score of ≥ –4.0
l Placebo, n = 1885
l RLX, 60 mg per
day, n = 1849
Daily calcium
(≤ 1200mg) and
vitamin D (400–800 IU)
36 months Percentage of
new vertebral
fractures, as
determined
by X-ray, at
36 months
Excluded if conditions that
influence bone metabolism,
history of thrombosis, hormonal
or bisphosphonate treatment
within 6 months
continued
D
O
I:
1
0
.3
3
1
0
/h
ta2
4
2
9
0
H
e
a
lth
T
e
ch
n
o
lo
g
y
A
sse
ssm
e
n
t
2
0
2
0
V
o
l.2
4
N
o
.2
9
©
Q
u
een
’s
P
rin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
2
0
.T
h
is
w
o
rk
w
as
p
ro
d
u
ced
b
y
D
avis
et
a
l.u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
an
d
So
cial
C
are.T
h
is
issu
e
m
ay
b
e
freely
rep
ro
d
u
ced
fo
r
th
e
p
u
rp
o
ses
o
f
p
rivate
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,
th
e
fu
ll
rep
o
rt)
m
ay
b
e
in
clu
d
ed
in
p
ro
fessio
n
al
jo
u
rn
als
p
ro
vid
ed
th
at
su
itab
le
ackn
o
w
led
gem
en
t
is
m
ad
e
an
d
th
e
rep
ro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g.
A
p
p
licatio
n
s
fo
r
co
m
m
ercial
rep
ro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:
N
IH
R
Jo
u
rn
als
Lib
rary,
N
atio
n
al
In
stitu
te
fo
r
H
ealth
R
esearch
,
E
valu
atio
n
,
Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,
A
lp
h
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
p
to
n
Scien
ce
P
ark,So
u
th
am
p
to
n
SO
1
6
7
N
S,U
K
.
1
4
3
TABLE 15 Trial characteristics (continued )
Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
MORE51,102 Randomised controlled
trial, multicentre, Canada,
Europe, South America,
USA
Postmenopausal (≥ 2 years)
women, femoral neck or lumbar
spine BMD T-score of < –2.5; or
one or more moderate or severe,
or two or more mild or moderate,
vertebral fractures
l Placebo, n = 2576
l RLX, 60 mg per
day, n = 2557
Daily calcium (500 mg)
and vitamin D
(400–600 IU)
36 months Incident vertebral
fractures and
BMD
Excluded if conditions that
influence bone metabolism,
history of thrombosis,
hormonal therapy 2 months,
bisphosphonates with 6 months,
pathologic fractures, unevaluable
by thoracic/lumbar X-ray
Lufkin 199852 Randomised controlled
trial, two centres, USA
Postmenopausal (≥ 5 years)
women, aged 45–75 years,
ambulatory, lumbar spine or
femoral neck BMD ≤ 10th
percentile of normal and one or
more non-traumatic vertebral
fracture
l Control, n = 48
l RLX, 60 mg per
day, n = 48
Daily calcium (750 mg)
and vitamin D (800 IU)
12 months Biochemical
markers of bone
turnover
Excluded if conditions that
influence bone metabolism,
history of thrombosis, prior
bisphosphonates, hormonal
therapy within 6 months
Mok 201153
(NCT00371956)
Randomised placebo-
controlled trial, Phase IV,
two sites, China
Postmenopausal (≥ 1 year)
women receiving long-term
glucocorticoid treatment
(prednisone, ≤ 10mg per day
or equivalent) for ≥ 6 months
l Placebo, n = 57
l RLX, 60 mg per
day, n = 57
Daily calcium (1000 mg)
and calcitrol (0.25 µg)
12 months Lumbar spine
and hip BMD
percentage
change from
baseline at
12 months
Excluded if history of thrombosis
or hypercoagulability, prior
bisphosphonates or PTH
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Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
ROMO vs. placebo
FRAME:
Cosman 201654
International, randomised
controlled trial – 25
countries across Latin
America, Central and
Eastern Europe, Western
Europe, Australia or New
Zealand, Asia Pacific and
the USA
Women aged 55–90 years with a
T-score of –2.5 to –3.5 at the
total hip or femoral neck
l Placebo, n = 3591
l ROMO, 210mg
s.c., n = 3589
l Both once monthly for
12 months then DEN
60mg s.c. every 6
months for 12 months
open label (both groups)
l Daily calcium
(500–1000mg) and
vitamin D3 or
D2 (600–800 IU)
l For patients with a
baseline serum
25-hydroxyvitamin D
level of ≤ 40 ng/ml,
a loading dose of
50,000–60,000 IU of
vitamin D was given
12 months from
randomisation then a
further 12 months
open label following
treatment-switching
New vertebral
fractures
Excluded if had a history of hip
or severe vertebral fracture,
conditions or treatment
affecting BMD, ONJ and low
25-hydroxyvitamin D level
Ishibashi 201755
(NCT01992159)
Randomised placebo-
controlled trial, Phase II,
multicentre, Japan
Postmenopausal women aged
55–85 years, ambulatory, lumbar
spine, femoral neck or total hip
BMD T-score of ≤ –2.5, lumbar
spine BMD of > –4.0, femoral
neck or total hip BMD of > –3.5
l Placebo, n = 63
l ROMO 210mg per
month, n= 63
l For 12 months
Daily calcium
(≥ 500mg) and
vitamin D (≥ 600 IU)
15 months Lumbar spine
BMD percentagte
change from
baseline at
12 months
Excluded if condition or prior
treatment influencing bone
metabolism, including i.v.
bisphosphonates within 5 years, oral
bisphosphonates within 6 months or
for ≥ 1 months within 1 year, or
> 3 years, or prior DEN within
18 months, or PTH within 1 year,
history of vertebral or hip fracture
BRIDGE:
(NCT02186171)56
Randomised placebo-
controlled trial, Phase III,
multicentre, Europe, Latin
America, Japan, North
America
Men aged 55–90 years, lumbar
spine, total hip or femoral neck
BMD T-score of ≤ –2.5, or ≤ –1.5
with fragility fracture, evaluable
for lumbar spine and hip DXA
l Placebo, n = 82
l ROMO, 210mg per
month, n= 163
l For 12 months
Daily calcium
(500–1000mg) and
vitamin D (600–800 IU)
15 months Lumbar spine
BMD percentage
change from
baseline at
12 months
Excluded if condition or current
treatment influencing bone
metabolism, hip or femoral neck
T-score of ≤ –3.5, hip fracture
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TABLE 15 Trial characteristics (continued )
Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
TPTD vs. placebo
Orwoll 200357 International, randomised,
placebo-controlled trial –
37 centres in 11 countries
(countries NR)
Men aged 30–85 years with
lumbar spine or proximal femur
(neck or total hip) BMD at least 2
SD below the average for young,
healthy men
l Placebo, n = 147
l TPTD, 20 µg s.c., n= 151
l Both daily
All subjects also
received supplemental
calcium and vitamin D
The study was
stopped after a
median duration of
11 months
Lumbar spine
BMD percentage
change from
baseline
Secondary causes of metabolic
bone disease, were excluded
Miyauchi 201058
(NCT00433160)
Randomised placebo-
controlled Phase III trial,
multicentre, Japan
Postmenopausal (≥ 5 years)
women and men, ambulatory,
aged ≥ 55 years, lumbar spine
BMD of < 80% YAM for Japanese
subjects (approximate T-score
–2.6) and one or more vertebral
fragility fracture; or aged ≥ 65
years approximate lumbar spine
BMD T-score of –1.7; or aged
≥ 55 years with lumbar spine
BMD of < 65% YAM
l Placebo for 12 months
then option of
open-label TPTD for
12 months, n= 70
l TPTD for 12 months
then open-label TPTD
for 12 months, n= 137
Daily calcium (610 mg)
and vitamin D (400 IU)
24 months Lumbar spine
BMD percentage
change from
baseline at
12 months
Miyauchi 200859 Randomised placebo-
controlled Phase II trial,
multicentre, Japan
Postmenopausal (≥ 5 years)
women, ambulatory, aged ≥ 55
years, lumbar spine BMD of
< 80% YAM for Japanese subjects
(approximate T-score of –2.6) and
one or more moderate, or two or
more mild, vertebral fragility
fracture; or aged ≥ 65 years and
< 70% YAM; or lumbar spine
BMD of < 60% YAM
l Placebo for 6
months, n= 38
l TPTD, 20 µg daily for
6 months, n= 39
Daily calcium (610 mg)
and vitamin D (400 IU)
6 months Lumbar spine
BMD percentage
change from
baseline at
24 weeks
Excluded if conditions that
influence bone metabolism,
treatment influencing bone
metabolism within 24 months
of randomisation
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Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
ACTIVE95
(NCT01343004)
Randomised placebo-
controlled Phase III trial,
multicentre, Argentina,
Brazil, Czech Republic,
Denmark, Estonia, Hong
Kong, Lithuania, Poland,
Romania, the USA
Postmenopausal women, age
49–86 years, femoral neck or
lumbar spine BMD T-score of
≤ –2.5 or > –5.0 and two or more
mild or one or more moderate
vertebral fractures, or other low-
trauma fracture within 5 years; or
age ≥ 65 years and T-score of
≤ –2.0 or > –5.0; or age ≥ 65
years without fracture and
T-score of ≤ –3.0 or > –5.0
l Placebo for 18 months
(blinded against
abaloparatide), n = 821
l TPTD, 20 µg daily for
18 months, open
label, n= 818
Adequate calcium
and vitamin D
(25-hydroxyvitamin D
concentrations in
serum > 37.5 nmol/l)
18 months Percentage with
one or more new
vertebral fracture
(as determined
by X-ray)
Excluded if severe, or four or
more mild/moderate, vertebral
fractures, < 2 evaluable lumbar
vertebrae, hip BMD unevaluable,
conditions that influence bone
metabolism, treatment
influencing bone metabolism,
bisphosphonates (≥ 3 months)
within 5 years, DEN within 1 year
Leder 201561 Randomised, parallel-
group, multicentre, dose-
finding, double-blind,
placebo-controlled trial –
30 centres in the USA,
Argentina, India and
the UK
Postmenopausal women aged
55–85 years with a T-score of
≤ –2.5 at the lumbar spine or
femoral neck or total hip, or
T-score of ≤ –2.0 plus low-trauma
fracture, or T-score of ≤ –2.0 plus
risk factor for osteoporosis
l Open label
l Placebo, n = 45
l TPTD, 20 µg, n= 45
l Both daily
All subjects received
supplemental calcium
(500–1000mg) and
vitamin D (400–800 IU)
6 months plus a
further 6-month
extension to
12 months
BMD percentage
change from
baseline and bone
turnover markers
Treatments and conditions
affecting BMD were excluded
continued
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TABLE 15 Trial characteristics (continued )
Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
FPT62
(NCT00670501)
Randomised placebo-
controlled Phase III trial,
multicentre, Argentina,
Australia, Austria, Belgium,
Canada, Czech Republic,
Denmark, Finland,
Hungary, Israel, Italy, the
Netherlands, New Zealand,
Norway, Poland, Sweden,
the USA
Postmenopausal (≥ 5 years)
women, ambulatory, one or more
moderate or two or more mild
atraumatic vertebral fractures;
or fewer than two moderate
fractures, T-score BMD hip or
lumbar spine of ≤ –1
l Placebo
l n= 544
l TPTD
l 20 µg daily
l N= 541
l Study halted at median
21 months
Daily calcium 1000mg
and vitamin D
400–1200IU
Trial stopped early.
Maximum follow-up
24 months. Median
follow-up of
21 months for
radiographic
outcomes and 19 for
other outcomes
Percentage with
1+ new vertebral
fracture (X-ray)
Excluded if conditions that
influence bone metabolism,
bisphosphonates within 3 months
before randomisation or for ≥ 60
days in the 24 months before
randomisation, other prior
treatment that influenced bone
metabolism within 6 months
Sethi 200863
(NCT00500409)
Randomised placebo-
controlled, open-label,
Phase III trial, multicentre,
India
Postmenopausal (≥ 3 years)
women, aged 45–75 years, lumbar
spine or femoral neck BMD
T-score of ≤ –2.5
l Control, n = 41
l TPTD, 20 µg
daily, n= 41
Daily calcium (1000 mg)
and vitamin D
180 days Lumbar spine
BMD percentage
change from
baseline at
6 months
Excluded if conditions that
influence bone metabolism,
lumbar spine BMD unevaluable,
prior treatment that influenced
bone metabolism within
6 months, current steroids,
anticoagulants or anticonvulsants
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Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
Head-to-head non-bisphosphonates
DATA64
(NCT00926380);
DATA-Switch65
Randomised controlled
Phase II trial, open-label
single centre, the USA
Postmenopausal women, aged
≥ 45 years, lumbar spine, femoral
neck or hip T-score of ≤ –2.5; or
T-score of ≤ –2.5 plus risk factor
for fracture; or T-score of ≤ –1.0
plus fragility fracture
l TPTD, 20 µg daily for
24 months, n= 36
l DATA-Switch: TPTD
followed by 24 months
of DEN
l DEN, 60mg every
6 months for
24 months, n= 27
l DATA-Switch: DEN
followed by 24 months
of TPTD, n= 27
Daily calcium (1200 mg)
and vitamin D
(25-hydroxyvitamin D
concentrations in
serum > 50 nmol/l)
24 months Lumbar spine
BMD percentage
change from
baseline at
12 months
Excluded if conditions that
influence bone metabolism,
history of i.v. bisphosphonates
or strontium ranelate;
glucocorticoids or oral
bisphosphonates within 6 months;
hormonal or calcium therapy with
3 months of randomisation
EUROFORS66 Randomised controlled
open-label trial,
multicentre, Austria,
Belgium, Denmark, France,
Germany, Greece, Iceland,
Portugal, Spain, the UK
Postmenopausal (≥ 2 years)
women, aged ≥ 55 years, lumbar
spine or femoral neck or total hip
BMD T-score of ≤ –2.5, one or
more vertebral or non-vertebral
fragility fracture within 3 years,
≥ 2 BMD evaluable lumbar
vertebrae
l Control 12
months, n= 102
l RLX, 60 mg
daily, n= 100
l TPTD, 20 µg
daily, n= 305
l All following 12 months
of TPTD
Daily calcium
(≥ 500mg) and
vitamin D (400–800 IU)
12 months post
randomisation
(24 months total)
Lumbar spine
BMD percentage
change from
baseline at
24 months
Excluded if conditions or
treatments that influence bone
metabolism
continued
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TABLE 15 Trial characteristics (continued )
Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
STRUCTURE67
(NCT01796301)
Randomised controlled
trial, open-label, Phase III,
multicentre, North
America, Latin America,
Europe
Postmenopausal osteoporosis
(≥ 3 years); aged 55–90 years;
vertebral fracture or non-
vertebral after age 50; lumbar
spine, femoral neck or total hip
BMD T-score of ≤ –2.5; ≥ 3 years
of bisphosphonate therapy;
evaluable for hip and lumbar
spine BMD
l TPTD, 20 µg per
day, n = 218
l ROMO, 210 mg per
month, n= 218
l For 12 months
l Following 12 months
of ALN
Daily calcium
(500–1000mg) and
vitamin D (600–800 IU)
12 months Hip BMD
percentage
change from
baseline at
12 months
Excluded if condition, or
non-bisphosphonate treatment,
influencing bone metabolism
McClung 201468 Phase III, multicentre,
international, randomised,
placebo-controlled,
parallel-group, eight-group
study – 28 centres in
Argentina, Austria,
Belgium, Canada, Denmark,
Spain, and the USA
Postmenopausal women aged
55–85 years with a T-score of
≤ –2.0 at the lumbar spine, total
hip or femoral neck and ≥ –3.5 at
each of these sites
l Open-label
l ALN, 70 mg
weekly, n = 51
l TPTD, 20 µg
daily, n= 55
l Blind
l Pooled placebo (mix of
administrations), n = 52
l ROMO, 210mg s.c.
monthly, n = 55
All the participants
were required to take
at least 1000mg of
elemental calcium and
800 IU of vitamin D
daily
12 months Lumbar spine
BMD percentage
change from
baseline
Treatments and conditions
affecting BMD were excluded
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Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
DEN vs. bisphosphonates
DECIDE69 Randomised controlled
trial, Phase III, non-
inferiority, multicentre,
Australia, Europe, North
America, South America
Postmenopausal women,
ambulatory, lumbar spine or total
hip BMD T-score of ≤ –2.0,
evaluable for hip and lumbar
spine BMD
l DEN, 60mg every
6 months plus
placebo, n = 594
l ALN, 70 mg per week
plus placebo, n= 595
Daily calcium
(≥ 500mg) and
vitamin D (400–800 IU)
12 months Lumbar spine
BMD percentage
change from
baseline at
12 months
Excluded if condition influencing
bone metabolism, prior i.v.
bisphosphonates, other
treatments influencing bone
metabolism within 3 months
STAND:
Kendler 201070
Phase III international,
multicentre, randomised,
double-blind, double-
dummy, parallel-group.
Countries NR
Women aged ≥ 55 years with a
lumbar spine or total hip T-score of
between –4.0 and –2.0, receiving
ALN equivalent to 70mg per week
for at least 6 months
Open-label ALN, 70 mg
weekly for 1 month then
one of the following:
l ALN, 70 mg
weekly, n = 251
l DEN, 60mg s.c., every
6 months, n= 253
l Both with placebo
Daily calcium (1000 mg)
and at least 400 IU of
vitamin D
12 months Total hip BMD
percentage
change from
baseline
Treatments and conditions
affecting BMD were excluded
DAPS:
Kendler 201171
and 2012109
Multicentre, randomised,
open-label, 2-year,
crossover – 20 centres in
the USA and five centres
in Canada
Postmenopausal women with low
BMD who had not received prior
bisphosphonate or DEN therapy,
with T-scores of between –4.0
and –2.0 at the lumbar spine,
total hip or femoral neck
l ALN, 70 mg
weekly, n = 124
l DEN, 60mg s.c., every
6 months, n= 126
l Open label
Daily calcium (1000 mg)
and vitamin D
(≥ 400 IU)
supplementation
12 months prior to
crossover
Treatment
adherence in the
first 12 months
Treatments and conditions
affecting BMD were excluded
continued
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TABLE 15 Trial characteristics (continued )
Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
AMG 162
Bone Loss study:
McClung 200672
Randomised, placebo-
controlled, dose-ranging
study – 29 study centres
in the USA
Osteopenic and osteoporotic
postmenopausal women ages
≤ 80 years with a T-score of –1.8
to –4.0 at the lumbar spine or
–1.8 to –3.5 at either the femoral
neck or total hip
l Placebo s.c. every
3 months, n= 46
l ALN, 70 mg weekly,
n= 47 (open label)
l DEN 60mg s.c., every
6 months, n= 47
Daily calcium (1 g) and
vitamin D (400 IU)
12 months Lumbar spine
BMD percentage
change from
baseline
Treatments and conditions
affecting BMD were excluded
Recknor 201373 Randomised, open-label,
parallel-group study –
74 centres in the USA
and Europe
Postmenopausal women aged
≥ 55 years with T-score of ≤ –2 or
≥ –4 at the total hip who had
either discontinued or had
insufficient adherence to
bisphosphonates for ≥ 1 month
before screening
l IBN, 150 mg every
month, n= 416
l DEN, 60mg s.c., every
6 months, n= 417
Daily calcium
(≥ 500mg) and
vitamin D (≥800 IU)
12 months Total hip BMD
percentage
change from
baseline
Treatments and conditions
affecting BMD were excluded
Saag 201874 Phase II, international,
randomised, double-blind,
double-dummy, active-
controlled, non-inferiority
study – 79 centres in 16
countries in Europe, Latin
America, Asia and the USA
Women and men aged ≥ 18 years
who were either continuing or
initiating glucocorticoids (≥ 7.5 mg
prednisone, or its equivalent,
daily). Patients aged < 50 years
had to have a history of
osteoporosis-related fracture.
Continuing patients had to have
total hip, femoral neck or lumbar
spine T-score of ≤ 2.0 or ≤ 1.0
with a history of fracture
l RIS, 5 mg daily, n = 397
l DEN, 60mg s.c., every
6 months, n= 398
l Both groups received
a placebo
At least 1000mg of
calcium and at least
800 IU of vitamin D
daily
12 months Lumbar spine
BMD percentage
change from
baseline
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Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
Miller 201675 International, multicentre,
randomised, double-blind,
double-dummy, active-
controlled, parallel-group
study – 37 study centres in
Belgium, Denmark, Poland,
Spain, Canada, the USA
and Australia
Postmenopausal women aged
≥ 55 years who received oral
bisphosphonate therapy for
≥ 2 years with a T-score of
≤ 2.5 at the lumbar spine,
total hip or femoral neck
l ZOL, 5 mg i.v.
annually, n = 322
l DEN, 60mg s.c., every
6 months, n= 321
l Both groups received
a placebo
≥ 1000 mg of elemental
calcium and ≥ 800 IU of
vitamin D daily
12 months Lumbar spine
BMD percentage
change from
baseline
Treatments and conditions
affecting BMD were excluded
RLX vs. bisphosphonates
EFFECT
(International):
Sambrook 200476
Randomised, double-
masked, double-dummy,
multinational study –
50 centres in 16 countries
throughout Europe, South
America and Asia-Pacific
Postmenopausal women with low
BMD at least 2.0 SD below the
young normal mean at either the
total hip or lumbar spine
l ALN, 10 mg, n = 246
l RLX, 60 mg, n = 241
l Both daily
Calcium and vitamin D 12 months Lumbar spine
BMD percentage
change from
baseline
Treatments and conditions
affecting BMD were excluded
EFFECT (USA):
Luckey 200477
Double-blind, randomised,
active-controlled,
multicentre study –
52 centres in the USA
Postmenopausal women aged
> 40 years with low BMD at least
2.0 SD below the young normal
mean at either the total hip or
lumbar spine
l ALN, 70 mg
weekly, n = 223
l RLX, 60 mg
daily, n= 233
l Both groups received
a placebo
500–1000mg of
calcium and 200 IU of
vitamin D daily
12 months Lumbar spine
BMD percentage
change from
baseline
Treatments and conditions
affecting BMD were excluded
Johnell 200278 Phase III, randomised,
double-blind study –
30 centres in Australia,
Belgium, Canada, Italy,
Mexico, South Africa,
Spain and Sweden
Postmenopausal women aged
≥ 75 years, femoral neck BMD
≥ 2.0 SD below peak bone mass
for healthy premenopausal
women
l Placebo (ALN and
RLX), n= 82
l ALN, 10 mg and RLX
placebo, n = 83
l RLX 60mg and ALN
placebo, n = 82
l All daily
Daily elemental calcium
(500 mg) and vitamin D
(400–600 IU)
12 months Lumbar spine
BMD and femoral
neck BMD
percentage
change from
baseline
Treatments and conditions
affecting BMD were excluded
continued
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TABLE 15 Trial characteristics (continued )
Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
Muscoso 200479 Randomised trial – centres
and countries NR
Women with osteoporosis. No
further details of inclusion or
exclusion criteria reported
l ALN, 10 mg, n = 1000
l RIS, 5 mg, n= 100
l RLX, 60 mg, n = 100
l All daily
1000 mg of calcium and
800 IU of vitamin D
daily
24 months l NR
l Lumbar spine
BMD and
incidence
fractures
reported
EVA: Recker
200780
Randomised double-blind
study – 13 centres in
Canada and the USA
(NCT00035971)
Postmenopausal women aged
50–80 years with femoral neck
T-score of –2.5 to –4.0 and no
prevalent vertebral fractures
l ALN, 10 mg, n = 716
l RLX, 60 mg, n = 717
l Both daily
Calcium (500 mg per
day) and vitamin D
(400 IU per day)
l 24 months
l Assessments also
planned at 3 and
5 years, but trial
was stopped early
Number of
women with one
or more new
osteoporotic
vertebral or non-
vertebral fracturesTreatments and conditions
affecting BMD were excluded
Sanad 201181 Randomised clinical study
– single centre, Egypt
Postmenopausal women aged
50–70 years with BMD at lumbar
spine or femoral neck of –2.5 SDs
below a reference population of
young postmenopausal women
l ALN, 10 mg, n = 44
l RLX, 60 mg, n = 46
l Both daily
1500 mg of calcium
carbonate and 400 IU
of vitamin D3
12 months l NR
l Lumbar spine,
femoral neck
and total hip
BMD; bone
turnover,
and lipid
metabolism
reported
Treatments and conditions
affecting BMD were excluded
Michalska 200682 Placebo-controlled,
randomised trial – single
centre, Austria
Postmenopausal women aged
50–80 years with previous
treatment with ALN (10 mg per
day) for > 3 years and lumbar
spine or femoral neck T-score of
< –2.5
l Open-label
l ALN, 10 mg, n = 33
l Blind
l Placebo, n = 33
l RLX, 60 mg, n = 33
l All daily
Calcium (500 mg per
day) and vitamin D
(800 IU per day)
12 months followed
by 12 months open-
label extension
Lumbar spine
BMD percentage
change from
baseline
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Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
ROMO vs. bisphosphonates
ARCH: Saag
201783
Phase III, multicentre,
international, randomised,
double-blind trial – 137
centres (NCT01631214)
Postmenopausal women aged
55–90 years with either T-score
of ≤ –2.5 at the total hip or
femoral neck plus one or more
moderate/severe or two or
more mild vertebral fractures;
or T-score of ≤ –2.0 with two or
more moderate/severe vertebral
or proximal femur fractures
l ALN, 70 mg
weekly, n = 2047
l ROMO, 210mg s.c.
monthly, n = 2046
l Both for 12 months
then ALN 70mg weekly
open label (both groups)
for 12 months
Daily calcium and
vitamin D
12 months from
randomisation then a
further 12 months
open label following
treatment-switching
Vertebral
fractures and
clinical fracture
(non-vertebral
and symptomatic
vertebral fracture)
at 24 months
TPTD vs. bisphosphonates
FACT:
McClung 200584
Randomised, double-blind,
active comparator study –
19 clinical sites globally
Postmenopausal women aged
45–84 years, with lumbar spine or
femoral neck T-score of between
–2.5 and –4.0
l ALN, 10 mg, n = 101
l TPTD, 20 µg s.c., n= 102
l Both daily
l Both groups received
a placebo
Daily supplementation
of calcium (1000 mg)
and vitamin D
(400–800 IU)
18 months Lumbar spine
and hip BMD
percentage
change from
baseline
Treatments and conditions
affecting BMD were excluded
Saag 200985 Randomised, double-blind,
double-dummy, active
comparator–controlled –13
countries at 76 centres
Women aged ≥ 21 years who had
taken prednisone or its equivalent
at a dosage of ≥ 5mg per day for
≥ 3 months with lumbar spine,
femoral neck, or total hip BMD
T-score of ≤ –2 or of ≤ –1 plus a
prevalent fracture
l ALN, 10 mg, n = 214
l TPTD, 20 µg s.c., n= 214
l Both daily
l Both groups received
a placebo
Calcium (1000 mg per
day) and vitamin D
(800 IU per day) were
provided
36 months Lumbar spine
BMD percentage
change from
baseline
Panico 201186 Randomised controlled
trial, single centre, Italy
Postmenopausal women, lumbar
spine or femoral neck BMD
T-score of ≤ –2.5, two or more
fractures, back pain, prior
treatment for osteoporosis
l TPTD, 20 µg
daily, n= 42
l ALN, 70 mg per
week, n = 39
Daily calcium (1000 mg)
and vitamin D (800 IU)
18 months Percentage
change from
baseline in
biochemical
markers of bone
turnover
Excluded if condition influencing
bone metabolism, increased risk
of osteosarcoma
continued
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TABLE 15 Trial characteristics (continued )
Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
EuroGIOPs:
Glüer 201387
Phase III, randomised,
open-label, active
comparator-controlled
study – 16 centres in
Germany, Greece, Italy
and Spain
Men aged ≥ 25 years with a
lumbar spine, femoral neck or
total hip T-score ≤ 1.5 SDs below
normal young adult male taking
glucocorticoids (≥ 5.0 mg of
prednisone, or its equivalent,
daily) for ≥ 3 months
l Open label
l RIS, 35 mg
weekly, n = 47
l TPTD, 20 µg s.c.
daily, n= 45
1000 mg of calcium and
800–1200 IU of
vitamin D per day
18 months Lumbar spine BMD
percentage change
from baseline,
measured by QCT
Treatments and conditions
affecting BMD were excluded
Anastasilakis
200888
Randomised, open-label
trial – Greece
Postmenopausal women with
osteoporosis and T-score of
< –2.5 (site NR)
l Open label
l RIS, 35 mg
weekly, n = 22
l TPTD, 20 µg s.c.
daily, n= 22
500 mg of elemental
calcium and 400 IU of
vitamin D daily
12 months Bone turnover
markers
Treatments and conditions
affecting BMD were excluded
Walker 201389 Randomised, double-blind,
placebo-controlled trial –
USA
Men aged 30–85 years with low
BMD secondary to idiopathic
osteoporosis, and lumbar spine,
femoral neck or total hip T-score
of < –2.0
l RIS, 35 mg
weekly, n = 10
l TPTD, 20 µg s.c.
daily, n= 9
l Both groups received
a placebo
500 mg of calcium and
400 IU of vitamin D
daily
18 months Lumbar spine
BMD percentage
change from
baseline
Treatments and conditions
affecting BMD were excluded
VERO:
Kendler 201899
Randomised, double-blind,
active-controlled, parallel-
group trial – 123 centres
14 countries in Europe,
South America and
the USA
Postmenopausal women aged
> 45 years with a lumbar spine,
femoral neck or total hip T-score
of ≥ –1.50 with prevalent
vertebral fragility fracture
l RIS, 35 mg
weekly, n = 683
l TPTD, 20 µg s.c.
daily, n= 683
l Both groups received
a placebo
l 680 participants in each
group started treatment
Daily supplements
of 500–1000mg of
calcium and 400–800 IU
of vitamin D3 or D2,
or 2000 IU per day,
if baseline serum
25-hydroxyvitamin D
levels were ≤ 40 ng/ml
24 months New radiographic
vertebral fractures
Treatments and conditions
affecting BMD were excluded
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Trial name:
first author
and year Trial design Population eligibility
Intervention and
comparators, number
randomised to each group
Concomitant
treatment Follow-up duration Primary outcome
Hadji 201291 Randomised, parallel,
double-blind, double-
dummy, active-controlled
trial – 72 international
study locations
(NCT00343252)
Postmenopausal women aged
≥ 45 years with a history of
back pain likely to be caused by
osteoporotic vertebral fracture,
with lumbar spine, femoral neck
or total hip T-score of ≤ –2; and
a minimum of one moderate
vertebral fracture
l RIS, 35 mg
weekly, n = 350
l TPTD, 20 µg s.c.
daily, n= 360
l Both groups received
a placebo
1000 mg per day of
calcium and 800 IU per
day of vitamin D
18 months Proportion of
patients
experiencing ≥ 30%
reduction in worst
back pain at
6 months
Treatments and conditions
affecting BMD were excluded
MOVE: Abtahi
2016101 and
Malouf-Sierra
201792
Multinational, multicentre,
prospective, randomised,
active-controlled study –
17 countries including the
USA and Mexico, and
countries in Europe
Men and postmenopausal women
with low bone mass (T-score of
< –2.0 s at the total hip, femoral
neck or lumbar spine who had
sustained a recent unilateral
pertrochanteric fracture
l RIS, 35 mg
weekly, n = 113
l TPTD, 20 µg s.c.
daily, n= 111
l Both groups received
a placebo
l Blind until 6 months
then open label
Calcium (500–1000mg
per day) and vitamin D
(800 IU per day). For
patients with a baseline
serum 25-hydroxyvitamin
D level of ≤ 40 ng/ml,
loading dose of
100,000 IU of vitamin D2
or D3
l 6 months101
l 18 months92
Lumbar spine
BMD percentage
change from
baseline
Cosman 201193 Partial double-blinded,
randomised, multicentre,
multinational – centres and
countries NR
Women aged 45–89 years with
BMD T-scores of ≤ –2.5 at the
femoral neck, total hip or lumbar
spine or a BMD T-score of
≤ –2.0 at any site plus one or
more documented vertebral or
non-vertebral fractures
l ZOL, 5 mg i.v.
annually, n = 137
l TPTD, 20 µg s.c.
daily, n= 138
l Only those on TPTD
received a placebo
Daily calcium
(1000–1200mg)
and vitamin D
(400–800 IU)
12 months Lumbar spine
BMD percentage
change from
baseline
Treatments and conditions
affecting BMD were excluded
ADAMO, A multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety DenosumAb versus placebo in Males with Osteoporosis; NA, not applicable;
NR, not reported; OLE, open-label extension; PTH, parathyroid hormone; QCT, quantitative computerised tomography; YAM, Young Adult Mean.
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TABLE 16 Population baseline characteristics
Trial name:
first author
and year Treatment arms (n)
Age (years),
mean (SD) Sex (% female)
T-score femoral neck
(or lumbar spine if
femoral neck not
reported), mean (SD)
BMD at femoral neck
(or lumbar spine if
femoral neck not
reported) (g/cm2),
mean (SD)
Fractures
(at baseline),
n (%)
Prior treatment for
osteoporosis (%)
DEN vs. placebo
FREEDOM41,104 Placebo, n= 3906 72.3 (5.2) 100 –2.17 (0.71) NR 915 (23.4) 0
DEN, 60 mg s.c. every
6 months, n= 3902
72.3 (5.2) 100 –2.15 (0.72) NR 929 (23.8) 0
ADAMO42 Placebo for 1 year, then
open-label DEN for 1 year,
n = 121
65.0 (SD 9.1) 0 –1.9 (0.6) NR 48 (39.7) NR
DEN: 60mg of DEN every
6 months for 2 years (1 year
blinded, then 1 year open
label), n= 121
64.9 (SD 10.5) 0 –1.9 (0.6) NR 47 (38.8) NR
DIRECT:
Nakamura 201443
Placebo, n= 480 69.0 (7.67) 95.0 –2.29 (0.71) NR 471 (98.1) NR
DEN, 60 mg every 6 months,
n = 472
69.9 (7.36) 95.1 –2.38 (0.70) NR 466 (98.7) NR
Nakamura 201244 Placebo, n= 55 64.6 (7.0) 100 Lumbar spine: –3.02
(0.34)
Lumbar spine: 0.652
(0.040)
7 (12.7) NR
DEN, 60 mg every 6 months,
n = 54
65.1 (6.3) 100 Lumbar spine: –3.10
(0.44)
Lumbar spine: 0.642
(0.051)
7 (13.0) NR
Koh 201645
(NCT01457950)
Placebo for 6 months
then open-label DEN for
6 months, n= 66
66.0 (4.77) 100 –2.4 (0.61) NR 15 (23) NR
DEN, 60 mg for 6 months
then open-label DEN for
6 months, n= 69
67.0 (4.86) 100 –2.5 (0.56) NR 21 (30) NR
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Trial name:
first author
and year Treatment arms (n)
Age (years),
mean (SD) Sex (% female)
T-score femoral neck
(or lumbar spine if
femoral neck not
reported), mean (SD)
BMD at femoral neck
(or lumbar spine if
femoral neck not
reported) (g/cm2),
mean (SD)
Fractures
(at baseline),
n (%)
Prior treatment for
osteoporosis (%)
RLX vs. placebo
Adami 200846 Placebo, n= 172 67.1 (6.5) 100 NR 0.62 (0.10) NR 0
RLX, 60 mg daily, n= 157 66.7 (6.4) 100 NR 0.64 (0.10) NR 0
Morii 200347 Placebo, n= 97 64.3 (6.5) 100 NR 0.64 (0.05) 26 (26.8) NR
RLX, 60 mg per day, n = 90 65.2 (6.2) 100 NR 0.66 (0.5) 22 (24.4) NR
Liu 200448 Placebo, n= 102 65.1 (5.4) 100 NR NR l Thoracic: 10 (9.8)
l Lumbar: 6 (5.9)
0
RLX, n = 102 165.5 (6.5) 100 NR NR l Thoracic:
11 (10.8)
l Lumbar: 9 (8.8)
0
Gorai 201249 Alfacalcidol, n = 46 165.2 (6.5) 100 NR Lumbar spine: 0.663
(0.082)
NR NR
RLX, n = 42 164.4 (6.6) 100 NR Lumbar spine: 0.678
(0.083)
NR NR
Alfacalcidol plus RLX, n = 45 65.1 (7.6) 100 NR Lumbar spine: 0.670
(0.067)
NR NR
Silverman 200850
(NCT00205777)
Placebo, n= 1885 66.5 (6.8) 100 –1.8 (0.9) NR 981 (56.4) NR
RLX, n = 1849 66.4 (6.7) 100 1–1.7 (0.9) NR 954 (56.3) NR
MORE51,102 Placebo, n= 2576 66.6 (7.1) 100 NR l Reported
by subgroup
l Mean ranged from
0.565 to 0.719
(36.4) NR
RLX, n = 2557 66.5 (7.0) 100 NR l Reported
by subgroup
l Mean ranged from
0.569 to 0.720
(38.1) NR
continued
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TABLE 16 Population baseline characteristics (continued )
Trial name:
first author
and year Treatment arms (n)
Age (years),
mean (SD) Sex (% female)
T-score femoral neck
(or lumbar spine if
femoral neck not
reported), mean (SD)
BMD at femoral neck
(or lumbar spine if
femoral neck not
reported) (g/cm2),
mean (SD)
Fractures
(at baseline),
n (%)
Prior treatment for
osteoporosis (%)
Lufkin 199852 Control, n = 48 68.2 (0.7) 100 NR LS 0.54 (0.01) NR NR
RLX, n = 48 69.9 (0.5) 100 NR LS 0.52 (0.01) NR NR
Mok 201153
(NCT00371956)
Placebo, n= 57 55.2 (7.6) 100 NR 0.683 (0.126) 2 (4) 5
RLX, n = 57 55.4 (7.8) 100 NR 0.647 (0.117) 4 (7) 11
ROMO vs. placebo
FRAME:
Cosman 201654
l Placebo, n= 3591
l Then DEN, 60 mg s.c.
every 6 months for
12 months, open label
70.8 (6.9) 100 –2.74 (0.29) NR 496 (13.8) 0
l ROMO, 210mg per
month, n = 3589
l Then DEN, 60 mg s.c.
every 6 months for
12 months, open label
70.9 (7.0) 100 –2.76 (0.28) NR 506 (14.1) 0
Ishibashi 201755
(NCT01992159)
Placebo, n= 63 67.8 (7.2) 100 –2.31 (0.47) NR 0 NR
RLX, n = 63 68.3 (5.9) 100 –2.32 (0.59) NR 0 NR
BRIDGE56
(NCT02186171)
Placebo, n= 82 71.5 (6.9) 0 –2.3 (0.52) NR 46 (56.1) l Bisphosphonates
5 (6.1)
l PTH 0
l DEN 3 (3.7)
ROMO, n = 163 72.4 (7.4) 0 –2.34 (0.52) NR 86 (52.8) l Bisphosphonates
1 (0.6)
l PTH 1 (0.6)
l DEN 3 (1.8)
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Trial name:
first author
and year Treatment arms (n)
Age (years),
mean (SD) Sex (% female)
T-score femoral neck
(or lumbar spine if
femoral neck not
reported), mean (SD)
BMD at femoral neck
(or lumbar spine if
femoral neck not
reported) (g/cm2),
mean (SD)
Fractures
(at baseline),
n (%)
Prior treatment for
osteoporosis (%)
TPTD vs. placebo
Orwoll 200357 Placebo, n= 147 59 (13) 0 –2.7 (0.8) Lumber spine BMD:
0.85 (0.14)
NR 8.16
TPTD, 20 µg s.c. daily,
n = 151
59 (13) 0 –2.6 (0.8) 0.89 (0.15) NR 7.95
Miyauchi 201058 Placebo for 12 months and
then option of open-label
TPTD for 12 months, n= 67
70.4 (5.4) 92.5 NR Lumbar spine: 0.638
(0.079)
29 (43.3) 34.3
TPTD for 12 months and
then open-label TPTD for
12 months, n= 136
69.2 (6.3) 93.4 NR Lumbar spine: 0.639
(0.069)
54 (39.7) 36.8
Miyauchi 200859 Placebo, n= 38 69.9 (3.6) 100 NR 0.5068 (0.0802) 17 (44.7) 21.1
TPTD, 20 µg daily, n= 39 71.5 (5.1) 100 NR 0.5168 (0.0927)
(n= 38)
16 (41.0) 25.6
ACTIVE95
(NCT01343004)
Placebo, n= 821 68.7 (6.5) 100 –2.2 (0.7) 0.732 (0.099) 514 (62.6) NR
TPTD, 20 µg daily, n= 818 68.8 (6.6) 100 –2.1 (0.7) 0.737 (0.096) 510 (62.3) NR
Leder 201561 Placebo, n= 45 65.0 (7.1) 100 –2.26 (0.72) 0.65 (0.11) NR 0
TPTD, 20 µg daily, n= 45 64.5 (7.5) 100 –2.09 (0.75) 0.66 (0.11) NR 0
FPT62
(NCT00670501)
Placebo, n= 448 69 (7) 100 NR Lumbar spine: 0.82
(0.17)
448 (100) 15
TPTD, 20 µg daily, n= 444 69 (7) 100 NR Lumbar spine: 0.82
(0.17)
444 (100) 16
Sethi 200863
(NCT00500409)
Control, n = 41 63.0 (6.3) 100 –2.34 (0.73) 0.62 (0.09) NR NR
TPTD, 20 µg daily, n= 41 61.0 (6.3) 100 –2.49 (0.55) 0.62 (0.08) NR NR
continued
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TABLE 16 Population baseline characteristics (continued )
Trial name:
first author
and year Treatment arms (n)
Age (years),
mean (SD) Sex (% female)
T-score femoral neck
(or lumbar spine if
femoral neck not
reported), mean (SD)
BMD at femoral neck
(or lumbar spine if
femoral neck not
reported) (g/cm2),
mean (SD)
Fractures
(at baseline),
n (%)
Prior treatment for
osteoporosis (%)
Head-to-head non-bisphosphonates
DATA64 TPTD, 20 µg daily, n= 36 65.5 (7.9) 100 –1.9 (0.5) 0.643 (0.061) 16 (52) Bisphosphonates: 42
DEN, 60 mg every 6 months,
n = 34
66.3 (8.3) 100 –1.9 (0.8) 0.641 (0.086) 12 (36) Bisphosphonates: 36
EUROFORS66 l Control for 12 months,
n = 102
l Following 12 months
of TPTD
69.1 (8.6) 100 Lumbar spine: –3.1
(0.89)
Lumbar spine: 0.75
(0.11)
102 (100) Antiresorptive: 62.7
l RLX 12 months, n= 97
l Following 12 months
of TPTD
69.4 (7.0) 100 Lumbar spine: –3.2
(0.85)
Lumbar spine: 0.75
(0.12)
97 (100) Antiresorptive: 64.9
l TPTD for 12 months,
n = 304
l Following 12 months
of TPTD
69.2 (7.2) 100 Lumbar spine: –3.2
(0.87)
Lumbar spine: 0.74
(0.11)
304 (100) Antiresorptive: 72.4
STRUCTURE67 TPTD, n = 218 71.2 (7.7) 100 –2.43 (0.66) NR (99.5) Bisphosphonates:
100
ROMO, n = 218 71.8 (7.4) 100 –2.49 (0.67) NR (100) Bisphosphonates:
100
McClung 201468 Pooled placebo (mix of
administrations), n = 52
67.0 (6.5) 100 –1.76 (0.56) NR NR 0
Open-label ALN, 70 mg
weekly, n = 51
67.1 (5.8) 100 –1.91 (0.61) NR NR 0
TPTD, 20 µg daily, n= 54 66.8 (5.7) 100 –1.79 (0.67) NR NR 0
ROMO 210mg s.c.
monthly, 55
66.3 (6.5) 100 –1.87 (0.58) NR NR 0
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Trial name:
first author
and year Treatment arms (n)
Age (years),
mean (SD) Sex (% female)
T-score femoral neck
(or lumbar spine if
femoral neck not
reported), mean (SD)
BMD at femoral neck
(or lumbar spine if
femoral neck not
reported) (g/cm2),
mean (SD)
Fractures
(at baseline),
n (%)
Prior treatment for
osteoporosis (%)
DEN vs. bisphosphonates
DECIDE69 DEN plus placebo, n = 594 64.1 (8.6) 100 Lumbar spine: –2.57
(0.75)
NR (40) l Any: 23
l Bisphosphonates:
13
ALN plus placebo, n = 595 64.6 (8.3) 100 Lumbar spine: –2.57
(0.75)
NR (41) l Any: 24
l Bisphosphonates:
11
STAND: Kendler
201070
ALN, 70 mg per week plus
placebo, n = 251
68.2 (7.7) 100 Lumbar spine T-score:
–2.62 (0.79)
NR NR 0
DEN, 60 mg s.c., every
6 months plus placebo,
n = 253
66.9 (7.8) 100 –2.64 (0.75) NR NR 0
DAPS: Kendler
201171 and
2012109
ALN, 70 mg per week,
n = 124
65.3 (7.7) 100 –2.03 (0.62) NR NR 0
DEN, 60 mg s.c., every
6 months, n= 126
65.1 (7.6) 100 –2.01 (0.55) NR NR 0
AMG 162
Bone Loss study72
Placebo, s.c. every 3 months,
n = 46
63.7 (9.1) 100 –1.9 (0.6) NR 0 0
ALN, 70 mg per week, n = 47
(open label)
62.8 (8.2) 100 –1.9 (0.7) NR 0 0
DEN, 60 mg s.c., every
6 months, n= 47
63.1 (8.1) 100 –1.9 (0.7) NR 0 0
Recknor 201373 IBN, 150 mg every month,
n = 416
66.2 (7.8) 100 –2.1 (0.7) NR NR Prior
bisphosphonate: 374
(89.9)
DEN, 60 mg s.c., every
6 months, n= 417
67.2 (8.1) 100 –2.1 (0.7) NR NR Prior
bisphosphonate: 377
(90.4)
continued
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TABLE 16 Population baseline characteristics (continued )
Trial name:
first author
and year Treatment arms (n)
Age (years),
mean (SD) Sex (% female)
T-score femoral neck
(or lumbar spine if
femoral neck not
reported), mean (SD)
BMD at femoral neck
(or lumbar spine if
femoral neck not
reported) (g/cm2),
mean (SD)
Fractures
(at baseline),
n (%)
Prior treatment for
osteoporosis (%)
Saag 201874 RIS, 5 mg daily plus placebo,
n = 39
l Continuing
GCC: RIS,
61.3 (11.1)
l Initiating
GCC: 64.4
(10.0)
l Continuing
GCC, 73%
l Initiating
GCC, 64%
Lumbar spine T-score:
l Continuing GCC,
–2.0 (1.4)
l Initiating GCC,
–1.1 (1.6)
NR l Continuing GCC,
80/252 (32)
l Initiating GCC,
26/145 (18)
0
DEN, 60 mg s.c., every
6 months plus placebo,
n = 398
l Continuing
GCC, 61.5
(11.6)
l Initiating
GCC, 67.5
(10.1)
l Continuing
GCC, 73%
l Initiating
GCC, 64%
Lumbar spine T-score:
l Continuing GCC,
DEN –1.9 (1.4)
l Initiating GCC,
–0.9 (1.9)
NR l Continuing GCC,
67/253 (26)
l Initiating GCC,
21/145 (14)
0
Miller 201675 ZOL, 5 mg i.v. annually plus
placebo, n = 322
69.5 (7.7) 100 Lumbar spine T-score:
–2.64 (0.86)
NR 159 (49.4) Prior oral
bisphosphonates
(years), mean (SD):
6.4 (3.7)
DEN, 60 mg s.c., every
6 months plus placebo,
n = 321
68.5 (7.1) 100 –2.74 (0.83) NR 169 (52.6) Prior oral
bisphosphonates,
(years), mean (SD):
6.2 (3.8)
RLX vs. bisphosphonates
EFFECT:
Sambrook 200476
ALN, 10 mg plus placebo,
n = 246
61.5 (8.2) 100 Lumbar spine T-score:
–2.89 (0.78)
NR NR 0
RLX, 60 mg daily plus
placebo, n = 241
61.8 (7.7) 100 Lumbar spine T-score:
–2.86 (0.76)
NR NR 0
EFFECT:
Luckey 200477
ALN, 70 mg weekly plus
placebo, n = 223
63.8 (9.9) 100 Lumbar spine T-score:
–2.43 (0.78)
NR NR 0
RLX, 60 mg daily plus
placebo, n = 233
64.7 (9.8) 100 Lumbar spine T-score:
–2.5 (0.69)
NR NR 0
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Trial name:
first author
and year Treatment arms (n)
Age (years),
mean (SD) Sex (% female)
T-score femoral neck
(or lumbar spine if
femoral neck not
reported), mean (SD)
BMD at femoral neck
(or lumbar spine if
femoral neck not
reported) (g/cm2),
mean (SD)
Fractures
(at baseline),
n (%)
Prior treatment for
osteoporosis (%)
Johnell 200278 Placebo (ALN and RLX),
n = 82
63.8 (5.3) 100 NR 0.62 (0.09) NR 0
ALN, 10 mg daily, and RLX
placebo, n = 83
63.7 (6.0) 100 NR 0.62 (0.08) NR 0
RLX, 60 mg daily, and ALN
placebo, n = 82
63.4 (6.3) 100 NR 0.62 (0.07) NR 0
Muscoso 200479 ALN, 10 mg daily, n = 1000 71 (8) 100 NR NR NR NR
RIS, 5 mg daily, n= 100 66 (9) 100 NR NR NR NR
RLX, 60 mg daily, n= 100 64 (3) 100 NR NR NR NR
EVA: Recker
200780
ALN, 10 mg daily, n = 716 65.7 (7.8) 100 –2.39 (0.56) 0.61 (0.09) 0 0
RLX, 60 mg daily, n= 717 65.5 (7.7) 100 –2.39 (0.54) 0.61 (0.09) 0 0
Sanad 201181 ALN, 10 mg daily, n = 31 61.7 (4.3 100 NR 0.63 (0.03) NR 0
RLX, 60 mg daily, n= 35 62.5 (3.9) 100 NR 0.63 (0.05); NR 0
Michalska 200682 Blind placebo, n = 33 64.5 (6.3) 100 NR 0.616 (0.075) Non-vertebral,
18/33 (54.5)
100 (≥ 3 years ALN)
Open-label ALN, 10 mg daily,
n = 33
65.4 (6.8) 100 NR 0.609 (0.063) 9/33 (27.3) 100 (≥ 3 years ALN)
RLX, 60 mg daily, n= 33 65.6 (7.1) 100 NR 0.633 (0.087) 16/33 (48.5) 100 (≥ 3 years ALN)
ROMO vs. bisphosphonates
ARCH:
Saag 201783
ALN, 70 mg weekly
(n= 2047) for 12 months
then ALN 70mg weekly
open label, for 12 months
74.2 (7.5) 100 –2.90 (0.50) NR 1964/2047 (95.9) 0
ROMO, 210mg s.c. monthly
(n= 2046) for 12 months
then ALN, 70 mg weekly
open label, for 12 months
74.4 (7.5) 100 1–2.89 (0.49) NR 1969/2046 (96.2) 0
continued
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TABLE 16 Population baseline characteristics (continued )
Trial name:
first author
and year Treatment arms (n)
Age (years),
mean (SD) Sex (% female)
T-score femoral neck
(or lumbar spine if
femoral neck not
reported), mean (SD)
BMD at femoral neck
(or lumbar spine if
femoral neck not
reported) (g/cm2),
mean (SD)
Fractures
(at baseline),
n (%)
Prior treatment for
osteoporosis (%)
TPTD vs. bisphosphonates
FACT:
McClung 200584
ALN, 10 mg daily plus
placebo, n = 101
66.6 (8.5) 100 –2.3 (0.8) NR NR 0
TPTD, 20 µg s.c. daily plus
placebo, n = 102
65.3 (8.4) 100 –2.3 (0.6) NR NR 0
Saag 200985
and 2007103
ALN, 10 mg daily plus
placebo, n = 214
57.3 (14.0) 100 –2.1 (0.10) 0.721 (0.013) X-ray confirmed,
53/214 (25)
0
TPTD, 20 µg s.c. daily plus
placebo, n = 214
56.1 (13.4) 100 –2.2 (0.10) 0.705 (0.013) X-ray confirmed,
63/214 (30)
0
Panico 201186 TPTD, n = 42 65 (9.0) 100 –3.07 (0.60) NR 42 (100) 100
ALN, n= 39 60 (14.4) 100 –3.02 (0.61) NR 38 (97) 97
EuroGIOPs:
Glüer 201387
Open-label RIS, 35 mg
weekly, n = 47
55.1 (15.5) 0 –1.82 (0.91) NR 17/47 (36.2) 0
TPTD, 20 µg s.c. daily, n= 45 57.5 (12.8) 0 –1.95 (0.78) NR 19/45 (42.2) 0
Anastasilakis
200888
Open-label RIS, 35 mg
weekly, n = 22
64.7 (7.0) 100 NR Lumbar spine BMD:
0.757 (0.08)
NR 0
TPTD, 20 µg s.c. daily, n= 22 65.4 (7.5) 100 NR Lumbar spine BMD:
0.764 (0.11)
NR 0
Walker 201389 RIS, 35 mg weekly plus
placebo, n = 10
54.0 (6.3) 100 –2.1 (0.63) 0.669 (0.09) 0 Bisphosphonates: 20
TPTD, 20 µg s.c. daily plus
placebo, n = 9
51.6 (11.7) 100 –2.0 (0.9) 0.659 (0.12) 33 Bisphosphonates: 33
VERO: Kendler
201899
RIS, 35 mg weekly plus
placebo, n = 680
71.6 (8.58) 100 –2.24 (0.74) 0.67 (0.11) (100) 71
TPTD, 20 µg s.c. daily plus
placebo, n = 680
72.6 (8.77) 100 –2.27 (0.76) 0.66 (0.11) (100) 73
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Trial name:
first author
and year Treatment arms (n)
Age (years),
mean (SD) Sex (% female)
T-score femoral neck
(or lumbar spine if
femoral neck not
reported), mean (SD)
BMD at femoral neck
(or lumbar spine if
femoral neck not
reported) (g/cm2),
mean (SD)
Fractures
(at baseline),
n (%)
Prior treatment for
osteoporosis (%)
Hadji 201291 RIS, 35 mg weekly plus
placebo, n = 350
71.6 (8.1) 100 –2.44 (0.67) NR 90% confirmed by
X-ray (all back pain
likely to be due to
vertebral fracture)
73.7
TPTD, 20 µg s.c. daily plus
placebo, n = 360
70.5 (8.8) 100 –2.32 (0.75) NR 89.7% confirmed by
X-ray (all back pain
likely to be due to
vertebral fracture)
74.2
MOVE: Abtahi
2016101 and
Malouf-Sierra
201792
RIS, 35 mg weekly plus
placebo, n = 85
76.4 (7.5) 77.6 –2.63 (0.657) 0.602 (0.116) (100) 12.9
TPTD, 20 µg s.c. daily plus
placebo, n = 86
77.2 (8.0) 76.7 –2.63 (0.519) 0.603 (0.098) (100) 14.0
Cosman 201193 ZOL, 5 mg i.v. annually,
n = 137
66.1 (9.0) 100 Lumbar spine T-score:
–2.88 (0.883)
NR 21 (15.3) 0
TPTD, 20 µg s.c. daily plus
placebo, n = 138
63.8 (9.1) 100 Lumbar spine T-score:
–2.87 (0.807)
NR 22 (15.9) 0
ADAMO, A multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety DenosumAb versus placebo in Males with Osteoporosis;
GCC, glucocorticoid; NR, not reported; PTH, parathyroid hormone.
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Appendix 5 Clinical effectiveness results
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TABLE 17 Vertebral fracture data reported by the included studies
Trial name: first author
and year; population
Efficacy or
safety
outcome
Method of vertebral
fracture assessment
(clinical/morphometric)
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Vertebral fracture
outcomes n/N (%) (reported
between-group difference)
DEN vs. placebo
FREEDOM: Cummings
2009;41 postmenopausal
women with osteoporosis
Efficacy l Morphometric, new
l Definition: increase of
at least Genant et al.35
grade 1, ≥ 20%
reduction in anterior,
middle and/or posterior
height and a reduction
in area of 10–20%
l Placebo, 3906
l DEN, 3902
l Placebo, 3691
l DEN, 3702
36 l Placebo, 264/3691 (7.15)
l DEN, 86/3702 (2.32)
l (RD to 4.8, 95% CI 3.9 to 5.8;
RR 0.32, 95% CI 0.26 to 0.41;
p < 0.001)
FREEDOM: Cummings
2009;41 postmenopausal
women with osteoporosis
Efficacy Clinical l Placebo, 3906
l DEN, 3902
l Placebo, 3906
l DEN, 3902
36 l Placebo, 92/3906 (2.36)
l DEN, 29/3902 (0.74)
l (RD to 1.7, 95% CI 1.1 to 2.3;
RR 0.31, 95% CI 0.20 to 0.47;
p < 0.001)
FREEDOM: Cummings
2009;41 postmenopausal
women with osteoporosis
Efficacy Morphometric, multiple
(> 2)
l Placebo, 3906
l DEN, 3902
l Placebo, 3691
l DEN, 3702
36 l Placebo, 59/3691 (1.60)
l DEN, 23/3702 (0.62)
l (RD to 1.0, 95% CI 0.5 to 1.5;
RR 0.39, 95% CI 0.24 to 0.63;
p < 0.001)
FREEDOM: Bone 2017104
postmenopausal women
with osteoporosis
Efficacy Morphometric, new l Placebo, 3906
l DEN, 3902
l Placebo, 3691
l DEN, 3702
0–12 l Placebo, 82/3691 (2.22)
l DEN, 32/3702 (0.86)
l Estimated (from graph) RR
0.39, 95% CI 0.26 to 0.58;
p < 0.00001
FREEDOM: Bone 2017104
postmenopausal women
with osteoporosis
Efficacy Morphometric, new As above l Placebo, 3691
l DEN, 3702
12–24 l Placebo, 116/3691 (3.14)
l DEN, 26/3702 (0.70)
l Estimated (from graph), RR
0.22, 95% CI 0.15 to 0.34;
p < 0.00001
FREEDOM: Bone 2017104
postmenopausal women
with osteoporosis
Efficacy Morphometric, new As above l Placebo, 3691
l DEN, 3702
24–36 l Placebo, 114/3691 (3.09)
l DEN, 40/3702 (1.08)
l Estimated (from graph), RR
0.35, 95% CI 0.24 to 0.50;
p < 0.00001
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Trial name: first author
and year; population
Efficacy or
safety
outcome
Method of vertebral
fracture assessment
(clinical/morphometric)
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Vertebral fracture
outcomes n/N (%) (reported
between-group difference)
FREEDOM Bone 2017105
OLE; postmenopausal
women with osteoporosis
Efficacy Morphometric, new l Entered OLE
l Placebo to
DEN, 2207
l DEN to DEN, 2343
l Placebo/DEN, 1991
l DEN/DEN, 2116
84 from OLE l Placebo/DEN, 145/1991 (7.30)
l DEN/DEN, 149/2116 (7.04)
l Estimated RR 0.97, 95% CI
0.78 to 1.21; p = 0.76
ADAMO: Orwoll 2012;42
men with osteoporosis
Safety Clinical l Placebo, 121
l DEN, 121
l Safety Ns
l Placebo, 120
l DEN, 120
12 l Placebo, 1/120 (0.83)
l DEN, 0/120 (0)
l Estimated RR 0.33, 95% CI
0.01 to 8.10; p = 0.50
DIRECT: Nakamura
2014;43 women and men
with osteoporosis
Efficacy l Morphometric, new
l Definition: increase of
at least Genant et al.35
grade 1, ≥ 20%
reduction in anterior,
posterior, or central
vertebra height
l Placebo, 511
l DEN, 500
l Placebo, 480
l DEN, 472
24 l Placebo, 41/480 (8.60)
l DEN, 10/472 (2.20)
l (HR 0.260, 95% CI 0.129 to
0.521; p < 0.0001)
DIRECT: Nakamura
2014;43 women and men
with osteoporosis
Efficacy Morphometric, new or
worsening
As above l Placebo, 480
l DEN, 472
24 l Placebo, 49/480 (10.30)
l DEN, 17/472 (3.60)
l (HR 0.343, 95% CI 0.194 to
0.606; p = 0.0001)
DIRECT: Sugimoto
2015;106 women and men
with osteoporosis
Efficacy Morphometric, new l Placebo to
DEN, 406
l DEN to DEN, 404
l 12 months
open label
l Placebo/DEN, 406
l DEN/DEN, 404
36 including 12
OLE
l Placebo/DEN, 42/406 (10.30)
l DEN/DEN, 10/404 (2.50)
l Estimated RR 0.24, 95% CI
0.12 to 0.47; p < 0.0001
DIRECT: Sugimoto
2015;106 women and men
with osteoporosis
Efficacy Morphometric, new or
worsening
As above l Placebo/DEN, 406
l DEN/DEN, 404
36 including 12
OLE
l Placebo/DEN, 48/406 (11.80)
l DEN/DEN, 15/404 (3.71)
l Estimated RR 0.31, 95% CI
0.18 to 0.55; p < 0.0001
DIRECT: Sugimoto
2015;106 women and men
with osteoporosis
Efficacy Morphometric, new As above l Placebo/DEN, 406
l DEN/DEN, 404
12 OLE l Placebo/DEN, 8/406 (2.00)
l DEN/DEN, 1/404 (0.25)
l Estimated RR 0.13, 95% CI
0.02 to 1.00; p = 0.05
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TABLE 17 Vertebral fracture data reported by the included studies (continued )
Trial name: first author
and year; population
Efficacy or
safety
outcome
Method of vertebral
fracture assessment
(clinical/morphometric)
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Vertebral fracture
outcomes n/N (%) (reported
between-group difference)
DIRECT: Sugimoto
2015;106 women and men
with osteoporosis
Efficacy Morphometric, new or
worsening
As above l Placebo/DEN, 406
l DEN/DEN, 404
12 OLE l Placebo/DEN, 2/406 (0.50)
l DEN/DEN, 1/404 (0.25)
l Estimated RR 0.50, 95% CI
0.05 to 5.52; p = 0.57
Nakamura 2012;44
postmenopausal women
with osteoporosis
Efficacy Morphometric, new or
worsening
l Placebo, 55
l DEN, 54
l Placebo, 55
l DEN, 54
12 l Placebo, 0/55 (0)
l DEN, 0/54 (0)
l NE
RLX vs. placebo
Morii 2003;47
postmenopausal women
with osteoporosis
Efficacy l Morphometric, new
l Definition: Genant
et al.35 method
l Placebo, 97
l RLX, 90
l Placebo, 87
l RLX, 79
12 l Placebo, 2/87 (2.30)
l RLX, 0/79 (0)
l Estimated RR 0.22, 95% CI
0.01 to 4.51; p = 0.33
Liu 2004;48
postmenopausal women
with osteoporosis
Efficacy Clinical l Placebo, 102
l RLX, 102
l Placebo, 102
l RLX, 102
12 l Placebo, 5/102 (4.90)
l RLX, 0/102 (0)
l (RR 0.09, 95% CI 0.005 to
1.580; p > 0.05)
Silverman 2008;50
postmenopausal women
with osteoporosis
Efficacy l Morphometric, new
l Definition: Genant
et al.35 method
l Placebo, 1855
l RLX, 1849
l Placebo, 1741
l RLX, 1696
36 l Placebo, 71/1741 (4.10)
l RLX, 40/1696 (2.36)
l (HR 0.58, 95% CI 0.38 to
0.89; p < 0.05)
Silverman 200850 and
NCT00205777;117
postmenopausal women
with osteoporosis
Efficacy Clinical As above l Placebo, 1741
l RLX, 1696
36 l Placebo, 16/1741 (0.92)
l RLX, 15/1696 (0.88)
l (p = 0.89)
MORE: Ettinger 1999;51
women with osteoporosis
Efficacy l Morphometric, new
l Definition: Genant
et al.35 method
l Placebo, NR
l RLX, NR
l Placebo, 1522
l RLX, 1490
36 l Placebo, 68/1522 (4.50)
l RLX, 35/1490 (2.30)
l (RR 0.5, 95% CI 0.4 to 0.9;
estimated p = 0.002)
MORE: Ettinger 1999;51
women with low
BMD + fracture
Efficacy Morphometric, new l Placebo, NR
l RLX, NR
l Placebo, 770
l RLX, 769
36 l Placebo, 163/770 (21.20)
l RLX, 113/769 (14.70)
l (RR 0.7, 95% CI 0.6 to 0.9;
estimated p = 0.001)
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Trial name: first author
and year; population
Efficacy or
safety
outcome
Method of vertebral
fracture assessment
(clinical/morphometric)
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Vertebral fracture
outcomes n/N (%) (reported
between-group difference)
MORE: Maricic 2002;102
postmenopausal women
with osteoporosis
Efficacy Clinical l Placebo, 2576
l RLX, 2557
l Placebo, 2292
l RLX, 2259
0–12 l Placebo, 19/2292 (0.80)
l RLX, 6/2259 (0.20)
l (RR 0.32, 95% CI 0.13 to
0.79; p < 0.001)
MORE: Maricic 2002;102
postmenopausal women
with osteoporosis
Efficacy Clinical As above l Placebo, 2292
l RLX, 2259
12–24 l Placebo, 33/2292 (1.40)
l RLX, 22/2259 (1.00)
l Estimated RR 0.68, 95% CI
0.40 to 1.16; p = 0.15
MORE: Maricic 2002;102
postmenopausal women
with osteoporosis
Efficacy Clinical As above l Placebo, 2292
l RLX, 2259
24–36 l Placebo, 29/2292 (1.30)
l RLX, 19/2259 (0.80)
l Estimated RR 0.66, 95% CI
0.37 to 1.18; p = 0.16
MORE: Maricic 2002;102
postmenopausal women
with osteoporosis
Efficacy Clinical As above l Placebo, 2292
l RLX, 2259
36 l Placebo, 81/2292 (3.50)
l RLX, 47/2259 (2.10)
l Estimated RR 0.59, 95% CI
0.41 to 0.84; p = 0.003
MORE: Maricic 2002;102
postmenopausal women
with osteoporosis
Efficacy Clinical As above l Placebo, 2292
l RLX, 2259
24 l Placebo, 35/2292 (1.54)
l RLX, 22/2259 (0.97)
l Estimated RR (from graph)
0.64, 95% CI 0.38 to
1.08; p = 0.10
Lufkin 1998;52
postmenopausal women
with osteoporosis
Efficacy l Morphometric, new
l Definition: 15%
decrease in the
same vertebra
l Placebo, 48
l RLX, 48
l Placebo, 45
l RLX, 43
12 l Placebo, 18/45 (40.00)
l RLX, 21/43 (48.84)
l Estimated RR 1.22, 95% CI
0.76 to 1.96; p = 0.41
Mok 2011;53
postmenopausal women
on long-term GCCs
Efficacy l Morphometric, new
l Definition: loss of at
least 25% of vertebral
height in previously
normal vertebrae
l Placebo, 57
l RLX, 57
l Placebo, 56
l RLX, 51
12 l Placebo, 3/56 (5.36)
l RLX, 0/51 (0)
l (p = 0.24)
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TABLE 17 Vertebral fracture data reported by the included studies (continued )
Trial name: first author
and year; population
Efficacy or
safety
outcome
Method of vertebral
fracture assessment
(clinical/morphometric)
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Vertebral fracture
outcomes n/N (%) (reported
between-group difference)
ROMO vs. placebo
FRAME: Cosman 2016;54
postmenopausal women
with osteoporosis
Efficacy l Morphometric, new
l Definition: Genant
et al.35 method
l Placebo, 3591
l ROMO, 3589
l Placebo, 3322
l ROMO, 3321
12 l Placebo, 59/3322 (1.78)
l ROMO, 16/3321 (0.48)
l (RR 0.27, 95% CI 0.16 to 0.47;
nominal p < 0.001;
adjusted p < 0.001)
FRAME: Cosman 2016;54
postmenopausal women
with osteoporosis
Efficacy Morphometric, multiple or
worsening
As above l Placebo, 3322
l ROMO, 3321
12 l Placebo, 9/3322 (0.27)
l ROMO, 1/3321 (0.03)
l (RR 0.11, 95% CI 0.01 to 0.87;
nominal p = 0.011)
FRAME: Cosman 2016;54
postmenopausal women
with osteoporosis
Efficacy Morphometric, new l Placebo to
DEN, 3591
l ROMO to
DEN, 3589
l 12 months
open label
l Placebo, 3327
l ROMO, 3325
24 l Placebo/DEN, 84/3327 (2.52)
l ROMO/DEN, 21/3325 (0.63)
l (RR 0.25, 95% CI 0.16 to 0.40;
nominal p < 0.001;
adjusted p < 0.001)
FRAME: Cosman 2016;54
postmenopausal women
with osteoporosis
Efficacy Morphometric, multiple or
worsening
As above l Placebo, 3327
l ROMO, 3325
24 l Placebo/DEN, 17/3327 (0.51)
l ROMO/DEN, 1/3325 (0.03)
l (RR 0.06, 95% CI 0.01 to 0.44;
nominal p < 0.001)
FRAME: Cosman 2016;20
postmenopausal women
with osteoporosis
Efficacy Morphometric, new l Placebo to
DEN, 3591
l ROMO to
DEN, 3589
l 12 months
open label
l Placebo, 3327
l ROMO, 3325
36 l Placebo/DEN, 94/3327 (2.8)
l ROMO/DEN, 32/3327 (1.0)
l (RR reduction 66%, 95% CI
49% to 77%; RR 0.34; nominal
p < 0.001)
FRAME: Cosman 2016;20
postmenopausal women
with osteoporosis
Efficacy Morphometric, multiple or
worsening
As above l Placebo, 3327
l ROMO, 3325
36 l Placebo/DEN, 94/3327 (2.8)
l ROMO/DEN, 33/3327 (1.0)
l (RR reduction 65%, 95% CI
48% to 76%, RR 0.35; nominal
p < 0.001)
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Trial name: first author
and year; population
Efficacy or
safety
outcome
Method of vertebral
fracture assessment
(clinical/morphometric)
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Vertebral fracture
outcomes n/N (%) (reported
between-group difference)
TPTD vs. placebo
ACTIVE: Miller 2016;95
postmenopausal women
with osteoporosis
Efficacy l Morphometric, new
l Definition: Genant
et al.35 method
l Placebo, 821
l TPTD, 818
l Placebo, 821
l TPTD, 818
18 l Placebo, 30/711 (4.20)
l TPTD, 6/717 (0.80)
l (RD –3.38, 95% CI –5.18 to
–1.80; RR 0.20, 95% CI 0.08
to 0.47; p < 0.001)
ACTIVE: Miller 2016;95
postmenopausal women
with osteoporosis
Efficacy Clinical As above l Placebo, 821
l TPTD, 818
18 l Placebo, 9/821 (1.10)
l TPTD, 3/818 (0.40)
l Estimated RR 0.59, 95% CI
0.29 to 1.17; p = 0.10
Miyauchi 2010;58 women
and men with osteoporosis
Efficacy Morphometric, any l Placebo, 70
l TPTD, 137
l Placebo, 67
l TPTD, 136
12 l Placebo, 4/67 (5.97)
l TPTD, 6/136 (4.41)
l Estimated RR 0.33, 95% CI
0.09 to 1.23; p = 0.63
Miyauchi 2010;58 women
and men with osteoporosis
Efficacy l Morphometric, new
l Definition:
deterioration of at
least one grade by
Genant et al.35 method
As above l Placebo, 67
l TPTD, 136
12 l Placebo, 4/67 (5.97)
l TPTD, 5/136 (3.68)
l Estimated RR 0.74, 95% CI
0.22 to 2.53; p = 0.46
Miyauchi 2010;58 women
and men with osteoporosis
Efficacy l Morphometric,
worsening
l Definition:
deterioration of at
least one grade by
Genant et al.35 method
As above l Placebo, 67
l TPTD, 136
12 l Placebo, 0/67 (0)
l TPTD, 2/136 (1.47)
l Estimated RR 0.62, 95% CI
0.17 to 2.22; p = 0.56
FPT: Neer 2001;62
postmenopausal women
with osteoporosis
Efficacy l Morphometric, one or
more fractures
l Definition: Genant
et al.35 method
l Placebo, 544
l TPTD, 541
l Placebo, 448
l TPTD, 444
24 (trial stopped
early; mean time
to last radiograph
was 21 months)
l Placebo, 64/448 (14.00)
l TPTD,22/444 (5.00)
l (RR 0.35, 95% CI 0.22 to 0.55;
reduction in absolute risk to
9%; p ≤ 0.001)
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TABLE 17 Vertebral fracture data reported by the included studies (continued )
Trial name: first author
and year; population
Efficacy or
safety
outcome
Method of vertebral
fracture assessment
(clinical/morphometric)
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Vertebral fracture
outcomes n/N (%) (reported
between-group difference)
FPT: Neer 2001;62
postmenopausal women
with osteoporosis
Efficacy Morphometric, one or
more fractures
As above As above 24 (trial stopped
early; mean time
to last radiograph
was 21 months)
l Placebo, 22/448 (5.00)
l TPTD, 5/444 (1.00)
l (RR 0.23, 95% CI 0.09 to 0.60;
reduction in absolute risk to
4%; p ≤ 0.001)
FPT: Neer 2001;62
postmenopausal women
with osteoporosis
Efficacy Morphometric, one or
more moderate or severe
fractures
As above As above 24 (trial stopped
early; mean time
to last radiograph
was 21 months)
l Placebo, 42/448 (9.00) to
TPTD, 4/444 (0.90)
l (RR 0.10, 95% CI 0.04 to 0.27;
reduction in absolute risk to
9%; p ≤ 0.001)
Head-to-head non-bisphosphonates
EUROFORS: Eastell
2009;66 postmenopausal
women with osteoporosis
pre treated with TPTD
Efficacy Clinical l TPTD, 304
l RLX, 97
l Control,a 102
l TPTD, 304
l RLX, 97
l Control, 102
12 l TPTD, 4/304 (1.32)
l RLX, 0/97 (0)
l Control, 0/102 (0)
l (Not significant, p-value NR)
DEN vs. bisphosphonates
Saag 2018;74 women and
men on GCCs with
osteoporosis or low
BMD + fracture
Efficacy Clinical l RIS, 397
l DEN, 398
l Both with placebo
l RIS, 397
l DEN, 398
12 l RIS, 15/342 (4.0)
l DEN, 10/333 (3.00)
l Estimated RR 0.67, 95% CI
0.30 to 1.52; p = 0.34
Miller 201675 Safety NR l ZOL, 322
l DEN, 321
l Both with placebo
l ZOL, 320
l DEN, 320
12 l ZOL, 4 fractures
l DEN, 0 fractures
l Number of participants NR
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Trial name: first author
and year; population
Efficacy or
safety
outcome
Method of vertebral
fracture assessment
(clinical/morphometric)
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Vertebral fracture
outcomes n/N (%) (reported
between-group difference)
RLX vs. bisphosphonates
EFFECT: Sambrook 200476
(international not
including USA);
postmenopausal women
with osteoporosis
Safety NR l ALN, 246
l RLX, 241
l Both with placebo
l ALN, 246
l RLX, 241
12 l ALN, 0/246 (0)
l RLX, 0/241 (0)
l NE
Muscoso 2004;79
postmenopausal women
with osteoporosis
Efficacy NR l ALN, 1000
l RLX, 100
l RIS, 100
l All daily open label
l ALN, 1000
l RLX, 100
l RIS, 100
0–12 l ALN, 2/1000 (0.2)
l RLX, 0/100 (0)
l RIS, 0/100 (0)
l ALN vs. RLX: estimated RR
1.99, 95% CI 0.09 to
41.68; p = 0.66
l RIS vs. RLX: NE
Muscoso 2004;79
postmenopausal women
with osteoporosis
Efficacy NR As above l ALN, 1000
l RLX, 100
l RIS, 100
12–24 l ALN, 4/1000 (0.4)
l RLX, 0/100 (0)
l RIS, 0/100 (0)
l ALN vs. RLX: estimated RR
1.10, 95% CI 0.06 to
20.61; p = 0.95
l RIS vs. RLX: NE
EVA: Recker 2007;80
postmenopausal women
with osteoporosis
Efficacy l Morphometric, new
l Definition: Genant
et al.35 method
l ALN, 716
l RLX, 707
l Both with placebo
l ALN, 255
l RLX, 259
Mean 312
(SD 252) days
l ALN, 8/255 (3.14)
l RLX, 5/259 (1.93)
l Estimated RR 0.62, 95% CI
0.20 to 1.86; p = 0.39
EVA: Recker 2007;80
postmenopausal women
with osteoporosis
Efficacy l Morphometric,
moderate/severe
l Definition: Genant
et al.35 method
> 25% loss of height
l ALN, 716
l RLX, 707
l Both with placebo
l ALN, 255
l RLX, 259
Mean 312
(SD 252) days
l ALN, 4/255 (1.57)
l RLX, 0/259 (0)
l Estimated RR 0.11, 95% CI
0.01 to 2.02; p = 0.14
EVA: Recker 2007;80
postmenopausal women
with osteoporosis
Efficacy Clinical As above l ALN, 713
l RLX, 699
Mean 312
(SD 252) days
l ALN, 3/713 (0.40)
l RLX, 0/699 (0)
l Estimated RR 0.15, 95% CI
0.01 to 2.82; p = 0.20
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TABLE 17 Vertebral fracture data reported by the included studies (continued )
Trial name: first author
and year; population
Efficacy or
safety
outcome
Method of vertebral
fracture assessment
(clinical/morphometric)
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Vertebral fracture
outcomes n/N (%) (reported
between-group difference)
ROMO vs. bisphosphonates
ARCH: Saag 2017;83
postmenopausal women
with osteoporosis
Efficacy l Morphometric, new
ITT MI
l Definition: Genant35
method
l ALN, 2047
l ROMO, 2046
l Both with placebo
l ALN, 2047
l ROMO, 2046
12 l ALN, 128/2047 (6.3)
l ROMO, 82/2046 (4.00)
l (RR 0.63, 95% CI 0.47 to
0.85; p = 0.003)
ARCH: Saag 2017;83
postmenopausal women
with osteoporosis
Efficacy Morphometric, new,
ITT LOCF
As above l ALN, 1703
l ROMO, 1696
12 l ALN, 85/1703 (5.00)
l ROMO, 55/1696 (3.20)
l (RR 0.64, 95% CI 0.46 to
0.89; p = 0.008)
ARCH: Saag 2017;83
postmenopausal women
with osteoporosis
Efficacy Morphometric new or
worsening
As above l ALN, 1703
l ROMO, 1696
12 l ALN, 101/1703 (5.90)
l ROMO, 67/1696 (4.00)
l (RR 0.66, 95% CI 0.49 to
0.89; p = 0.006)
ARCH: Saag 2017;83
postmenopausal women
with osteoporosis
Efficacy Clinical As above l ALN, 2047
l ROMO, 2046
12 l ALN, 18/2047 (0.90)
l ROMO, 10/2046 (0.50)
l (HR 0.56, 95% CI 0.26 to
1.22; p = 0.14)
ARCH: Saag 2017;83
postmenopausal women
with osteoporosis
Efficacy Morphometric, new, ITT
MI
l ALN to ALN, 2047
l ROMO to
ALN, 2046
l Open label
l ALN/ALN, 2047
l ROMO/ALN, 2046
24 l ALN/ALN, 243/2047 (11.90)
l ROMO/ALN, 127/2046 (6.20)
l (RR 0.52, 95% CI 0.40 to
0.66; p < 0.001)
ARCH: Saag 2017;83
postmenopausal women
with osteoporosis
Efficacy Morphometric, new, ITT
LOCF
As above l ALN/ALN, 1843
l ROMO/ALN, 1825
24 l ALN/ALN, 147/1834 (8.00)
l ROMO/ALN, 74/1825 (4.55)
l (RR 0.50, 95% CI 0.38 to
0.66; p < 0.001)
ARCH: Saag 2017;83
postmenopausal women
with osteoporosis
Efficacy Morphometric, new or
worsening
As above l ALN/ALN, 1843
l ROMO/ALN, 1825
24 l ALN/ALN, 168/1834 (9.20)
l ROMO/ALN, 87/1825 (4.77)
l (RR 0.52, 95% CI 0.40 to
0.66; p < 0.001)
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Trial name: first author
and year; population
Efficacy or
safety
outcome
Method of vertebral
fracture assessment
(clinical/morphometric)
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Vertebral fracture
outcomes n/N (%) (reported
between-group difference)
TPTD vs. bisphosphonates
Saag 2009;103 women and
men on GCCs with
osteoporosis or low
BMD + fracture
Efficacy l Morphometric, new
l Definition: Genant
et al.35 method
l Women and men
l ALN, 214
l TPTD, 214
l Both with placebo
l ALN, 165
l TPTD, 171
18 l ALN, 10/165 (6.10)
l TPTD, 1/171 (0.6)
l (p = 0.004)
Saag 2009;103 women and
men on GCCs with
osteoporosis or low
BMD + fracture
Efficacy Clinical As above l ALN, 165
l TPTD, 171
18 l ALN, 3/165 (1.80)
l TPTD, 0/171 (0)
l (p = 0.07)
Saag 2009;103 women and
men on GCCs with
osteoporosis or low
BMD + fracture
Efficacy Morphometric, new As above l ALN, 169
l TPTD, 173
36 l ALN, 13/169 (7.70)
l TPTD, 3/173 (1.70)
l (p = 0.007)
Saag 200985 Efficacy Clinical As above l ALN, 169
l TPTD, 173
36 l ALN, 4/169 (2.40)
l TPTD, 0/173 (0)
l (p = 0.037)
Langdahl 2009;107 women
and men on GCCs with
osteoporosis or low
BMD + fracture
Efficacy Morphometric, new l Women
l ALN, 173
l TPTD, 171
l Both with placebo
l ALN, 134
l TPTD, 139
18 l ALN, 6/134 (4.48)
l TPTD, 1/139 (0.72)
l Estimated RR 0.16, 95% CI
0.02 to 1.32; p = 0.09
Langdahl 2009;107 women
and men on GCCs with
osteoporosis or low
BMD + fracture
Efficacy Morphometric, new l Men
l ALN, 41
l TPTD, 42
l Both with placebo
l ALN, 31
l TPTD, 31
18 l ALN, 4/31 (12.90)
l TPTD, 0/31 (0)
l Estimated RR 0.11, 95% CI
0.01 to 1.98; p = 0.13
Panico 2011;86
postmenopausal
women with severe
osteoporosis + fracture
and on treatment for
osteoporosis
Efficacy Morphometric, new l ALN weekly, 39
l TPTD, 42
l Without placebo
l ALN, 39
l TPTD, 42
18 l ALN 6/39 (15.7)
l TPTD 1/42 (2.4)
l Estimated RR 0.15, 95% CI
0.02 to 1.23; p = 0.08
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TABLE 17 Vertebral fracture data reported by the included studies (continued )
Trial name: first author
and year; population
Efficacy or
safety
outcome
Method of vertebral
fracture assessment
(clinical/morphometric)
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Vertebral fracture
outcomes n/N (%) (reported
between-group difference)
Walker 2013;89 men with
osteoporosis
Efficacy l Morphometric, new
l Definition: Genant
et al.35 method
l RIS weekly, 10
l TPTD, 9
l Both with placebo
l RIS, 10
l TPTD, 9
18 l RIS, 1/10 (10.00)
l TPTD, 0/9 (0)
l Estimated RR 0.37, 95% CI
0.02 to 8.01; p = 0.52
Hadji 2012;91
postmenopausal women
with osteoporosis
Efficacy l Morphometric, new
l Definition: Genant
et al.35 method
l RIS weekly, 350
l TPTD, 360
l Both with placebo
l RIS, 350
l TPTD, 360
6 l RIS, 18/350 (5.10)
l TPTD, 15/360 (4.20)
l (p = 0.6)
Hadji 2012;91
postmenopausal women
with osteoporosis
Efficacy Morphometric, new or
worsening
As above l RIS, 350
l TPTD, 360
6 l RIS, 22/350 (6.30)
l TPTD, 23/360 (6.40)
l (p = 1.00)
Hadji 2012;91
postmenopausal women
with osteoporosis
Efficacy Morphometric, new As above l RIS, 350
l TPTD, 360
18 l RIS, 3/350 (9.40)
l TPTD, 16/360 (4.40)
l (p = 0.01)
Hadji 2012;91
postmenopausal women
with osteoporosis
Efficacy Morphometric, new or
worsening
As above l RIS, 350
l TPTD, 360
18 l RIS, 39/350 (11.10)
l TPTD, 24/360 (6.70)
l (p < 0.05)
VERO: Kendler 2018;99
postmenopausal women
with osteoporosis
Efficacy l Morphometric, new
l Definition: Genant
et al.35 method
l RIS weekly, 680
l TPTD, 680
l Both with placebo
l RIS, 533
l TPTD, 516
24 l RIS, 64/533 (12.00)
l TPTD, 28/516 (5.00)
l (RR 0.44, 95% CI 0.29 to
0.68; p < 0.0001)
VERO: Kendler 2018;99
postmenopausal women
with osteoporosis
Efficacy Morphometric, new and
worsening
As above l RIS, 533
l TPTD, 516
24 l RIS, 69/533 (13.00)
l TPTD, 31/516 (6.00)
l (RR 0.46, 95% CI 0.31 to
0.68; p < 0.0001)
VERO: Kendler 2018;99
postmenopausal women
with osteoporosis
Efficacy Morphometric, multiple As above l RIS, 533
l TPTD, 516
24 l RIS, 12/533 (2.00)
l TPTD, 2/516 (0.39)
l (RR 0.16, 95% CI 0.04 to
0.74; p = 0.007)
VERO: Kendler 2018;99
postmenopausal women
with osteoporosis
Efficacy Morphometric, multiple As above l RIS, 533
l TPTD, 516
12 l RIS, 11/533 (2.10)
l TPTD, 4/516 (0.78)
l Estimated RR (from graph)
0.38, 95% CI 0.12 to
1.17; p = 0.09
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Trial name: first author
and year; population
Efficacy or
safety
outcome
Method of vertebral
fracture assessment
(clinical/morphometric)
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Vertebral fracture
outcomes n/N (%) (reported
between-group difference)
MOVE: Aspenberg
2016;108 women and men
with low BMD+ recent
hip fracture surgery
Safety Clinical l RIS daily, 113
l TPTD, 111
l Both with placebo
l RIS, 113
l TPTD, 111
6 l RIS, 0/110 (0)
l TPTD, 0/116 (0)
l NE
MOVE: Malouf-Sierra
2017;92 women and men
with low BMD+ recent
hip fracture surgery
Safety Clinical As above l RIS, 113
l TPTD, 111
18 l RIS, 1/110 (1.00)
l TPTD, 0/116 (0)
l (p = 1.00)
Cosman 2011;93
postmenopausal women
with osteoporosis
Safety AE l ZOL,b 137
l TPTD+ ZOL
Placebo, 138
l ZOL, 137
l TPTD + placebo,
138
12 l ZOL, 5/137 (3.70)
l TPTD+ placebo, 1/137 (0.70)
l Estimated RR 0.20, 95% CI
0.02 to 1.69; p = 0.14
ADAMO, A multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety DenosumAb versus placebo in Males with Osteoporosis; CI, confidence
interval; EFFECT, EFficacy of Fosamax versus Evista Comparison Trial; GCC, glucocorticoid; ITT, intention to treat; MI, multiple imputation; MORE, Multiple Outcomes of Raloxifene
Evaluation; NE, not estimable; NR, not reported; OLE, open-label extension; RD, risk difference.
a No active treatment.
b Not placebo controlled for TPTD.
Notes
Definition of morphometric not provided in all studies.
ALN, 10 mg daily or 70 mg weekly; DEN, 60 mg s.c. every 6 months; IBN, 150 mg oral every month; RLX, 60 mg daily; ROMO, 210mg s.c. monthly; TPTD, 20 µg s.c. daily; ZOL, 5 mg
i.v. annually.
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TABLE 18 Non-vertebral fracture outcomes
Trial name or
first author
and year
Efficacy or
safety
outcome
Treatments,
n randomised
Follow-up
(months)
Non-vertebral fractures, n/N (%)
(reported between-group
difference)
DEN vs. placebo
FREEDOM41 Efficacy l Placebo, 3906
l DEN, 3902
36 l Placebo, 293/3906 (7.50)
l DEN, 238/3902 (6.10)
l (RD 1.5, 95% CI 0.3 to 2.7;
RR 0.80, 95% CI 0.67 to
0.95; p = 0.01)
FREEDOM104 Efficacy l Placebo, 3906
l DEN, 3902
0–12 l Placebo, 120/3906 (3.06)
l DEN, 101/3902 (2.59)
l Values estimated from graph
FREEDOM104 Efficacy l Placebo, 3906
l DEN, 3902
12–24 l Placebo, 113/3906 (2.89)
l DEN, 82/3902 (2.09)
l Values estimated from graph
FREEDOM104 Efficacy l Placebo, 3906
l DEN, 3902
24–36 l Placebo, 98/3906 (2.50)
l DEN, 84/3902 (2.15)
l Values estimated from graph
FREEDOM OLE105 Efficacy l Entered OLE
l Placebo/DEN, 2207
l DEN/DEN, 2343
84 from OLE l Placebo/DEN, 219/2207
(9.92)
l DEN/DEN, 172/2343 (7.34)
ADAMO42 Safety l Placebo, 121
l DEN, 121
12 l Placebo, 2/120 (1.67)
l DEN, 1/120 (0.83)
DIRECT43 Efficacy l Placebo, 511
l DEN, 500
24 All:
l Placebo, 20/480 (4.10)
l DEN, 19/472 (4.10)
l (HR 1.002, 95% CI 0.521 to
1.926; p = 0.9951)
Major (proximal humerus,
forearm, ribs/clavicle, pelvis, hip,
distal femur, and proximal tibia):
l Placebo, 18/480 (3.70)
l DEN, 8/472 (1.60)
l (HR 0.434, 95% CI 0.178 to
1.055; p = 0.0577)
Non-major:
l Placebo, 2/480 (0.40)
l DEN, 12/472 (2.50)
l (HR 5.552, 95% CI 1.231 to
25.042; p = 0.0120)
DIRECT106 Efficacy l Placebo to DEN, 406
l DEN to DEN, 404
36 including
12 OLE
All:
l Placebo/DEN, 27/406 (6.65)
l DEN/DEN, 21/404 (5.20)
Major (proximal humerus
forearm ribs/clavicle pelvis hip
distal femur and proximal tibia):
l Placebo/DEN, 22/406 (5.42)
l DEN/DEN, 8/404 (1.98)
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TABLE 18 Non-vertebral fracture outcomes (continued )
Trial name or
first author
and year
Efficacy or
safety
outcome
Treatments,
n randomised
Follow-up
(months)
Non-vertebral fractures, n/N (%)
(reported between-group
difference)
Koh 201645 Safety l Placebo, 66
l DEN, 69
6 l Placebo, 1/66 (1.52)
l DEN, 1/69 (1.45)
Koh 2016 OLE45 Safety l Placebo to DEN, 66
l DEN to DEN, 69
6–12 OLE l Placebo, 1/63 (1.60)
l DEN, 0/60 (0)
RLX vs. placebo
Morii 200347 Efficacy l Placebo, 97
l RLX, 90
12 l Placebo, 4/97 (4.12)
l RLX, 0/88 (0)
Silverman 200850
(NCT00205777)
Efficacy l Placebo, 1855
l RLX, 1849
36 l Placebo, 118/1885 (5.70)
l RLX, 109/1849 (6.30)
l Non-significant p-value NR
Lufkin 199852 Efficacy l Placebo, 48
l RLX, 48
12 l Placebo, 3/45 (6.67)
l RLX, 0/43 (0)
ROMO vs. placebo
FRAME54 Efficacy l Placebo, 3591
l ROMO, 3589
12 l Placebo, 75/3591 (2.1)
l ROMO, 56/3589 (1.6)
l (HR 0.75, 95% CI 0.53 to
1.05; p = 0.096)
FRAME54 Efficacy l Placebo to
DEN, 3591
l ROMO to
DEN, 3589
24 l Placebo, 129/3591 (3.6)
l ROMO, 96/3589 (2.7)
l (HR 0.75, 95% CI 0.57 to
0.97; p = 0.029)
Ishibashi 201755 Safety l Placebo, 63
l ROMO, 63
12 l Placebo, 1/63 (1.59)
l ROMO, 2/63 (3.17)
TPTD vs. placebo
Miyauchi 201058 Efficacy l Placebo, 70
l TPTD, 137
12 l Placebo, 4/67 (6.00)
l TPTD, 3/136 (2.20)
Fragility:
l Placebo, 1/67 (1.50)
l TPTD, 1/136 (0.70)
Miyauchi 201058 Efficacy l Entered extension
l Placebo to TPTD, 59
l TPTD to TPTD, 119
12–18 OLE l Placebo/TPTD, 4/59 (6.78)
l TPTD/TPTD, 3/119 (2.52)
l Estimated from graph
Miyauchi 201058 Efficacy l Entered extension
l Placebo to TPTD, 59
l TPTD to TPTD, 119
18–24 OLE l Placebo/TPTD, 4/50 (8.0)
l TPTD/TPTD, 3/102 (2.94)
l Estimated from graph
ACTIVE95 Efficacy l Placebo, 821
l TPTD, 818
18 l Placebo, 33/821 (4.70)
l TPTD, 24/818 (3.30)
l (RD –1.46, 95% CI –3.50
to 0.58; HR 0.72, 95% CI
0.42 to 1.22; p = 0.22)
FPT62 Efficacy l Placebo, 544
l TPTD, 541
24 (trial stopped
early; mean time
to last visit was
19 months)
l Placebo, 53/544 (9.74)
l TPTD, 34/541 (6.28)
l (p = 0.04)
Fragility:
l Placebo, 30/544 (5.51)
l TPTD, 14/541 (2.59)
l (p = 0.02)
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TABLE 18 Non-vertebral fracture outcomes (continued )
Trial name or
first author
and year
Efficacy or
safety
outcome
Treatments,
n randomised
Follow-up
(months)
Non-vertebral fractures, n/N (%)
(reported between-group
difference)
Head-to-head non-bisphosphonates
EUROFORS66 Efficacy l TPTD, 304
l RLX, 97
l Control, 102
12 l TPTD, 9/304 (2.96)
l RLX, 2/97 (2.06)
l No treatment, 1/102 (0.98)
l Non-significant p-value NR
STRUCTURE67 Safety l ROMO, 218
l TPTD, 218
12 l ROMO, 7/218 (3.21)
l TPTD, 8/214 (3.67)
Non-bisphosphonates vs. bisphosphonates
STAND70 Safety l ALN, 251
l DEN, 253
12 l ALN, 4/249 (1.61)
l DEN, 8/253 (3.16)
DAPS109 Safety l ALN, 124
l DEN, 126
12 l ALN, 1/118 (0.85)
l DEN, 1/125 (0.80)
DAPS109 Safety l ALN to DEN, 106
l DEN to ALN, 115
12–24 l ALN/DEN, 3/106 (2.83)
l DEN/ALN, 1/110 (0.90)
Saag 201874 Efficacy l RIS plus
placebo, 397
l DEN plus
placebo, 398
12 l RIS, 10/397 (3.0)
l DEN, 17/398 (4.0)
EFFECT (USA)77 Safety l ALN, 223
l RLX, 233
12 l ALN, 5/199 (2.51)
l RLX, 8/206 (3.88)
Muscoso 200479 Efficacy l ALN, 1000
l RLX, 100
l RIS, 100
0–12 l ALN, 2/1000 (0.2)
l RLX, 0/100 (0)
l RIS, 0/100 (0)
Muscoso 200479 Efficacy l ALN, 1000
l RLX, 100
l RIS, 100
12–24 l ALN, 2/1000 (0.2)
l RLX, 0/100 (0)
l RIS, 0/100 (0)
EVA80 Efficacy l ALN, 716
l RLX, 707
Mean 312
(SD 252) days
l ALN, 14/713 (2.00)
l RLX, 15/699 (2.20)
l (RR 0.92, 95% CI 0.45
to 1.86)
Michalska 200682 Safety l Placebo, 33
l RLX, 33
l Open-label ALN, 33
24 l Placebo, 2/33 (6.06)
l RLX, 1/33 (3.03)
l ALN, 1/33 (3.03)
ARCH83 Efficacy l ALN, 2047
l ROMO, 2046
12 l ALN, 95/2047 (4.60)
l ROMO, 70/2046 (3.40)
l (HR 0.74, 95% CI 0.54 to
1.01; p = 0.057)
ARCH83 Efficacy l ALN, 2047
l ROMO, 2046
12 Major (pelvis, distal femur,
proximal tibia, ribs, proximal
humerus, forearm and hip):
l ALN, 88/2047 (4.30)
l ROMO, 59/2046 (2.90)
l (HR 0.67, 95% CI 0.48 to
0.94; p = 0.019)
ARCH83 Efficacy l ALN to ALN, 2047
l ROMO to
ALN, 2046
24 l ALN/ALN, 217/2047 (10.60)
l ROMO/ALN, 178/2046 (8.70)
l (HR 0.81, 95% CI 0.66 to
0.99; p = 0.037)
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TABLE 18 Non-vertebral fracture outcomes (continued )
Trial name or
first author
and year
Efficacy or
safety
outcome
Treatments,
n randomised
Follow-up
(months)
Non-vertebral fractures, n/N (%)
(reported between-group
difference)
ARCH83 Efficacy l ALN to ALN, 2047
l ROMO to
ALN, 2046
24 Major (pelvis, distal femur,
proximal tibia, ribs, proximal
humerus, forearm and hip):
l ALN/ALN, 196/2047 (9.60)
l ROMO/ALN, 146/2046 (7.10)
l (HR 0.73, 95% CI 0.59 to
0.90; p = 0.004)
Saag 2009103 Efficacy Men and women
l ALN, 214
l TPTD, 214
18 l ALN, 8/214 (3.70)
l TPTD, 12/214 (5.60)
l (p = 0.36)
Saag 2009103 Efficacy Men and women
l ALN, 214
l TPTD, 214
36 l ALN, 15/214 (7.00)
l TPTD, 16/214 (7.50)
l (p = 0.843)
Saag 2009107 Efficacy Men
l ALN, 41
l TPTD, 42
18 l ALN, 2/71 (2.82)
l TPTD, 1/42 (2.38)
l (p = 0.58)
Saag 2009107 Efficacy Women
l ALN, 173
l TPTD, 171
18 l ALN, 6/173 (3.47)
l TPTD, 11/171 (6.43)
l (Postmenopausal p = 0.36;
premenopausal p = 0.32)
EuroGIOPs87 Safety l RIS, 47
l TPTD, 45
18 l RIS, 5/47 (10.60)
l TPTD, 0/45 (0)
l (p = 0.056)
VERO99 Efficacy l RIS plus
placebo, 680
l TPTD plus
placebo, 680
24 l RIS, 38/680 (6.00)
l TPTD, 25/680 (4.00)
l (HR 0.66, 95% CI 0.39 to
1.10; p = 0.10)
VERO99 Efficacy l RIS plus
placebo, 680
l TPTD plus
placebo, 680
12 l RIS, 23/680 (3.32)
l TPTD, 15/680 (2.21)
l Estimated from graph
Hadji 201291 Efficacy l RIS, 350
l TPTD, 360
6 l RIS, 29/350 (8.30)
l TPTD, 28/360 (7.80)
l (p = 0.89)
MOVE92 Safety l RIS, 350
l TPTD, 360
18 l RIS, 10/110 (9.10)
l TPTD, 5/116 (4.70)
l (p = 0.286)
Cosman 201193 Safety l ZOL (no placebo),
137
l TPTD plus
placebo, 138
12 l ZOL, 8/137 (5.84)
l TPTD+ placebo, 7/137 (5.11)
ADAMO, A multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety
DenosumAb versus placebo in Males with Osteoporosis; CI, confidence interval; DAPS, Denosumab Adherence
Preference Satisfaction; EFFECT, EFficacy of Fosamax versus Evista Comparison Trial; NR, not reported; OLE, open
label extension; RD, risk difference; STAND, Study of Transitioning from Alendronate to Denosumab; STRUCTURE,
STudy evaluating effect of RomosozUmab Compared with Teriparatide in postmenopaUsal women with osteoporosis at
high risk for fracture pReviously treated with bisphosphonatE therapy.
Note
All reported treatment arms at licensed dose.
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TABLE 19 Fractures of the hip, wrist or proximal humerus
Trial name or
first author
and year Treatment arms
Follow-up
(months)
Fracture, n/N (%) (reported between-group difference)
Hip Wrist
Proximal
humerus
DEN vs. placebo
FREEDOM41 Placebo 0–36 43/3906 (1.2) NR NR
DEN l 26/3902 (0.7)
l Difference 0.3
(95% CI –0.1
to 0.7)
l HR 0.60 (95% CI
0.37 to 0.97)
l p = 0.04
NR NR
FREEDOM104 Placebo 1–12 21/3906 (0.55) NR NR
DEN l 11/3902 (0.29)
l Non-significant
(p-value NR)
NR NR
Placebo 12–24 14/3906 (0.36) NR NR
DEN l 3/3902 (0.08)
l Non-significant
(p-value NR)
NR NR
Placebo 24–36 11/3906 (0.27) NR NR
DEN l 12/3902 (0.32)
l Non-significant
(p-value NR)
NR NR
ADAMO42 Placebo 12 NR NR 1/120 (0.8)
DEN NR NR 0/120 (0)
DIRECT43 Placebo 24 2/480 (0.4) NR NR
DEN 0/472 (0) NR NR
RLX vs. placebo
Silverman 2008;50
NCT00205777117
Placebo 36 6/1885 (0.3) 31/1885 (1.6) NR
RLX 5/1849 (0.3) 46/1849 (2.5)117 NR
Lufkin 199852 Placebo 12 0/45 (0) 0/45 (0) NR
RLX 0/43 (0) 0/43 (0) NR
ROMO vs. placebo
FRAME54 Placebo 12 13/3591 (0.4) NR NR
ROMO l 7/3589 (0.2)
l HR 0.54 (95% CI
0.22 to 1.35);
p = 0.18
NR NR
FRAME54 Placebo followed
by DEN
24 22/3591 (0.6) NR NR
ROMO followed
by DEN
l 11/3589 (0.3)
l HR 0.50 (95% CI
0.24 to 1.04);
p = 0.059
NR NR
Ishibashi 201755 Placebo 12 NR 0/63 (0) NR
ROMO NR 1/63 (1.6) NR
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TABLE 19 Fractures of the hip, wrist or proximal humerus (continued )
Trial name or
first author
and year Treatment arms
Follow-up
(months)
Fracture, n/N (%) (reported between-group difference)
Hip Wrist
Proximal
humerus
TPTD vs. placebo
ACTIVE95 Placebo 18 2/821 (0.2) 15/821 (1.8) 3/821 (0.4)
TPTD l 0/818 (0)
l NR
l 17/818 (2.1)
l NR
l 2/818 (0.2)
l NR
FPT62 Placebo 24 (trial
stopped early;
mean time to
last visit was
19 months)
All:
l 4/544 (0.7)
Fragility:
l 4/544 (0.7)
All:
l 13/544 (2.4)
Fragility:
l 7/544 (1.3)
All:
l 5/544 (0.9)
Fragility:
l 2/544 (0.4)
TPTD All:
l 2/541 (0.4)
Fragility:
l 1/541 (0.2)
All:
l 7/541 (1.3)
Fragility:
l 2/541 (0.4)
All:
l 4/541 (0.7)
Fragility:
l 2/541 (0.4)
Head-to-head non-bisphosphonates
EUROFORS66 No active treatment
(for 12 months)
(following pre-
randomisation TPTD
for 12 months)
24 0/102 (0) 0/102 (0) 0/102 (0)
RLX (following TPTD) 0/97 (0) 0/97 (0) 1/97 (1.0)
TPTD (for 12 months)
(following 12 months
of pre-randomisation
TPTD)
1/304 (0.3) 3/304 (1.0) 0/304 (0)
STRUCTURE67 TPTD 12 0/218 (0) 4/218 (1.8) 1/218 (0.5)
ROMO 1/218 (0.5) 1/218 (0.5) 0/218 (0)
Non-bisphosphonates vs. bisphosphonates
STAND70 ALN 12 NR 2/249 (0.8) 0/249 (0)
DEN NR 3/253 (1.2) 1/253 (0.4)
Saag 201874 RIS 12 1/397 (0.3) NR 3/397 (0.8)
DEN 1/398 (0.3) NR 3/398 (0.8)
EFFECT
(International)76
RLX plus placebo 12 1/241 (0.4) NR NR
ALN plus placebo 0/246 (0) NR NR
EFFECT (USA)77 RLX plus placebo 12 NR 1/206 (0.5) 1/206 (0.5)
ALN plus placebo NR 0/199 (0) 0/199 (0)
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TABLE 19 Fractures of the hip, wrist or proximal humerus (continued )
Trial name or
first author
and year Treatment arms
Follow-up
(months)
Fracture, n/N (%) (reported between-group difference)
Hip Wrist
Proximal
humerus
Muscoso 200479 ALN 12 1/1000 (0.1) 1/1000 (0.1) NR
RLX 10/100 (0) 0/100 (0) NR
RIS 0/100 (0) 0/100 (0) NR
ALN 12–24 2/1000 (0.2) 0/1000 (0) NR
RLX 0/100 (0) 0/100 (0) NR
RIS 0/100 (0) 0/100 (0) NR
EVA80 RLX 24 2/699 (0.3) 8/699 (1.1) NR
ALN l 1/713 (0.1)
l RR 0.49 (95% CI
0.04 to 3.77)
l 6/713 (0.8)
l RR 0.74 (95% CI
0.27 to 2.02)
NR
ARCH83 ROMO 12 14/2046 (0.7) NR NR
ALN l 22/2047 (1.1)
l p = 0.19
NR NR
ROMO followed
by ALN
Median
2.7 years
41/2046 (2.0) NR NR
ALN followed by ALN l 66/2047 (3.2)
l p = 0.015
NR NR
EUROGIOPs87 RIS 18 1/47 (2.1) NR 1/47 (2.1)
TPTD 0/45 (0) NR 0/45(0)
VERO99 RIS 24 5/680 (0.7) 15/680 (2.2) 2/680 (0.3)
TPTD 2/680 (0.3) 6/680 (0.9) 14/680 (0.6)
Hadji 201291 RIS 18 2/350 (0.6) 2/350 (0.6) 5/350 (1.4)
TPTD 5/360 (1.4) 4/360 (1.1) 4/360 (1.1)
MOVE101 RIS 6 5/110 (4.5) NR 1/110 (0.9)
TPTD 2/106 (1.9) NR 1/106 (0.9)
MOVE92 RIS 18 7/110 (6.4) NR 1/110 (0.9)
TPTD 2/106 (1.9) NR 1/106 (0.9)
ADAMO, A multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety
DenosumAb versus placebo in Males with Osteoporosis; EFFECT, EFficacy of Fosamax versus Evista Comparison Trial;
NR, not reported; STAND, Study of Transitioning from Alendronate to Denosumab; STRUCTURE, STudy evaluating
effect of RomosozUmab Compared with Teriparatide in postmenopaUsal women with osteoporosis at high risk for
fracture pReviously treated with bisphosphonatE therapy.
Note
All reported arms at licensed dose.
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TABLE 20 Femoral neck BMD data reported by the included studies
Trial name: first author
and year; population
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Femoral neck BMD,
percentage change from
baseline, mean (SD)
Which data
were estimated
from graph?
Femoral neck BMD,
reported (estimated)
between-group
difference
DEN vs. placebo
FREEDOM: Bone 2017;104
postmenopausal women
with osteoporosis
l Placebo, 3906
l DEN, 3902
l Placebo, 3906
l DEN, 3902
36 l Placebo, + 7.1 (NR)
l DEN, + 9.0 (NR)
Nothing l NR
l (NE)
FREEDOM: Bone 2017
OLE;105 postmenopausal
women with osteoporosis
l Entered OLE
l Placebo to DEN, 2207
l DEN to DEN, 2343
l Placebo/DEN, 2809
l DEN/DEN, 2210
84 from OLE l Placebo/DEN,
+ 7.40 (5.83)
l DEN/DEN, + 3.40 (6.00)
Nothing l NR
l (MD –4.00, 95% CI
–4.35 to –3.65;
p < 0.00001)
ADAMO: Orwoll 2012;42
men with osteoporosis
l Placebo, 121
l DEN, 121
l Placebo, 117
l DEN, 111
12 l Placebo, 0.00 (3.31a)
l DEN, + 2.10 (3.35a)
95% CIs p < 0.0001
DIRECT: Nakamura
2014;43 women and men
with osteoporosis
l Placebo, 511
l DEN, 500
l Placebo, 480
l DEN, 472
24 l Placebo, –1.10 (4.30a)
l DEN, + 4.00 (4.82a)
95% CIs p < 0.0001
DIRECT: Sugimoto
2015;106 women and men
with osteoporosis
l Placebo to DEN, 406
l DEN to DEN, 404
l Placebo/DEN, 406
l DEN/DEN, 404
36 including
12 OLE
l Placebo/DEN,
+ 1.1 (4.32a)
l DEN/DEN, + 4.8 (4.61a)
95% CIs l NR
l (MD + 3.70, 95% CI
3.08 to 4.32;
p < 0.00001)
DIRECT: Sugimoto
2015;106 women and men
with osteoporosis
l Placebo to DEN, 406
l DEN to DEN, 404
l Placebo/DEN, 406
l DEN/DEN, 404
24–36 OLE l Placebo/DEN, + 0.8 (NR)
l DEN/DEN, + 2.30 (NR)
Nothing l NR
l (NE)
Koh 2016;45
postmenopausal women
with osteoporosis
l Placebo, 66
l DEN, 69
l Placebo, 66
l DEN, 68
6 l Placebo, + 0.73 (2.88a)
l DEN, + 4.37 (4.50a)
Means and
95% CIs
MD between groups in
percentage change:
1.4% (95% CI 0.4% to
2.3%; p = 0.0042
Koh 2016;45
postmenopausal women
with osteoporosis
l Entered OLE
l Placebo to DEN, 63
l DEN to DEN, 60
l OLE
l Placebo/DEN, 59
l DEN/DEN, 59
6–12 OLE l Placebo/DEN,
+ 3.48 (3.29a)
l DEN/DEN, + 5.59 (4.04a)
Means and
95% CIs
l NR
l (MD + 2.11, 95% CI
0.78 to 3.44;
p = 0.002)
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TABLE 20 Femoral neck BMD data reported by the included studies (continued )
Trial name: first author
and year; population
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Femoral neck BMD,
percentage change from
baseline, mean (SD)
Which data
were estimated
from graph?
Femoral neck BMD,
reported (estimated)
between-group
difference
RLX vs. placebo
Adami 2008;46
postmenopausal women
with osteoporosis pre
treated with TPTD
l Placebo, 172
l RLX, 157
l Placebo, 154
l RLX, 145
12 l Placebo, + 0.20 (3.72b)
l RLX, + 2.30 (4.82b)
Nothing p < 0.001
Adami 2008;46
postmenopausal women
with osteoporosis pre
treated with TPTD
l OLE
l Placebo to RLX, 172
l RLX to RLX, 157
l Placebo/RLX, 146
l RLX/RLX, 139
36 including
24 OLE
l Placebo, 1.70 (4.83b)
l RLX, 2.20 (5.89b)
Nothing l NR
l (MD + 0.50, 95% CI
–0.75 to 1.75;
p = 0.43)
Liu 2004;48
postmenopausal women
with osteoporosis
l Placebo, 102
l RLX, 102
l Placebo, 102
l RLX, 102
12 l Placebo, –0.40 (5.80)
l RLX, 0.9 (5.40)
Nothing l NR
l (MD + 1.30, 95% CI
–0.24 to 2.84;
p = 0.10)
Silverman 2008;50
postmenopausal women
with osteoporosis
l Placebo, 1855
l RLX, 1849
l Placebo, 1711
l RLX, 1662
36 l Placebo, –1.30 (6.20b)
l RLX, 0.80 (6.11b)
Nothing l NR
l (MD + 2.10, 95% CI
1.68 to 2.52;
p < 0.00001)
MORE: Ettinger 1999;51
women with osteoporosis
l Placebo, NR
l RLX, NR
l Placebo, 1522
l RLX, 1490
36 NR Nothing RLX group increased by
2.1% compared with
placebo, p < 0.001
Mok 2011;53
postmenopausal women
on long-term GCCs
l Placebo, 57
l RLX, 57
l Placebo, 56
l RLX, 51
12 l Placebo, –0.45 (4.71b)
l RLX, –0.59 (3.86b)
Mean and
SEMs
l NR
l (MD –0.14, 95% CI
–1.77 to 1.49;
p = 0.87)
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Trial name: first author
and year; population
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Femoral neck BMD,
percentage change from
baseline, mean (SD)
Which data
were estimated
from graph?
Femoral neck BMD,
reported (estimated)
between-group
difference
ROMO vs. placebo
FRAME: Cosman 2016;54
postmenopausal women
with osteoporosis
l Placebo, 3591
l ROMO, 3589
Substudy
l Placebo, 62
l ROMO, 66
12 l Placebo, –0.70 (8.60a)
l ROMO, + 5.20 (8.10a)
95% CIs ROMO group
compared with placebo:
5.9% (95% CI 4.3 to
7.4); p < 0.001
FRAME: Cosman 2016;54
postmenopausal women
with osteoporosis
l Placebo to DEN, 3591
l ROMO to DEN, 3589
l 12 months’ open label
l Placebo/DEN, 62
l ROMO/DEN, 66
24 l Placebo/DEN,
+ 0.60 (8.30a)
l ROMO/DEN,
+ 6.60 (8.70a)
95% CIs ROMO group
compared with placebo:
6.0% (95% CI 4.4 to
7.7); p < 0.001
Ishibashi 2017;55
postmenopausal women
with osteoporosis
l Placebo, 63
l ROMO, 63
l Placebo, 59
l ROMO, 59
12 l Placebo, + 0.30 (3.53a)
l ROMO, + 3.80 (4.31a)
Nothing ROMO group compared
with placebo: 3.5%
(one-sided 95% CI 2.3%,
NA); (p< 0.00001)
BRIDGE;56 men with
osteoporosis
l Placebo, 82
l ROMO, 63
l Placebo, 79
l ROMO, 158
12 l Placebo, –0.20 (4.00a)
l ROMO, + 2.20 (4.60a)
95% CIs p < 0.001
TPTD vs. placebo
ACTIVE: Miller 2016;95
postmenopausal women
with osteoporosis
l Placebo, 821
l TPTD, 818
l Placebo, 821
l TPTD, 818
18 l Placebo, –0.44 (3.57)
l TPTD, + 2.26 (3.57)
Nothing p < 0.0001
Orwoll 2003;57 men with
osteoporosis
l Placebo, 147
l TPTD, 151
l Placebo, 147
l TPTD, 151
12 l Placebo, + 0.31 (4.1)
l TPTD, + 1.53 (3.95)
Nothing p = 0.029
Miyauchi 2010;58
women and men with
osteoporosis
l Placebo, 70
l TPTD, 137
l Placebo, 67
l TPTD, 136
12 l Placebo, + 0.46 (3.89)
l TPTD, + 2.24 (6.01)
Nothing p = 0.015
Miyauchi 2010;58
women and men with
osteoporosis
l Placebo to TPTD, 59
l TPTD to TPTD, 119
l Placebo/TPTD, 58
l TPTD/TPTD, 117
12–18 OLE l Placebo, + 1.22 (4.72)
l TPTD, + 2.92 (4.83)
Nothing l NR
l (MD + 1.70, 95% CI
0.20 to 3.20;
p = 0.03)
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TABLE 20 Femoral neck BMD data reported by the included studies (continued )
Trial name: first author
and year; population
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Femoral neck BMD,
percentage change from
baseline, mean (SD)
Which data
were estimated
from graph?
Femoral neck BMD,
reported (estimated)
between-group
difference
Miyauchi 2010;58 women
and men with
osteoporosis
l Placebo to TPTD, 50
l TPTD to TPTD, 102
l Placebo/TPTD, 48
l TPTD/TPTD, 95
18–24 OLE l Placebo, + 2.43 (4.99)
l TPTD, + 3.25 (4.49)
Nothing l NR
l (MD + 0.82, 95% CI
–0.86 to 2.50;
p = 0.34)
Miyauchi 2008;59
postmenopausal women
with osteoporosis
l Placebo, 39
l TPTD, 39
l Placebo, 34
l TPTD, 36
6 l Placebo, –0.71 (4.68)
l TPTD, + 0.96 (4.86)
Nothing l NR
l MD + 1.67, 95% CI
–0.56 to 3.90;
p = 0.14)
Leder 2015;61
postmenopausal women
with osteoporosis
l Placebo, 45
l TPTD, 45
l Placebo, 41
l TPTD, 38
6 l Placebo, + 0.8 (4.8)
l TPTD, + 1.1 (4.6)
Nothing p < 0.01
Leder 2015;61
postmenopausal women
with osteoporosis
l Entered extension
l Placebo, 11
l TPTD, 14
l Placebo, 11
l TPTD, 14
12 l Placebo, + 1.0 (NR)
l TPTD, + 2.2 (NR)
Nothing l NR
l (NE)
Neer 2001;62
postmenopausal women
with osteoporosis
l Placebo, 544
l TPTD, 541
l Placebo, 479
l TPTD, 479
24 (trial stopped
early; mean time
to last visit
was 19)
l Placebo, –0.7 (5.4)
l TPTD, + 2.8 (5.7)
Nothing p < 0.001
Sethi 2008;63
postmenopausal women
with osteoporosis
l Calcium+
vitamin D, 41
l Calcium +
vitamin D, 35
l TPTD + calcium+
vitamin D, 38
6 l Calcium+ vitamin D,
+ 2.12 (5.92)
l TPTD+ calcium +
vitamin D, + 1.97 (4.25)
Nothing l NR
l (MD –0.15, 95% CI
–2.53 to 2.23;
p = 0.90)
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Trial name: first author
and year; population
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Femoral neck BMD,
percentage change from
baseline, mean (SD)
Which data
were estimated
from graph?
Femoral neck BMD,
reported (estimated)
between-group
difference
Head-to-head non-bisphosphonates
DATA: Tsai 2013;64
postmenopausal women
with osteoporosis
l TPTD, 36
l DEN, 34
l Without placebo
open-label
l TPTD, 31
l DEN, 33
12 l TPTD, + 0.80 (4.10)
l DEN, + 2.10 (3.80)
Nothing p = 0.1939
DATA: Leder 2014;110
postmenopausal women
with osteoporosis
As above l TPTD, 31
l DEN, 33
24 l TPTD, + 2.80 (3.90)
l DEN, + 4.10 (3.80)
Nothing p = 0.23
DATA-Switch65 l OLE
l TPTD to DEN, 27
l DEN to TPTD, 27
l TPTD/DEN, 27
l DEN/TPTD, 27
0–24 l TPTD/DEN, + 8.30 (5.83a)
l DEN/TPTD, + 4.90 (7.02a)
Nothing p < 0.0005
DATA-Switch65 l OLE
l TPTD to DEN, 27
l DEN to TPTD, 27
l TPTD/DEN, 27
l DEN/TPTD, 27
24–48 l TPTD/DEN, + 5.60 (4.77a)
l DEN/TPTD, + 1.20 (5.83a)
Nothing p < 0.0005
EUROFORS: Eastell
2009;66 postmenopausal
women with osteoporosis
pre treated with TPTD
l TPTD, 304
l RLX, 97
l Control,c 102
l TPTD, 304
l RLX, 97
l Control, 102
24 l TPTD, + 1.30 (NR)
l RLX, + 3.10 (NR)
l Control, + 3.50 (NR)
Nothing l p < 0.05 TPTD vs. no
active treatment;
other comparisons
NR
l (NE)
STRUCTURE;67
postmenopausal women
with osteoporosis pre
treated with ALN
l TPTD, 218
l ROMO, 218
l Without placebo,
open label
l TPTD, 209
l ROMO, 206
12 l TPTD, –0.20 (4.43a)
l ROMO, + 3.20 (3.30a)
Nothing p < 0.0001
continued
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TABLE 20 Femoral neck BMD data reported by the included studies (continued )
Trial name: first author
and year; population
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Femoral neck BMD,
percentage change from
baseline, mean (SD)
Which data
were estimated
from graph?
Femoral neck BMD,
reported (estimated)
between-group
difference
McClung 2014;68
postmenopausal women
with osteoporosis
l Placebo, 52
l TPTD, 55
l ROMO, 52
l ALN, 51
l Placebo, 47
l TPTD, 46
l ROMO, 50
l ALN, 47
12 l Placebo, + 1.10 (3.15a)
l TPTD, + 1.10 (3.11a)
l ROMO, + 1.40 (3.25a)
l ALN, + 1.2 (3.15a)
Nothing l NR
l (TPTD vs. ROMO –
MD –0.30, 95% CI
–1.59 to 0.99;
p = 0.65)
l (ROMO vs. placebo,
p = 0.0002)
l (TPTD vs. placebo,
p = 0.0007)
l (ROMO vs. ALN,
p = 0.73)
l (TPTD vs. ALN,
p = 0.88)
DEN vs. bisphosphonates
DECIDE;69
postmenopausal women
with osteoporosis
l ALN, 595
l DEN, 594
l Both with placebo
l ALN, 586
l DEN, 593
12 l ALN, + 1.80 (3.77a)
l DEN, + 2.40 (3.17a)
95% CIs Absolute treatment
difference 0.6%
(95% CI 0.3 to 1.0);
p = 0.0001
STAND;70 postmenopausal
women with osteoporosis
already on ALN
l ALN, 251
l DEN, 253
l Without placebo
l ALN, 233
l DEN, 241
12 l ALN, + 0.41 (3.81a)
l DEN, + 1.40 (3.34a)
Means and
95% CIs
p < 0.0121
DAPS;71 postmenopausal
women with osteoporosis
l ALN, 124
l DEN, 126
l Without placebo
l ALN, 106
l DEN, 113
12 l ALN, + 2.00 (3.60)
l DEN, + 2.90 (3.50)
Nothing l NR
l (MD + 0.90, 95% CI
–0.04 to 1.84;
p = 0.06)
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Trial name: first author
and year; population
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Femoral neck BMD,
percentage change from
baseline, mean (SD)
Which data
were estimated
from graph?
Femoral neck BMD,
reported (estimated)
between-group
difference
DAPS:109 postmenopausal
women with osteoporosis
l Cross-over
l ALN to DEN, 92
l DEN to ALN, 102
l ALN/DEN, 92
l DEN/ALN, 102
12–24 (post
cross-over)
l ALN/DEN, –0.10 (NR)
l DEN/ALN, + 1.70 (NR)
Nothing l NR
l (NE)
McClung 2006;72
postmenopausal women
with osteoporosis or
osteopenia
l Placebo for DEN, 46
l ALN, 47
l DEN, 47
l Placebo, 40
l ALN, 45
l DEN, 42
12 l Placebo, –0.30 (3.16b)
l ALN, + 2.10 (3.35b)
l DEN, + 2.10 (3.24b)
Nothing ALN and DEN vs.
placebo, both p < 0.001
(ALN vs. DEN MD 0.00,
95% CI –1.38 to 1.38;
p = 1.00)
Recknor 2013;73
postmenopausal women
with osteoporosis
l IBN, 416
l DEN, 414
l Without placebo
l IBN, 368
l DEN, 399
12 l IBN, + 0.70 (4.79a)
l DEN, + 1.70 (3.96a)
95% CIs p < 0.001
Saag 2018;74 women and
men continuing GCCs
with osteoporosis or low
BMD + fracture
l RIS, 252
l DEN, 145
l Both with placebo
l RIS, 215
l DEN, 217
12 l RIS, + 0.60 (3.37a)
l DEN, + 1.60 (3.76a)
95% CIs p = 0.004
Saag 2018;74 women and
men initiating GCCs with
osteoporosis or low
BMD + fracture
l RIS, 253
l DEN, 145
l Both with placebo
l RIS, 128
l DEN, 119
12 l RIS, –0.20 (4.33a)
l DEN, + 0.90 (4.17a)
95% CIs p = 0.020
Miller 2016;75
postmenopausal women
with osteoporosis
previously treated with
bisphosphonates
l ZOL, 322
l DEN, 321
l Both with placebo
l ZOL, 309
l DEN, 311
12 l ZOL, –0.10 (3.34a)
l DEN, + 1.20 (3.96a)
Nothing p < 0.0001
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TABLE 20 Femoral neck BMD data reported by the included studies (continued )
Trial name: first author
and year; population
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Femoral neck BMD,
percentage change from
baseline, mean (SD)
Which data
were estimated
from graph?
Femoral neck BMD,
reported (estimated)
between-group
difference
RLX vs. bisphosphonates
EFFECT: Sambrook 200476
(international not
including USA);
postmenopausal women
with osteoporosis
l ALN, 246
l RLX, 241
l Both with placebo
l ALN, 246
l RLX, 241
12 l ALN, + 2.20 (5.02b)
l RLX, + 1.00 (4.66b)
SEMs 1.3%, 95% CI 0.5 to
2.1; p = 0.0001
EFFECT (USA);77
postmenopausal women
with osteoporosis
l ALN, 223
l RLX, 233
l Both with placebo
l ALN, 199
l RLX, 206
12 l ALN, + 1.72 (4.23b)
l RLX, + 1.35 (4.59b)
Means and
SEMs
p = 0.396
Johnell 2002;78
postmenopausal women
with osteoporosis
l Placebo, 82
l ALN, 83
l RLX, 82
l Placebo, 77
l ALN, 77
l RLX, 77
12 l Placebo, + 0.20 (3.51b)
l RLX, + 1.70 (3.51b)
l ALN, + 2.70 (4.39b)
Nothing l ALN and RLX both
significantly
different to
placebo (p < 0.05)
l ALN significantly
different to
RLX (p < 0.05)
EVA: Recker 2007;80
postmenopausal women
with osteoporosis
l ALN, 716
l RLX, 707
l Both with placebo
l ALN, 64
l RLX, 58
24 l ALN, + 3.88 (4.96b)
l RLX, + 2.31 (3.96b)
SEMs p = 0.002
Sanad 2011;81
postmenopausal women
with osteoporosis
l ALN weekly, 46
l RLX, 44
l Without placebo
l ALN, 31
l RLX, 35
12 l ALN, + 3.11 (NR)
l RLX, + 3.48 (NR)
Means l NR
l (NE)
Michalska 2006;82
postmenopausal women
with osteoporosis
previously treated with
bisphosphonates
l Placebo, 33
l RLX, 33
l ALN, 33
l Placebo, 33
l RLX, 33
l ALN, 33
12 l Placebo, + 1.11 (NR)
l RLX, + 2.07 (NR)
l ALN, + 2.32 (NR)
Means (SEMs in
graph overlap –
unable to
extract)
l p ≥ 0.05
l (NE)
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Trial name: first author
and year; population
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Femoral neck BMD,
percentage change from
baseline, mean (SD)
Which data
were estimated
from graph?
Femoral neck BMD,
reported (estimated)
between-group
difference
Michalska 2006;82
postmenopausal women
with osteoporosis
previously treated with
bisphosphonates
l OLE
l No treatment, 33
l RLX, 33
l ALN, 33
l No treatment, 33
l RLX, 33
l ALN, 33
24 including
12 OLE
l No treatment,
+ 0.89 (3.27b)
l RLX, + 1.14 (2.81b)
l ALN, + 2.86 (3.73b)
Means and
SEMs
l NR
l (RLX vs. ALN MD
–1.72, 95% CI –3.31
to –0.13; p = 0.03)
l (RLX vs. no treatment
MD + 0.25, 95% CI
–1.22 to 1.72;
p = 0.74)
ROMO vs. bisphosphonates
ARCH: Saag 2017;83
postmenopausal women
with osteoporosis
l ALN, 2047
l ROMO, 2046
l Both with placebo
l ALN, 1826
l ROMO, 1829
12 l ALN, + 1.70 (5.67a)
l ROMO, + 4.90 (6.33a)
l ITT LOCF
Nothing p < 0.001
ARCH: Saag 2017;83
postmenopausal women
with osteoporosis
l ALN to ALN, 2047
l ROMO to ALN, 2046
l Open label
l ALN/ALN, 1826
l ROMO/ALN, 1829
24 l ALN/ALN, + 2.30 (6.65a)
l ROMO/ALN, + 6.00 (7.42a)
l ITT LOCF
Nothing p < 0.001
ARCH: Saag 2017;83
postmenopausal women
with osteoporosis
As above l ALN/ALN, 1826
l ROMO/ALN, 1829
36 l ALN/ALN, + 2.40 (7.19a)
l ROMO/ALN, + 6.00 (7.90a)
l ITT LOCF
Nothing p < 0.001
TPTD vs. bisphosphonates
FACT;84 postmenopausal
women with osteoporosis
l ALN, 101
l TPTD, 102
l Both with placebo
l ALN, 101
l TPTD, 102
18 l ALN, + 3.50 (3.18a)
l TPTD, + 3.90 (4.51a)
95% CIs p = 0.05
Saag 2009;103 women and
men on GCCs with
osteoporosis or low
BMD + fracture
l ALN, 214
l TPTD, 214
l Both with placebo
l ALN, 113
l TPTD, 120
36 l ALN, + 3.40 (4.93a)
l TPTD, + 6.29 (5.03a)
95% CIs p < 0.001
EUROGIOPs;87 men on
GCCs with osteoporosis
l RIS, 47
l TPTD, 45
l Without placebo;
open label
l RIS, 37
l TPTD, 38
18 l RIS, –1.10 (7.00b)
l TPTD, + 1.52 (6.66b)
SEMs p = 0.026
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TABLE 20 Femoral neck BMD data reported by the included studies (continued )
Trial name: first author
and year; population
Treatments,
n randomised
Treatments,
n analysed
Follow-up
(months)
Femoral neck BMD,
percentage change from
baseline, mean (SD)
Which data
were estimated
from graph?
Femoral neck BMD,
reported (estimated)
between-group
difference
Walker 2013;89 men with
osteoporosis
l RIS weekly, 10
l TPTD, 9
l Both with placebo
l RIS, 10
l TPTD, 9
18 l RIS, + 0.5 (5.38b)
l TPTD, + 3.89 (5.10b)
Nothing p ≥ 0.05
Hadji 2012;91
postmenopausal women
with osteoporosis
l RIS weekly, 350
l TPTD, 360
l Both with placebo
l RIS, 338
l TPTD, 351
18 l RIS, + 0.77 (7.35b)
l TPTD, + 2.11 (7.58b)
Nothing p = 0.02
MOVE: Malouf-Sierra
2017;92 women and men
with low BMD+ recent
hip fracture surgery
l RIS daily, 113
l TPTD, 111
l Both with placebo
l RIS, 81
l TPTD, 80
18 l RIS, –1.19 (NR)
l TPTD, + 1.96 (NR)
Nothing p = 0.003
Cosman 2011;93
postmenopausal women
with osteoporosis
l ZOL,d 137
l TPTD+ ZOL
placebo, 138
l ZOL, 129
l TPTD + placebo,
129
12 l ZOL, + 1.90 (5.22b)
l TPTD+ placebo,
+ 0.09 (4.20b)
Nothing p < 0.05
ADAMO, A multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety DenosumAb versus placebo in Males with Osteoporosis; CI, confidence
interval; DAPS, Denosumab Adherence Preference Satisfaction; DECIDE, Determining Efficacy: Comparison of Initiating Denosumab versus alendronate; FACT, Forteo Alendronate
Comparator Trial; GCC, glucocorticoid; ITT, intention to treat; MORE, Multiple Outcomes of Raloxifene Evaluation; NE, not estimable; NR, not reported; OLE, open-label extension;
SEM, standard error of the mean; STAND, Study of Transitioning from Alendronate to Denosumab; STRUCTURE, STudy evaluating effect of RomosozUmab Compared with
Teriparatide in postmenopaUsal women with osteoporosis at high risk for fracture pReviously treated with bisphosphonatE therapy.
a Estimated from 95% CI.
b Estimated from standard error.
c No active treatment.
d Not placebo controlled for TPTD.
Note
ALN, 10 mg daily or 70 mg weekly.
DEN, 60 mg s.c. every 6 months.
IBN, 150 mg oral every month.
RLX, 60 mg daily.
ROMO, Romosozumab 210mg s.c. monthly.
TPTD, 20 µg s.c. daily.
ZOL, 5 mg i.v. annually
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TABLE 21 Adverse events: mortality
Trial name: first
author and year
Treatment arm
(n participants)
Follow-up
(months)
Overall mortality,
n/N (%)
Reported
between-group
difference
DEN vs. placebo
FREEDOM:
Cummings 200941
and Bone 2017104
l Placebo, 3876
l DEN, 3882
36 l Placebo, 90/3876
(2.3)
l DEN, 70/3886 (1.8)41
p = 0.08
ADAMO: Orwoll
201242
l Placebo, 120
l DEN, 120
l Both for 12 months
then DEN open label
(both groups) for
12 months
12 l 1/120 (0.8)
l 1/120 (0.8)
NR
ADAMO: Langdahl
2015111
l Placebo, 116
l DEN, 111
l Both for 12 months
then DEN open label
(both groups) for
12 months
12–24 l 0/116 (0)
l 1/111 (1)
NR
DIRECT: Nakamura
201443
l Placebo, 481
l DEN, 475
24 l 5/481 (1.0)
l 5/475 (1.1)
NR
DIRECT: Sugimoto
2015106
l Placebo, 406
l DEN, 404
l Both for 24 months
then DEN open label
(both groups) for
12 months
24–36 l 2/406 (0.5)
l 4/404 (1.0)
NR
Nakamura 201244 l Placebo, 55
l DEN, 54
12 l NR NR
Koh 201645
(NCT01457950)
l Placebo, 66
l DEN, 69
6 l 0/66 (0)
l 1/69 (< 1)
NR
Koh 201645
(NCT01457950)
l Placebo, 63
l DEN, 60
l Both for 6 months
then DEN open label
(both groups) for
12 months
6–12 l 0/63 (0)
l 0/60 (0)
NR
RLX vs. placebo
Adami 200846 All TPTD for 12 months
then:
l Placebo, 172
l RLX, 157
12 NR NR
Morii 200347 l Placebo, 97
l RLX, 90
12 NR NR
Liu 200448 l Placebo, 102
l RLX, 102
12 l 0/102 (0)
l 0/102 (0)
NR
Gorai 201294 l Alfacalcidol, 44
l RLX, 45
l Alfacalcidol plus
RLX, 48
12 NR NR
Silverman 200850
(NCT00205777)
l Placebo, 1885
l RLX, 1849
36 l 11/1885 (0.6)
l 19/1849 (1.0)
NR
continued
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TABLE 21 Adverse events: mortality (continued )
Trial name: first
author and year
Treatment arm
(n participants)
Follow-up
(months)
Overall mortality,
n/N (%)
Reported
between-group
difference
MORE: Ettinger
199951 and Maricic
2002102
l Placebo, 2576
l RLX, 2557
36 NR NR
Lufkin 199852 l Control (no active
treatment), 48
l RLX, 48
12 NR NR
Mok 201153
(NCT00371956)
l Placebo, 57
l RLX, 57
12 NR NR
ROMO vs. placebo
BRIDGE: Lewiecki
2018;56
(NCT02186171)
l Placebo, 82
l ROMO, 163
12 l Placebo, 1/81 (1.2)
l ROMO, 2/163 (1.2)
NR
FRAME: Cosman
201654
l Placebo, 3591
l ROMO, 3589
l For 12 months then
DEN for 12 months
open label
(both groups)
12 and 24 12 months:
l Placebo, 23/3576
(0.6)
l ROMO, 29/3581
(0.8)
24 months:
l Placebo-DEN,
47/3576 (1.3)
l ROMO-DEN,
52/3581 (1.5)
NR
Ishibashi 201755
(NCT01992159)
l Placebo, 63
l ROMO, 63
12 l Placebo, 0/63 (0)
l ROMO, 0/63 (0)
NR
TPTD vs. placebo
Orwoll 200357 l Placebo, 147
l TPTD, 151
Median 11 l Placebo, 0/147 (0)
l TPTD, 2/151 (1.3)
NR
Miyauchi 201058 l Placebo, 67
l TPTD, 136
l Both for 12 months
then TPTD open label
(both groups) for
12 months
24 l 0/67 (0)
l 0/136 (0)
NR
Miyauchi 200859 l Placebo, 38
l TPTD, 39
6 l 0/38 (0)
l 0/39 (0)
NR
ACTIVE95
(NCT01343004)
l Placebo, 820
l TPTD, 818
18 l 5/820 (0.6)
l 3/818 (0.4)
NR
Leder 201561 l Placebo, 45
l TPTD, 45
l Open label
6, plus a further
6-month extension
to 12 months
6 months:
l Placebo, 0/45 (0)
l TPTD, 0/45 (0)
12 months NR
NR
Neer 200162
(NCT00670501)
l Placebo, 544
l TPTD months, 541
24 (stopped early;
mean time to
last visit was
19 months)
NR Reports no
significant
difference.
Data NR
Sethi 200863
(NCT00500409)
l Control (calcium+
vitamin D), 41
l TPTD and calcium +
vitamin D, 41
6 l 0/41 (0)
l 0/41 (0)
Reports no
significant
difference
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TABLE 21 Adverse events: mortality (continued )
Trial name: first
author and year
Treatment arm
(n participants)
Follow-up
(months)
Overall mortality,
n/N (%)
Reported
between-group
difference
Head-to-head non-bisphosphonates
DATA64 l DEN, 34
l TPTD, 36
12 NR NR
DATA64
(NCT00926380)
l DEN, 34
l TPTD, 36
24 NR NR
DATA-Switch65 l DEN, 27
l TPTD, 27
l Both for 24 months
then DEN switched to
TPTD and TPTD
switched to DEN
open label for
12 months
24–48 NR NR
EUROFORS: Eastell
200966
l All TPTD for
12 months then:
l Control (no active
treatment), 102
l TPTD, 304
l RLX, 97
24 NR NR
STRUCTURE67 l ROMO, 218
l TPTD, 214
12 l 1/218 (0.5)
l 1/214 (0.5)
NR
McClung 201468 l ROMO, 51 (blind)
l TPTD, 55 (open-label)
l Pooled placebo
(mix of ALN, TPTD
and ROMO
administrations),
50 (blind)
l ALN, 51 (open label)
12 l ROMO, 0/51 (0)
l TPTD, 0/54 (0)
l Placebo, 1/50 (2)
l ALN, 0/51 (0)
NR
DEN vs. bisphosphonates
DECIDE69 l ALN, 586
l DEN, 593
l Both plus placebo
12 l 1/593 (0.2)
l 1/586 (0.2)
l NR
l (Not
significant)
STAND: Kendler
201070
l ALN, 251
l DEN, 253
12 l ALN, 0/249 (0)
l DEN, 1/253 (0.4)
p = 1.0000
DAPS: Kendler
201171 and
Freemantle 2012109
l ALN, 124
l DEN, 126
l Open label
12 NR NR
McClung 200672 l Placebo for
abaloparatide s.c.
every 3 months, 46
l ALN open-label, 47
l DEN, 47
12 l Placebo, 0/46 (0)
l ALN, 0/46 (0)
l DEN, 0/47 (0)
NR
Recknor 201373 l IBN, 416
l DEN, 417
12 l IBN, 1/410 (0.2)
l DEN, 0/411 (0)
p = 0.299
Saag 201874
(NCT01575873)
l RIS, 384
l DEN, 394
l Both with placebo
12 l RIS, 9/384 (2.34)
l DEN, 13/394 (3.30)
NR
Miller 201675 l ZOL, 322
l DEN, 321
l Both with placebo
12 Fatal AEs:
l ZOL, 1/320 (0.3)
l DEN, 0/320 (0.0)
NR
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TABLE 21 Adverse events: mortality (continued )
Trial name: first
author and year
Treatment arm
(n participants)
Follow-up
(months)
Overall mortality,
n/N (%)
Reported
between-group
difference
RLX vs. bisphosphonates
EFFECT
(international,
excluding USA):
Sambrook 200476
l ALN, 246
l RLX, 241
12 l ALN, 0/246 (0)
l RLX, 1/241 (< 1)
l NR
l (Not
significant)
EFFECT (USA):
Luckey 200477
l ALN, 223
l RLX, 233
l Both groups
received placebo
12 NR NR
Johnell 200278 l Placebo (ALN and
RLX), 82
l ALN, 83
l RLX, 82
l ALN and RLX
received placebo
12 NR NR
Muscoso 200479 l ALN, 1000
l RIS, 100
l RLX, 100
l All daily
24 NR NR
EVA: Recker 200780 l ALN, 716
l RLX, 707
24 l ALN, 1/716 (< 1)
l RLX, 1/707 (< 1)
l NR
l (Not
significant)
Sanad 201181 l ALN, 44
l RLX, 46
12 NR NR
Michalska 200682 Open label:
l ALN, 33
Blind:
l Placebo, 33
l RLX, 33
12, followed by 12
months’ open-label
extension
NR NR
ROMO vs. bisphosphonates
ARCH: Saag 201783 l ALN, 2014
l ROMO, 2040
l Both for 12 months
then ALN open label
(both groups) for
12 months
12 from
randomisation,
then a further
12 open label,
following
treatment-
switching
0–12 months:
l ALN, 21/2014 (1.0)
l ROMO, 30/2040
(1.5)
0–24 months
l ALN/ALN,
90/2014 (4.5)
l ROMO/ALN,
90/2040 (4.4)
NR
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TABLE 21 Adverse events: mortality (continued )
Trial name: first
author and year
Treatment arm
(n participants)
Follow-up
(months)
Overall mortality,
n/N (%)
Reported
between-group
difference
TPTD vs. bisphosphonates
FACT: McClung
200584
l ALN, 101
l TPTD, 102
l Both with placebo
18 NR NR
Saag 200985
(NCT01575873)
l ALN, 214
l TPTD, 214
l Both with placebo
36 l ALN, 4/214 (1.87)
l TPTD 2/214 (0.93)
l NR
l (Not
significant)
Panico 201186 l ALN, 39
l TPTD, 42
l Open label
18 NR NR
EuroGIOPs: Glüer
201387
l RIS, 47
l TPTD, 45
l Open label
18 l RIS, 1/47 (2.1)
l TPTD, 2/45 (4.4)
p = 0.613
Anastasilakis 200888 l RIS, 22
l TPTD, 22
l Open label
12 NR NR
Walker 201389 l RIS, 10
l TPTD, 9
l Both with placebo
18 NR NR
Hadji 201291 l RIS, 350
l TPTD, 360
l Both with placebo
18 l RIS, 5/350 (1.4)
l TPTD, 4/360 (1.1)
p = 0.75
VERO: Kendler
201899
l RIS, 680
l TPTD, 680
l Both with placebo
24 l RIS, 7/680 (1.0)
l TPTD, 15/690 (2.2)
p = 0.13
MOVE: Abtahi
2016101
l RIS, 110
l TPTD, 106
l Both with placebo
l Blind until 6 months
then open label
6 l RIS, 5/110 (4.5)
l TPTD, 2/106 (1.9)
p = 0.446
MOVE:
Malouf-Sierra 201792
24 l RIS, 7/110 (6.4)
l TPTD, 2/106 (1.9)
p = 0.171
Cosman 201193 l ZOL, 137
l TPTD, 137
l Only TPTD group
received placebo
12 l ZOL, 1/137 (< 1)
l TPTD, 0/137 (0)
NR
ADAMO, A multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety
DenosumAb versus placebo in Males with Osteoporosis; DAPS, Denosumab Adherence Preference Satisfaction;
DECIDE, Determining Efficacy: Comparison of Initiating Denosumab versus alendronate; FACT, Forteo Alendronate
Comparator Trial; MORE, Multiple Outcomes of Raloxifene Evaluation; NR, not reported; STAND, Study of Transitioning
from Alendronate to Denosumab; STRUCTURE, STudy evaluating effect of RomosozUmab Compared with Teriparatide in
postmenopaUsal women with osteoporosis at high risk for fracture pReviously treated with bisphosphonatE therapy.
Notes
ALN, 10 mg daily or 70 mg weekly.
DEN, 60 mg s.c. every 6 months.
IBN, 150 mg oral every month.
RLX, 60 mg daily.
ROMO, 210mg s.c. monthly.
RIS, 5 mg daily or 35 mg weekly.
TPTD, 20 µg s.c. daily.
ZOL, 5 mg i.v. annually.
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TABLE 22 Adverse events and SAEs
Trial name: first
author and year
Treatment arm
(n participants) Follow-up (months)
One or more SAE(s),
n/N (%)
Reported
between-group
difference
One or more AE(s),
n/N (%)
Reported
between-group
difference
DEN vs. placebo
FREEDOM: Cummings
200941 and Bone
2017104
l Placebo, 3876
l DEN, 3886
l Both every 6 months
36 l Placebo, 972/
3876 (25.1)
l DEN, 1004/3886
(25.8)41
p = 0.61 l Placebo, 3607/
3876 (93.1)
l DEN, 3605/3886
(92.8)41
p = 0.91
ADAMO: Orwoll
201242
l Placebo, 120
l DEN, 120
l Both for 12 months
then DEN open-label
(both groups) for
12 months
12 l Placebo, 10/120 (8.3)
l DEN, 11/120 (9.2)
NR l Placebo, 84/120 (70.0)
l DEN, 86/120 (71.7)
NR
ADAMO: Langdahl
2015111
l Placebo, 116
l DEN, 111
l Both for 12 months
then DEN open-label
(both groups) for
12 months
12–24 l Placebo, 5/116 (4)
l DEN, 9/111 (8)
NR l Placebo, 60/116 (52)
l DEN 70/111 (63)
NR
DIRECT: Nakamura
201443
l Placebo, 481
l DEN, 475
24 l Placebo, 68/481 (14.1)
l DEN, 66/475 (13.9)
NR l Placebo, 446/
481 (92.7)
l DEN, 448/475 (94.3)
NR
DIRECT106 l Placebo, 406
l DEN, 404
l Both for 24 months
then DEN open label
(both groups) for
12 months
24–36 l Placebo, 27/406 (6.7)
l DEN, 30/404 (7.4)
NR l Placebo, 339/
406 (83.5)
l DEN, 343/404 (84.9)
NR
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Trial name: first
author and year
Treatment arm
(n participants) Follow-up (months)
One or more SAE(s),
n/N (%)
Reported
between-group
difference
One or more AE(s),
n/N (%)
Reported
between-group
difference
Nakamura 201244 l Placebo, 55
l DEN, 54
12 l Placebo, 4/54 (7.4)
l DEN, 6/53 (11.3)
NR l Placebo, 49/54 (90.7)
l DEN, 47/54 (87.0)
NR
Koh 201645
(NCT01457950)
l Placebo, 66
l DEN, 69
6 l Placebo, 1/66 (2)
l DEN, 2/69 (3)
NR l Placebo, 32/66 (48)
l DEN, 38/69 (55)
NR
Koh 201645
(NCT01457950)
l Placebo, 63
l DEN, 60
l Both for 6 months then
DEN open label (both
groups) for 12 months
6–12 l Placebo /DEN, 3/63 (5)
l DEN, 1/60 (2)
NR l Placebo/DEN, 29/
63 (46)
l DEN, 22/60 (37)
NR
RLX vs. placebo
Adami 200846 All TPTD for 12 months
then:
l Placebo, 172
l RLX, 157
12 NR NR NR NR
Morii 200347 l Placebo, 97
l RLX, 90
12 l Placebo, 7 (7.2)
l RLX, 5 (5.4)
p = 0.452 l Placebo, TEAE
l 33 (34.0)
l RLX, TEAE
l 32 (34.8)
l p = 0.444
l [All AEs
(number NR)
p = 0.851]
Liu 200448 l Placebo, 102
l RLX, 102
12 l Placebo, 5/102 (4.9)
l RLX, 2/102 (2.0)
Not significant
at p < 0.05
NR
Gorai 201294 l Alfacalcidol, 44
l RLX, 45
l Alfacalcidol plus
RLX, 48
12 NR NR l Alfacalcidol 11/44
(25.0)
l RLX, 17/45 (37.8)
l Alfacalcidol plus RLX
13/48 (27.1)
NR
Silverman 200850
(NCT00205777)
l Placebo, 1885
l RLX, 1849
36 l Placebo, 353/
1885 (18.7)
l RLX, 344/1849 (18.6)
NR l Placebo, 1813/1885
(96.2)
l RLX, 1775/1885 (96.0)
NR
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TABLE 22 Adverse events and SAEs (continued )
Trial name: first
author and year
Treatment arm
(n participants) Follow-up (months)
One or more SAE(s),
n/N (%)
Reported
between-group
difference
One or more AE(s),
n/N (%)
Reported
between-group
difference
MORE: Ettinger 199951
and Maricic 2002102
l Placebo, 2576
l RLX, 2557
36 NR NR NR NR
Lufkin 199852 l Control (no active
treatment), 48
l RLX, 48
12 NR NR NR NR
Mok 201153
(NCT00371956)
l Placebo, 57
l RLX, 57
12 NR NR NR NR
ROMO vs. placebo
BRIDGE56
(NCT02186171)
l Placebo, 82
l ROMO, 163
12 l TEAE placebo,
10/81 (12.3)
l ROMO TEAE,
21/163 (12.9)
NR l TEAE placebo, 65/81
(80.2)
l TEAE ROMO, 123/163
(75.5)
NR
FRAME: Cosman
201654
l Placebo, 3591
l ROMO, 3589
l For 12 months then
DEN for 12 months
open label
(both groups)
12 from randomisation,
then a further 12
following treatment-
switching
12 months:
l Placebo, 312/3576
(8.7)
l ROMO, 344/3581 (9.6)
24 months:
l Placebo-DEN,
550/3576 (15.1)
l ROMO-DEN,
565/3581 (15.8)
NR 12 months:
l Placebo, 2850/3576
(79.7)
l ROMO, 2806/3581
(78.4)
24 months:
l Placebo DEN, 3069/
3576 (85.8)
l ROMO-DEN, 3053/
3581 (85.3)
NR
Ishibashi 201755
(NCT01992159)
l Placebo, 63
l ROMO, 63
12 l Placebo, 4/63 (6.3)
l ROMO, 2/63 (3.2)
NR l Placebo, 43/63 (68.3)
l ROMO, 47/63 (74.6)
NR
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Trial name: first
author and year
Treatment arm
(n participants) Follow-up (months)
One or more SAE(s),
n/N (%)
Reported
between-group
difference
One or more AE(s),
n/N (%)
Reported
between-group
difference
TPTD vs. placebo
Orwoll 200357 l Placebo, 147
l TPTD, 151
l Both daily
Median 11 NR NR Reports that the overall
incidence of AEs was
similar across groups.
No data
NR
Miyauchi 201058 l Placebo, 67
l TPTD, 136
l Both for 12 months
then TPTD open label
(both groups) for
12 months
24 l Placebo,13/67 (19.4)
l TPTD, 12/136 (8.8)
Reported as
not significant.
p-value NR
l Placebo, 64/67 (95.5)
l TPTD, 125/136 (91.9)
Reported as
not significant.
p-value NR
Miyauchi 200859 l Placebo, 38
l TPTD, 39
6 NR as number of
participants with SAE
l Placebo, TEAE
29 (76.3)
l TPTD, TEAE 33 (84.6)
NR
ACTIVE95
(NCT01343004)
l Placebo, 820
l TPTD, 818
18 l Placebo, 90/820 (11.0)
l TPTD, 82/818 (10.0)
NR l Placebo, 718/820
(87.6)
l TPTD, 727/818 (88.9)
NR
Leder 201561 l Placebo, 45
l TPTD, 45
l Open label
6, plus a further
6-month extension to
12 months
6 months:
l Placebo, 1/45 (2.2)
l TPTD, 0/45 (0)
12 months:
l Placebo, 1/45 (2.2)
l TPTD, 0/45 (0)
NR 6 months:
l Placebo, 32/45 (71.1)
l TPTD, 35/45 (77.8)
12 months:
l Placebo, 16/45 (36)
l TPTD, 14/45 (30)
NR
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TABLE 22 Adverse events and SAEs (continued )
Trial name: first
author and year
Treatment arm
(n participants) Follow-up (months)
One or more SAE(s),
n/N (%)
Reported
between-group
difference
One or more AE(s),
n/N (%)
Reported
between-group
difference
Neer 200162
(NCT00670501)
l Placebo, 544
l TPTD, 541
24 (stopped early;
mean time to last visit
was 19 months)
l Placebo, NR
l [Withdrew because of
AE 32 (6%)]
l TPTD, NR
NR NR NR
Sethi 200863
(NCT00500409)
l Control (calcium +
vitamin D), 41
l TPTD and calcium +
vitamin D, 41
6 l Control, 0/41 (0)
l TPTD, 0/41 (0)
Reported as
not significant.
p-value NR
l Control, 9/41 (21.9)
l TPTD, 9/41 (21.9)
Reported as
not significant.
p-value NR
Head-to-head non-bisphosphonates
DATA64 l DEN, 34
l TPTD, 36
12 l DEN, 1/34 (2.9)
l TPTD, NR –
three events
NR NR NR
DATA64
(NCT00926380)
l DEN, 34
l TPTD, 36
24 l DEN, 1/33 (3.0)
l TPTD, 2/31 (6.5)
NR l TPTD, 5/31 (16.1)
l DEN, 4/33 (12.1)
NR
DATA-Switch65 l DEN, 27
l TPTD, 27
l Both for 24 months
then DEN switched
to TPTD and TPTD
switched to DEN open
label for 12 months
24–48 l DEN/TPTD, 4/27 (14.8)
l TPTD/DEN, 6/27 (22.2)
NR NR NR
STRUCTURE67 l ROMO, 218
l TPTD, 214
12 l TPTD, 23/214 (11)
l ROMO, 17/218 (8)
NR l TPTD, 148/214 (69)
l ROMO, 164/218 (75)
NR
EUROFORS66 All TPDT for
12 months then:
l Control (no active
treatment), 102
l TPTD, 304
l RLX, 97
24 NR NR l Control, TEAE, 56/102
(54.9)
l TPTD, TEAE, 174/304
(57.0)
l RLX, TEAE, 53/97
(54.6)
Not significant at
p < 0.05
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Trial name: first
author and year
Treatment arm
(n participants) Follow-up (months)
One or more SAE(s),
n/N (%)
Reported
between-group
difference
One or more AE(s),
n/N (%)
Reported
between-group
difference
McClung 201468 l ROMO, 51 (blind)
l TPTD, 55 (open-label)
l Pooled placebo (mix of
ALN, TPTD and ROMO
administrations),
50 (blind)
l ALN, 51 (open label)
12 l ROMO, 5/51 (10)
l TPTD, 5/54 (9)
l Placebo, 7/50 (14)
l ALN, 4/51 (8)
NR l ROMO, 42/51 (82)
l TPTD, 37/54 (69)
l Placebo, 45/50 (90)
l ALN, 44/51 (86)
NR
DEN vs. bisphosphonates
DECIDE69 l ALN, 586
l DEN,593
l Both plus placebo
12 l ALN, 37/586 (6.3)
l DEN, 34/593 (5.7)
0.71 l ALN, 482/586 (82.3)
l DEN, 480/593 (80.9)
Non-significant
p = 0.60
STAND: Kendler 201070 l ALN, 251
l DEN, 253
12 l ALN, 16/249 (6.4)
l DEN, 15/253 (5.9)
p = 0.8546 l ALN, 196/249 (78.7)
l DEN, 197/253 (77.9)
p = 0.8294
DAPS: Kendler 201171
and 2012109
l ALN, 124
l DEN, 126
l Open label
12 l ALN, 5/117 (4.3)
l DEN, 3/125 (2.4)
NR l ALN, 75/117 (64.1)
l DEN, 90/125 (72.0)
p = 0.403
McClung 200672 l Placebo for
abaloparatide s.c. every
3 months, 46
l ALN open-label, 47
l DEN, 47
12 l Placebo, 2/46 (4.3)
l ALN, 1/46 (2.2)
l DEN, NR
l 18/314 (5.7) across all
DEN dosing arms
NR l Placebo, 41/46 (89.1)
l ALN, 42/46 (91.3)
l DEN, NR
l 274/314 (87.3) across
all DEN dosing arms
NR
Recknor 201373 l IBN, 416
l DEN, 417
12 l IBN, 22/410 (5.4)
l DEN, 39/411 (9.5)
p = 0.046 l IBN, 230/410 (56.1)
l DEN, 245/411 (59.6)
p = 0.635
Saag 201874 l RIS, 384
l DEN, 394
l Both with placebo
12 l RIS, 65/384 (17)
l DEN, 63/394 (16)
NR l RIS, 265/384 (69)
l DEN, 285/394 (72)
NR
Miller 201675 l ZOL, 322
l DEN, 321
l Both with placebo
12 l ZOL 29/320 (9.1)
l DEN, 25/320 (7.8)
NR l ZOL, 199/320 (62.2)
l DEN, 199/320 (62.2)
NR
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TABLE 22 Adverse events and SAEs (continued )
Trial name: first
author and year
Treatment arm
(n participants) Follow-up (months)
One or more SAE(s),
n/N (%)
Reported
between-group
difference
One or more AE(s),
n/N (%)
Reported
between-group
difference
RLX vs. bisphosphonates
EFFECT (international
excluding USA);
Sambrook 200476
l ALN, 246
l RLX, 241
12 l ALN, 11/246 (4.5)
l RLX, 14/241 (5.8)
p = 0.543 l ALN, 154/246 (62.6)
l RLX, 157/241 (65.1)
p = 0.573
EFFECT (USA); Luckey
200477
l ALN, 223
l RLX, 233
l Both groups
received placebo
12 l ALN, 11/221 (5.0)
l RLX, 16/230 (7.0)
p = 0.43 l ALN, 164/221 (74.2)
l RLX, 173/230 (75.2)
p = 0.83
Johnell 200278 l Placebo (ALN and
RLX), 82
l ALN, 83
l RLX, 82
l ALN and RLX
received placebo
12 NR NR NR NR
Muscoso 200479 l ALN, 1000
l RIS, 100
l RLX, 100
l All daily
24 NR NR NR NR
EVA: Recker 200780 l ALN, 716
l RLX, 707
24 NR NR l ALN, 397/716 (55.5)
l RLX, 390/707 (55.2)
p = 0.92
Sanad 201181 l ALN, 44
l RLX, 46
12 NR NR NR NR
Michalska 200682 Open label:
l ALN, 33
Blind:
l Placebo, 33
l RLX, 33
12, followed by 12
months’ open-label
extension
NR NR l Placebo, 2/33 (6)
l ALN, 4/33 (12)
l RLX, 8/33 (24)
p = 0.126
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Trial name: first
author and year
Treatment arm
(n participants) Follow-up (months)
One or more SAE(s),
n/N (%)
Reported
between-group
difference
One or more AE(s),
n/N (%)
Reported
between-group
difference
ROMO vs. bisphosphonates
ARCH: Saag 201783 l ALN, 2014
l ROMO, 2040
l Both for 12 months
then ALN open label
(both groups) for
12 months
12 from randomisation,
then a further 12 open
label, following
treatment-switching
0–12 months:
l ALN, 278/2014 (13.8)
l ROMO, 262/2040
(12.8)
0–24 months:
l ALN/ALN, 605/
2014 (30.0)
l ROMO/ALN, 586/
2040 (28.7)
NR 0–12 months:
l ALN, 1584/2014 (78.6)
l ROMO, 1544/2040
(75.7)
0–24 months:
l ALN/ALN, 1784/
2014 (88.6)
l ROMO/ALN, 1766/
2040 (86.6)
NR
TPTD vs. bisphosphonates
FACT: McClung 200584 l ALN, 101
l TPTD, 102
l Both with placebo
18 NR NR NR NR
Saag 200985 l ALN, 214
l TPTD, 214
l Both with placebo
36 l ALN, 64/214 (30)
l TPTD, 70/214 (33)
p = 0.518 l ALN, 184/214 (86)
l TPTD, 194/214 (91)
p = 0.116
Panico 201186 l ALN, 39
l TPTD, 42
l Open label
18 NR NR NR NR
EuroGIOPs: Glüer
201387
l RIS, 47
l TPTD, 45
l Open label
12 l RIS, 22/47 (46.8)
l TPTD, 13/45 (28.9)
p = 0.089 l RIS, 35/45 (74.5)
l TPTD, 25/47 (55.6)
p = 0.080
Anastasilakis 200888 l RIS, 22
l TPTD, 22
l Open label
12 NR NR l RIS, 7/22 (33.3)
l TPTD, 11/22 (39.1)
Not significant at
p < 0.05
Walker 201389 l RIS, 10
l TPTD, 9
l Both with placebo
18 NR NR NR NR
continued
D
O
I:
1
0
.3
3
1
0
/h
ta2
4
2
9
0
H
e
a
lth
T
e
ch
n
o
lo
g
y
A
sse
ssm
e
n
t
2
0
2
0
V
o
l.2
4
N
o
.2
9
©
Q
u
een
’s
P
rin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
2
0
.T
h
is
w
o
rk
w
as
p
ro
d
u
ced
b
y
D
avis
et
a
l.u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
an
d
So
cial
C
are.T
h
is
issu
e
m
ay
b
e
freely
rep
ro
d
u
ced
fo
r
th
e
p
u
rp
o
ses
o
f
p
rivate
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,
th
e
fu
ll
rep
o
rt)
m
ay
b
e
in
clu
d
ed
in
p
ro
fessio
n
al
jo
u
rn
als
p
ro
vid
ed
th
at
su
itab
le
ackn
o
w
led
gem
en
t
is
m
ad
e
an
d
th
e
rep
ro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g.
A
p
p
licatio
n
s
fo
r
co
m
m
ercial
rep
ro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:
N
IH
R
Jo
u
rn
als
Lib
rary,
N
atio
n
al
In
stitu
te
fo
r
H
ealth
R
esearch
,
E
valu
atio
n
,
Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,
A
lp
h
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
p
to
n
Scien
ce
P
ark,So
u
th
am
p
to
n
SO
1
6
7
N
S,U
K
.
2
1
1
TABLE 22 Adverse events and SAEs (continued )
Trial name: first
author and year
Treatment arm
(n participants) Follow-up (months)
One or more SAE(s),
n/N (%)
Reported
between-group
difference
One or more AE(s),
n/N (%)
Reported
between-group
difference
Hadji 201291 l RIS, 350
l TPTD, 360
l Both with placebo
18 l RIS, 65/350 (18.6)
l TPTD, 55/360 (15.3)
p = 0.27 l RIS, 285/350 (81.4)
l TPTD, 285/360 (79.2)
p = 0.45
VERO: Kendler 201899 l RIS, 680
l TPTD, 680
l Both with placebo
24 l RIS, 115/680 (16.9)
l TPTD, 137/680 (20.1)
p = 0.13 l RIS, 500/680 (73.5)
l TPTD, 495/680 (72.8)
p = 0.76
MOVE: Abtahi 2016101 l RIS, 110
l TPTD, 106
l Both with placebo
l Blind until 6 months
then open label
6 l RIS, 21/110 (19.1)
l TPTD, 14/106 (13.2)
p = 0.271 l RIS, 50/110 (45.5)
l TPTD, 52/106 (49.1)
p = 0.683
MOVE: Malouf-Sierra
201792
24 l RIS, 27/110 (24.5)
l TPTD, 21/106 (19.8)
p = 0.418 l RIS, 58/110 (52.7)
l TPTD, 59/106 (55.7)
p = 0.684
Cosman 201193
(NCT00439244)
l ZOL, 137
l TPTD, 137
l Only TPTD
received placebo
12 l ZOL, 20/137 (14.60)
l TPTD, 15/137 (10.95)
NR l ZOL, 115/137 (83.94)
l TPTD, 96/137 (70.07)
NR
ADAMO, A multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety DenosumAb versus placebo in Males with Osteoporosis;
BRIDGE, phase III randomized placeBo-contRolled double-blind study evaluatIng the efficacy and safety of Romosozumab in treatinG mEn with osteoporosis; DAPS, Denosumab
Adherence Preference Satisfaction; DECIDE, Determining Efficacy: Comparison of Initiating Denosumab versus alendronate; EFFECT, EFficacy of Fosamax versus Evista Comparison
Trial; FACT, Forteo Alendronate Comparator Trial; MORE, Multiple Outcomes of Raloxifene Evaluation; NR, not reported; STAND, Study of Transitioning from Alendronate to
Denosumab; STRUCTURE, STudy evaluating effect of RomosozUmab Compared with Teriparatide in postmenopaUsal women with osteoporosis at high risk for fracture pReviously
treated with bisphosphonatE therapy; TEAE, treatment-emergent adverse event.
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TABLE 23 Lumbar spine BMD for studies not reporting femoral neck BMD
Trial
Intervention and
comparators (n)
Follow-up
duration
(months)
Lumbar spine BMD percentage change from baseline,
mean (SD) (reported between-group difference)
Nakamura 201244 Placebo, n = 55 12 l 3.2 (NR)
l Estimated from graph, p < 0.0001
DEN, n= 54 16.73 (NR)
Morii 200347 Placebo, n = 97 12 l 0.0 (SE 0.3)
l Estimated from graph, p < 0.001
RLX, n = 90 l 3.5 (SE 0.3)
l Estimated from graph
Gorai 201249 Alfacalcidol,
n= 34
24 –0.8 (4.6)
RLX, n = 33 l 2.8 (3.9)
l Significant increase compared with alfacalcidol
(p-value NR)
Alfacalcidol plus
RLX, n = 31
l 4.7 (4.4)
l Significant increase compared with alfacalcidol
(p-value NR)
Lufkin 199852 Control, n = 48 12 l 1.44 (0.74), non-significant
l p-value NR
RLX, n = 48 1.34 (1.02)
Muscoso 200479 ALN, n = 1000 24 7.2 (1.9)
RIS, n= 100 6.2 (2.0)
RLX, n = 100 2.4 (1.1)
Anastasilakis 200888 RIS, n= 22 12 l 3.3 (NR)
l Calculated
l Non-significant
l p-value NR
TPTD, n= 22 l 5.9 (NR)
l Calculated
NR, not reported; SE, standard error.
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Appendix 6 Health-related quality of life
TABLE 24 Published results of validated HRQoL measures
Trial Measure Follow-up Treatment group Results (change from baseline)
FREEDOM116,118 OPAQ-SV329 36 months Placebo, n=NR Mean:
l Physical function, –1.2
l Emotional status, –1.6
l Back pain, 4.3
DEN, n =NR
(n across both groups:
l Physical function,
6152
l Emotional status,
6154
l Back pain, 6164)116
l Mean:
¢ Physical function, –1.3
¢ Emotional status, –1.4
¢ Back pain, 4.1
l Non-significant between groups
l p-value NR
Silverman 200850
(NCT00205777)
Women’s Health
Questionnaire330
36 months Placebo, n= 1179 Least squares, mean (SE): 0.005 (0.005)
RLX, n= 1168 l Least squares, mean (SE):
0.005 (0.005)
l Non-significant between groups
l 0.98
QUALEFFO-41331 36 months Placebo, n= 1176 Least squares, mean (SE): –0.35 (0.3)
RLX, n= 1168 l Least squares, mean (SE): 0.26 (0.3)
l Non-significant between groups
l p = 0.11
EQ-VAS332 36 months Placebo, n= 1120 Least squares, mean (SE): 4.66 (1.70)
RLX, n= 1092 l Least squares, mean (SE): 1.60 (1.71)
l Non-significant between groups
l p = 0.16
EQ-5D Health
State Profile
Utility Score332
36 months Placebo, n= 1128 Least squares, mean (SE): –0.00 (0.01)
RLX, n= 1111 l Least squares, mean (SE):
–0.01 (0.01)
l Non-significant between groups
l p = 0.92
Panico 201186 QUALEFFO-41331 18 months ALN, n = 39 l Pain, –9.7%
l Everyday activities, 11%
l Domestic job, 2.9%
l Locomotor function, 11.5%
l Social activities, 105%
l Health perception, 12.8%
l Mood, 1.8%
TPTD, n = 42 l Pain, –22.0%
l Everyday activities, 27.3%
l Domestic job, 29%
l Locomotor function, 37.8%
l Social activities, 28.4%
l Health perception, 33.9%
l Mood, 29.7%
continued
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The UCB S.A. company submission20 reported that, in both the FRAME54 (ROMO vs. PBO) and the
ARCH83 (ROMO vs. ALN) studies, there was (confidential information has been removed) between
treatment groups in HRQoL, (confidential information has been removed).
The Amgen Inc. company submission100 reported that the Determining Efficacy: Comparison of
Initiating Denosumab versus alendronate (DECIDE)69 study found (confidential information has been
removed) difference between DEN and ALN, as measured by the EQ-5D.
TABLE 24 Published results of validated HRQoL measures (continued )
Trial Measure Follow-up Treatment group Results (change from baseline)
VERO90 EQ-VAS UK332 24 months RIS plus placebo l Least squares, mean 0.04
l Baseline: 0.62 (SD 0.228)
l 24 months: 0.68 (SD 0.205)
TPTD plus placebo l Least squares, mean 0.06
l Baseline: 0.59 (SD 0.243)
l 24 months: 0.65 (SD 0.249)
l Between groups –0.0, 95% CI
–0.03 to 0.02; p = 0.757
MOVE101 SF-36 Physical
Function
Component (post
surgery)333
26 weeks RIS plus placebo Mean (SD):
l Baseline, 31.8 (1.53)
l 26 weeks, 45.8 (1.55)
TPTD plus placebo Mean (SD):
l Baseline, 30.1 (1.51)
l 26 weeks, 46.4 (1.59)
Between groups p = 0.267
NR, not reported; OPAQ-SV, Osteoporosis Assessment Questionnaire-Short Version; SE, standard error; SF-36, Short
Form questionnaire-36 items.
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Appendix 7 Specific adverse events
Bisphosphonate studies: specific adverse events
Three additional bisphosphonate RCTs130,137,138 were identified by the search (Table 25). Of these,
two RCTs assessed atypical femoral fractures and found no incidences of atypical femoral fractures in
participants treated with ZOL compared with those treated with ALN,138 or those treated with ZOL
compared with those treated with placebo.130 One study assessed ONJ and found no incidences in
participants treated with ZOL or placebo.130
Non-bisphosphonate studies: specific adverse events
Venous thromboembolism
Across the studies comparing a non-bisphosphonate with placebo, five reported thrombotic events
of venous origin,43,46,47,50,51 and one study reported on arterial limb thrombosis.42 Across these studies,
event rates were ≤ 1%. The estimated between-group differences were not statistically significant at
p < 0.05 (p-values not presented), with the exception of one study comparing RLX with placebo at
36 months in postmenopausal women with osteoporosis, which was statistically significantly in favour
of placebo (estimated p = 0.005).51
None of the studies that compared bisphosphonates with non-bisphosphonates head-to-head reported
on VTE.
Across the studies comparing a non-bisphosphonate with a bisphosphonate, two studies reported
on thrombosis but did not specify whether this was venous or arterial in origin,72,74 eight reported
on thrombotic events of venous origin,74,77,80,81,91,98,99,103 and one reported on peripheral artery
thrombosis.75 Across these studies, event rates were ≤ 3%. The estimated between-group differences
were not statistically significant at p < 0.05 (p-values not presented).
Stroke
Across the studies comparing a non-bisphosphonate with placebo, four reported on stroke.41,50,56,111
Across these studies, event rates were ≤ 2% and no statistically significant between-group differences
were evident (reported or estimated).
TABLE 25 Specific AEs: additional bisphosphonate trials
Trial name: first author
and year
Treatment
arms (n)
Follow-up
(months)
AE
VTE(s),
n/N (%)
Stroke,
n/N (%) ONJ, n/N (%)
Atypical femoral
fractures, n/N (%)
TRIO: Paggiosi 2014137 l ALN, 57
l IBN, 57
l RIS, 58
24 NR NR NR NR
Tan 2016138 l ALN, 53
l ZOL, 52
36 NR NR NR l ALN, 0/53 (0)
l ZOL, 0/52 (0)
ZONE130 l Placebo,
331
l ZOL, 330
24 NR NR l Placebo, 0/331
l ZOL, 0/330
l Placebo, 0/331
(0)
l ZOL, 0/330 (0)
NR, not reported; ZONE, ZOledroNate treatment in Efficacy to osteoporosis.
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None of the studies that compared bisphosphonates with non-bisphosphonates head-to-head reported
on stroke.
Across the studies comparing a non-bisphosphonate with placebo, eight reported on stroke.72,74,83,91,93,98,99,103
Across these studies, event rates were ≤ 2%. The estimated between-group differences were not statistically
significant at p < 0.05 (p-values not presented). However, the estimated between-group difference in
stoke for one of these studies comparing ROMO with ALN in postmenopausal women with osteoporosis
was statistically significant at 24 months following treatment-switching to ALN, in favour of the continued
ALN group (p = 0.004).83
Osteonecrosis of the jaw
Osteonecrosis of the jaw was reported by nine studies comparing a non-bisphosphonate with
placebo,41,42,44,45,54–56,111 one study comparing non-bisphosphonates head to head67 and three studies
comparing a non-bisphosphonate with a bisphosphonate.71,74,83 Across these studies, event rates were
≤ 1% and no statistically significant between-group differences were evident (reported or estimated).
Atypical femoral fracture
Atypical femoral fracture was reported by nine studies comparing a non-bisphosphonate with
placebo,41,42,45,54–56,106,111,334 one study comparing non-bisphosphonates head to head67 and three studies
comparing a non-bisphosphonate with a bisphosphonate.74,75,83,109 Across these studies, event rates
were ≤ 1% and no statistically significant between-group differences were evident (reported or
estimated).
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TABLE 26 Specific AEs: non-bisphosphonate studies
Trial name: first
author and year;
population Treatment arms (n) Follow-up (months)
AE
VTE(s), n/N (%) Stroke, n/N (%) ONJ, n/N (%)
Atypical femoral
fractures, n/N (%)
DEN vs. placebo
FREEDOM:
Cummings 2009;41
postmenopausal
women with
osteoporosis
l Placebo, 3607
l DEN, 3886
36 NR l Placebo, 54/3607 (1.4)
l DEN, 56/3886 (1.4)
l p = 0.8941
l Placebo, 0/3607 (0)
l DEN, 0/3886 (0)41
l Placebo, 0/3607 (0)
l DEN, 0/3886 (0)335
ADAMO: Orwoll
2012;42 men with
osteoporosis
l Placebo, 120
l DEN, 120
12 Arterial limb
thrombosis
l Placebo, 0/120 (0)
l DEN, 1/120 (1.7)
NR l Placebo, 0/120 (0)
l DEN, 0/120 (0)
l Placebo, 0/120 (0)
l DEN, 0/120 (0)
ADAMO: Langdahl
2015;111 men with
osteoporosis
l Placebo to DEN, 120
l DEN to DEN, 120
24, including 12 OLE NR Transient ischaemic
attack
l Placebo/DEN,
1/120 (< 1)
l DEN/DEN, 0/120 (0)
l Placebo/DEN,
0/120 (0)
l DEN/DEN, 0/120 (0)
l Placebo/DEN,
0/120 (0)
l DEN/DEN, 0/120 (0)
DIRECT: Nakamura
2014;334 women and
men with osteoporosis
(NCT00680953)
l Placebo, 481
l DEN, 475
24 l 1/481 (0.21)
l 0/475 (0)
NR l Placebo, 0/481 (0)
l DEN, 0/475 (0)
l Placebo, 0/481 (0)
l DEN, 0/475 (0)
DIRECT: Sugimoto
2015;106 women and
men with osteoporosis
l Placebo to DEN, 406
l DEN to DEN, 404
l 12 months,
open label
24–36 NR NR l Placebo/DEN,
1/406 (0.2) (0)
l DEN/DEN, 0/404 (0)
l Placebo/DEN,
0/406 (0)
l DEN/DEN, 0/404 (0)
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TABLE 26 Specific AEs: non-bisphosphonate studies (continued )
Trial name: first
author and year;
population Treatment arms (n) Follow-up (months)
AE
VTE(s), n/N (%) Stroke, n/N (%) ONJ, n/N (%)
Atypical femoral
fractures, n/N (%)
Nakamura 2012;44
postmenopausal
women with
osteoporosis
l Placebo, 54
l DEN, 54
12 NR NR l Placebo, 0/54 (0)
l DEN, 0/54 (0)
NR
Koh 2016;45
postmenopausal
women with
osteoporosis
l Placebo, 66
l DEN, 69
6 NR NR l Placebo, 0/69 (0)
l DEN, 0/69 (0)
l Placebo, 0/69 (0)
l DEN, 0/69 (0)
Koh 2016;45
postmenopausal
women with
osteoporosis
l Entered OLE
l Placebo to DEN, 63
l DEN to DEN, 60
6–12 OLE NR NR l Placebo/DEN, 0/63 (0)
l DEN/DEN, 0/60 (0)
l Placebo/DEN, 0/63 (0)
l DEN/DEN, 0/60 (0)
RLX vs. placebo
Adami 2008;46
postmenopausal
women with
osteoporosis pre
treated with TPTD
l Placebo, 172
l RLX, 157
12 months l Placebo, 0/172 (0%)
l RLX, 1/157 (< 1%)
retinal vein
thrombosis
NR NR NR
Morii 2003;47
postmenopausal
women with
osteoporosis
l Placebo, 97
l RLX, 90
12 l Placebo, 0/97 (0%)
l RLX, 0/90 (0%)
NR NR NR
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Trial name: first
author and year;
population Treatment arms (n) Follow-up (months)
AE
VTE(s), n/N (%) Stroke, n/N (%) ONJ, n/N (%)
Atypical femoral
fractures, n/N (%)
Liu 2004;48
postmenopausal
women with
osteoporosis
l Placebo, 102
l RLX, 102
12 l Placebo, 0/102 (0%)
l RLX, 0/102 (0%)
NR NR NR
Gorai 2012;94
postmenopausal
women with low
osteopenia
l Alfacalcidol, 44
l RLX, 45
l Alfacalcidol + RLX,
48
12 NR NR NR NR
Silverman 2008;50,117
postmenopausal
women with
osteoporosis
l Placebo, 1855
l RLX, 1849
36 l DVT
l Placebo, 1/1855
(0.1%)
l RLX, 8/1849 (0.4%)
l PE
l Placebo, 4/1855
(0.2%)
l RLX, 4/1849 (0.2%)
l Retinal
l Placebo, 3/1855
(0.2%)
l RLX, 0/1849 (0%)
l Placebo,
20/1855 (1.1%)
l RLX, 15/1849 (0.8%)
NR NR
MORE: Ettinger
1999;51 women with
osteoporosis
l Placebo, 2576
l RLX, 2557
36 l 8/2576 (0.3%)
l 25/2557 (1.0%)
l Estimated p = 0.005
NR NR NR
Lufkin 1998;52
postmenopausal
women with
osteoporosis
l Placebo, 48
l RLX, 48
12 l Placebo, 0/48 (0%)
l RLX, 0/48 (0%)
NR NR NR
Mok 2011;53
postmenopausal
women on long-term
GCCs
l Placebo, 57
l RLX, 57
12 l Placebo, 0/57 (0%)
l RLX, 0/57 (0%)
NR NR NR
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TABLE 26 Specific AEs: non-bisphosphonate studies (continued )
Trial name: first
author and year;
population Treatment arms (n) Follow-up (months)
AE
VTE(s), n/N (%) Stroke, n/N (%) ONJ, n/N (%)
Atypical femoral
fractures, n/N (%)
ROMO vs. placebo
FRAME:
Cosman 2016;54
postmenopausal
women with
osteoporosis
l Placebo, 3591
l ROMO, 3589
12 NR NR l Placebo, 0/3576 (0)
l ROMO, 1/3581 (< 0.1)
l Placebo, 0/3576 (0)
l ROMO, 1/3581 (< 0.1)
FRAME:
Cosman 2016;54
postmenopausal
women with
osteoporosis
l Placebo to
DEN, 3591
l ROMO to
DEN, 3589
l 12 months,
open label
24 NR NR l Placebo-DEN,
0/3576 (0)
l ROMO-DEN,
2/3581 (< 0.1)
l Placebo-DEN,
0/3576 (0)
l ROMO-DEN,
1/3581 (< 0.1)
Ishibashi 2017;55
postmenopausal
women with
osteoporosis
l Placebo, 63
l ROMO, 63
12 NR NR l Placebo, 0/63 (0)
l ROMO, 0/63 (0)
l Placebo, 0/63 (0)
l ROMO, 0/63 (0)
BRIDGE;56 men with
osteoporosis
l Placebo, 82
l ROMO, 163
12 NR l Placebo, 1/82 (1.2)
l ROMO, 3/163 (1.8)
l Placebo, 0/82 (0)
l ROMO, 0/163 (0)
l Placebo, 0/82 (0)
l ROMO, 0/163 (0)
TPTD vs. placebo
ACTIVE:
Miller 2016;95
postmenopausal
women with
osteoporosis
l Placebo, 820
l TPTD, 818
18 NR NR NR NR
Orwoll 2003;57 men
with osteoporosis
l Placebo, 147
l TPTD, 151
The study was
stopped after a
median duration of
11 months
NR NR NR NR
Miyauchi 2010;58
women and men with
osteoporosis
l Placebo, 67
l TPTD, 136
12 NR NR NR NR
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Trial name: first
author and year;
population Treatment arms (n) Follow-up (months)
AE
VTE(s), n/N (%) Stroke, n/N (%) ONJ, n/N (%)
Atypical femoral
fractures, n/N (%)
Miyauchi 2010;58
women and men with
osteoporosis
l Placebo to TPTD, 59
l TPTD to TPTD, 119
24, including 12 OLE NR NR NR NR
Miyauchi 2008;59
postmenopausal
women with
osteoporosis
l Placebo, 38
l TPTD, 39
6 NR NR NR NR
Leder 2015;61,336
postmenopausal
women with
osteoporosis
l Placebo, 45
l TPTD, 45
6 NR NR NR NR
Neer 2001;62
postmenopausal
women with
osteoporosis
l Placebo, 544
l TPTD, 541
24 (stopped early;
mean time to last
visit was 19 months)
NR NR NR NR
Sethi 2008;63
postmenopausal
women with
osteoporosis
l Calcium+ vitamin D,
41
l TPTD + calcium+
vitamin D, 41
6 NR NR NR NR
Head-to-head non-bisphosphonates
DATA: Tsai 2013;64
postmenopausal
women with
osteoporosis
l TPTD, 36
l DEN, 34
l Without placebo,
open label
12 NR NR NR NR
DATA: Leder 2014;110
postmenopausal
women with
osteoporosis
l TPTD, 36
l DEN, 34
l Without placebo,
open label
24 NR NR NR NR
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TABLE 26 Specific AEs: non-bisphosphonate studies (continued )
Trial name: first
author and year;
population Treatment arms (n) Follow-up (months)
AE
VTE(s), n/N (%) Stroke, n/N (%) ONJ, n/N (%)
Atypical femoral
fractures, n/N (%)
EUROFORS:
Eastell 2009;66
postmenopausal
women with
osteoporosis pre
treated with TPTD
l TPTD, 304
l RLX, 97
l Control,a 102
24 NR NR NR NR
STRUCTURE;67
postmenopausal
women with
osteoporosis pre
treated with ALN
l TPTD, 218
l ROMO, 218
l Without placebo,
open label
12 NR NR l TPTD, 0/218 (0)
l ROMO, 0/218 (0)
l TPTD, 0/218 (0)
l ROMO, 0/218 (0)
McClung 2014;68
postmenopausal
women with
osteoporosis
l Placebo, 52
l TPTD, 55
l ROMO, 52
l ALN, 51
12 NR NR NR NR
DEN vs. bisphosphonates
DECIDE;69
postmenopausal
women with
osteoporosis
l ALN, 586
l DEN, 593
l Both with placebo
12 NR NR NR NR
STAND;70
postmenopausal
women with
osteoporosis already
on ALN
l ALN, 251
l DEN, 253
l Both with placebo
12 NR NR NR NR
DAPS;71
postmenopausal
women with
osteoporosis
l ALN, 124
l DEN, 126
l Without placebo
12 NR NR l ALN, 0/117 (0)
l DEN, 0/125 (0)
NR
DAPS;109
postmenopausal
women with
osteoporosis
l Cross-over
l ALN to DEN, 92
l DEN to ALN, 102
24 NR NR l ALN, 0/228 (0)
l DEN, 0/230 (0)
l ALN, 0/228 (0)
l DEN, 0/230 (0)
A
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Trial name: first
author and year;
population Treatment arms (n) Follow-up (months)
AE
VTE(s), n/N (%) Stroke, n/N (%) ONJ, n/N (%)
Atypical femoral
fractures, n/N (%)
McClung 2006;72,337
postmenopausal
women with
osteoporosis or
osteopenia
l Placebo for DEN, 46
l ALN, 47
l DEN, 47
12 Thrombosis
l Placebo, 0/46 (0.00)
l ALN, 0/46 (0.00)
l DEN, 0/47 (0.00)
l Placebo, 0/46 (0.00)
l ALN, 0/46 (0.00)
l DEN, 0/47 (0.00)
NR NR
Recknor 2013;73
postmenopausal
women with
osteoporosis
l IBN, 416
l DEN, 417
l Without placebo
12 NR NR NR NR
Saag 2018;74,338
women and men
on GCCs with
osteoporosis or low
BMD + fracture
(NCT01575873)
l RIS, 384
l DEN, 394
l Both with placebo
12 DVT
l RIS, 2/385 (0.52)
l DEN, 0/394 (0.00)
Thrombosis
l RIS, 1/385 (0.26)
l DEN, 0/394 (0.00)
l RIS, 1/384 (0.26)
l DEN, 3/394 (0.76)
l RIS, 0/384 (0)
l DEN, 0/394 (0)
l RIS, 0/384 (0)
l DEN, 1/394 (< 1)
Miller 2016;75,339
postmenopausal
women with
osteoporosis
previously treated
with bisphosphonates
(NCT01732770)
l ZOL, 322
l DEN, 321
l Both with placebo
12 Peripheral artery
thrombosis
l ZOL, 1/320 (0.31)
l DEN, 0/320 (0.00)
NR NR l ZOL, 1/320 (0.3)
l DEN, 2/320 (0.6)
RLX vs. bisphosphonates
EFFECT: Sambrook
200476 (international
not including USA);
postmenopausal
women with
osteoporosis
l ALN, 246
l RLX, 241
l Both with placebo
12 NR NR NR NR
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TABLE 26 Specific AEs: non-bisphosphonate studies (continued )
Trial name: first
author and year;
population Treatment arms (n) Follow-up (months)
AE
VTE(s), n/N (%) Stroke, n/N (%) ONJ, n/N (%)
Atypical femoral
fractures, n/N (%)
EFFECT (USA);77
postmenopausal
women with
osteoporosis
l ALN, 223
l RLX, 233
l Both with placebo
12 l ALN, 0/221 (0)
l RLX, 1/230 (< 1)
NR NR NR
Johnell 2002;78
postmenopausal
women with
osteoporosis
l Placebo, 82
l ALN, 83
l RLX, 82
12 NR NR NR NR
Muscoso 2004;79
postmenopausal
women with
osteoporosis
l ALN, 1000
l RLX, 100
l RIS, 100
l All daily open label
24 NR NR NR NR
EVA: Recker 2007;80
postmenopausal
women with
osteoporosis
l ALN, 716
l RLX, 707
l Both with placebo
24 DVT:
l ALN, 1/716 (< 1)
PE:
l RLX, 1/707 (< 1)
NR NR NR
Sanad 2011;81
postmenopausal
women with
osteoporosis
l ALN weekly, 31
l RLX, 35
l Without placebo
12 l DVT, 0/31 (0)
l ALN, 1/35 (2.9)
NR NR NR
Michalska 2006;82
postmenopausal
women with
osteoporosis
previously treated
with bisphosphonates
l Placebo, 33
l RLX, 33
l ALN, 33
12 NR NR NR NR
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Trial name: first
author and year;
population Treatment arms (n) Follow-up (months)
AE
VTE(s), n/N (%) Stroke, n/N (%) ONJ, n/N (%)
Atypical femoral
fractures, n/N (%)
ROMO vs. bisphosphonates
ARCH: Saag 2017;83
postmenopausal
women with
osteoporosis
l ALN, 2047
l ROMO, 2046
l Both with placebo
12 NR l ALN, 7/2014 (0.3)
l ROMO, 16/2040 (0.8)
l ALN, 0/2014 (0)
l ROMO, 0/2040 (0)
l ALN, 0/2014 (0)
l ROMO, 0/2040 (0)
ARCH: Saag 2017;83
postmenopausal
women with
osteoporosis
l ALN to ALN, 2047
l ROMO to ALN, 2046
l Open label
24, including
12 months’ OLE
NR l ALN/ALN,
27/2014 (1.3)
l ROMO/ALN,
45/2040 (2.2)
l Estimated p = 0.004
l ALN/ALN,
1/2014 (< 0.1)
l ROMO/ALN,
1/2040 (< 0.1)
l ALN/ALN,
4/2014 (< 0.2)
l ROMO/ALN,
2/2040 (< 0.1)
TPTD vs. bisphosphonates
FACT;84
postmenopausal
women with
osteoporosis
l ALN, 101
l TPTD, 102
l Both with placebo
18 NR NR NR NR
Saag 2009,103
Langdahl 2009107 and
Lips 1999;340 women
and men on GCCs
with osteoporosis or
low BMD+ fracture
(NCT01732770)
l ALN, 214
l TPTD, 214
l Both with placebo
36 DVT:
l ALN, 1/214 (0.47)
l TPTD, 2/214 (0.93)
VTE:
l ALN, 0/214 (0)
l TPTD, 1/214 (0.47)
l ALN, 1/214 (0.47)
l TPTD, 0/214 (0)
NR NR
Panico 2011;86
postmenopausal
women with severe
osteoporosis +fracture
and on treatment for
osteoporosis
l ALN weekly, 39
l TPTD, 42
l Without placebo
18 NR NR NR NR
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TABLE 26 Specific AEs: non-bisphosphonate studies (continued )
Trial name: first
author and year;
population Treatment arms (n) Follow-up (months)
AE
VTE(s), n/N (%) Stroke, n/N (%) ONJ, n/N (%)
Atypical femoral
fractures, n/N (%)
Anastasilakis 200888 l RIS, 22
l TPTD, 22
l Without placebo,
open label
12 NR NR NR NR
EUROGIOPs;87 men
with osteoporosis on
GCCs
l RIS, 47
l TPTD, 45
l Without placebo,
open label
18 NR NR NR NR
Walker 2013;89 men
with osteoporosis
l RIS weekly, 10
l TPTD, 9
l Both with placebo
18 NR NR NR NR
Hadji 2012;91
postmenopausal
women with
osteoporosis
(NCT00343252)
l RIS weekly, 350
l TPTD, 360
l Both with placebo
18 DVT
l 1/350 (0.29)
l 0/360 (0.00)
Pulmonary thrombosis
l 1/350 (0.29)
l 0/360 (0.00)
l RIS, 6/350 (1.71)
l TPTD, 1/360 (0.28)
NR NR
VERO: Kendler
2018;99
postmenopausal
women with
osteoporosis
(NCT01709110)
l RIS weekly, 680
l TPTD, 680
l Both with placebo
24 DVT
l RIS, 3/683 (0.44)
l TPTD, 2/683 (0.29)
Vena cava thrombosis
l RIS, 1/683 (0.15)
l TPTD, 0/683 (0.00)
l RIS, 1/683 (0.15)
l TPTD, 2/683 (0.29)
NR NR
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Trial name: first
author and year;
population Treatment arms (n) Follow-up (months)
AE
VTE(s), n/N (%) Stroke, n/N (%) ONJ, n/N (%)
Atypical femoral
fractures, n/N (%)
MOVE: Aspenberg
201698 and Malouf-
Sierra 201792,128
(NCT00887354)
l RIS, 110
l TPTD, 106
l Both with placebo to
6 months then OLE
to 12 months
NR Venous thrombosis
l RIS, 1/110 (0.91)
l TPTD, 0/106 (0.00)
l RIS, 2/110 (1.82)
l TPTD, 0/106 (0.00)
NR NR
Cosman 2011;93
postmenopausal
women with
osteoporosis
(NCT00439244)
l ZOL,b 137
l TPTD + ZOL
placebo, 138
12 NR l ZOL, 0/137 (0.00)
l TPTD, 0/137 (0.00)
NR NR
ADAMO, A multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety DenosumAb versus placebo in Males with Osteoporosis; BRIDGE,
phase III randomized placeBo-contRolled double-blind study evaluatIng the efficacy and safety of Romosozumab in treatinG mEn with osteoporosis; DAPS, Denosumab Adherence
Preference Satisfaction; DECIDE, Determining Efficacy: Comparison of Initiating Denosumab versus alendronate; EFFECT, EFficacy of Fosamax versus Evista Comparison Trial;
FACT, Forteo Alendronate Comparator Trial; GCC, glucocorticoid; MORE, Multiple Outcomes of Raloxifene Evaluation; NR, not reported; OLE, open-label extension; STAND, Study of
Transitioning from Alendronate to Denosumab; STRUCTURE, STudy evaluating effect of RomosozUmab Compared with Teriparatide in postmenopaUsal women with osteoporosis at
high risk for fracture pReviously treated with bisphosphonatE therapy.
a No active treatment.
b Not placebo controlled for TPTD.
Notes
ALN, ALN 10mg daily or 70 mg weekly.
DEN, DEN 60mg s.c. every 6 months.
IBN, 150 mg oral every month.
RLX, RLX 60mg daily.
ROMO, 210 mg s.c. Monthly.
TPTD, 20 µg s.c. daily.
ZOL, ZOL 5mg i.v. annually.
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Appendix 8 Statistical methods for the
network meta-analysis
Statistical model for the network meta-analysis of fracture outcomes
The RCTs presented data in terms of the number of individuals experiencing at least one fracture. For
each fracture type, rik is defined as the number of events out of the total number of participants, nik,
where the participants are receiving treatment tik in arm k of trial i. The data generation process is
assumed to follow a binomial likelihood such that:
rik∼bin(pik , nik), (1)
where pik represents the probability of an event in arm k of trial i (i = 1, . . . ns, k = 1 . . . na) after
follow-up time fi. For all RCTs, the number of arms included in the analysis is two (i.e. na = 2) and
the number of RCTs, ns, varies according to fracture type.
To account for different trial durations, an underlying Poisson process is assumed for each trial arm, so
that tik (the time until a fracture occurs in arm k of study i) follows an exponential distribution, tik ∼ exp
(λik), where λik is the event rate in arm k of study i, assumed constant over time. The probability that
there are no events at time fi is given by the survivor function P(Tik > fi) = exp(–λikfi). For each study, i,
the probability of an event in arm k after follow-up time fi can be written as:
pik = 1 – P(T ik > f i) = 1 – exp(–λikf i), (2)
which is dependent on follow-up time. The probabilities of fracture are non-linear functions of event
rates, and so were modelled using the complementary log–log link function:
cloglog(pik) = log(f i) + µi + δi, 1kIk≠1. (3)
Here, the µi are trial-specific baselines, representing the log-hazards of fracture in the baseline
treatment, which is assumed to be arm k = 1 for all trials. Note that, for some trials, the baseline may
be an active treatment rather than placebo. The trial-specific treatment effects, δi,1k, are log-hazard
ratios of fracture for the treatment in arm k, relative to the baseline treatment.
As described later, two different modelling strategies were considered for the treatment effects:
(1) standard independent random (treatment) effects model and (2) exchangeable treatment effects
(i.e. a class effect) for bisphosphonate treatments with unrelated treatment effects for all other
interventions. The main results are based on model 2, and the results for the standard independent
random-effects model are provided here for comparison.
Standard independent random-effects model
The trial-specific treatment effects, δi,1k, were assumed to arise from a common population distribution
with mean treatment effect relative to the reference treatment, which was defined as placebo for this
analysis, such that:
δi, 1k ∼N(dti1tik , τ
2), (4)
where dti1tik represents the mean effect of the treatment in arm k of study i (tik) compared with the
treatment in arm 1 of study i (ti1) and τ2 represents the between-study variance in treatment effects
(heterogeneity), which is assumed to be the same for all treatments.
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The model was completed by specifying prior distributions for the parameters. When there were
sufficient sample data, conventional reference prior distributions were used:
l trial-specific baseline, µi ∼ N(0,1002)
l treatment effects relative to reference treatment, d1k ∼ N(0,1002)
l between-study SD of treatment effects, τ ∼ U(0,2).
For hip, wrist and proximal humerus fracture outcomes, there were relatively few RCTs to allow
Bayesian updating (i.e. estimation of parameters from the sample data alone) of the reference prior
distribution for the between-study SD. When prior distributions do not represent reasonable prior
beliefs, then, in the absence of sufficient sample data, posterior distributions will not represent
reasonable posterior beliefs. Therefore, rather than using a reference prior distribution, a weakly
informative prior distribution was used for the between-study SD, such that τ ∼ HN(0,0.322).
Primary analysis model
In the previous NICE assessment for bisphosphonates, a class-effects model was used. Not all RCTs
contributing wrist fracture data provide evidence about all bisphosphonates; in particular, there was no
evidence about ZOL. To allow an assessment of the uncertainty associated with ZOL for inclusion in
the economic model, a class-effects model was fitted, from which the predictive distribution of a new
intervention in the same class can be generated. This modelling approach also has the benefit of
addressing data sparsity in the hip network.
For the primary analysis model, a class effects was assumed for bisphosphonate treatments only. Under
a class-effects model, the trial-specific treatment effects are again assumed to be normally distributed
as in equation (3), but the mean effects of each treatment are assumed to be exchangeable and
assumed to arise from a normal distribution with mean, D, with variance τ2
D:
dti1tik ∼N(Dτ
2
D). (5)
The model was completed by specifying prior distributions for the parameters:
l mean bisphosphonate effect, D ∼ N(0,1002)
l between-treatment SD, τD ∼ U(0,2).
For hip, wrist and proximal humerus outcomes, a weakly informative prior was used for the between-
treatment SD, such that: σ2D∼HN(0,0:32
2).
Predicting effects in new randomised controlled trials
To account for heterogeneity in the effect of treatments between RCTs, results are also presented for
the predictive distributions of the effect of treatment in a new (randomly chosen) study.
From equation (4), it follows that the study-specific population log-hazard ratio, δi,j, for study i,
evaluating any given treatment j in reference to the control treatment can be written as:
δi, j = d1 j + εij, (6)
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where εij ∼ N(0,τ2). The predictive distribution for the effect of a particular treatment δi,j in a new study
is as follows:
δnew, j∼N(d1 j, τ
2), (7)
The class-effects model also allows generation of the predictive distribution of a new, randomly
chosen bisphosphonate treatment from the same class. From Equation 5, it follows that the population
log-hazard ratio for each treatment can be written as:
d1 j = D + ξ j, (8)
where ξ∼N(0, τ2D). Therefore, combining Equations 6 and 8, the study-specific population log-hazard
ratio, δi,j, for study i evaluating bisphosphonate j is:
δi, j = D + ζ j + εij, (9)
For a new, randomly chosen bisphosphonate, the expectation is E½δij = E½D + ζ j + εij = D, with variance:
V½δij = V½D + ζ j + εij = τ
2
+ τ2D. (10)
Therefore, the predictive distribution for the effect of a new, randomly chosen, study from the same
class is:
δnew ∼N(D, τ
2
D + τ
2), (11)
which accounts for both between-study, τ2, and between-treatment within class, τ2D, heterogeneity for
any (including a new) treatment.
It is the predictive distribution of a new treatment within the class and the predictive distribution of a
new study for a new treatment within the class that we use to characterise the uncertainty about the
effect of ZOL for hip fractures.
Statistical model for the network meta-analysis of femoral neck bone
mineral density
Data for femoral neck BMD outcomes were presented in two different formats: either as the
percentage change in femoral neck BMD for each treatment group or as the mean difference in the
percentage change between treatment groups. Two different data generation (i.e. likelihood) models
are therefore required.
Percentage change in femoral neck bone mineral density
The majority of RCTs presented data as the percentage change in femoral neck BMD, yik, and
associated standard errors, seik, for arm k of trial i with study duration fi years. The data generation
process is assumed to follow a normal likelihood, such that:
y ik ∼N(θik, se
2
ik), (12)
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where the population variance of the mean, se2ik , is assumed to be known and equal to the sample
estimate. The parameters of interest, θik, are modelled using the identity link function and, to account
for differing trial durations, study duration was included as a trial-level covariate. The link function is
given by:
θik = µi + δi, 1k + (β1tik – β1ti1 )f i
 
Ik≠1, (13)
Where β11 = 0, and β1k(k = 2, . . . na) are the treatment-specific interactions, describing the relationship
between the effect of treatment on percentage change in femoral neck BMD and duration of study.
The trial baselines, µi, represent the percentage change in femoral neck BMD from baseline in the
reference arm. The treatment effects, δi,1k, represent the difference between the percentage change
in the treatment group and the reference group. Assumptions about the relationship between the
interaction terms are described further in the meta-regression section.
Difference between treatments in mean change in femoral neck bone
mineral density
Some RCTs provided data in terms of the mean difference in percentage change in femoral neck BMD
between two treatments, defined as:
MDi, 1k = yik – yi1, (14)
together with the associated standard errors of the mean difference, νi,1k, rather than the percentage
change in femoral neck BMD for individual treatments. The difference between treatments in the mean
change are also assumed to be normally distributed, such that:
MDi, 1k ∼N(θ
′
ik , v
2
i1k), (15)
where the population standard error of the difference, v2i1k, is assumed to be known and equal to the
sample estimate. From the mean differences, no trial-specific effects of the baseline treatment can be
estimated. The linear predictor is then given by:
θ′
ik
= ðδi, 1k + (β1tik – β1ti1 )f iÞIk≠1. (16)
The study-specific treatment effects, δi,1k, have the same interpretation as those from Equation 13; thus,
they can be combined to estimate the mean effects for each treatment, regardless of the way the data
were reported.
A class-effects model was assumed such that the treatment effects of the individual bisphosphonates were
assumed to be exchangeable and to arise from a normal distribution with mean, D, with variance τ2
D:
dti1tik ∼N(D, τ
2
D
). (17)
The model was completed by specifying prior distributions for the parameters, using conventional
reference prior distributions:
l trial-specific baseline, µi ∼ N(0,1002)
l treatment effects relative to reference treatment, d1k ∼ N(1,1002)
l between-study SD of treatment effects, τ ∼ U(0,100).
l mean of related treatment effects, D ∼ N(0,1002)
l between-treatment SD, τD ∼ U(0,100).
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Meta-regression
When appropriate, heterogeneity in treatment effects was explored by considering potential treatment
effect modifiers. Meta-regression was used to test for interactions between the treatment effects and
trial-level covariates, as described in Dias et al.:121
An interaction term, β, is introduced on the treatment effect by replacing:
δ˜ i, 1k = δi, 1k + (β1tik – β1ti1 )(xi –x), (18)
Where xi is the trial-level covariate for trial i and may represent a subgroup, continuous covariate or
baseline risk (as described in more detail later), and β11 = 0. The regression is centred at the mean
value of the covariate across the RCTs so that the interpretation of the treatment effect is as the
effect at the average value of the covariate.
Different assumptions can be made about the relationship between the interaction terms for each
treatment. For the main analysis, we assume a common interaction for each treatment relative to
treatment 1, such that:
β1, tik = b, (19)
for k = 2, . . . , na. We also considered a model in which the interaction terms for each treatment were
considered to be related but not identical (i.e. exchangeable), such that:
β1, tik∼N(b, τ
2
B). (20)
Meta-regression on baseline risk/response
Baseline risk/response can be used as a proxy for differences in patient characteristics across trials
that may be modifiers of treatment effect, and so introduce a potential source of heterogeneity in the
NMA. Adjustment for baseline risk/response was assessed using the method of Achana et al.122
Dependence on baseline risk is introduced through an interaction term, so that:
δ˜ i, 1k = dti1tik + βti1tik (µiP – µP) + εi, ti1tik , (21)
where εi, ti1tik∼N(0, τ
2) The updated study-specific treatment effects, δ˜i,1k, are now adjusted using the
‘true’ but unobserved baseline risk/response in the placebo arm of trial i, µiP. The coefficient, βti1tik ,
represents the change in the treatment effect (e.g. log HR or difference between treatments in mean
change) per unit change in the baseline risk/response. The baseline risk/response is centred on µP, the
observed mean (e.g. log HR or difference between treatments in mean change) in the placebo group,
and β11 = 0.
For RCTs with an active treatment control, (t11 ≠ P), there is no direct estimate of the placebo baseline
risk/response. Under the consistency of evidence arising from the exchangeability assumption, the
substitution dti1tik = dPtik–dPti1 can be made, allowing Equation 21 to be expressed as:
δ˜ i, 1k = (dPtik –dPti1 ) + (βPtik – βPtik )(µiP – µP). (22)
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Although a placebo treatment may not be included in all RCTs, the assumption of exchangeability
means that the treatment arms can be assumed missing at random without loss to efficacy, and the
baseline risk/response in RCTs without a placebo arm can be estimated, borrowing strength from
other RCTs.
As previously described, some RCTs report data on the mean differences in percentage change
between two treatments. Under the model described in Equations 15 and 16, study-specific effects
of the baseline treatment cannot be estimated. These RCTs still contribute to the model through
estimation of the treatment effects, but do not directly contribute to estimation of the slope in the
meta-regression.
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Appendix 9 Data contributing to the
network meta-analysis
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TABLE 27 Data contributing to the NMA of vertebral fractures
Study
Treatment
Assessment
time point
Number of participants in
study arm
Number of events in
study arm
Main analysis SA1 SA2 SA3 SA41 2 3 1 2 3 1 2 3
Liberman 1995134 Placebo ALN – 36 355 175 – 22 5 – 1 0 0 0 1
Orwoll 2000286 Placebo ALN – 24 94 146 – 7 1 – 1 0 0 0 1
FIT I: Black 1996280 Placebo ALN – 36 965 981 – 192 83 – 1 0 0 1 1
FIT I: Black 1996280 Placebo ALN – 36 1000 1000 – 50 23 – 0 0 1 0 0
FIT II: Cummings 1998281 Placebo ALN – 48 2077 2057 – 78 43 – 1 0 0 1 1
Dursun 2001131 Placebo ALN – 12 35 38 – 14 12 – 1 1 0 0 1
Carfora 1998134 Placebo ALN – 30 34 34 – 4 1 – 1 0 0 0 0
Cohen 1999296 Placebo RIS – 12 35 34 – 5 2 – 1 1 0 1 1
Fogelman 2000297 Placebo RIS – 24 125 112 – 17 8 – 1 0 0 1 1
VERT-USA: Harris 1999298 Placebo RIS – 36 678 696 – 93 61 – 1 0 0 1 1
VERT-USA: Harris 1999298 Placebo RIS – 12 660 669 – 42 16 – 0 1 0 0 0
VERT-EU: Reginster 2000300 Placebo RIS – 36 346 344 – 89 53 – 1 0 0 1 1
VERT-EU: Reginster 2000300 Placebo RIS – 12 334 333 – 45 19 – 0 1 0 0 0
Hooper 2005132 Placebo RIS – 24 125 129 – 10 10 – 1 0 0 0 1
Reid 2000303 Placebo RIS – 12 60 60 – 9 3 – 1 1 0 1 1
Boonen 2009295 Placebo RIS – 24 80 179 – 0 2 – 1 0 0 1 0
Ringe 2006304 Placebo RIS – 12 158 158 – 20 8 – 1 1 1 1 1
Boonen 2012309 Placebo ZOL – 24 574 533 – 28 9 – 1 0 0 1 1
Boonen 2012309 Placebo ZOL – 12 574 553 – 16 5 – 0 1 0 0 0
HORIZON-PFT: Black 2007133 Placebo ZOL – 36 3861 3875 – 84 19 – 0 0 1 0 0
HORIZON-PFT: Black 2007133 Placebo ZOL – 12 3861 3875 – 143 58 – 0 1 0 0 0
HORIZON-PFT: Black 2007133 Placebo ZOL – 36 3861 3875 – 310 92 – 1 0 0 0 0
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Study
Treatment
Assessment
time point
Number of participants in
study arm
Number of events in
study arm
Main analysis SA1 SA2 SA3 SA41 2 3 1 2 3 1 2 3
HORIZON-RFT: Lyles 2007307 Placebo ZOL – 36 1062 1065 – 39 21 – 1 0 1 1 0
HORIZON-RFT: Lyles 2007307 Placebo ZOL – 12 1057 1054 – 21 13 – 0 1 0 0 0
BONE: Chesnut 2004136 Placebo IBN daily – 36 975 977 – 73 37 – 1 0 0 0 1
BONE: Chesnut 2004136 Placebo IBN daily – 12 889 929 – 24 13 – 0 1 0 0 0
BONE: Chesnut 2004136 Placebo IBN daily – 36 975 977 – 41 22 – 0 0 1 0 0
HORIZON-SIO Reid 2009317 RIS ZOL – 12 381 378 – 3 5 – 1 1 0 1 1
MOTION: Miller 2008308 ALN IBN monthly – 12 859 874 – 5 5 – 1 1 1 1 1
ZONE: Nakamura 2017130 Placebo ZOL – 24 327 330 – 29 10 – 1 0 0 1 1
ZONE: Nakamura 2017130 Placebo ZOL – 24 331 330 – 17 5 – 0 0 1 0 0
ZONE: Nakamura 2017130 Placebo ZOL – 12 331 330 – 6 4 – 0 1 0 0 0
FREEDOM: Bone 2017104 Placebo DEN – 36 3691 3702 – 264 86 – 1 0 0 1 1
FREEDOM: Bone 2017104 Placebo DEN – 36 3906 3902 – 92 29 – 0 0 1 0 0
FREEDOM: Bone 2017104 Placebo DEN – 12 3691 3702 – 82 32 – 0 1 0 0 0
FRAME: Cosman 201654 Placebo ROMO – 12 3322 3321 – 59 16 – 1 1 0 1 1
FRAME: Cosman 201654 Placebo ROMO – 12 3591 3589 – 17 3 – 0 0 0 0 0
ADAMO: Orwoll 201242 Placebo DEN – 12 120 120 – 1 0 – 1 1 1 1 1
DIRECT: Nakamura 201443 Placebo DEN – 24 480 472 – 41 10 – 1 0 0 0 1
DIRECT: Nakamura 201443 Placebo DEN – 12 480 472 – 9 6 – 0 1 0 0 0
Miyauchi 201058 Placebo TPTD – 12 67 136 – 4 5 – 1 1 0 1 0
ACTIVE: Miller 201675 Placebo TPTD – 18 711 717 – 30 6 – 1 0 0 0 1
ACTIVE: Miller 201675 Placebo TPTD – 18 821 818 – 9 3 – 0 0 1 0 0
Neer 200162 Placebo TPTD – 24 448 444 – 64 22 – 1 0 0 0 0
Morii 200347 Placebo RLX – 12 87 79 – 2 0 – 1 1 0 1 1
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TABLE 27 Data contributing to the NMA of vertebral fractures (continued )
Study
Treatment
Assessment
time point
Number of participants in
study arm
Number of events in
study arm
Main analysis SA1 SA2 SA3 SA41 2 3 1 2 3 1 2 3
Liu 200448 Placebo RLX – 12 102 102 – 5 0 – 1 1 1 1 1
Silverman 200850 Placebo RLX – 36 1741 1696 – 71 40 – 1 0 0 0 1
Silverman 200850 Placebo RLX – 36 1741 1696 – 16 15 – 0 0 1 0 0
MORE: Maricic 2002102 Placebo RLX – 12 2292 2259 – 19 6 – 0 1 0 0 0
MORE: Maricic 2002102 Placebo RLX – 36 2292 2259 – 81 47 – 0 0 1 0 0
MORE: Maricic 2002102 Placebo RLX – 36 2292 2259 – 231 148 – 1 0 0 1 1
Lufkin 199852 Placebo RLX – 12 45 43 – 18 21 – 1 1 0 1 1
Saag 2007103 ALN TPTD – 36 169 173 – 13 3 – 1 0 0 1 1
Saag 2007103 ALN TPTD – 36 169 173 – 4 0 – 0 0 1 0 0
Walker 201389 RIS TPTD – 18 10 9 – 1 0 – 1 0 0 1 1
VERO: Kendler 201799 RIS TPTD – 24 533 516 – 64 28 – 1 0 0 1 0
VERO: Kendler 201799 RIS TPTD – 12 533 516 – 11 4 – 0 1 1 0 0
Hadji 201291 RIS TPTD – 18 309 317 – 33 16 – 1 0 0 1 0
MOVE: Malouf-Sierra 201792 RIS TPTD – 18 106 116 – 1 0 – 1 0 1 0 1
Cosman 201193 ZOL TPTD – 12 137 137 – 5 1 – 1 1 0 0 1
EVA: Recker 200780 ALN RLX – 10.26 255 259 – 8 5 – 1 0 0 0 1
EVA: Recker 200780 ALN RLX – 10.26 713 699 – 3 0 – 0 0 1 0 0
Muscoso 200479 ALN RLX RIS 12 1000 100 100 2 0 0 0 1 0 0 0
Muscoso 200479 ALN RLX RIS 24 1000 100 100 6 0 0 1 0 0 1 0
ARCH: Saag 201783 ALN ROMO – 12 1703 1696 – 85 55 – 0 1 0 0 0
ARCH: Saag 201783 ALN ROMO/ALN – 24 1834 1825 – 147 74 – 1 0 0 1 1
ARCH: Saag 201783 ALN ROMO/ALN – 24 2047 2046 – 18 10 – 0 0 1 0 0
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Study
Treatment
Assessment
time point
Number of participants in
study arm
Number of events in
study arm
Main analysis SA1 SA2 SA3 SA41 2 3 1 2 3 1 2 3
Panico 201186 ALN TPTD – 18 39 42 – 6 1 – 1 0 0 0 1
Saag 201874 RIS DEN – 12 342 333 – 15 10 – 1 1 0 1 1
Mok 201153 Placebo RLX – 12 56 51 – 3 0 – 1 1 0 1 0
Miller 2004129 Placebo ALN – 12 41 80 – 3 6 – 1 1 0 0 1
Miller 2004129 Placebo ALN – 12 58 109 – 3 5 – 0 0 1 0 0
ADAMO, A multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety DenosumAb versus placebo in Males with Osteoporosis; BONE, iBandronate
Osteoporosis vertebral fracture trial in North America and Europe; FIT, Fracture Intervention Trial; MORE, Multiple Outcomes of Raloxifene Evaluation; MOTION, Monthly Oral Therapy
with Ibandronate for Osteoporosis iNtervention; PFT, Pivotal Fracture Trial; RFT, Recurrent Fracture Trial; SIO, steroid induced osteoporosis; VERT, Vertebral Efficacy with Risedronate
Therapy; ZONE, ZOledroNate treatment in Efficacy to osteoporosis.
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TABLE 28 Data contributing to the NMA of non-vertebral fractures
Study
Treatment
Assessment
time point
Number of
participants
in study arm
Number of
events in
study arm
1 2 3 1 2 3 1 2 3
FREEDOM: Cummings 200941 Placebo DEN – 36 3906 3902 – 293 238 –
FRAME: Cosman 201654 Placebo ROMO – 12 3591 3589 – 75 56 –
Orwoll 200357 Placebo TPTD – 12 147 151 – 3 2 –
ADAMO: Orwoll 201242 Placebo DEN – 12 120 120 – 2 1 –
DIRECT: Nakamura 201443 Placebo DEN – 24 480 472 – 20 19 –
Koh 201645 Placebo DEN – 6 66 69 – 1 1 –
Miyauchi 201058 Placebo TPTD – 12 67 136 – 1 1 –
ACTIVE: Miller 201695 Placebo TPTD – 18 821 818 – 33 24 –
Neer 200162 Placebo TPTD – 24 544 541 – 30 14 –
Silverman 200850 Placebo RLX – 36 1885 1849 – 118 109 –
Ishibashi 201755 Placebo RLX – 12 63 63 – 1 2 –
STRUCTURE: Langdahl 201767 ROMO TPTD – 12 218 214 – 7 8 –
STAND: Kendler 201070 ALN DEN – 12 249 253 – 4 8 –
DAPS: Freemantle 2012109 ALN DEN – 12 118 125 – 1 1 –
Saag 200985 ALN TPTD – 36 214 214 – 15 16 –
EuroGIOPs: Glüer 201387 RIS TPTD – 18 47 45 – 5 0 –
VERO: Kendler 201799 RIS TPTD – 24 680 680 – 38 25 –
Hadji 201291 RIS TPTD – 18 350 360 – 29 28 –
Malouf-Sierra 201792 RIS TPTD – 18 110 106 – 10 5 –
Cosman 201193 ZOL TPTD – 12 137 137 – 8 7 –
Muscoso 200479 ALN RLX RIS 24 1000 100 100 4 0 0
ARCH: Saag 201783 ALN ROMO/ALN – 32.4 2047 2046 – 217 178 –
EFFECT (USA): Luckey 200477 ALN RLX – 12 199 206 – 5 8 –
ZONE: Nakamura 2017130 Placebo ZOL – 24 331 330 – 37 20 –
Lufkin 199852 Placebo RLX – 12 45 43 – 3 0 –
Saag 201874 RIS DEN – 12 397 398 – 10 17 –
Michalská 200682 Placebo ALN RLX 24 33 33 33 2 1 1
Fogelman 2000297 Placebo RIS – 36 125 112 – 13 7 –
VERT-USA: Harris 1999298 Placebo RIS – 36 815 812 – 52 33 –
VERT-EU: Reginster 2000300 Placebo RIS – 24 406 406 – 51 36 –
Hooper 2005132 Placebo RIS – 12 125 129 – 6 5 –
Ringe 2006304 Placebo RIS – 48 158 158 – 17 10 –
FIT I: Black 1996280 Placebo ALN – 36 1005 1022 – 148 122 –
FIT II: Cummings 1998281 Placebo ALN – 48 2218 2214 – 294 261 –
Orwoll 2000286 Placebo ALN – 24 94 146 – 5 6 –
FOSIT: Pols 1999287 Placebo ALN – 12 958 950 – 37 19 –
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TABLE 28 Data contributing to the NMA of non-vertebral fractures (continued )
Study
Treatment
Assessment
time point
Number of
participants
in study arm
Number of
events in
study arm
1 2 3 1 2 3 1 2 3
Bone 2000282 Placebo ALN – 24 50 92 – 4 5 –
HORIZON-PFT: Black 2007133 Placebo ZOL – 11 3861 3875 – 388 292 –
HORIZON-RFT: Lyles 2007307 Placebo ZOL – 36 1062 1065 – 107 79 –
BONE: Chesnut 2004136 Placebo IBN daily – 36 975 977 – 80 89 –
MOTION: Miller 2008311 ALN IBN monthly – 12 859 874 – 12 14 –
Morii 200347 Placebo RLX – 12 97 88 – 4 1 –
ADAMO, A multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety
DenosumAb versus placebo in Males with Osteoporosis; BONE, iBandronate Osteoporosis vertebral fracture trial
in North America and Europe; DAPS, Denosumab Adherence Preference Satisfaction; EFFECT, EFficacy of Fosamax
versus Evista Comparison Trial; FIT, Fracture Intervention Trial; FOSIT, FOSamax International Trial; MOTION, Monthly
Oral Therapy with Ibandronate for Osteoporosis iNtervention; PFT, Pivotal Fracture Trial; RFT, Recurrent Fracture Trial;
STAND, Study of Transitioning from Alendronate to Denosumab; STRUCTURE, STudy evaluating effect of RomosozUmab
Compared with Teriparatide in postmenopaUsal women with osteoporosis at high risk for fracture pReviously treated
with bisphosphonatE therapy; VERT, Vertebral Efficacy with Risedronate Therapy; ZONE, ZOledroNate treatment in
Efficacy to osteoporosis.
TABLE 29 Data contributing to the NMA of hip fractures
Study
Treatment
Assessment
time point
Number of
participants
in study arm
Number of
events in
study arm
1 2 3 1 2 3 1 2 3
FREEDOM: Cummings 200941 Placebo DEN – 36 3906 3902 – 43 26 –
FRAME: Cosman 201654 Placebo ROMO – 12 3591 3589 – 13 7 –
DIRECT: Nakamura 201443 Placebo DEN – 24 480 472 – 2 0 –
ACTIVE: Miller 201675 Placebo TPTD – 18 821 818 – 2 0 –
Neer 200162 Placebo TPTD – 24 544 541 – 4 1 –
STRUCTURE: Langdahl 201767 ROMO TPTD – 12 218 218 – 1 0 –
Miller 201675 ZOL DEN – 12 320 320 – 2 1 –
EuroGIOPs: Glüer 201387 RIS TPTD – 18 47 45 – 1 0 –
VERO: Kendler 201799 RIS TPTD – 24 680 680 – 5 2 –
Hadji 201291 RIS TPTD – 18 350 360 – 2 5 –
EFFECT: Sambrook 200476 ALN RLX – 12 246 241 – 0 1 –
MOVE: Malouf-Sierra 201792 RIS TPTD – 18 110 106 – 7 2 –
Muscoso 200479 ALN RLX RIS 24 1000 100 100 3 0 0
ARCH: Saag 201783 ALN ROMO/ALN – 32.4 2047 2046 – 66 41 –
Saag 201874 RIS DEN – 12 397 398 – 1 1 –
Silverman 200850 Placebo RLX – 36 1885 1849 – 6 5 –
VERT-USA: Harris 1999298 Placebo RIS – 36 815 812 – 15 12 –
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TABLE 29 Data contributing to the NMA of hip fractures (continued )
Study
Treatment
Assessment
time point
Number of
participants
in study arm
Number of
events in
study arm
1 2 3 1 2 3 1 2 3
VERT-EU: Reginster 2000300 Placebo RIS – 36 406 406 – 11 9 –
FIT I: Black 1996280 Placebo ALN – 36 1005 1022 – 22 11 –
FIT II: Cummings 1998281 Placebo ALN – 48 2218 2214 – 24 19 –
Greenspan 2002283 Placebo ALN – 24 164 163 – 4 2 –
HORIZON-PFT: Black 2007133 Placebo ZOL – 36 3861 3875 – 88 52 –
HORIZON-RFT: Lyles 2007307 Placebo ZOL – 36 1062 1065 – 33 23 –
EFFECT, EFficacy of Fosamax versus Evista Comparison Trial; FIT, Fracture Intervention Trial; PFT, Pivotal Fracture Trial;
RFT, Recurrent Fracture Trial; STRUCTURE, STudy evaluating effect of RomosozUmab Compared with Teriparatide in
postmenopaUsal women with osteoporosis at high risk for fracture pReviously treated with bisphosphonatE therapy;
VERT, Vertebral Efficacy with Risedronate Therapy.
TABLE 30 Data contributing to the NMA of wrist fractures
Study
Treatment
Assessment
time point
Number of
participants
in study arm
Number of
events in
study arm
1 2 3 1 2 3 1 2 3
ACTIVE: Miller 201695 Placebo TPTD – 18 821 818 – 15 17 –
Neer 200162 Placebo TPTD – 24 544 541 – 7 2 –
Ishibashi 201755 Placebo RLX – 12 63 63 – 0 1 –
STRUCTURE: Langdahl 201767 ROMO TPTD – 12 218 218 – 1 4 –
STAND: Kendler 201070 ALN DEN – 12 249 253 – 2 3 –
VERO: Kendler 201799 RIS TPTD – 24 680 680 – 15 6 –
Hadji 201291 RIS TPTD – 18 350 360 – 2 4 –
Muscoso 200479 ALN RLX RIS 24 1000 100 100 1 0 0
EFFECT (USA): Luckey 200477 ALN RLX – 12 199 206 – 0 1 –
Silverman 200850 Placebo RLX – 36 1885 1849 – 31 46 –
VERT-USA: Harris 1999298 Placebo RIS – 36 815 812 – 22 14 –
VERT-EU: Reginster 2000300 Placebo RIS – 36 406 406 – 21 15 –
FIT I: Black 1996280 Placebo ALN – 36 1005 1022 – 41 22 –
FIT II: Cummings 1998281 Placebo ALN – 48 2218 2214 – 70 83 –
McClung 2009291 Placebo IBN monthly – 12 83 77 – 0 1 –
EFFECT, EFficacy of Fosamax versus Evista Comparison Trial; FIT, Fracture Intervention Trial; STAND, Study of
Transitioning from Alendronate to Denosumab; STRUCTURE, STudy evaluating effect of RomosozUmab Compared
with Teriparatide in postmenopaUsal women with osteoporosis at high risk for fracture pReviously treated with
bisphosphonatE therapy; VERT, Vertebral Efficacy with Risedronate Therapy.
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
244
TABLE 31 Data contributing to the NMA of proximal humerus fractures
Study
Treatment
Assessment
time point
Number of participants
in study arm
Number of events
in study arm
1 2 1 2 1 2
ADAMO: Orwoll 201242 Placebo DEN 12 120 120 1 0
ACTIVE: Miller 201695 Placebo TPTD 18 821 818 3 2
Neer 200162 Placebo TPTD 24 544 541 2 2
STRUCTURE: Langdahl 201767 ROMO TPTD 12 218 218 0 1
STAND: Kendler 201070 ALN DEN 12 249 253 0 1
EuroGIOPs: Glüer 201387 RIS TPTD 18 47 45 1 0
VERO: Kendler 201799 RIS TPTD 24 680 680 2 4
Hadji 201291 RIS TPTD 18 350 360 5 4
MOVE: Malouf-Sierra 201792 RIS TPTD 18 110 106 1 1
EFFECT (USA): Luckey 200477 ALN RLX 12 199 206 0 1
Saag 201874 RIS DEN 12 391 398 3 3
VERT-MN Harris 1999298 Placebo RIS 36 815 812 10 4
VERT-MN Reginster 2000300 Placebo RIS 36 406 406 14 7
ADAMO, A multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety DenosumAb
versus placebo in Males with Osteoporosis; EFFECT, EFficacy of Fosamax versus Evista Comparison Trial; STAND, Study of
Transitioning from Alendronate to Denosumab; STRUCTURE, STudy evaluating effect of RomosozUmab Compared with
Teriparatide in postmenopaUsal women with osteoporosis at high risk for fracture pReviously treated with bisphosphonatE
therapy; VERT-MN, Vertebral Efficacy with Risedronate Therapy-Multinational.
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Appendix 10 Network meta-analysis
results from random-effects model
Treatment effects versus placebo from the random-effects model is shown in Figure 13, and asummary of model fit and heterogeneity is shown in Table 32. For all outcomes the DIC was larger
for the random-effects model, implying that the primary model (class effect for bisphosphonate
treatments, and unrelated treatment effects for all other interventions) provides a better fit to the
data. Treatment effects from the random-effects model are generally consistent with primary model.
Treatment
Vertebral
TPTD
ROMO/ALN
ROMO
DEN
ZOL
IBN daily
IBN monthly
ALN
RIS
RLX
Non-vertebral
TPTD
RIS
ZOL
ROMO/ALN
ROMO
ALN
DEN
RLX
IBN monthly
IBN daily
Hip
TPTD
ROMO/ALN
DEN
ROMO
ALN
ZOL
RIS
RLX
Wrist
ROMO
TPTD
RIS
ALN
DEN
RLX
IBN monthly
Humerus
ALN
ROMO
DEN
RIS
RLX
TPTD
0 1 2 3 4
0.56
0.53
0.49
0.43
0.10
0.09
5.32
1.65
1.25
0.82
0.78
0.64
0.12
0.93
0.72
0.63
0.62
0.56
0.56
0.38
0.36
1.12
0.90
0.89
0.86
0.78
0.71
0.71
0.69
0.63
0.57
0.62
0.54
0.51
0.49
0.49
0.35
0.31
0.27
0.25
0.23
HR 95% Crl 95% Prl Rank.PB.
2 (34%)
2 (26%)
3 (26%)
4 (3%)
5 (0%)
7 (0%)
7 (10%)
8 (0%)
8 (0%)
9 (0%)
1 (51%)
3 (23%)
4 (3%)
4 (2%)
4 (10%)
6 (0%)
8 (0%)
8 (0%)
8 (11%)
11 (0%)
2 (43%)
2 (36%)
4 (5%)
4 (11%)
5 (0%)
5 (1%)
6 (0%)
8 (3%)
1 (85%)
3 (3%)
4 (2%)
4 (2%)
6 (6%)
7 (0%)
8 (3%)
2 (39%)
2 (44%)
4 (3%)
4 (2%)
4 (11%)
5 (1%)
0.17 to 0.32 0.14 to 0.38
0.14 to 0.52
0.12 to 0.54
0.18 to 0.51
0.23 to 0.61
0.26 to 0.95
0.12 to 2.00
0.33 to 0.86
0.33 to 0.82
0.36 to 0.95
0.40 to 0.80
0.39 to 0.91
0.50 to 0.97
0.51 to 0.94
0.45 to 1.08
0.55 to 1.00
0.64 to 1.23
0.60 to 1.27
0.37 to 2.14
0.72 to 1.71
0.14 to 0.88
0.16 to 0.87
0.26 to 1.08
0.20 to 1.58
0.32 to 1.15
0.36 to 1.14
0.36 to 1.44
0.29 to 2.89
0.00 to 1.36
0.21 to 1.84
0.27 to 2.15
0.28 to 2.12
0.12 to 15.63
0.55 to 5.27
0.00 to 4.35
0.00 to 3.49
0.07 to 2.28
0.20 to 1.15
0.00 to 995.29
0.19 to 1.59
0.15 to 2316.92
0.16 to 0.45
0.13 to 0.50
0.21 to 0.42
0.27 to 0.50
0.29 to 0.85
0.13 to 1.91
0.40 to 0.69
0.42 to 0.68
0.45 to 0.79
0.43 to 0.74
0.42 to 0.86
0.55 to 0.88
0.58 to 0.85
0.48 to 1.03
0.62 to 0.92
0.69 to 1.11
0.65 to 1.19
0.38 to 2.09
0.77 to 1.62
0.15 to 0.81
0.18 to 0.78
0.30 to 0.96
0.22 to 1.47
0.37 to 1.01
0.42 to 0.94
0.40 to 1.28
0.30 to 2.76
0.00 to 1.26
0.30 to 1.29
0.41 to 1.46
0.42 to 1.43
0.15 to 14.20
0.75 to 3.88
0.00 to 4.23
0.00 to 3.40
0.07 to 2.12
0.24 to 0.98
0.22 to 1.40
0.00 to 967.09
0.17 to 2155.25
FIGURE 13 Forest plot of HRs for all fracture outcomes using a random-effects model.
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Treatment effects from the two models appear most different for proximal humerus fractures. Using a
random-effects model, ALN has a highly beneficial HR (0.09, 95% CrI 0 to 4.23) and PB of 0.39. Under the
class-effects model, the HR for ALN is less extreme (0.46, 95% CrI 0.15 to 1.27) as it is also influenced by
the estimate for RIS (the only other bisphosphonate included in the network). The estimate for ALN is only
contributed by one study77 with zero events in the ALN arm and one event in the RLX arm, and so is
highly uncertain.
TABLE 32 Model fit and heterogeneity for random-effects sensitivity analysis: all outcomes
Outcome
Absolute model fit
DIC SDb (95% CI)Dres
a Data points
Vertebral fractures 93.42 93 156.43 0.15 (0.01 to 0.37)
Non-vertebral fractures 73.93 86 129.50 0.08 (0.01 to 0.24)
Hipc 39.58 47 72.37 0.13 (0.01 to 0.45)
Wristc 30.76 31 56.63 0.34 (0.05 to 0.71)
Proximal humerusc 22.87 26 44.02 0.17 (0.01 to 0.58)
Femoral neck BMD
a Total residual deviance.
b Between-study SD.
c For hip, wrist and humerus fractures, weakly informative priors were used for the between-study and between-
treatment SDs.
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Appendix 11 Vertebral fracture sensitivity
analyses
Four sensitivity analyses were conducted for the vertebral fracture network:
l SA1: 12-month data only
l SA2: clinically assessed fractures only
l SA3: exclusion of studies with quality issues
l SA4: exclusion of studies in which prior bisphosphonate treatment had been received.
Treatment effects versus placebo is summarised in Figure 14, and a summary of model fit and
heterogeneity is shown in Table 33.
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Treatment HR 95% Crl 95% Prl Rank.PB.
0 1 2 3 4
Bisphosphonate class efect
RLX
RIS
IBN daily
IBN monthly
ALN
ZOL
DEN
ROMO
ROMO/ALN
TPTD
RLX
RIS
Bisphosphonate class efect
Vertebral SA4
IBN monthly
ALN
ZOL
DEN
ROMO
ROMO/ALN
TPTD
Vertebral SA3
Bisphosphonate class efect
RLX
ALN
IBN daily
IBN monthly
RIS
ZOL
DEN
ROMO/ALN
TPTD
ROMO
Vertebral SA2
Bisphosphonate class efect
RLX
ALN
IBN monthly
IBN daily
ZOL
RIS
DEN
ROMO
TPTD
Vertebral SA1
Bisphosphonate class efect
RLX
RIS
ALN
ZOL
IBN daily
IBN monthly
DEN
ROMO
ROMO/ALN
TPTD
Vertebral
0.23
0.25
0.27
0.30
0.40
0.48
0.48
0.50
0.52
0.61
0.47
0.23
0.30
0.39
0.44
0.46
0.47
0.47
0.49
0.58
0.47
0.16
0.17
0.28
0.31
0.38
0.44
0.46
0.47
0.51
0.54
0.45
0.22
0.24
0.26
0.32
0.47
0.48
0.49
0.51
0.66
0.49
0.13
0.24
0.26
0.31
0.48
0.49
0.50
0.50
0.52
0.63
0.49 0.36 to 0.65
0.16 to 0.32 0.13 to 0.38
0.13 to 0.50
0.12 to 0.57
0.17 to 0.51
0.25 to 0.69
0.28 to 0.83
0.24 to 0.99
0.32 to 0.81
0.32 to 0.82
0.36 to 0.98
0.19 to 1.16
0.09 to 0.59
0.15 to 0.61
0.20 to 0.78
0.25 to 0.82
0.27 to 0.89
0.25 to 0.97
0.23 to 1.09
0.28 to 0.97
0.25 to 1.12
0.2 to 1.21
0.02 to 0.82
0.04 to 0.61
0.06 to 1.50
0.09 to 1.10
0.14 to 1.14
0.15 to 1.36
0.15 to 1.87
0.16 to 1.50
0.19 to 1.62
0.16 to 1.44
0.11 to 2.11
0.13 to 0.39
0.13 to 0.46
0.12 to 0.54
0.19 to 0.54
0.28 to 0.75
0.31 to 0.77
0.24 to 0.96
0.32 to 0.76
0.39 to 1.07
0.31 to 0.75
0.06 to 0.27
0.14 to 0.44
0.13 to 0.52
0.19 to 0.47
0.28 to 0.71
0.34 to 0.74
0.27 to 0.87
0.32 to 0.77
0.35 to 0.75
0.41 to 0.94
0.25 to 0.95
0.15 to 0.43
0.13 to 0.52
0.21 to 0.43
0.29 to 0.55
0.33 to 0.71
0.26 to 0.90
0.40 to 0.64
0.42 to 0.65
0.44 to 0.80
0.33 to 0.69
0.10 to 0.51
0.18 to 0.50
0.24 to 0.63
0.32 to 0.60
0.35 to 0.65
0.31 to 0.79
0.27 to 0.93
0.36 to 0.78
0.31 to 0.97
0.33 to 0.72
0.08 to 1.10
0.12 to 0.77
0.22 to 0.66
0.22 to 0.88
0.21 to 1.31
0.25 to 0.97
0.31 to 1.05
0.25 to 0.95
0.25 to 0.91
0.14 to 0.34
0.14 to 0.40
0.13 to 0.49
0.22 to 0.47
0.33 to 0.62
0.38 to 0.63
0.26 to 0.88
0.40 to 0.64
0.47 to 0.90
0.2 to 1.22
0.06 to 0.25
0.15 to 0.39
0.14 to 0.49
0.22 to 0.41
0.31 to 0.61
0.40 to 0.61
0.29 to 0.78
0.36 to 0.67
0.42 to 0.63
0.48 to 0.80
0.03 to 0.65
0.06 to 0.45
2 (38%)
2 (30%)
3 (27%)
4 (3%)
5 (0%)
7 (0%)
7 (1%)
8 (0%)
8 (0%)
10 (0%)
1 (69%)
2 (24%)
3 (4%)
5 (0%)
6 (0%)
6 (1%)
6 (1%)
7 (0%)
9 (1%)
2 (46%)
2 (36%)
3 (11%)
4 (4%)
5 (0%)
7 (0%)
7 (0%)
7 (0%)
8 (0%)
9 (0%)
2 (42%)
2 (31%)
3 (24%)
4 (2%)
6 (0%)
6 (0%)
7 (0%)
9 (0%)
1 (89%)
2 (5%)
3 (6%)
4 (0%)
6 (0%)
7 (0%)
7 (0%)
7 (0%)
8 (0%)
10 (0%)
6 (1%)
FIGURE 14 Forest plot of vertebral fracture network sensitivity analyses.
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TABLE 33 Summary of model fit and heterogeneity between studies and between treatments for vertebral fracture
network sensitivity analyses
Outcome
Absolute model fit
DIC
Heterogeneity, SD (95% CrI)
Dres
a Data points Between study Between treatment
Vertebral fractures 91.21 93 153.31 0.17 (0.02 to 0.37) 0.21 (0.01 to 0.90)
SA1: 12-month data 56.17 59 95.94 0.17 (0.01 to 0.51) 0.15 (0.01 to 0.86)
SA2: clinical fractures 40.14 40 72.49 0.32 (0.02 to 0.89) 0.29 (0.02 to 1.33)
SA3: excluding studies
with quality issues
58.27 61 99.4 0.13 (0.01 to 0.38) 0.149 (0.01 to 1.04)
SA4: excluding studies
with prior treatment
69.83 72 117.47 0.11 (0.01 to 0.34) 0.117 (0.01 to 0.69)
a Total residual deviance.
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Appendix 12 Pairwise summary tables
Pairwise summary tables for all outcomes are shown in this appendix. Median HR and 95% CrIs arepresented below the diagonal, median HR and 95% PrI are shown above the diagonal.
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TABLE 34 Pairwise comparisons, vertebral fractures main analysis
Placebo ALN RIS ZOL IBN daily IBN monthly DEN ROMO TPTD RLX ROMO/ALN
Placebo 0.50 (0.32 to 0.81) 0.52 (0.32 to 0.82) 0.39 (0.25 to 0.69) 0.48 (0.28 to 0.83) 0.48 (0.24 to 0.99) 0.31 (0.17 to 0.51) 0.27 (0.12 to 0.57) 0.23 (0.13 to 0.38) 0.62 (0.36 to 0.98) 0.25 (0.13 to 0.50)
ALN 0.50 (0.40 to 0.64) 1.06 (0.53 to 1.90) 0.78 (0.42 to 1.61) 0.98 (0.47 to 1.87) 0.96 (0.42 to 2.16) 0.61 (0.29 to 1.20) 0.53 (0.21 to 1.28) 0.47 (0.23 to 0.88) 1.24 (0.60 to 2.29) 0.49 (0.23 to 1.06)
RIS 0.52 (0.42 to 0.65) 1.03 (0.77 to 1.39) 0.74 (0.42 to 1.63) 0.93 (0.47 to 1.86) 0.92 (0.41 to 2.17) 0.58 (0.29 to 1.19) 0.51 (0.20 to 1.25) 0.44 (0.23 to 0.85) 1.17 (0.59 to 2.28) 0.47 (0.22 to 1.09)
ZOL 0.40 (0.29 to 0.55) 0.81 (0.54 to 1.08) 0.77 (0.52 to 1.08) 1.23 (0.57 to 2.43) 1.19 (0.53 to 2.91) 0.79 (0.34 to 1.50) 0.68 (0.24 to 1.60) 0.60 (0.26 to 1.11) 1.58 (0.68 to 2.90) 0.63 (0.26 to 1.37)
IBN
daily
0.48 (0.33 to 0.71) 0.98 (0.63 to 1.43) 0.95 (0.61 to 1.37) 1.18 (0.82 to 1.99) 0.99 (0.42 to 2.40) 0.63 (0.29 to 1.32) 0.55 (0.21 to 1.40) 0.48 (0.23 to 0.99) 1.27 (0.59 to 2.56) 0.51 (0.22 to 1.21)
IBN
monthly
0.48 (0.26 to 0.90) 0.98 (0.51 to 1.75) 0.95 (0.47 to 1.71) 1.14 (0.68 to 2.50) 1.00 (0.49 to 1.98) 0.64 (0.25 to 1.52) 0.55 (0.19 to 1.56) 0.48 (0.19 to 1.13) 1.28 (0.52 to 2.91) 0.51 (0.20 to 1.34)
DEN 0.30 (0.21 to 0.43) 0.61 (0.39 to 0.91) 0.58 (0.40 to 0.88) 0.77 (0.46 to 1.19) 0.63 (0.38 to 1.03) 0.64 (0.31 to 1.26) 0.87 (0.33 to 2.23) 0.76 (0.36 to 1.57) 2.01 (0.95 to 4.14) 0.81 (0.35 to 1.97)
ROMO 0.27 (0.13 to 0.52) 0.53 (0.25 to 1.06) 0.51 (0.25 to 1.03) 0.67 (0.30 to 1.35) 0.55 (0.25 to 1.16) 0.55 (0.22 to 1.36) 0.87 (0.40 to 1.86) 0.87 (0.34 to 2.22) 2.31 (0.89 to 5.79) 0.93 (0.33 to 2.71)
TPTD 0.23 (0.16 to 0.32) 0.46 (0.31 to 0.66) 0.44 (0.32 to 0.61) 0.58 (0.36 to 0.90) 0.47 (0.29 to 0.77) 0.48 (0.25 to 0.95) 0.76 (0.46 to 1.20) 0.87 (0.41 to 1.87) 2.65 (1.28 to 5.45) 1.06 (0.48 to 2.61)
RLX 0.61 (0.44 to 0.80) 1.23 (0.82 to 1.71) 1.17 (0.82 to 1.68) 1.54 (0.94 to 2.32) 1.26 (0.78 to 1.97) 1.27 (0.65 to 2.47) 2.01 (1.25 to 3.13) 2.30 (1.09 to 4.83) 2.66 (1.72 to 4.11) 0.40 (0.18 to 0.98)
ROMO/
ALN
0.25 (0.15 to 0.43) 0.50 (0.30 to 0.80) 0.47 (0.28 to 0.86) 0.62 (0.33 to 1.11) 0.51 (0.28 to 0.98) 0.51 (0.24 to 1.12) 0.81 (0.44 to 1.59) 0.93 (0.40 to 2.29) 1.06 (0.60 to 2.06) 0.40 (0.23 to 0.78)
Pairwise HR and 95% CrIs (lower triangle, not shaded), predictive effects in a new study and 95% PrI (upper triangle, shaded).
Bold font shows comparisons that indicate a statistically significant difference between interventions.
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TABLE 35 Pairwise comparisons, non-vertebral fractures main analysis
Placebo ALN RIS ZOL IBN daily IBN monthly DEN ROMO TPTD RLX ROMO/ALN
Placebo 0.78 (0.56 to 0.99) 0.73 (0.53 to 0.98) 0.73 (0.54 to 0.95) 0.89 (0.60 to 1.38) 0.79 (0.50 to 1.31) 0.86 (0.64 to 1.23) 0.71 (0.45 to 1.09) 0.58 (0.41 to 0.81) 0.90 (0.60 to 1.29) 0.63 (0.40 to 0.92)
ALN 0.77 (0.64 to 0.90) 0.95 (0.65 to 1.43) 0.94 (0.65 to 1.42) 1.15 (0.75 to 1.91) 1.02 (0.63 to 1.78) 1.10 (0.76 to 1.84) 0.92 (0.56 to 1.56) 0.75 (0.51 to 1.18) 1.16 (0.74 to 1.87) 0.81 (0.52 to 1.27)
RIS 0.73 (0.59 to 0.88) 0.96 (0.73 to 1.19) 1.00 (0.66 to 1.48) 1.22 (0.76 to 2.11) 1.07 (0.65 to 1.96) 1.18 (0.79 to 1.91) 0.97 (0.57 to 1.65) 0.80 (0.52 to 1.20) 1.23 (0.76 to 1.97) 0.86 (0.51 to 1.38)
ZOL 0.73 (0.61 to 0.85) 0.96 (0.76 to 1.17) 1.00 (0.79 to 1.28) 1.23 (0.77 to 2.08) 1.07 (0.65 to 1.93) 1.18 (0.79 to 1.90) 0.97 (0.58 to 1.63) 0.80 (0.52 to 1.24) 1.24 (0.76 to 1.94) 0.86 (0.52 to 1.37)
IBN
daily
0.88 (0.67 to 1.32) 1.13 (0.91 to 1.76) 1.20 (0.93 to 1.98) 1.20 (0.93 to 1.91) 0.91 (0.47 to 1.49) 0.95 (0.57 to 1.69) 0.79 (0.43 to 1.43) 0.65 (0.38 to 1.09) 1.00 (0.57 to 1.71) 0.70 (0.39 to 1.19)
IBN
monthly
0.78 (0.54 to 1.27) 1.01 (0.70 to 1.66) 1.05 (0.74 to 1.84) 1.05 (0.74 to 1.83) 0.93 (0.50 to 1.32) 1.08 (0.61 to 1.98) 0.90 (0.47 to 1.68) 0.74 (0.40 to 1.28) 1.14 (0.61 to 2.00) 0.79 (0.43 to 1.38)
DEN 0.86 (0.69 to 1.12) 1.12 (0.87 to 1.57) 1.18 (0.90 to 1.63) 1.18 (0.91 to 1.63) 0.97 (0.62 to 1.46) 1.09 (0.65 to 1.73) 0.83 (0.46 to 1.38) 0.68 (0.41 to 1.05) 1.05 (0.60 to 1.65) 0.74 (0.40 to 1.16)
ROMO 0.71 (0.48 to 1.03) 0.92 (0.62 to 1.39) 0.97 (0.64 to 1.49) 0.97 (0.64 to 1.47) 0.79 (0.47 to 1.28) 0.90 (0.50 to 1.53) 0.82 (0.51 to 1.26) 0.82 (0.48 to 1.41) 1.27 (0.71 to 2.25) 0.88 (0.48 to 1.57)
TPTD 0.58 (0.45 to 0.76) 0.76 (0.57 to 1.02) 0.80 (0.61 to 1.04) 0.80 (0.60 to 1.08) 0.66 (0.40 to 0.96) 0.74 (0.42 to 1.14) 0.68 (0.47 to 0.94) 0.82 (0.53 to 1.28) 1.55 (0.93 to 2.53) 1.08 (0.62 to 1.79)
RLX 0.90 (0.65 to 1.21) 1.17 (0.84 to 1.63) 1.23 (0.85 to 1.77) 1.23 (0.87 to 1.74) 1.01 (0.62 to 1.53) 1.14 (0.66 to 1.83) 1.05 (0.68 to 1.49) 1.27 (0.78 to 2.05) 1.55 (1.03 to 2.28) 0.70 (0.40 to 1.19)
ROMO/
ALN
0.63 (0.44 to 0.86) 0.81 (0.61 to 1.09) 0.86 (0.58 to 1.25) 0.86 (0.59 to 1.23) 0.70 (0.42 to 1.06) 0.79 (0.46 to 1.26) 0.73 (0.46 to 1.06) 0.88 (0.53 to 1.44) 1.08 (0.70 to 1.62) 0.70 (0.44 to 1.08)
Pairwise HR and 95% CrIs (lower triangle, not shaded), predictive effects in a new study and 95% PrI (upper triangle, shaded).
Bold font shows comparisons that indicate a statistically significant difference between interventions.
TABLE 36 Pairwise comparisons, hip fractures main analysis
Placebo ALN RIS ZOL DEN ROMO TPTD RLX ROMO/ALN
Placebo 0.64 (0.39 to 1.04) 0.66 (0.40 to 1.12) 0.63 (0.39 to 1.01) 0.56 (0.28 to 1.04) 0.56 (0.20 to 1.50) 0.34 (0.14 to 0.78) 0.93 (0.29 to 2.82) 0.39 (0.19 to 0.80)
ALN 0.64 (0.45 to 0.88) 1.03 (0.56 to 2.01) 1.00 (0.54 to 1.85) 0.88 (0.38 to 1.94) 0.88 (0.29 to 2.64) 0.54 (0.20 to 1.37) 1.48 (0.44 to 4.81) 0.62 (0.29 to 1.28)
RIS 0.66 (0.46 to 0.99) 1.02 (0.71 to 1.63) 0.97 (0.51 to 1.79) 0.85 (0.36 to 1.84) 0.85 (0.27 to 2.63) 0.52 (0.21 to 1.23) 1.41 (0.42 to 4.71) 0.59 (0.26 to 1.32)
ZOL 0.64 (0.47 to 0.86) 1.00 (0.70 to 1.44) 0.99 (0.62 to 1.38) 0.88 (0.39 to 1.91) 0.88 (0.29 to 2.65) 0.54 (0.20 to 1.34) 1.48 (0.44 to 4.82) 0.62 (0.27 to 1.37)
DEN 0.56 (0.31 to 0.94) 0.88 (0.45 to 1.63) 0.85 (0.43 to 1.57) 0.88 (0.46 to 1.59) 1.00 (0.31 to 3.31) 0.61 (0.21 to 1.77) 1.68 (0.47 to 5.95) 0.70 (0.28 to 1.89)
ROMO 0.56 (0.22 to 1.43) 0.88 (0.33 to 2.41) 0.85 (0.31 to 2.33) 0.88 (0.33 to 2.36) 1.01 (0.33 to 3.04) 0.61 (0.17 to 2.19) 1.65 (0.37 to 7.39) 0.70 (0.21 to 2.41)
TPTD 0.35 (0.15 to 0.73) 0.54 (0.23 to 1.19) 0.52 (0.23 to 1.06) 0.54 (0.23 to 1.18) 0.62 (0.24 to 1.58) 0.61 (0.19 to 1.97) 2.74 (0.68 to 11.24) 1.14 (0.40 to 3.51)
RLX 0.94 (0.31 to 2.67) 1.48 (0.49 to 4.20) 1.42 (0.45 to 4.21) 1.47 (0.48 to 4.27) 1.69 (0.50 to 5.45) 1.64 (0.41 to 6.67) 2.73 (0.73 to 10.19) 0.42 (0.12 to 1.52)
ROMO/ALN 0.39 (0.21 to 0.72) 0.62 (0.36 to 1.03) 0.59 (0.31 to 1.12) 0.61 (0.32 to 1.13) 0.70 (0.32 to 1.62) 0.70 (0.22 to 2.14) 1.14 (0.44 to 3.09) 0.42 (0.13 to 1.39)
Pairwise HR and 95% CrIs (lower triangle, not shaded), predictive effects in a new study and 95% PrI (upper triangle, shaded).
Bold font shows comparisons that indicate a statistically significant difference between interventions.
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TABLE 38 Pairwise comparisons, humerus fractures main analysis
Placebo ALN RIS DEN ROMO TPTD RLX
Placebo 0.46 (0.13 to 1.43) 0.48 (0.20 to 1.13) 0.55 (0.11 to 2.60) 0.10 (0.00 to 3.80) 0.55 (0.19 to 1.59) 2.48 (0.06 to 1215.07)
ALN 0.46 (0.15 to 1.27) 1.03 (0.36 to 3.52) 1.21 (0.24 to 6.59) 0.23 (0.00 to 10.16) 1.22 (0.32 to 4.89) 5.48 (0.16 to 2806.02)
RIS 0.49 (0.23 to 0.96) 1.01 (0.47 to 2.78) 1.13 (0.24 to 5.46) 0.22 (0.00 to 8.19) 1.15 (0.38 to 3.48) 5.27 (0.14 to 2596.20)
DEN 0.55 (0.12 to 2.41) 1.21 (0.26 to 5.68) 1.14 (0.28 to 4.57) 0.19 (0.00 to 9.50) 1.00 (0.18 to 5.72) 4.63 (0.09 to 2621.17)
ROMO 0.10 (0.00 to 3.66) 0.23 (0.00 to 9.49) 0.22 (0.00 to 7.54) 0.19 (0.00 to 8.82) 5.11 (0.16 to 2773.07) 34.06 (0.14 to 132817.46)
TPTD 0.55 (0.21 to 1.41) 1.22 (0.39 to 4.05) 1.15 (0.50 to 2.63) 1.00 (0.20 to 5.02) 5.10 (0.17 to 2692.22) 4.63 (0.11 to 2511.00)
RLX 2.46 (0.06 to 1204.07) 5.43 (0.17 to 2598.02) 5.19 (0.15 to 2496.67) 4.64 (0.10 to 2526.10) 33.91 (0.15 to 126105.00) 4.58 (0.12 to 2345.00)
Pairwise HR and 95% CrIs (lower triangle, not shaded), predictive effects in a new study and 95% PrI (upper triangle, shaded).
Bold font shows comparisons that indicate a statistically significant difference between interventions.
TABLE 37 Pairwise comparisons, wrist fractures main analysis
Placebo ALN RIS IBN monthly DEN ROMO TPTD RLX
Placebo 0.82 (0.28 to 2.12) 0.78 (0.27 to 2.15) 5.34 (0.15 to 2316.92) 1.24 (0.12 to 15.63) 0.12 (0.00 to 1.36) 0.64 (0.21 to 1.84) 1.64 (0.55 to 5.27)
ALN 0.82 (0.42 to 1.43) 0.96 (0.24 to 4.30) 6.77 (0.16 to 3022.57) 1.55 (0.15 to 20.29) 0.14 (0.00 to 2.15) 0.79 (0.18 to 3.59) 2.01 (0.50 to 9.64)
RIS 0.78 (0.41 to 1.46) 0.96 (0.42 to 2.43) 6.89 (0.16 to 3288.50) 1.59 (0.13 to 23.95) 0.15 (0.00 to 2.04) 0.83 (0.21 to 3.19) 2.10 (0.47 to 10.22)
IBN monthly 5.32 (0.17 to 2155.25) 6.60 (0.20 to 2849.07) 6.89 (0.19 to 2995.07) 0.22 (0.00 to 18.93) 0.02 (0.00 to 1.60) 0.12 (0.00 to 5.15) 0.31 (0.00 to 13.60)
DEN 1.25 (0.15 to 14.20) 1.54 (0.20 to 16.36) 1.60 (0.17 to 18.83) 0.23 (0.00 to 15.84) 0.08 (0.00 to 2.91) 0.52 (0.03 to 6.41) 1.31 (0.09 to 17.37)
ROMO 0.12 (0.00 to 1.26) 0.14 (0.00 to 1.72) 0.15 (0.00 to 1.62) 0.02 (0.00 to 1.42) 0.09 (0.00 to 2.37) 5.57 (0.46 to 188.50) 14.49 (0.99 to 574.10)
TPTD 0.64 (0.30 to 1.29) 0.79 (0.32 to 2.08) 0.82 (0.39 to 1.70) 0.12 (0.00 to 4.25) 0.51 (0.04 to 4.92) 5.44 (0.57 to 159.42) 2.55 (0.57 to 12.79)
RLX 1.65 (0.75 to 3.88) 2.02 (0.82 to 5.87) 2.12 (0.79 to 6.12) 0.31 (0.00 to 11.44) 1.32 (0.11 to 13.41) 14.42 (1.17 to 500.04) 2.57 (0.92 to 7.92)
Pairwise HR and 95% CrIs (lower triangle, not shaded), predictive effects in a new study and 95% PrI (upper triangle, shaded).
Bold font shows comparisons that indicate a statistically significant difference between interventions.
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TABLE 39 Pairwise comparisons, femoral neck BMD main analysis
Placebo ALN RIS ZOL IBN daily IBN monthly IBN i.v. DEN ROMO TPTD RLX ROMO/ALN
Placebo 2.48
(0.71 to 4.25)
1.80
(0.01 to 3.58)
3.16
(1.27 to 5.04)
1.84
(–0.30 to 3.85)
2.30
(0.41 to 4.24)
2.38
(0.06 to 4.56)
3.35
(1.51 to 5.16)
4.20
(2.24 to 6.17)
2.58
(0.77 to 4.40)
1.52
(–0.33 to 3.42)
6.09
(3.55 to 8.61)
ALN 2.49
(2.05 to 2.91)
–0.70
(–3.20 to 1.78)
0.68
(–1.91 to 3.19)
–0.65
(–3.37 to 1.98)
–0.19
(–2.74 to 2.37)
–0.12
(–2.97 to 2.66)
0.87
(–1.69 to 3.36)
1.71
(–0.94 to 4.34)
0.10
(–2.41 to 2.57)
–0.97
(–3.49 to 1.60)
3.60
(0.57 to 6.64)
RIS 1.80
(1.22 to 2.37)
–0.69
(–1.29 to –0.09)
1.36
(–1.22 to 3.95)
0.03
(–2.66 to 2.70)
0.51
(–2.03 to 3.10)
0.58
(–2.30 to 3.37)
1.56
(–0.95 to 4.08)
2.40
(–0.25 to 5.10)
0.79
(–1.70 to 3.30)
–0.26
(–2.84 to 2.35)
4.27
(1.25 to 7.38)
ZOL 3.17
(2.38 to 3.95)
0.68
(–0.09 to 1.49)
1.37
(0.41 to 2.28)
–1.32
(–4.14 to 1.41)
–0.86
(–3.48 to 1.85)
–0.77
(–3.72 to 2.08)
0.18
(–2.39 to 2.77)
1.04
(–1.67 to 3.76)
–0.58
(–3.21 to 2.06)
–1.63
(–4.24 to 1.02)
2.92
(–0.15 to 5.99)
IBN daily 1.85
(0.53 to 2.93)
–0.63
(–1.97 to 0.41)
0.05
(–1.24 to 1.15)
–1.31
(–2.86 to –0.06)
0.48
(–2.17 to 3.17)
0.54
(–2.18 to 3.28)
1.52
(–1.20 to 4.27)
2.39
(–0.52 to 5.22)
0.75
(–1.94 to 3.51)
–0.29
(–3.05 to 2.52)
4.25
(1.07 to 7.52)
IBN monthly 2.32
(1.50 to 3.13)
–0.16
(–0.99 to 0.63)
0.51
(–0.33 to 1.41)
–0.83
(–1.95 to 0.15)
0.47
(–0.56 to 1.73)
0.07
(–2.80 to 2.88)
1.04
(–1.55 to 3.64)
1.91
(–0.87 to 4.59)
0.29
(–2.38 to 2.87)
–0.78
(–3.47 to 1.87)
3.78
(0.64 to 6.90)
IBN i.v. 2.39
(0.83 to 3.78)
–0.10
(–1.66 to 1.32)
0.56
(–0.92 to 2.09)
–0.73
(–2.53 to 0.64)
0.52
(–0.69 to 1.92)
0.06
(–1.47 to 1.54)
0.97
(–1.90 to 3.87)
1.82
(–1.16 to 4.85)
0.21
(–2.62 to 3.15)
–0.86
(–3.69 to 2.15)
3.72
(0.33 to 7.10)
DEN 3.36
(2.74 to 3.97)
0.87
(0.24 to 1.49)
1.56
(0.83 to 2.30)
0.19
(–0.70 to 1.09)
1.52
(0.33 to 2.91)
1.04
(0.16 to 1.95)
0.97
(–0.50 to 2.60)
0.85
(–1.79 to 3.53)
–0.78
(–3.31 to 1.80)
–1.82
(–4.36 to 0.80)
2.73
(–0.36 to 5.83)
ROMO 4.20
(3.23 to 5.16)
1.71
(0.67 to 2.75)
2.40
(1.28 to 3.51)
1.03
(–0.22 to 2.28)
2.36
(0.88 to 3.95)
1.88
(0.65 to 3.12)
1.82
(0.10 to 3.65)
0.84
(–0.30 to 1.96)
–1.63
(–4.27 to 1.00)
–2.66
(–5.40 to 0.03)
1.88
(–1.33 to 5.12)
TPTD 2.58
(2.00 to 3.17)
0.09
(–0.56 to 0.75)
0.78
(0.02 to 1.54)
–0.59
(–1.52 to 0.35)
0.73
(–0.47 to 2.14)
0.25
(–0.68 to 1.22)
0.19
(–1.30 to 1.85)
–0.78
(–1.57 to 0.01)
–1.62
(–2.63 to –0.60)
–1.04
(–3.65 to 1.56)
3.51
(0.41 to 6.59)
RLX 1.53
(0.78 to 2.31)
–0.95
(–1.74 to –0.14)
–0.26
(–1.19 to 0.66)
–1.63
(–2.70 to –0.56)
–0.30
(–1.64 to 1.17)
–0.79
(–1.86 to 0.31)
–0.85
(–2.42 to 0.87)
–1.82
(–2.77 to –0.86)
–2.66
(–3.89 to –1.42)
–1.04
(–1.98 to –0.09)
4.55
(1.42 to 7.67)
ROMO/ALN 6.08
(4.25 to 7.91)
3.59
(1.81 to 5.37)
4.29
(2.40 to 6.14)
2.92
(0.93 to 4.86)
4.26
(2.14 to 6.42)
3.76
(1.79 to 5.73)
3.70
(1.41 to 6.03)
2.72
(0.83 to 4.61)
1.89
(–0.22 to 3.98)
3.50
(1.57 to 5.41)
4.55
(2.57 to 6.50)
Pairwise HR and 95% CrIs (lower triangle, not shaded), predictive effects in a new study and 95% PrI (upper triangle, shaded).
Bold font shows comparisons that indicate a statistically significant difference between interventions.
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Appendix 13 Assessment of inconsistency
Vertebral fractures
Twelve treatment contrasts have both direct and indirect evidence; however, only 10 of these were
assessed for consistency. RIS–ALN was not assessed because the direct comparison is contributed by
one small study79 with a zero count in the control arm. ZOL–TPTD was not assessed because the direct
comparison is contributed by one small study,93 with only one event in the TPTD arm. Multiple testing
should be taken into account when considering p-values.
Comparing the DIC for the different node-splits with that of the full consistency NMA model, only the
placebo–ZOL comparison provides a lower DIC when the node is split. However, the difference is small
(–0.7); therefore, there is not a clear advantage of one model over the other. The HRs from both the
direct and indirect evidence favour ZOL and the combined estimate is more heavily influenced by the
direct studies. It was concluded that there is no strong evidence for inconsistency in the network.
Non-vertebral fractures
Fourteen treatment contrasts have both direct and indirect evidence; however, only 13 of these were
assessed for consistency. RIS–ALN was not assessed because the direct comparison is contributed by
one small study79 with a zero count in the RIS arm. Multiple testing should be taken into account when
considering p-values.
Comparing the DIC for the different node-splits with that of the full consistency NMA model, only the
placebo–ALN comparison provides a lower DIC when the node is split. However, the difference is
small; therefore, there is not a clear advantage of one model over the other, and the p-values are large
for all comparisons. It was concluded that there is no strong evidence for inconsistency in the network.
Hip fractures
Fourteen treatment contrasts have both direct and indirect evidence; however, only nine of these were
assessed for consistency. For five of these (RIS–ALN, RIS–DEN, RIS–RLX, ZOL–DEN, ROMO–TPTD),
the direct comparison is contributed by small studies.67,79,341 Multiple testing should be taken into
account when considering p-values.
Comparing the DIC for the different node-splits with that of the full consistency NMA model, for all
comparisons there is a higher DIC (indicating a less favourable model) when the node is split and the
p-values are large. It was concluded that there is no strong evidence for inconsistency in the network.
Wrist
Eight treatment contrasts have both direct and indirect evidence; however, only five of these were
assessed for consistency. For three of these (RIS–ALN, ALN–RLX, RIS–RLX), the direct comparison is
contributed by small studies.77,79 Multiple testing should be taken into account when considering p-values.
Comparing the DIC for the different node-splits with that of the full consistency NMA model, for all
comparisons there is a higher DIC (indicating a less favourable model) when the node is split and the
p-values are large. It was concluded that there is no strong evidence for inconsistency in the network.
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TABLE 40 Assessment of inconsistency between direct and indirect evidence for vertebral fractures, assessed through node-splitting in the NMA
Treatment 1 Treatment 2
Heterogeneity Model fit HRs (95% CrI)
p-valuedSDa (95% CrI) SDtb (95% CrI) Dres
c DIC All evidence Direct Indirect
Placebo ALN 0.14 (0.01 to 0.34) 0.42 (0.05 to 1.48) 90.4 152.7 0.50 (0.40 to 0.64) 0.46 (0.36 to 0.62) 0.76 (0.43 to 1.68) 0.18
Placebo RIS 0.16 (0.01 to 0.37) 0.19 (0.01 to 0.86) 92.31 155 0.52 (0.41 to 0.65) 0.57 (0.42 to 0.74) 0.45 (0.32 to 0.65) 0.31
Placebo ZOL 0.12 (0.01 to 0.31) 0.13 (0.00 to 0.92) 91.29 151.6 0.40 (0.29 to 0.55) 0.33 (0.25 to 0.45) 0.56 (0.38 to 1.25) 0.03
Placebo TPTD 0.17 (0.02 to 0.37) 0.19 (0.01 to 0.89) 90.18 153.33 0.23 (0.16 to 0.32) 0.30 (0.19 to 0.49) 0.18 (0.11 to 0.28) 0.12
RIS ZOL 0.16 (0.01 to 0.35) 0.23 (0.02 to 0.97) 92.07 155.02 0.78 (0.52 to 1.08) 1.78 (0.40 to 9.98) 0.73 (0.49 to 1.05) 0.26
RIS DEN 0.18 (0.01 to 0.38) 0.21 (0.01 to 0.91) 91.95 155.44 0.59 (0.39 to 0.88) 0.67 (0.26 to 1.65) 0.56 (0.35 to 0.90) 0.72
RIS TPTD 0.18 (0.02 to 0.39) 0.20 (0.01 to 0.90) 91.82 155.24 0.44 (0.32 to 0.61) 0.44 (0.27 to 0.68) 0.45 (0.27 to 0.72) 0.94
Placebo RLX 0.16 (0.01 to 0.36) 0.20 (0.01 to 0.90) 91.58 154.34 0.61 (0.44 to 0.80) 0.64 (0.47 to 0.85) 0.30 (0.09 to 0.90) 0.19
Placebo DEN 0.18 (0.02 to 0.38) 0.21 (0.01 to 0.90) 91.97 155.54 0.30 (0.21 to 0.43) 0.29 (0.19 to 0.43) 0.35 (0.14 to 0.90) 0.72
ALN TPTD 0.15 (0.01 to 0.35) 0.22 (0.02 to 0.92) 90.5 153.26 0.46 (0.31 to 0.66) 0.18 (0.04 to 0.51) 0.53 (0.35 to 0.77) 0.06
Consistency model
0.17 (0.02 to 0.37) 0.20 (0.01 to 0.91) 91.24 152.34
a Between-study SD.
b Between-bisphosphonate treatment SD.
c Total residual deviance.
d Bayesian p-value.
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TABLE 41 Assessment of inconsistency between direct and indirect evidence for non-vertebral fractures, assessed through node-splitting in the NMA
Treatment 1 Treatment 2
Heterogeneity Model fit HRs (95% CrI)
p-valuedSDa (95% CrI) SDtb (95% CrI) Dres
c DIC All evidence Direct Indirect
Placebo RLX 0.88 (0.62 to 1.19) 1.14 (0.39 to 3.23) 74.61 129.85 0.90 (0.65 to 1.21) 0.88 (0.62 to 1.19) 1.14 (0.39 to 3.23) 0.65
Placebo ALN 0.81 (0.65 to 0.95) 0.66 (0.39 to 0.91) 73.06 127.94 0.77 (0.64 to 0.90) 0.81 (0.65 to 0.95) 0.66 (0.39 to 0.91) 0.31
Placebo RIS 0.65 (0.48 to 0.86) 0.80 (0.59 to 1.12) 73.8 128.78 0.73 (0.59 to 0.88) 0.65 (0.48 to 0.86) 0.80 (0.59 to 1.12) 0.28
Placebo ZOL 0.71 (0.57 to 0.86) 0.78 (0.42 to 1.33) 74.3 129.46 0.73 (0.61 to 0.85) 0.71 (0.57 to 0.86) 0.78 (0.42 to 1.33) 0.65
Placebo DEN 0.82 (0.65 to 1.05) 1.34 (0.69 to 2.61) 73.41 128.2 0.86 (0.69 to 1.12) 0.82 (0.65 to 1.05) 1.34 (0.69 to 2.61) 0.19
Placebo ROMO 0.75 (0.49 to 1.14) 0.50 (0.16 to 1.46) 74.45 129.95 0.71 (0.48 to 1.03) 0.75 (0.49 to 1.14) 0.50 (0.16 to 1.46) 0.49
Placebo TPTD 0.60 (0.39 to 0.89) 0.57 (0.40 to 0.80) 74.6 129.91 0.58 (0.45 to 0.76) 0.60 (0.39 to 0.89) 0.57 (0.40 to 0.80) 0.88
ALN TPTD 1.06 (0.52 to 2.23) 0.71 (0.52 to 0.96) 73.84 128.86 0.76 (0.57 to 1.02) 1.06 (0.52 to 2.23) 0.71 (0.52 to 0.96) 0.3
RIS DEN 1.75 (0.78 to 4.16) 1.12 (0.85 to 1.57) 74.15 129.18 1.18 (0.90 to 1.63) 1.75 (0.78 to 4.16) 1.12 (0.85 to 1.57) 0.33
RIS TPTD 0.69 (0.47 to 0.99) 0.97 (0.66 to 1.46) 72.89 128.22 0.80 (0.61 to 1.04) 0.69 (0.47 to 0.99) 0.97 (0.66 to 1.46) 0.22
ZOL TPTD 0.85 (0.29 to 2.51) 0.79 (0.58 to 1.07) 74.84 130.26 0.80 (0.60 to 1.08) 0.85 (0.29 to 2.51) 0.79 (0.58 to 1.07) 0.89
ROMO TPTD 1.15 (0.37 to 3.53) 0.77 (0.46 to 1.24) 74.43 129.92 0.82 (0.53 to 1.28) 1.15 (0.37 to 3.53) 0.77 (0.46 to 1.24) 0.49
ALN DEN 0.07 (0.00 to 0.23) 0.16 (0.01 to 0.74) 74.49 129.77 1.12 (0.87 to 1.57) 1.83 (0.58 to 6.33) 1.09 (0.84 to 1.52) 0.39
Consistency model
0.08 (0 to 0.24) 0.15 (0.01 to 0.73) 74.047 128.4
a Between-study SD.
b Between-bisphosphonate treatment SD.
c Total residual deviance.
d Bayesian p-value.
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TABLE 42 Assessment of inconsistency between direct and indirect evidence for hip fractures, assessed through node-splitting in the NMA
Treatment 1 Treatment 2
Heterogeneity Model Fit HRs (95% CrI)
p-valuedSDa (95% CrI) SDtb (95% CrI) Dres
c DIC All evidence Direct Indirect
Placebo ALN 0.16 (0.01 to 0.63) 0.38 (0.02 to 1.77) 39.72 73.1 0.64 (0.41 to 0.94) 0.62 (0.35 to 1.07) 0.62 (0.16 to 1.92) 0.98
Placebo RIS 0.15 (0.00 to 0.61) 0.32 (0.01 to 1.70) 39.32 72.68 0.67 (0.43 to 1.10) 0.80 (0.40 to 1.58) 0.57 (0.19 to 1.22) 0.45
Placebo ZOL 0.16 (0.01 to 0.63) 0.43 (0.02 to 1.81) 39.58 72.92 0.64 (0.44 to 0.92) 0.62 (0.39 to 1.02) 0.72 (0.20 to 4.39) 0.76
Placebo DEN 0.15 (0.01 to 0.59) 0.24 (0.01 to 1.59) 39.76 73.08 0.56 (0.29 to 0.99) 0.57 (0.28 to 1.05) 0.41 (0.04 to 2.75) 0.73
Placebo ROMO 0.14 (0.01 to 0.58) 0.23 (0.01 to 1.60) 40.01 73.68 0.56 (0.20 to 1.48) 0.52 (0.17 to 1.48) 1.97 (0.05 to 642.60) 0.49
Placebo TPTD 0.15 (0.01 to 0.59) 0.25 (0.01 to 1.60) 39.75 73.33 0.34 (0.15 to 0.77) 0.19 (0.02 to 1.03) 0.39 (0.14 to 0.98) 0.49
Placebo RLX 0.14 (0.01 to 0.58) 0.23 (0.01 to 1.57) 39.91 73.18 0.94 (0.31 to 2.85) 0.83 (0.22 to 3.08) 1.10 (0.10 to 7.81) 0.84
ALN RLX 0.15 (0.01 to 0.58) 0.23 (0.01 to 1.57) 40.03 73.46 1.49 (0.47 to 4.66) 1.73 (0.16 to 11.56) 1.31 (0.31 to 5.34) 0.83
RIS TPTD 0.15 (0.01 to 0.58) 0.25 (0.01 to 1.58) 39.42 72.97 0.51 (0.23 to 1.07) 0.59 (0.24 to 1.41) 0.27 (0.04 to 1.33) 0.42
Consistency model
0.14 (0.01 to 0.56) 0.23 (0.01 to 1.54) 39.0876 71.572
a Between-study SD.
b Between-bisphosphonate treatment SD.
c Total residual deviance.
d Bayesian p-value.
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TABLE 43 Assessment of inconsistency between direct and indirect evidence for wrist fractures, assessed through node-splitting in the NMA
Treatment 1 Treatment 2
Heterogeneity Model Fit HR’s (95% CrI)
p-valuedSDa (95% CrI) SDtb (95% CrI) Dres
c DIC All evidence Direct Indirect
Placebo ALN 0.34 (0.06 to 0.71) 0.20 (0.01 to 0.69) 30.48 55.35 0.83 (0.51 to 1.30) 0.85 (0.43 to 1.52) 0.77 (0.29 to 1.86) 0.85
Placebo RIS 0.31 (0.04 to 0.68) 0.20 (0.01 to 0.68) 30.44 55.17 0.82 (0.50 to 1.30) 0.79 (0.32 to 1.79) 0.99 (0.49 to 2.24) 0.40
Placebo TPTD 0.31 (0.04 to 0.68) 0.17 (0.01 to 0.62) 30.80 55.57 0.66 (0.33 to 1.26) 0.79 (0.32 to 1.79) 0.47 (0.15 to 1.43) 0.45
Placebo RLX 0.32 (0.05 to 0.68) 0.17 (0.01 to 0.61) 31.21 56.44 1.65 (0.78 to 3.65) 1.59 (0.70 to 3.75) 2.29 (0.18 to 24.15) 0.79
RIS TPTD 0.31 (0.04 to 0.67) 0.17 (0.01 to 0.62) 30.83 55.65 0.81 (0.40 to 1.58) 0.62 (0.24 to 1.65) 1.05 (0.37 to 2.68) 0.45
Consistency model
0.32 (0.04 to 0.67) 0.17 (0.01 to 0.62) 30.38 54.64
a Between-study SD.
b Between-bisphosphonate treatment SD.
c Total residual deviance.
d Bayesian p-value.
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Humerus
Five treatment contrasts have both direct and indirect evidence; however, only four of these were
assessed for consistency. For the placebo–DEN comparison, the direct comparison is contributed by
one small study42 with zero events in the DEN arm. Multiple testing should be taken into account when
considering p-values.
Comparing the DIC for the different node-splits with that of the full consistency NMA model, for all
comparisons there is a higher DIC (indicating a less favourable model) when the node is split and the
p-values are large. It was concluded that there is no strong evidence for inconsistency in the network.
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TABLE 44 Assessment of inconsistency between direct and indirect evidence for proximal humerus fractures, assessed through node-splitting in the NMA
Treatment 1 Treatment 2
Heterogeneity Model fit HRs (95% CrI)
p-valuedSDa (95% CrI) SDtb (95% CrI) Dres
c DIC All evidence Direct Indirect
Placebo RIS 0.18 (0.01 to 0.59) 0.21 (0.01 to 0.71) 22.98 43.98 0.48 (0.24 to 0.96) 0.45 (0.19 to 0.98) 0.63 (0.12 to 3.00) 0.71
Placebo TPTD 0.17 (0.01 to 0.60) 0.21 (0.01 to 0.72) 22.86 43.99 0.55 (0.21 to 1.41) 0.77 (0.17 to 3.30) 0.42 (0.11 to 1.47) 0.53
RIS DEN 0.17 (0.01 to 0.58) 0.22 (0.01 to 0.72) 23.05 43.93 1.14 (0.28 to 4.57) 0.97 (0.15 to 5.91) 1.40 (0.13 to 14.31) 0.8
RIS TPTD 0.17 (0.01 to 0.59) 0.21 (0.01 to 0.72) 22.61 43.46 1.15 (0.50 to 2.63) 1.00 (0.38 to 2.65) 1.80 (0.33 to 9.58) 0.54
Consistency model
0.17 (0.01 to 0.57) 0.21 (0.01 to 0.7) 21.9908 41.832
a Between-study SD.
b Between-bisphosphonate treatment SD.
c Total residual deviance.
d Bayesian p-value.
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Appendix 14 Network meta-analysis
results of meta-regressions
A summary of meta-regression models (covariate estimate, model fit, heterogeneity) is provided inTable 45 for all outcomes.
Note that, for age and sex, a common meta-regression coefficient is assumed for all treatments
(see Dias et al.121 for further details). Alternative models were also considered, but did not improve
model fit.
For meta-regressions on baseline response, the results for all outcomes assume a common meta-
regression coefficient for all treatments (as for age and sex), and the baselines of each study were
assumed to follow a normal distribution with common mean and between-treatment variance (see
Achana et al.122 for further details). Alternative models were also considered, but did not improve
model fit. Results are provided in Table 45.
Meta-regression on baseline risk, model selection
For the vertebral fractures network, four different baseline risk models were considered, allowing
different assumptions about the model for baseline risk and covariate treatment interaction:
l A1: unconstrained baseline and common slope
l A2: normal distribution for baseline risk and common slope
l B1: unconstrained baseline and common slope
l B2: normal distribution for baseline risk and common slope.
Alternative models were considered for vertebral fractures only (which provide the largest network
of evidence). Models with an unconstrained baseline (A1, B1) had a high DIC. Model A2, with normal
distribution for baseline risk and assumption of common slope parameter for treatment–covariate
interaction, was chosen for the main meta-regression model because this provided the lowest DIC.
The results of using this model are provided in Table 45 for all outcomes.
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TABLE 45 Results of meta-analysis on sex, age and baseline response for all outcomes
Outcome/model
Absolute model fit
DIC
Heterogeneity, SD (95% CI)
Covariate estimate
(95% CI)
Baseline parameters
Dres
a
Data
points SDb SDtc Covariate SD
Vertebral
Age 92.15 93 155.19 0.176 (0.018 to 0.378) 0.191 (0.011 to 0.882) –0.028 (–0.227 to 0.192) NA NA
Sex 91.31 93 154.81 0.185 (0.03 to 0.379) 0.2 (0.01 to 0.939) 0.06 (–0.117 to 0.263) NA NA
Baseline response 88.57 93 147.16 0.18 (0.02 to 0.37) 0.17 (0.01 to 0.8) 0.13 (–0.04 to 0.3) –3.1 (–3.41 to –2.8) 0.96 (0.76 to 1.23)
Non-vertebral
Age 74.62 86 130.01 0.08 (0.003 to 0.244) 0.166 (0.009 to 0.768) 0.014 (–0.16 to 0.207)
Sex 74.75 86 129.92 0.077 (0.004 to 0.236) 0.14 (0.006 to 0.694) 0.062 (–0.132 to 0.256)
Baseline response M2 73.44 86 119.99 0.1 (0.01 to 0.28) 0.15 (0.01 to 0.76) 0.05 (–0.16 to 0.32) –3.41 (–3.61 to –3.22) 0.53 (0.39 to 0.73)
Hip
Age 39.83 47 72.83 0.12 (0.007 to 0.434) 0.266 (0.011 to 1.594) –0.103 (–0.782 to 0.538) NA NA
Sex 39.55 47 72.39 0.135 (0.006 to 0.47) 0.248 (0.01 to 1.6) –0.118 (–1.048 to 0.845) NA NA
Baseline response M2 39.14 47 67.24 0.13 (0.01 to 0.47) 0.29 (0.01 to 1.66) 0.08 (–0.37 to 0.74) –5.21 (–5.62 to –4.77) 0.77 (0.48 to 1.29)
Wrist
Age 30.91 31 55.58 0.24 (0.01 to 0.63) 0.47 (0.02 to 1.85) –0.67 (–1.58 to 0.16) NA NA
Baseline response M2 28.82 31 49.16 0.34 (0.03 to 0.70) 0.46 (0.02 to 1.82) 0.35 (–1.56 to 3.18)
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Outcome/model
Absolute model fit
DIC
Heterogeneity, SD (95% CI)
Covariate estimate
(95% CI)
Baseline parameters
Dres
a
Data
points SDb SDtc Covariate SD
Humerus
Age 23.92 26 46.12 0.179 (0.008 to 0.619) 0.998 (0.049 to 1.953) 0.273 (–2.788 to 3.6) NA NA
Sex 24.01 26 46.38 0.171 (0.008 to 0.582) 0.988 (0.052 to 1.951) 0.412 (–1.351 to 3.199) NA NA
Baseline response 22.17 26 38.53 0.18 (0.01 to 0.59) 1 (0.05 to 1.95) –0.26 (–1.36 to 3.04) –5.15 (–6.03 to –3.73) 0.72 (0.13 to 3.09)
Femoral neck BMD
Age 144.5 137 259.24 0.86 (0.65 to 1.14) 0.76 (0.25 to 2.28) –0.01 (–0.07 to 0.05) NA NA
Sex 145.7 137 258.73 0.80 (0.59 to 1.08) 0.77 (0.28 to 2.34) 0.01 (0 to 0.02) NA NA
Baseline response NA 137 NA 0.81 (0.61 to 1.08) 0.67 (0.24 to 1.65) 0.16 (–0.32 to 0.81) –0.31 (–0.57 to –0.04) 1.92 (0.91 to 4.18)
NA, not applicable.
a Total residual deviance.
b Between-study SD.
c Between-bisphosphonate treatment SD.
TABLE 46 Meta-regression on baseline risk, comparison of alternative models, vertebral fractures
Model
Absolute model fit
DIC
Heterogeneity, SD (95% CI) Covariate treatment interaction Baseline parameters
Dres
a
Data
points SDb SDtc Estimate (95% CrI) SD (95% CrI) Covariate (95% CrI) SD covariate (95% CrI)
A1 89.91 93 171.57 1.06 (0.06 to 1.4) 0.31 (0.01 to 1.47) –1 (–1.01 to 0.09) NA NA NA
A2 88.57 93 147.16 0.18 (0.02 to 0.37) 0.17 (0.01 to 0.8) 0.13 (–0.04 to 0.3) NA –3.1 (–3.41 to –2.8) 0.96 (0.76 to 1.23)
B1 92.85 93 157.38 0.16 (0.02 to 0.39) 0.2 (0.01 to 1.11) 0.03 (–0.16 to 0.22) 0.13 (0.01 to 0.6) NA NA
B2 89.48 93 148.39 0.17 (0.02 to 0.37) 0.18 (0.01 to 0.94) 0.14 (–0.03 to 0.33) 0.09 (0.01 to 0.47) –3.11 (–3.41 to –2.81) 0.96 (0.77 to 1.24)
NA, not applicable.
a Total residual deviance.
b Between-study SD.
c Between-bisphosphonate treatment SD.
Results in bold indicate the model with the lowest DIC.
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Appendix 15 Studies excluded, at full-text
sift, from the review of published
economic evaluations
Citation Reason for exclusion
Alexander W, Strom O, Macarios D. American Society for Bone and Mineral Research:
DEN (Prolia): a cost-effectiveness model. P T 2009;34:633
Abstract only
Davies A, Compston J, Ferguson S, McClosky E, Shearer A, Taylor A. Cost-effectiveness
of DEN in the treatment of postmenopausal osteoporosis in Scotland. Value Health
2011;14:A310
Abstract only
Hagen G. Comparative Effectiveness and Cost-Effectiveness of Generic ALN, RIS, DEN
and zolendronic acid for secondary prevention of fragility fractures – perliminay
results. Value Health 2015;18:A648
Abstract only
Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM. The cost-effectiveness of
therapy with TPTD and ALN in women with severe osteoporosis. Arch Intern Med
2006;166:1209–17
Non-UK
Meadows ES, Klein R, Rousculp MD, Smolen L, Ohsfeldt RL, Johnston JA.
Cost-effectiveness of preventative therapies for postmenopausal women with
osteopenia. BMC Womens Health 2007;7:6
Non-UK
Mobley LR, Hoerger TJ, Wittenborn JS, Galuska DA, Rao JK. Cost-effectiveness of
osteoporosis screening and treatment with hormone replacement therapy, RLX, or
ALN. Med Decis Making 2006;26:194–206
Non-UK
Murphy DR, Klein RW, Smolen LJ, Klein TM, Roberts SD. Using common random
numbers in health care cost-effectiveness simulation modelling. Health Serv Res
2013;48:1508–25
Non-UK
O’Hanlon CE, Parthan A, Kruse M, Cartier S, Stollenwerk B, Jiang Y, et al. A Model for
assessing the clinical and economic benefits of bone-forming agents for reducing
fractures in postmenopausal women at high, near-term risk of osteoporotic fracture.
Clin Ther 2017;39:1276–90
Non-UK
Pfister AK, Welch CA, Lester MD, Emmett MK, Saville PD, Duerring SA.
Cost-effectiveness strategies to treat osteoporosis in elderly women.
South Med J 2006;99:123–31
Non-UK
Turner DA, Khioe RFS, Shepstone L, Lenaghan E, Cooper C, Gittoes N, et al.
The cost-effectiveness of screening in the community to reduce osteoporotic fractures
in older women in the UK: economic evaluation of the SCOOP study. J Bone Miner Res
2018;33:845–51
Not a relevant comparison –
compares screening with
usual care with treatment
after screening directed by
clinician
Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B. Cost-effectiveness of the
treatment and prevention of osteoporosis – a review of the literature and a reference
model. Osteoporos Int 2007;18:9–23
Non-UK
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Appendix 16 Health-related quality of life:
review of utility values following fracture
To inform the model, data were needed on the proportionate decrease in HRQoL that occurs in theyear following fracture and in subsequent years. This was then used to calculate a utility multiplier,
which was applied to the pre-fracture utility value to calculate the post-fracture utility. For example, a
proportionate decrease of 10% would translate into a utility multiplier of 0.9. If a patient’s prior fracture
utility is 0.8, then the post-fracture utility would be 0.72. Data on the absolute HRQoL after fracture can
be obtained from studies that measure HRQoL of patients who have experienced a recent fracture.
However, the proportionate decrease can be obtained only if there is some estimate of pre-fracture
utility. Ideally, HRQoL would be measured prospectively in a cohort of patients at risk of fracture and
these patients would be followed up with HRQoL re-measured at regular intervals with the time of any
incident fracture being recorded so that the correlation between HRQoL and incident fracture can be
obtained after adjusting for other confounding factors. However, many studies simply recruit patients
at the time of fracture and ask them to recall their pre-fracture health state, which is subject to recall
bias. Other studies may compare the HRQoL of individuals who have fractured with that of matched
controls or population norms, in which case the estimates may be confounded by differences in other
factors between cases and controls.
Our intention was to conduct a rapid update of the systematic review of HRQoL data conducted
for TA464.34 Systematic searches were undertaken to identify studies reporting on health utilities
associated with different states for osteoporosis published since 2014. Searches were undertaken in
July 2018 in the following electronic databases:
l MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations: Ovid, 1946–2018.
l EMBASE: Ovid, 1974–2018.
In line with the NICE reference case,139 and the approach taken previously for TA464, the searches
focused specifically on studies that reported HRQoL estimates for health states that were measured
and valued using the EQ-5D. The search strategy comprised sensitive Medical Subject Headings
(MeSH) or Emtree Thesauri terms and free-text synonyms for ‘osteoporosis’ combined with free-text
synonyms for ‘EQ-5D’. The search strategies are presented in Appendix 1.
This search retrieved 111 unique references. The results of the economic searches described above were
combined with the results of the searches conducted for the review of published cost-effectieness
studies (see Chapter 4, Systematic review of existing cost-effectiveness evidence, Methods), to give a total of
3853 unique references, and a combined sift was conducted to pick up any cross-relevant papers. This
initial sift of paper titles by a first reviewer reduced the number thought to be relevant to the HRQoL
review to 131. A further sift of the abstracts by a second reviewer identified 53 citations that could
be excluded (48 conference proceedings, three non-English papers and two commentaries), leaving
81 studies reporting health utility in patients with an incident osteoporotic fracture. However, values
measured during RCTs were excluded because of the possibility that the study interventions may affect
HRQoL independently of their impact on fracture. Studies reporting the quality-of-life impact of prevalent
fractures were also excluded on the basis that there is no way of knowing how long ago the prevalent
fracture was sustained. Furthermore, studies reporting the HRQoL associated with osteoporotic fractures
using instruments other than the EQ-5D, such as the Health Utilities Index or Short Form questionnaire-6
Dimensions, were excluded. A further study342 that fulfilled these inclusion criteria was excluded because
resulting EQ-5D utilities at specific time points following fracture were presented only graphically, rather
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than numerically, which means that accurate estimates of the utility values were impossible. This left four
studies. A PRISMA flow diagram representing this process is presented in Figure 15.
These four remaining studies209,210,212,213 are summarised in Table 47. All four studies reported outcomes
from ICUROS. As this study had been previously identified in the review conducted for TA464,34 no
new quality appraisal of this study was required. However, the four new papers identified reported
additional data. All four provided HRQoL data for hip fracture, three provided it for wrist (distal
forearm) fracture,209,210,213 three for vertebral fracture209,210,213 and one for fracture of the proximal
humerus (shoulder).210 One study also reported HRQoL for fracture of the ankle and other fracture.210
All four studies were based on ICUROS: two of the papers presented values for individual countries
in the ICUROS cohort (Australia210 and Estonia212) and two presented values for groups of ICUROS
counties.209,213 One of these papers presented HRQoL utility values for patients in 10 ICUROS
countries (Austria, Australia, Estonia, France, Italy, Lithuania, Mexico, Russia, Spain and the UK) who
sustained a hip, vertebral and wrist fracture.213 Utility was measured pre fracture (recall), post fracture
(within 2 weeks of the fracture being sustained), 4 months post fracture, 12 months post fracture and
18 months post fracture. However, only data from patients who completed all instruments (not just the
EQ-5D) at all time points are included. The second paper presents HRQoL utility values for patients in
11 ICUROS countries (Austria, Australia, Estonia, France, Italy, Lithuania, Mexico, Russia, Spain, the UK
and the USA) who sustained a hip, vertebral and wrist fracture.209 Utility was measured pre fracture
Systematic literature search
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Citations screened at
abstract stage
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abstract stage
(n = 53)
Full-text articles excluded
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FIGURE 15 The PRISMA flow diagram for study selection for the review of HRQoL.
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TABLE 47 Summary of included papers reporting EQ-5D quality-of-life measures associated with osteoporotic fracture
First author
and year of
publication Country Study design Cohort description
Sample size at baseline and
% of missing data
Valuation set
used for EQ-5D
Svedbom 2018213 Multicentre
(10 countries)
Prospective
observational
cohort study
l ICUROS included patients aged
≥ 50 years living in their own home
prior to fracture who sustained a
low-energy fracture
l Initial post-fracture assessment of
HRQoL taking place within 2 weeks
of fracture
l Hip fracture, n = 505
l Vertebral fracture, n= 316
l Distal forearm fracture, n = 589
l (Patients lost to follow-up were
excluded from analyses)
UK (TTO)
Svedbom 2018209 Multicentre
(11 countries)
Prospective
observational
cohort study
l Hip fracture, n = 1415
l Vertebral fracture, n= 559
l Distal forearm fracture, n = 1047
l (Patients lost to follow-up were
excluded from analyses)
UK (TTO)
Abimanyi-Ochom 2015210 Australia Prospective
observational
cohort study
l All fractures, n= 915 (41%)a
l Hip fracture, n = 224 (49%)a
l Distal forearm fracture, n = 308 (24%)a
l Vertebral fracture, n= 92 (45%)a
l Humerus fracture, n = 65 (48%)a
l Ankle fracture, n = 89 (48%)a
l Other fracture, n= 137 (53%)a
UK (TTO)
Jurisson 2016212 Estonia Prospective
observational
cohort study
Hip fracture, n = 205 (18%) UK (TTO)
TTO, time trade-off.
a Percentage of baseline cohort lost by 18 months.
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(recall), post fracture (within 2 weeks of the fracture being sustained), 4 months post fracture,
12 months post fracture and 18 months post fracture. However, in this analysis, data were included
from patients who completed the EQ-5D instrument at all time points. Thus, the HRQoL utility values
in the latter of these two studies209 was based on significantly more data (1415 patients for hip
fracture, 559 patients for vertebral fracture and 1047 patients for distal forearm (wrist) fracture,
compared with 505 patients for hip fracture, 316 patients for vertebral fracture and 589 for distal
forearm (wrist) fracture). As a result, the latter of these two studies209 was chosen to provide HRQoL
values for hip, vertebral and wrist fracture in the model.
Health-related quality-of-life values associated with proximal humerus fracture were still required by
the model, and the only study to provide such values was the study concerned with the Australian
ICUROS cohort210 in which the UK value set was used to convert the dimension scores into a utility
value. In this study, 65 patients provided HRQoL values at baseline (pre fracture and immediately
post fracture), 57 patients provided them at 4 months, 54 patients at 12 months and 34 patients at
18 months. Only 52% of baseline patients survived to 18 months and only 63% of the patients who
survived to 12 months survived to 18 months.
Values from four papers209,210,212,213 all came from one study (ICUROS), which included patients aged at
least 50 years living in their own home prior to fracture who sustained a low-energy fracture. Initial post-
fracture assessment of HRQoL took place within 2 weeks of fracture. Patients who sustained another
fracture in the follow-up period were excluded as were people who were lost to follow-up. However,
although two of the papers209,213 ensured that data relating to patients excluded at some later point in the
study were removed from summary HRQoL utility data at all time points, the remaining two papers 210,212
did not and used all available data at each time point.
The two multicentre papers reported broadly similar values at all time points, except for those recorded
at 2 weeks following fracture: those reported in the paper with the larger data set209 were lower than
those reported in the paper that excluded more patients for incomplete data213 (hip fracture: –0.11,
vertebral fracture: 0.17 and wrist fracture: 0.41, compared with hip fracture: –0.02, vertebral fracture:
0.27 and wrist fracture: 0.47). The study using Australian data but with a UK tariff210 reported values
that were, again, higher at 2 weeks following fracture (hip fracture: 0.11, vertebral fracture: 0.32 and
wrist fracture: 0.53); these higher values were also reflected at 4 months and 12 months, although by a
lessening degree, until the increase had become negligible by 18 months. The Estonian study, which again
used the UK tariff,212 also reported higher values at 2 weeks following fracture (0.07). This may raise
concerns about the values used in the model, even though they are based on a significantly larger sample
size. However, the excluded paper,342 which presented utility values in a graphical rather than a numerical
format, suggests similar values to the international ICUROS data set209 for a UK population, with the
HRQoL utility value at 2 weeks post fracture being approximately –0.15.
For hip, vertebral and wrist fractures, the utility multipliers for 0–12 months, 12–24 months and
> 24 months are presented by Svedbom et al.,209 together with 95% confidence intervals, enabling
SD to be calculated. However, we assume that improvements in utility in the period between 12 and
24 months post fracture are subject to significant uncertainty; thus, we apply the utility values presented
for the period > 24 months post fracture in the paper for any period beyond 12 months post fracture in
the model. For proximal humerus fracture, we assume that the utility drops at the point of fracture to
the value measured in the first 2 weeks post fracture and remains at this value for the first 2 weeks by
a gradual linear improvement to 4 months, 12 months and, finally, 18 months. We assume that utility at
18 months is maintained indefinitely. The utility multiplier for the first year post fracture was calculated by
dividing the total utility accrued by 12 months by the pre-fracture utility value. The utility value observed
at 12 months is assumed to persist in the long term, so the multiplier for the second and subsequent
years was calculated by dividing the total utility accrued between month 13 and month 24 again by the
pre-fracture utility value. These data are presented in Table 48 and graphically in Figures 16–19.
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TABLE 48 Utility values after fracture used in the TA464 Health Technology Assessment report34 and in the new review
Description
Hip fracture Vertebral fracture Humerus fracture Distal forearm fracture
TA46434 ICUROS209 TA46434 ICUROS209 TA46434 ICUROS210 TA46434 ICUROS209
Baseline
number of
patients
282 1415 76 559 38 65 325 1047
Utility index
Pre fracture 0.81 0.77 0.74 0.83 0.65 0.81 0.90 0.89
Post fracture 0.19 –0.11 0.18 0.17 0.36 0.21 0.56 0.41
4 months 0.64 0.49 0.49 0.60 0.58 0.70 0.83 0.77
12 months 0.69 0.59 0.49 0.70 0.65 0.77 0.88 0.85
18 months 0.72 0.66 0.49 0.70 – 0.83 0.90 0.88
Utility multiplier
Year 1
Mean 0.69 0.55 0.57 0.68 0.86 0.78 0.88 0.83
SD 0.02 0.01 0.03 0.01 0.08 0.03 0.02 0.01
Subsequently
Mean 0.85 0.86a 0.66 0.85a 1.00 1.00b 0.98 0.99a
SD NR 0.01 NR 0.01 NR 0.04 NR 0.01
NR, not reported.
a We apply the utility multipliers presented in the paper for year 3 onwards to our model from year 2 onwards.
b Capped at 1.0000.
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FIGURE 16 Utility associated with vertebral fracture used in the TA464 Health Technology Assessment report and that
chosen from ICUROS.
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FIGURE 18 Utility associated with distal forearm (wrist) fracture used in the TA464 Health Technology Assessment
report and that chosen from ICUROS.
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FIGURE 19 Utility associated with humerus (shoulder) fracture used in the TA464 Health Technology Assessment report
and that chosen from ICUROS.
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Appendix 17 Model validation methods
The model is designed to operate in several different modes, which facilitates debugging andvalidation. When running the model with fixed patient chacteristics, using determinisitic inputs
and with random number control switched on, the model generates identical results each time it is run.
This feature has been used to check that the model continues to operate in a consistent manner when
any change is made to the VBA code that aims to restructure the code without altering the basic
functioning of the model. The model can also be run in debug mode, whereby it outputs a detailed list
of the events experienced and their individual times for each patient. This has been used extensively
during model adaptations to check that the model is operating as intended. For example, it was used to
check that the additional dummy events required for the new intervention lines were occurring at the
correct times.
The code has been extensively commented, with any changes made since T464 identied by the date of
change. When making alterations to the VBA code, the developer set up break points where any new
code was implemented, allowing the model to be run quickly as far as the new code and then for the
new code to be stepped through under observation to check that it behaves as intended. The locals
window, within the VBA development environment, which allows the values of any object (variable,
array, etc.) to be checked, was used to observe that the various arrays and variables had been filled
with the intended data and to see changes to these variables when stepping through the code. The
developer also used the immediate window to output specific variables at specific points in the code
when trying to verify model behaviour. Error-handling was incorporated to ensure that inputs to
functions were within their required ranges and to initiate message boxes describing errors identified
and the values of inputs prior to the error.
To assess the face validity of the clinical outcomes predicted by model, the fractures prevented for
each treatment (broken down into the four main fractures types) were graphed and compared with the
absolute risk reduction for each fracture type multiplied by the ‘effective treatment duration’, which is
dependent on both the time on treatment and the offset period (i.e. a drug with a 5-year treatment
period and an additional 5-year offset period would have a 7.5-year effective treatment duration).
This was done for the outcomes of both the PSA model and the version using mean parameter inputs.
Table 49 lists the main changes to the model made since TA464 and the methods used to validate
each adapatation.
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TABLE 49 Model validation steps for key changes
Description of
adaptation needed Description of key changes to model Validation method
Increase the number of
treatment strategies
that can be modelled
The model was already set up to pull in
drug-specific inputs as arrays. These arrays
were extended to allow for up to 15 lines of
treatment to be modelled, with 11 being
used in the final analysis (no treatment, nine
interventions, with two needed to capture
the ROMO/ALN sequence)
The structural changes to the VBA code
required to incorporate additional
intervention lines were made without any
changes to model inputs, allowing outputs to
be compared with the TA464 version of the
model. New outputs were incoporated only
once the model was verified to be equivalent
for the additional intervention lines
Model inputs for interventions 6–10 and
11–15 were set equal to inputs for
interventions 1–5. Model was run in debug
mode and patient-level results were
checked to ensure that identical outputs
were being generated for intervention lines
with identical inputs
Allow for drug-specific
offset periods
In the TA464 version, the offset period was
twice the treatment period for all drugs
except ZOL and specific VBA code was used
to adjust the offset period for ZOL. In the
revised model, an array of offset inputs
were pulled into the model, allowing a
unique offset period for each drug
Results were run (with the model set up to
produce reproducible outputs) before and
after the code for handling the offset period
was altered and the outputs were compared
Allow for sequences of
treatments to be
modelled
Two additional input arrays were added:
one that says whether or not a treatment
switch should occur and one that says which
intervention should be swiched to. VBA
code for processing the end of treatment
event was adapated to reset the treatment
period and offset period to the second drug
in the sequence. VBA code was adapted to
differentiate between the treatment
sequence being modelled (drug_index_int)
and the current drug, which changes after
the swich (person_curr_drug). Costs, efficacy
and AEs were made dependent on
person_curr_drug
Intervention 6 was set up to have same
outcomes as intervention 1, but to achieve
this through a treatment switch to
intervention 11. To do this, intervention 6 was
set to have half the treatment duration of
intervention 1, but to switch to intervention
11 on completion. Intervention 11 was set
to have half the treatment duration of
intervention 1 but the same offset period
(as it is the second drug in the sequence that
determines the offset period). Costs for
intervention 6 and intervention 11 were set
equal to the cost for intervention 1
The model was run in debug mode to check
that outputs for intervention 6 were
identical to outputs for intervention 1
Allow resource use
for monitoring and
administration to be
specified for each drug
In TA464, no monitoring costs were
included and administration costs were
included only for i.v. IBN and i.v. ZOL. Total
intervention costs per annum were handled
as a single variable. In the revised model,
separate arrays are specified for drug costs,
resource use and unit costs
Adapatations were made to incorporate the
new arrays. The model was run and code
was stepped through, with break points
placed on the revised code to check that it
was performing as expected
The model was run in debug mode and
patient-level outputs were checked to see if
the total undiscounted costs matched the
total treatment costs (i.e. drug, administration
and monitoring) expected for patients
experiencing no fracture events
Additional inputs
required for non-
bisphosphonates and
new inputs for
bisphosphonates
The main changes were to drug costs,
efficacy inputs, treatment persistence,
teatment offset periods, resource use for
administration and monitoring, costs and
QALY adjustments for AEs (VTE, ONJ
and cellulitis) and post-fracture costs and
utilities
Cells that had inputs updated from TA464
were highlighted in orange and were
double-checked against the values described
in final report
Cells that were not marked as changed
were double-checked against the model
used in TA464
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Appendix 18 Summary clinical outcomes
when using FRAX
TABLE 50 Clinical outcomes across the whole population eligible for fracture risk assessment when using FRAX to
estimate fracture risk
Number of adverse clinical outcomes avoided per 100,000 patients treated, when
compared with no treatment
Total life-
years gained
per patient vs.
no treatment
Total
fractures
Hip
fracture
Vertebral
fracture
Proximal
humerus
fracture
Wrist
fracture
Nursing home/
residential
care admission
Fatal
fracture
When using FRAX to estimate risk of fracture
ALN 988 201 245 138 405 33 30 0.0026
RIS 1047 191 239 154 464 33 32 0.0026
Oral
IBN
847 182 243 107 315 30 30 0.0027
i.v. IBN 419 115 162 38 103 20 18 0.0015
ZOL 1787 333 467 254 733 53 54 0.0048
RLX 336 –11 164 95 88 20 –35 –0.0029
DEN 1611 407 587 212 404 89 29 0.0023
TPTD 1857 390 414 269 784 64 59 0.0052
ROMO/
ALN
2589 553 549 400 1088 106 89 0.0062
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Appendix 19 Base-case results from the
probabilistic sensitivity analysis for QFracture
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TABLE 51 Base-case results from 200,000 PSA samples for QFracture risk category 1 (average 10-year fracture risk of 0.5%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
No treatment 683 16.6049 0 – 0 0 0
ALN 777 16.6050 94 0.0001 675,004 –91 –90 £675,004
RIS 778 16.6050 94 0.0001 829,832 –92 –91 Dominated
RLX 778 16.6032 95 –0.0016 –58,385 –127 –143 Dominated
IBN (oral) 781 16.6050 97 0.0001 948,571 –95 –94 Dominated
ZOL 1403 16.6048 720 –0.0001 –9,181,178 –721 –722 Dominated
IBN (i.v.) 1541 16.6044 858 –0.0005 –1,784,152 –867 –872 Dominated
DEN 2454 16.6059 1770 0.0010 1,794,421 –1750 –1741 Extendedly
dominated
ROMO/ALN Confidential
information has
been removed
16.6071 Confidential
information has
been removed
0.0022 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 6502 16.6055 5819 0.0007 8,610,782 –5805 –5798 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 52 Base-case results from 200,000 PSA samples for QFracture risk category 2 (average 10-year fracture risk of 0.7%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
No treatment 1152 15.3523 0 – 0 0 0
RIS 1243 15.3525 91 0.0003 319,027 –85 –82 Extendedly
dominated
ALN 1243 15.3526 91 0.0003 290,229 –85 –82 290,229
IBN (oral) 1246 15.3526 94 0.0003 301,165 –88 –85 Extendedly
dominated
RLX 1297 15.3507 145 –0.0015 –96,336 –175 –190 Dominated
ZOL 1864 15.3525 713 0.0002 2,984,339 –708 –705 Dominated
IBN (i.v.) 2009 15.3518 857 –0.0004 –1,958,289 –866 –870 Dominated
DEN 2961 15.3539 1809 0.0017 1,092,301 –1776 –1760 1,279,494
ROMO/ALN Confidential
information has
been removed
15.3539 Confidential
information has
been removed
0.0016 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 6961 15.3532 5809 0.0010 5,871,874 –5790 –5780 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 53 Base-case results from 200,000 PSA samples for QFracture risk category 3 (average 10-year fracture risk of 1.0%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
No treatment 2260 14.0458 0 – 0 0 0
RIS 2349 14.0465 89 0.0007 129,889 –75 –68 Extendedly
dominated
ALN 2349 14.0465 89 0.0007 125,805 –75 –67 Extendedly
dominated
IBN (oral) 2352 14.0466 92 0.0008 119,370 –77 –69 £119,370
RLX 2378 14.0436 118 –0.0023 –52,066 –163 –186 Dominated
ZOL 2968 14.0467 707 0.0009 808,583 –690 –681 Extendedly
dominated
IBN (i.v.) 3113 14.0457 853 –0.0002 –5,378,179 –856 –858 Dominated
DEN 4041 14.0468 1781 0.0010 1,868,896 –1762 –1752 Extendedly
dominated
ROMO/ALN Confidential
information has
been removed
14.0475 Confidential
information has
been removed
0.0017 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 8059 14.0474 5799 0.0016 3,731,997 –5768 –5752 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 54 Base-case results from 200,000 PSA samples for QFracture risk category 4 (average 10-year fracture risk of 1.4%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
No treatment 2722 12.6966 0 – 0 0 0
ALN 2804 12.6973 82 0.0007 126,025 –69 –63 Extendedly
dominated
RIS 2804 12.6974 83 0.0008 100,618 –66 –58 £100,618
IBN (oral) 2813 12.6973 91 0.0007 137,375 –78 –71 Dominated
RLX 2847 12.6952 126 –0.0014 –91,201 –153 –167 Dominated
ZOL 3421 12.6976 699 0.0010 723,860 –680 –670 Extendedly
dominated
IBN (i.v.) 3572 12.6964 850 –0.0002 –4,066,084 –854 –856 Dominated
DEN 4487 12.6994 1766 0.0028 632,830 –1710 –1682 £855,463
ROMO/ALN Confidential
information has
been removed
12.7002 Confidential
information has
been removed
0.0036 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 8497 12.6985 5776 0.0019 3,083,847 –5738 –5720 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 55 Base-case results from 200,000 PSA samples for QFracture risk category 5 (average 10-year fracture risk of 2.0%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
No treatment 2936 11.6723 0 – 0 0 0
ALN 3016 11.6734 80 0.0010 77,059 –59 –49 £77,059
RIS 3019 11.6733 82 0.0010 81,404 –62 –52 Dominated
IBN (oral) 3021 11.6732 84 0.000 93,736 –66 –57 Dominated
RLX 3067 11.6712 130 –0.0011 –118,232 –153 –164 Dominated
ZOL 3625 11.6739 688 0.0016 442,296 –657 –642 Extendedly
dominated
IBN (i.v.) 3784 11.6722 848 –0.0001 –11,357,805 –849 –850 Dominated
DEN 4695 11.6757 1759 0.0034 523,142 –1692 –1658 £721,645
ROMO/ALN Confidential
information has
been removed
11.6763 Confidential
information has
been removed
0.0040 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 8695 11.6748 5759 0.0024 2,356,350 –5710 –5686 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 56 Base-case results from 200,000 PSA samples for QFracture risk category 6 (average 10-year fracture risk of 2.7%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
No treatment 3064 10.6107 0 – 0 0 0
ALN 3142 10.6119 78 0.0012 65,281 –54 –42 Dominated
RIS 3143 10.6119 79 0.0012 64,979 –55 –42 £64,979
IBN (oral) 3147 10.6119 83 0.0012 68,805 –59 –47 Dominated
RLX 3164 10.6095 100 –0.0012 –83,809 –124 –136 Dominated
ZOL 3753 10.6126 689 0.0019 353,780 –650 –631 Extendedly
dominated
IBN (i.v.) 3908 10.6109 843 0.0002 4,373,315 –840 –838 Dominated
DEN 4774 10.6141 1710 0.0034 502,655 –1642 –1608 £745,595
ROMO/ALN Confidential
information has
been removed
10.6150 Confidential
information has
been removed
0.0043 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 8798 10.6136 5733 0.0029 1,964,475 –5675 –5646 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 57 Base-case results from 200,000 PSA samples for QFracture risk category 7 (average 10-year fracture risk of 3.9%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
No treatment 3277 9.5502 0 – 0 0 0
ALN 3339 9.5522 62 0.0020 30,452 –21 –1 £30,452
RIS 3340 9.5521 63 0.0020 32,482 –24 –5 Dominated
IBN (oral) 3345 9.5521 68 0.0020 34,713 –29 –9 Dominated
RLX 3448 9.5476 171 –0.0026 –65,412 –223 –249 Dominated
ZOL 3933 9.5533 656 0.0031 210,441 –594 –562 £552,756
IBN (i.v.) 4109 9.5509 832 0.0007 1,250,818 –819 –812 Dominated
DEN 5009 9.5539 1733 0.0037 462,072 –1658 –1620 Extendedly
dominated
ROMO/ALN Confidential
information has
been removed
9.5562 Confidential
information has
been removed
0.0060 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 8954 9.5544 5677 0.0042 1,366,400 –5594 –5553 Dominated
a ICER vs. next least costly non-dominated strategy.
A
P
P
E
N
D
IX
1
9
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
a
lslib
ra
ry
.n
ih
r.a
c.u
k
2
9
0
TABLE 58 Base-case results from 200,000 PSA samples for QFracture risk category 8 (average 10-year fracture risk of 5.5%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
No treatment 3958 8.4539 0 – 0 0 0
ALN 4001 8.4568 43 0.0029 14,820 15 44 £14,820
RIS 4007 8.4568 48 0.0028 17,119 8 36 Dominated
IBN (oral) 4021 8.4568 63 0.0029 21,840 –5 23 Extendedly
dominated
RLX 4081 8.4531 123 –0.0008 –146,142 –139 –148 Dominated
ZOL 4591 8.4589 633 0.0050 127,491 –534 –484 £273,143
IBN (i.v.) 4784 8.4554 826 0.0015 564,407 –796 –782 Dominated
DEN 5613 8.4605 1655 0.0066 250,729 –1523 –1457 £625,518
ROMO/ALN Confidential
information has
been removed
8.4637 Confidential
information has
been removed
0.0098 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPT 9593 8.4597 5635 0.0058 971,695 –5519 –5461 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 59 Base-case results from 200,000 PSA samples for QFracture risk category 9 (average 10-year fracture risk of 8.4%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
No treatment 6197 6.6409 0 – 0 0 0
ALN 6221 6.6451 24 0.0042 5622 60 102 £5622
RIS 6227 6.6450 30 0.0041 7235 53 94 Dominated
IBN (oral) 6234 6.6448 37 0.0039 9443 41 80 Dominated
RLX 6308 6.6391 110 –0.0017 –63,265 –145 –163 Dominated
ZOL 6794 6.6472 597 0.0064 93,903 –470 –406 £266,114
IBN (i.v.) 6998 6.6429 801 0.0020 398,475 –761 –741 Dominated
DEN 7730 6.6501 1533 0.0092 166,441 –1349 –1257 £327,719
ROMO/ALN Confidential
information has
been removed
6.6513 Confidential
information has
been removed
0.0105 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 11,717 6.6491 5520 0.0082 671,001 –5355 –5273 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 60 Base-case results from 200,000 PSA samples for QFracture risk category 10 (average 10-year fracture risk of 16.0%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
ALN 13,370 4.0837 –51 0.0058 –8820 167 225
RIS 13,384 4.0833 –37 0.0054 –6896 144 197 Dominated
IBN (oral) 13,393 4.0831 –28 0.0051 –5417 130 181 Dominated
No treatment 13,421 4.0779 0 – 0 0 0 Dominated
RLX 13,524 4.0760 103 –0.0019 –53,780 –141 –160 Dominated
ZOL 13,897 4.0858 477 0.0079 60,300 –318 –239 £250,205
IBN (i.v.) 14,165 4.0807 744 0.0028 266,492 –689 –661 Dominated
DEN 14,768 4.0886 1347 0.0107 126,392 –1134 –1028 £315,774
ROMO/ALN Confidential
information has
been removed
4.0919 Confidential
information has
been removed
0.0140 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 18,604 4.0893 5183 0.0113 457,894 –4957 –4844 Dominated
a ICER vs. next least costly non-dominated strategy.
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Appendix 20 Base-case results from the
probabilistic sensitivity analysis for FRAX
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TABLE 61 Base-case results from 200,000 PSA samples for FRAX risk category 1 (average 10-year fracture risk of 3.1%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
No treatment 4241 13.6665 0 – 0 0 0
RIS 4315 13.6687 73 0.0023 32,429 –28 –5 Extendedly
dominated
ALN 4315 13.6690 73 0.0026 28,541 –22 4 £28,541
IBN (oral) 4319 13.6687 78 0.0023 34,519 –33 –10 Dominated
RLX 4350 13.6641 109 –0.0023 –47,105 –156 –179 Dominated
ZOL 4926 13.6705 685 0.0040 170,998 –605 –565 £427,431
IBN (i.v.) 5088 13.6671 846 0.0007 1,214,068 –832 –825 Dominated
DEN 5981 13.6708 1740 0.0044 398,751 –1653 –1609 Extendedly
dominated
ROMO/ALN Confidential
information has
been removed
13.6726 Confidential
information has
been removed
0.0061 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 10,011 13.6711 5770 0.0046 1,254,448 –5678 –5632 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 62 Base-case results from 200,000 PSA samples for FRAX risk category 2 (average 10-year fracture risk of 4.3%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
No treatment 4487 13.6230 0 – 0 0 0
RLX 4524 13.6228 37 –0.0002 –199,169 –41 –43 Dominated
RIS 4555 13.6255 68 0.0025 27,654 –19 6 Extendedly
dominated
ALN 4556 13.6256 69 0.0025 27,325 –19 7 £27,325
IBN (oral) 4557 13.6256 70 0.0026 27,349 –19 7 £28,946
ZOL 5151 13.6276 664 0.0046 145,587 –572 –527 £297,575
IBN (i.v.) 5331 13.6240 844 0.0010 853,480 –825 –815 Dominated
DEN 6159 13.6297 1672 0.0067 250,782 –1539 –1472 £478,086
ROMO/ALN Confidential
information has
been removed
13.6320 Confidential
information has
been removed
0.0090 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 10,236 13.6282 5749 0.0052 1,115,769 –5646 –5595 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 63 Base-case results from 200,000 PSA samples for FRAX risk category 3 (average 10-year fracture risk of 5.0%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost QALY
No treatment 4976 13.8999 0 – 0 0 0
RIS 5033 13.9035 57 0.0037 15,575 16 53 £15,575
ALN 5037 13.9035 61 0.0037 16,808 12 48 Dominated
IBN (oral) 5039 13.9034 63 0.0035 17,728 8 43 Dominated
RLX 5045 13.8992 69 –0.0007 –105,444 –83 –89 Dominated
ZOL 5635 13.9058 659 0.0059 110,846 –540 –481 £263,566
IBN (i.v.) 5810 13.9017 834 0.0019 443,563 –797 –778 Dominated
DEN 6636 13.9084 1660 0.0085 195,106 –1489 –1404 £390,788
ROMO/ALN Confidential
information has
been removed
13.9117 Confidential
information has
been removed
0.0118 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 10,708 13.9067 5732 0.0069 832,835 –5594 –5526 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 64 Base-case results from 200,000 PSA samples for FRAX risk category 4 (average 10-year fracture risk of 5.6%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
No treatment 5465 14.2478 0 – 0 0 0
ALN 5521 14.2515 56 0.0036 15,524 16 53 £15,524
IBN (oral) 5524 14.2514 59 0.0036 16,459 13 49 Dominated
RIS 5525 14.2513 60 0.0035 17,389 9 44 Dominated
RLX 5558 14.2458 94 –0.0020 –47,071 –133 –153 Dominated
ZOL 6116 14.2546 651 0.0068 96,012 –516 –448 £189,147
IBN (i.v.) 6295 14.2497 831 0.0019 430,771 –792 –773 Dominated
DEN 7152 14.2555 1687 0.0076 220,601 –1534 –1458 £1,197,064
ROMO/ALN Confidential
information has
been removed
14.2569 Confidential
information has
been removed
0.0091 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 11,185 14.2555 5720 0.0077 745,024 –5567 –5490 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 65 Base-case results from 200,000 PSA samples for FRAX risk category 5 (average 10-year fracture risk of 6.2%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
No treatment 5792 12.8154 0 – 0 0 0
ALN 5845 12.8201 54 0.0047 11,362 41 88 Extendedly
dominated
RIS 5846 12.8202 54 0.0048 11,265 42 90 £11,265
IBN (oral) 5849 12.8200 57 0.0047 12,209 36 83 Dominated
RLX 5873 12.8144 81 –0.0010 –82,569 –101 –110 Dominated
ZOL 6435 12.8232 644 0.0078 82,355 –487 –409 £194,815
IBN (i.v.) 6623 12.8178 831 0.0024 342,182 –783 –758 Dominated
DEN 7435 12.8243 1643 0.0089 184,386 –1465 –1375 Extendedly
dominated
ROMO/ALN Confidential
information has
been removed
12.8286 Confidential
information has
been removed
0.0132 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 11,479 12.8244 5687 0.0090 632,511 –5507 –5417 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 66 Base-case results from 200,000 PSA samples for FRAX risk category 6 (average 10-year fracture risk of 7.3%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
No treatment 5868 11.0066 0 – 0 0 0
RIS 5906 11.0111 39 0.0044 8736 50 95 £8736
ALN 5910 11.0114 43 0.0048 8951 53 101 £11,817
IBN (oral) 5922 11.0110 54 0.0044 12,389 33 77 Dominated
RLX 6012 11.0049 145 –0.0018 –82,686 –180 –197 Dominated
ZOL 6491 11.0142 623 0.0076 82,446 –472 –396 £209,233
IBN (i.v.) 6692 11.0089 825 0.0023 362,332 –779 –756 Dominated
DEN 7557 11.0154 1690 0.0087 193,385 –1515 –1428 Extendedly
dominated
ROMO/ALN Confidential
information has
been removed
11.0208 Confidential
information has
been removed
0.0142 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 11,507 11.0157 5640 0.0091 622,664 –5459 –5368 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 67 Base-case results from 200,000 PSA samples for FRAX risk category 7 (average 10-year fracture risk of 8.8%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
No treatment 5488 9.3617 0 – 0 0 0
ALN 5508 9.3671 20 0.0054 3791 87 140 £3,791
RIS 5511 9.3667 23 0.0050 4572 77 128 Dominated
IBN (oral) 5518 9.3667 30 0.0050 6035 70 120 Dominated
RLX 5584 9.3615 96 –0.0002 –455,927 –100 –102 Dominated
ZOL 6070 9.3709 582 0.0092 63,432 –399 –307 £147,034
IBN (i.v.) 6301 9.3639 813 0.0022 367,423 –769 –747 Dominated
DEN 7082 9.3731 1594 0.0113 140,582 –1367 –1254 Extendedly
dominated
ROMO/ALN Confidential
information has
been removed
9.3788 Confidential
information has
been removed
0.0170 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 11,069 9.3720 5581 0.0103 542,248 –5375 –5272 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 68 Base-case results from 200,000 PSA samples for FRAX risk category 8 (average 10-year fracture risk of 10.7%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
ALN 5754 8.1143 –11 0.0066 –1716 142 208
RIS 5764 8.1143 –2 0.0065 –297 132 198 Dominated
No treatment 5766 8.1077 0 – 0 0 0 Dominated
IBN (oral) 5770 8.1141 5 0.0064 734 123 187 Dominated
RLX 5820 8.1087 54 0.0009 57,050 –35 –26 Dominated
ZOL 6308 8.1184 542 0.0106 51,057 –330 –224 £136,054
IBN (i.v.) 6556 8.1114 790 0.0037 215,680 –717 –680 Dominated
DEN 7247 8.1233 1482 0.0156 95,158 –1170 –1014 £189,738
ROMO/ALN Confidential
information has
been removed
8.1266 Confidential
information has
been removed
0.0189 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 11,275 8.1203 5510 0.0125 439,478 –5259 –5133 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 69 Base-case results from 200,000 PSA samples for FRAX risk category 9 (average 10-year fracture risk of 14.9%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
ALN 8078 7.0926 –43 0.0082 –5233 208 290
RIS 8082 7.0923 –39 0.0080 –4904 200 280 Dominated
IBN (oral) 8085 7.0922 –36 0.0079 –4537 194 273 Dominated
No treatment 8121 7.0843 0 – 0 0 0 Dominated
RLX 8251 7.0837 130 –0.0006 –206,484 –142 –148 Dominated
ZOL 8615 7.0974 494 0.0131 37,737 –232 –101 £110,826
IBN (i.v.) 8881 7.0890 760 0.0047 163,225 –666 –620 Dominated
DEN 9560 7.1004 1439 0.0161 89,300 –1116 –955 £312,269
ROMO/ALN Confidential
information has
been removed
7.1056 Confidential
information has
been removed
0.0213 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 13,523 7.1000 5402 0.0157 343,693 –5088 –4930 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 70 Base-case results from 200,000 PSA samples for FRAX risk category 10 (average 10-year fracture risk of 25.1%)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
ALN 13,031 4.7140 –129 0.0110 –11,748 348 458
RIS 13,040 4.7134 –120 0.0104 –11,572 327 431 Dominated
IBN (oral) 13,048 4.7130 –112 0.0100 –11,122 312 413 Dominated
No treatment 13,160 4.7030 0 – 0 0 0 Dominated
RLX 13,276 4.7012 116 –0.0018 –63,139 –153 –172 Dominated
ZOL 13,487 4.7191 327 0.0161 20,257 –4 157 £88,002
IBN (i.v.) 13,853 4.7092 693 0.0062 111,944 –569 –507 Dominated
DEN 14,370 4.7236 1210 0.0206 58,730 –798 –592 £197,979
ROMO/ALN Confidential
information has
been removed
4.7303 Confidential
information has
been removed
0.0273 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TPTD 18,252 4.7238 5092 0.0208 244,558 –4676 –4468 Dominated
a ICER vs. next least costly non-dominated strategy.
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Appendix 21 Sensitivity analyses for
economic evaluation
Note that these sensitivity analyses are based on the model using mid-point parameter inputs,rather than the average outcomes across the PSA with the exception of Tables 74 and 75, which
used 500,000 PSA samples but fixed patient characteristics.
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TABLE 71 The ICERs vs. no treatment by risk deciles for QFracture and FRAX when using the base-case scenario
Drug
ICERs by risk decile (£)
1 2 3 4 5 6 7 8 9 10 All
Qfracture score (%) 0.5 0.7 1.0 1.4 2.0 2.7 3.9 5.5 8.4 16.0 NA
ALN 498,737 412,005 157,211 149,958 68,492 44,834 37,197 16,884 745 Dominates 29,766
RIS 565,069 441,369 160,348 158,750 69,748 47,388 38,372 16,920 2190 Dominates 31,628
IBN (oral) 463,164 427,947 156,817 144,798 70,576 46,196 37,906 17,487 837 Dominates 30,561
IBN (i.v.) Dominated Dominated Dominated Dominated 4,767,171 1,413,543 1,040,966 650,661 307,706 199,398 1,066,308
ZOL 241,951,112 21,001,049 1,200,415 870,723 469,207 308,198 227,473 133,550 79,528 58,085 233,405
RLX Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated
DEN 1,998,145 1,741,276 1,143,632 887,398 609,344 492,380 386,626 243,281 163,466 115,933 382,864
TPTD 7,503,596 6,096,105 4,057,889 3,088,025 2,244,920 1,700,544 1,405,530 910,295 608,736 453,776 1,361,877
ROMO/ALN Confidential
information
has been
removed
Confidential
information
has been
removed
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FRAX score (%) 3.1 4.3 5.0 5.6 6.2 7.3 8.8 10.7 14.9 25.1 NA
ALN 24,918 22,192 15,189 16,287 10,585 3769 1096 Dominates Dominates Dominates 1350
RIS 25,690 22,982 15,820 17,515 10,337 3911 1349 Dominates Dominates Dominates 1814
IBN (oral) 25,107 23,022 15,393 16,536 11,305 3733 1713 Dominates Dominates Dominates 1756
IBN (i.v.) 671,930 761,291 455,094 398,749 365,350 261,759 262,550 184,121 140,596 82,567 248,478
ZOL 152,696 146,559 111,458 96,479 78,835 66,241 57,551 48,346 33,954 18,654 63,969
RLX Dominated Dominated Dominated Dominated Dominated Dominated 18,508,020 158,275 115,977 56,599 Dominated
DEN 325,050 281,011 205,252 190,057 166,993 147,494 130,881 106,085 81,500 52,679 137,302
TPTD 1,123,470 983,834 869,760 767,917 670,930 601,318 482,831 444,825 330,544 232,180 532,666
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TABLE 72 The ICERs vs. no treatment by risk deciles for QFracture and FRAX when assuming full persistence with treatment
Drug
ICERs by risk decile (£)
1 2 3 4 5 6 7 8 9 10 All
Qfracture score (%) 0.5 0.7 1.0 1.4 2.0 2.7 3.9 5.5 8.4 16.0 NA
ALN 251,941 168,092 119,902 79,284 60,970 31,766 21,485 10,432 932 Dominates 24,274
RIS 268,409 173,111 121,180 81,223 62,848 33,001 22,356 11,356 1273 Dominates 25,717
IBN (oral) 249,462 167,996 116,962 80,518 62,242 32,880 21,962 10,972 1310 Dominates 25,052
IBN (i.v.) 6,829,412 3,436,012 2,239,222 1,466,327 1,139,102 652,143 477,492 326,477 231,761 173,580 568,098
ZOL 1,872,105 1,080,025 721,322 481,417 368,038 222,443 160,376 110,764 74,556 54,055 191,981
RLX Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated
DEN 1,961,321 1,264,758 1,002,128 693,856 526,207 357,560 265,653 186,577 128,911 94,665 322,714
TPTD 7,552,870 5,127,678 4,294,267 2,966,878 2,601,782 1,717,937 1,230,354 814,753 600,894 406,640 1,288,454
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FRAX score (%) 3.1 4.3 5.0 5.6 6.2 7.3 8.8 10.7 14.9 25.1 NA
ALN 20,826 13,265 10,205 8667 7096 4570 Dominates Dominates Dominates Dominates 629
RIS 21,225 13,435 10,374 9194 7051 4739 Dominates Dominates Dominates Dominates 1061
IBN (oral) 21,651 13,923 10,577 9059 7570 5066 26 Dominates Dominates Dominates 1060
IBN (i.v.) 424,242 313,920 269,844 243,798 238,418 216,521 174,715 133,701 114,229 84,510 187,936
ZOL 134,229 99,921 85,457 75,996 71,730 65,020 51,386 39,131 32,428 20,158 57,147
RLX Dominated Dominated Dominated Dominated Dominated Dominated Dominated 697,741 196,074 107,583 Dominated
DEN 243,364 184,578 159,477 141,243 137,427 120,484 97,963 77,542 63,636 42,333 109,566
TPTD 1,059,530 914,573 769,066 691,834 637,242 550,881 495,976 388,142 323,503 230,761 505,256
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TABLE 73 The ICERs vs. no treatment by risk deciles for QFracture and FRAX when using the class effect estimates for bisphosphonates
Drug
ICERs by risk decile (£)
1 2 3 4 5 6 7 8 9 10 All
Qfracture score (%) 0.5 0.7 1.0 1.4 2.0 2.7 3.9 5.5 8.4 16.0 NA
ALN 799,955 486,510 172,280 106,937 85,656 59,255 27,980 12,480 5185 Dominates 31,647
RIS 799,955 486,510 172,280 106,937 85,656 59,255 27,980 12,480 5185 Dominates 31,647
IBN (oral) 826,668 502,375 178,069 110,735 88,733 61,464 29,355 13,378 5907 Dominates 33,205
IBN (i.v.) Dominated Dominated Dominated Dominated 7,531,872 2,733,301 981,482 435,481 360,520 206,403 1,086,629
ZOL Dominated 10,002,667 1,313,565 794,622 556,859 336,315 196,111 130,628 100,210 62,599 248,980
RLX Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated
DEN 2,346,041 1,613,668 1,005,637 823,644 638,855 487,738 330,852 227,692 185,220 122,045 383,999
TPTD 8,161,900 5,841,080 4,235,494 3,154,275 2,175,649 1,968,959 1,205,259 885,276 714,965 481,048 1,415,644
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FRAX score (%) 3.1 4.3 5.0 5.6 6.2 7.3 8.8 10.7 14.9 25.1 NA
ALN 27,834 19,286 16,881 14,023 10,907 4553 1530 Dominates Dominates Dominates 2591
RIS 27,834 19,286 16,881 14,023 10,907 4553 1530 Dominates Dominates Dominates 2591
IBN (oral) 28,967 20,169 17,695 14,715 11,600 5160 2044 Dominates Dominates Dominates 3131
IBN (i.v.) 616,244 408,882 418,532 337,957 325,277 287,300 226,977 183,012 142,975 97,801 240,853
ZOL 178,326 130,666 122,750 96,355 106,623 78,832 63,178 54,261 38,658 24,279 72,230
RLX Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated 115,828 80,087 Dominated
DEN 321,955 245,827 211,101 175,962 177,597 153,423 127,213 109,102 83,514 56,914 138,658
TPTD 1,187,281 940,410 859,389 720,901 666,582 583,940 499,370 437,612 348,992 252,450 541,645
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TABLE 74 Scenario results for high-risk patient with FRAX risk of 30% (based on 500,000 PSA samples with fixed patient characteristics)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
ALN 7476 6.6254 –235 0.0199 –11,804 634 834
RIS 7479 6.6248 –232 0.0193 –12,014 618 811 Dominated
IBN (oral) 7509 6.6242 –202 0.0187 –10,776 576 764 Dominated
No treatment 7711 6.6055 0 – 0 0 0 Dominated
RLX 7832 6.6067 121 0.0012 105,283 –98 –87 Dominated
ZOL 8001 6.6308 290 0.0253 11,427 217 471 Extendedly
dominated
IBN (i.v.) 8329 6.6193 618 0.0138 44,785 –342 –204 Dominated
DEN 8491 6.6631 780 0.0576 13,544 372 948 £26,977
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TPTD 12,820 6.6418 5109 0.0363 140,684 –4383 –4020 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 75 Scenario results for high-risk patient with QFracture risk of 13.3% (based on 500,000 PSA samples with fixed patient characteristics)
Treatment strategy
Mean outcomes (discounted)
Incremental outcomes vs.
no treatment (discounted)
ICER vs. no
treatment (£)
Net benefit at
£20,000 per
QALY (£)
Net benefit at
£30,000 per
QALY (£)
Incremental
analysisaCost (£) QALY Cost (£) QALY
ALN 2782 6.8336 –24 0.0071 –3393 167 238
RIS 2782 6.8335 –24 0.0069 –3463 163 233 Dominated
IBN (oral) 2794 6.8331 –12 0.0065 –1819 143 208 Dominated
No treatment 2806 6.8265 0 – 0 0 0 Dominated
RLX 2947 6.8256 141 –0.0009 –152,373 –159 –169 Dominated
ZOL 3387 6.8352 581 0.0087 66,928 –407 –321 Extendedly
dominated
IBN (i.v.) 3577 6.8307 771 0.0042 183,707 –687 –645 Dominated
DEN 4205 6.8478 1399 0.0212 65,851 –974 –761 £100,788
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TPTD 8315 6.8398 5509 0.0133 414,209 –5243 –5110 Dominated
a ICER vs. next least costly non-dominated strategy.
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TABLE 76 The ICERs vs. no treatment by risk deciles for QFracture and FRAX when making alternative assumptions for the offset perioda
Drug
ICERs by risk decile (£)
1 2 3 4 5 6 7 8 9 10 All
Qfracture score (%) 0.5 0.7 1.0 1.4 2.0 2.7 3.9 5.5 8.4 16.0 NA
ALN 667,007 344,843 154,562 158,993 79,839 96,437 32,481 16,709 9373 Dominating 37,101
RIS 833,648 378,035 155,152 176,091 87,929 98,283 33,908 19,143 9239 Dominating 39,904
IBN (oral) 613,050 300,939 153,457 165,724 80,313 98,014 33,897 17,620 10,028 Dominating 38,227
IBN (i.v.) Dominated Dominated Dominated Dominated 6,497,796 Dominated 984,778 539,348 428,815 189,330 1,167,465
ZOL Dominated Dominated 3,032,964 2,134,060 694,683 813,434 266,397 215,493 141,142 79,915 359,734
RLX Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated Dominated
DEN 1,875,580 1,067,021 725,687 574,802 412,867 409,288 226,792 186,474 119,740 84,928 277,008
TPTD 7,103,236 5,463,987 4,344,868 4,130,127 2,585,616 2,577,445 1,336,591 1,136,165 771,301 499,965 1,581,013
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FRAX score (%) 3.1 4.3 5.0 5.6 6.2 7.3 8.8 10.7 14.9 25.1 NA
ALN 43,692 29,116 20,888 16,881 14,815 10,289 6445 1671 Dominating Dominating 5789
RIS 41,868 30,603 20,138 17,014 15,644 11,783 7082 2179 Dominating Dominating 6585
IBN (oral) 43,872 29,515 21,422 17,188 15,311 10,602 7219 2062 Dominating Dominating 6353
IBN (i.v.) 1,135,784 620,464 432,254 341,331 362,455 346,713 338,155 209,343 172,366 96,099 280,111
ZOL 292,309 212,340 171,060 135,810 139,460 124,920 113,027 81,472 62,310 33,641 106,395
RLX Dominated Dominated Dominated 316,965 Dominated Dominated Dominated 450,493 132,412 50,539 11,272,491
DEN 228,836 180,468 152,041 132,978 126,706 114,716 105,110 74,266 59,072 38,160 101,453
TPTD 1,492,180 1,109,874 933,843 782,904 858,530 704,890 658,543 504,232 418,570 280,094 637,237
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a Assuming offset period equal to treatment time for ZOL, RLX and DEN, and assuming offset period equal to 1 year for ALN, RIS, IBN (oral), IBN (i.v.) and TPTD.
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